var images_info;if (!images_info) images_info =[]; images_info["98"]={"98000":{"type":"graphic_figure","displayName":"Zenker's diverticulum endoscopic approach","title":"Illustration of endoscopic approach to endoscopic Zenker's therapy","html":"<div class=\"graphic\"><div style=\"width: 750px\" class=\"figure\"><div class=\"ttl\">Illustration of endoscopic approach to endoscopic Zenker's therapy</div><div class=\"cntnt\"><img style=\"width:730px; height:565px;\" src=\"images/GAST/98000_Znkr_dvrtclm_endscpc_apprch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Illustration of endoscopic approach to endoscopic Zenker's therapy.<br />(A) Zenker's diverticulum&nbsp;from a proximal lumenal perspective. The esophageal lumen is seen above and the diverticulum below.<br />(B) After therapy, the septum has been severed creating a common cavity between the esophagus and diverticulum.<br />(C) Lateral view of neck before treatment corresponding to panel A.<br />(D) Lateral view of neck before treatment corresponding to panel B.</div><div class=\"graphic_reference\">Reproduced from: Law R, Katzka DA, Baron TH. Zenker's diverticulum. Clin Gastroenterol Hepatol 2014; 12:1773. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98000 Version 1.0</div></div></div>"},"98001":{"type":"graphic_picture","displayName":"Flexible endoscopic cricopharyngeal myotomy for ZD therapy","title":"Flexible endoscopic cricopharyngeal myotomy for Zenker's diverticulum therapy","html":"<div class=\"graphic\"><div style=\"width: 744px\" class=\"figure\"><div class=\"ttl\">Flexible endoscopic cricopharyngeal myotomy for Zenker's diverticulum therapy</div><div class=\"cntnt\"><img style=\"width:724px; height:213px;\" src=\"images/GAST/98001_Flxbl_end_crcphryngl_myt_ZD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Endoscopic view with short, clear cap attached to endoscope tip. Nasogastric tube is in place, and hook knife sheath is seen.<br />(B) Midpoint of the cricopharyngeal myotomy procedure.<br />(C) Completion myotomy.</div><div class=\"graphic_footnotes\">ZD: Zenker's diverticulum.</div><div class=\"graphic_reference\">Reproduced from: Law R, Katzka DA, Baron TH. Zenker's diverticulum. Clin Gastroenterol Hepatol 2014; 12:1773. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98001 Version 2.0</div></div></div>"},"98002":{"type":"graphic_movie","displayName":"Endoscopic cricopharyngeal myotomy using needle-knife for ZD","title":"Endoscopic cricopharyngeal myotomy using needle-knife for Zenker's diverticulum","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Endoscopic cricopharyngeal myotomy using needle-knife for Zenker's diverticulum</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/GAST/98002_Zenkerdivrtneedlknifvid.mp4\" style=\"width:512px;height:352px\"></div><img style=\"width:556px; height:409px;\" src=\"images/GAST/98002_Zenkerdivrtneedlknifimg.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 98002 Version 2.0</div></div></div>"},"98005":{"type":"graphic_table","displayName":"Summary of recommendations for AS: Timing of intervention","title":"Summary of recommendations for AS: Timing of intervention","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of recommendations for AS: Timing of intervention</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Recommendations</td> <td class=\"subtitle1\">Class of recommendation</td> <td class=\"subtitle1\">Level of evidence</td> </tr> <tr> <td>AVR is recommended for symptomatic patients with severe high-gradient AS who have symptoms by history or on exercise testing (stage D1)</td> <td class=\"centered\">I</td> <td class=\"centered\">B</td> </tr> <tr> <td>AVR is recommended for asymptomatic patients with severe AS (stage C2) and LVEF &#60;50%</td> <td class=\"centered\">I</td> <td class=\"centered\">B</td> </tr> <tr> <td>AVR is indicated for patients with severe AS (stage C or D) when undergoing other cardiac surgery</td> <td class=\"centered\">I</td> <td class=\"centered\">B</td> </tr> <tr> <td>AVR is reasonable for asymptomatic patients with very severe AS (stage C1, aortic velocity &#8805;5.0 m/s) and low surgical risk</td> <td class=\"centered\">IIa</td> <td class=\"centered\">B</td> </tr> <tr> <td>AVR is reasonable in asymptomatic patients (stage C1) with severe AS and decreased exercise tolerance or an exercise fall in BP</td> <td class=\"centered\">IIa</td> <td class=\"centered\">B</td> </tr> <tr> <td>AVR is reasonable in symptomatic patients with low-flow/low-gradient severe AS with reduced LVEF (stage D2) with a low-dose dobutamine stress study that shows an aortic velocity &#8805;4.0 m/s (or mean pressure gradient &#8805;40 mmHg) with a valve area &#8804;1.0 cm<sup>2</sup> at any dobutamine dose</td> <td class=\"centered\">IIa</td> <td class=\"centered\">B</td> </tr> <tr> <td>AVR is reasonable in symptomatic patients who have low-flow/low-gradient severe AS (stage D3) who are normotensive and have an LVEF &#8805;50% if clinical, hemodynamic, and anatomic data support valve obstruction as the most likely cause of symptoms</td> <td class=\"centered\">IIa</td> <td class=\"centered\">C</td> </tr> <tr> <td>AVR is reasonable for patients with moderate AS (stage B) (aortic velocity 3.0 to 3.9 m/s) who are undergoing other cardiac surgery</td> <td class=\"centered\">IIa</td> <td class=\"centered\">C</td> </tr> <tr> <td>AVR may be considered for asymptomatic patients with severe AS (stage C1) and rapid disease progression and low surgical risk</td> <td class=\"centered\">IIb</td> <td class=\"centered\">C</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For the strength of recommendations: Class I means the procedure/treatment should be performed/administered. Class IIa means it is reasonable to perform the procedure/administer treatment. Class IIb means the procedure/treatment may be considered. Class III means that the procedure or treatment is not useful/effective and may be harmful.<br />For the level of evidence: Level A means multiple populations evaluated; data derived from multiple randomized clinical trials or meta-analyses. Level B means limited populations evaluated; data derived from a single randomized trial or nonrandomized studies. Level C means very limited populations evaluated; only consensus opinion of experts, case studies, or standard of care.</div><div class=\"graphic_footnotes\">AS: aortic stenosis; AVR: aortic valve replacement by either surgical or transcatheter approach; BP: blood pressure; LVEF: left ventricular ejection fraction.</div><div class=\"graphic_reference\">Reproduced from: Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:e57. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98005 Version 2.0</div></div></div>"},"98009":{"type":"graphic_table","displayName":"Neurologic and genetic disorders in patients with KLS symptoms","title":"Spectrum of neurologic and genetic disorders reported in association with Kleine-Levin syndrome (KLS) symptoms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Spectrum of neurologic and genetic disorders&nbsp;reported&nbsp;in association with Kleine-Levin syndrome (KLS) symptoms</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Brain pathology</td> <td class=\"subtitle1\">Number of cases</td> </tr> <tr> <td>Genetic or developmental diseases</td> <td class=\"centered\">7</td> </tr> <tr> <td class=\"indent1\">Asperger syndrome</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\">Cortical dysplasia and retinitis pigmentosa</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Prader-Willi syndrome</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Mosaicism with Robert's syndrome*</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Mental retardation and pyramidal syndrome</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Mental retardation, incontinentia pigmenti, acanthosis nigricans, and hereditary exostosis</td> <td class=\"centered\">1</td> </tr> <tr> <td>Stroke</td> <td class=\"centered\">5</td> </tr> <tr> <td class=\"indent1\">Traumatic hemorrhages of the right hemisphere</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Multi-infarct dementia</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Thalamic ischemic stroke</td> <td class=\"centered\">1</td> </tr> <tr> <td>Infectious encephalitis</td> <td class=\"centered\">3</td> </tr> <tr> <td>Others: multiple sclerosis, paraneoplastic syndrome, autoimmune encephalitis, hydrocephalus</td> <td class=\"centered\">1 case each</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Phocomelia, mild mental retardation, optic atrophy, and bilateral facial palsy.</div><div class=\"graphic_reference\">Source: Arnulf I, Zeitzer JM, File J, et al. Kleine-Levin syndrome: A systematic review of 186 cases in the literature. Brain 2005; 128:2763.</div><div id=\"graphicVersion\">Graphic 98009 Version 1.0</div></div></div>"},"98019":{"type":"graphic_diagnosticimage","displayName":"Imaging end-stage hydronephrosis","title":"End-stage hydronephrosis on pathology and CT scan","html":"<div class=\"graphic\"><div style=\"width: 744px\" class=\"figure\"><div class=\"ttl\">End-stage hydronephrosis on pathology and CT scan</div><div class=\"cntnt\"><img style=\"width:724px; height:305px;\" src=\"images/RADIOL/98019_Img_end_stg_hydronephrosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A surgical specimen of end-stage hydronephrosis shows extreme thinning of the renal parenchyma (arrow).<br />(B)&nbsp;A CT scan reconstructed in the coronal plane and shows end-stage hydronephrosis of the lower moiety of a left-sided duplex system (arrowhead). The upper moiety (arrow) shows no hydronephrosis and normal contrast excretion.<br />(C)&nbsp;A CT scan reconstructed in the coronal plane and shows end-stage hydronephrosis with a thin rim of parenchyma (arrowhead) caused by a left-sided bladder carcinoma (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 98019 Version 2.0</div></div></div>"},"98020":{"type":"graphic_diagnosticimage","displayName":"Imaging UPJ obstruction","title":"UPJ obstruction on imaging","html":"<div class=\"graphic\"><div style=\"width: 741px\" class=\"figure\"><div class=\"ttl\">UPJ obstruction on imaging</div><div class=\"cntnt\"><img style=\"width:721px; height:386px;\" src=\"images/RADIOL/98020_Imaging_UPJ_obstruction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) An ultrasound in sagittal projection shows severe hydronephrosis (asterisk).<br />(B)&nbsp;A CT scan reformatted in the coronal plane and shows severe hydronephrosis (asterisk). A dilated ureter is not present. <br />(C) A retrograde pyelogram shows severe hydronephrosis (asterisk) and a normal-sized ureter with the transition zone at the UPJ (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography; UPJ: ureteropelvic junction.</div><div id=\"graphicVersion\">Graphic 98020 Version 2.0</div></div></div>"},"98021":{"type":"graphic_diagnosticimage","displayName":"CT hydronephrosis bladder carcinoma","title":"Bladder cancer and hydronephrosis on CT","html":"<div class=\"graphic\"><div style=\"width: 743px\" class=\"figure\"><div class=\"ttl\">Bladder cancer and hydronephrosis on CT</div><div class=\"cntnt\"><img style=\"width:723px; height:394px;\" src=\"images/RADIOL/98021_CT_hydrnphrss_blddr_crcnm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) An axial CT scan through the lower pelvis shows a large left-sided bladder mass (arrowhead) impinging on the left ureteral orifice (arrow). <br />(B)&nbsp;A CT scan reformatted in the coronal plane and shows left-sided hydronephrosis (asterisk) and left hydroureter (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 98021 Version 3.0</div></div></div>"},"98022":{"type":"graphic_figure","displayName":"Capsules and ligaments of GH and AC joints - Anterior view","title":"Capsules and ligaments of glenohumeral and acromioclavicular joints: Anterior view","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Capsules and ligaments of glenohumeral and acromioclavicular joints: Anterior view</div><div class=\"cntnt\"><img style=\"width:485px; height:449px;\" src=\"images/EM/98022_AntvwcpsllgmntGHACjnt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The acromioclavicular, corocohumeral, and glenohumeral ligaments. Although shown on the external aspect of the joint capsule, the glenohumeral ligaments are actually a feature observed from the internal aspect of the joint. These ligaments strengthen the anterior aspect of the capsule of the glenohumeral joint, and the coracohumeral ligament strengthens the capsule superiorly.</div><div class=\"graphic_footnotes\">* Coracoid process&nbsp;+ coraco-acromial ligament acromion = coraco-acromial arch.</div><div class=\"graphic_reference\">Reproduced with permission from: Clinically Oriented Anatomy, 7th ed, Moore KL, Agur AM, Dalley AF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 98022 Version 4.0</div></div></div>"},"98023":{"type":"graphic_diagnosticimage","displayName":"Hydronephrosis and renal stent on CT","title":"Hydronephrosis and ureteral stent on CT urogram","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Hydronephrosis and ureteral stent on CT urogram</div><div class=\"cntnt\"><img style=\"width:720px; height:432px;\" src=\"images/RADIOL/98023_Hydronephrosis_renl_stnt_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A CT urogram shows right-sided hydronephrosis (arrowhead) with a stent in position (arrow). The bladder is distended (asterisk).<br />(B)&nbsp;A magnified view of the right-sided hydronephrosis (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 98023 Version 2.0</div></div></div>"},"98024":{"type":"graphic_diagnosticimage","displayName":"Doppler US of ureteral jets","title":"Ureteral jets on Doppler US","html":"<div class=\"graphic\"><div style=\"width: 744px\" class=\"figure\"><div class=\"ttl\">Ureteral jets on Doppler US</div><div class=\"cntnt\"><img style=\"width:724px; height:263px;\" src=\"images/RADIOL/98024_Doppler_US_ureteral_jets.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse Doppler US images of the bladder show right (A, arrow) and left (B, arrow) ureteral jets.</div><div class=\"graphic_footnotes\">US: ultrasound.</div><div id=\"graphicVersion\">Graphic 98024 Version 1.0</div></div></div>"},"98025":{"type":"graphic_picture","displayName":"Basic yoga poses","title":"Basic yoga poses","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Basic yoga poses</div><div class=\"cntnt\"><img style=\"width:494px; height:682px;\" src=\"images/PC/98025_Yoga_poses.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Warrior 1 (Virabhadrasana 1).<br />(B) Warrior 2 (Virabhadrasana 2).<br />(C) Warrior 3 (Virabhadrasana 3).<br />(D) Extended hand on the big toe (Utthita hasta padangustasana).<br />(E) Triangle (Trikonasana).<br />(F) Cobra (Bhujangasana)</div><div id=\"graphicVersion\">Graphic 98025 Version 1.0</div></div></div>"},"98026":{"type":"graphic_diagnosticimage","displayName":"CT obstructing ureterolithiais no hydronephrosis","title":"Obstructing ureterolithiasis with no hydronephrosis on CT","html":"<div class=\"graphic\"><div style=\"width: 743px\" class=\"figure\"><div class=\"ttl\">Obstructing ureterolithiasis with no hydronephrosis on CT</div><div class=\"cntnt\"><img style=\"width:723px; height:294px;\" src=\"images/RADIOL/98026_CT_obstrct_urtrlths_hydrnph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A CT scan through the kidneys shows minimal fullness of the left collecting system (arrow) but no hydronephrosis.<br />(B)&nbsp;A punctuate stone impacted in the left UVJ (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography: UVJ: ureterovesical junction.</div><div id=\"graphicVersion\">Graphic 98026 Version 2.0</div></div></div>"},"98027":{"type":"graphic_diagnosticimage","displayName":"CT peripelvic cysts","title":"Peripelvic cysts on contrast CT","html":"<div class=\"graphic\"><div style=\"width: 742px\" class=\"figure\"><div class=\"ttl\">Peripelvic cysts on contrast CT</div><div class=\"cntnt\"><img style=\"width:722px; height:379px;\" src=\"images/RADIOL/98027_CT_peripelvic_cysts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A transverse CT through the kidneys shows low-density peripelvic cysts displacing and surrounding the contrast-filled calyces (arrow).<br />(B)&nbsp;A CT scan reformatted in the coronal plane and shows an normal calyx displaced superiorly (arrow) by low-density peripelvic cysts (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 98027 Version 2.0</div></div></div>"},"98028":{"type":"graphic_picture","displayName":"Advanced yoga poses","title":"Advanced yoga poses","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Advanced yoga poses</div><div class=\"cntnt\"><img style=\"width:397px; height:794px;\" src=\"images/PC/98028_Difficult_yoga_poses.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Toe stand (Padangusthasana).<br />(B) Full lotus.<br />(C) Plow (Halasana).<br />(D) Shoulderstand (Sarvangasana).<br />(E) Headstand (Sirisasana).</div><div id=\"graphicVersion\">Graphic 98028 Version 1.0</div></div></div>"},"98029":{"type":"graphic_diagnosticimage","displayName":"CT extrarenal pelvis","title":"Extrarenal pelvis on CT","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Extrarenal pelvis on CT</div><div class=\"cntnt\"><img style=\"width:720px; height:440px;\" src=\"images/RADIOL/98029_CT_extrarenal_pelvis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) An axial CT scan through the kidneys shows bilateral extrarenal pelves (asterisks).<br />(B) A CT scan reformatted in the coronal plane shows normal cupping of the calyces (arrow) and bilateral extrarenal pelves (asterisks).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 98029 Version 2.0</div></div></div>"},"98030":{"type":"graphic_table","displayName":"IIEF questionnaire","title":"International index of erectile dysfunction (IIEF)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">International index of erectile dysfunction (IIEF)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>INSTRUCTIONS:</strong> These questions ask about your sex life <strong>over the past four weeks</strong>. Please answer the following questions as honestly and clearly as possible. In answering these questions, the following definitions apply:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li><strong>Sexual activity</strong> includes intercourse, caressing, foreplay, and masturbation </li> <li><strong>Sexual intercourse</strong> is defined as vaginal penetration of the partner (you entered your partner) </li> <li><strong>Sexual stimulation</strong> includes situations like foreplay with a partner, looking at erotic pictures, etc </li> <li><strong>Ejaculate</strong> is defined as the ejection of semen from the penis (or the feeling of this) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle1_single\">Check ONLY one box per question.</td> </tr> <tr> <td class=\"indent1\">1. <strong>Over the past four weeks</strong>, how often were you able to get an erection during sexual activity?</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 0 = No sexual activity</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 1 = Almost never or never</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 2 = A few times (much less than half the time)</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 3 = Sometimes (about half the time)</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 4 = Most times (much more than half the time)</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 5 = Almost always or always</td> </tr> <tr> <td class=\"indent1\">2. <strong>Over the past four weeks</strong>, when you had erections with sexual stimulation, how often were your erections hard enough for penetration?</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 0 = No sexual activity</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 1 = Almost never or never</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 2 = A few times (much less than half the time)</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 3 = Sometimes (about half the time)</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 4 = Most times (much more than half the time)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 5 = Almost always or always</td> </tr> <tr> <td class=\"subtitle1_single\">The next&nbsp;eight questions will ask about the erections you may have had during sexual intercourse.</td> </tr> <tr> <td class=\"indent1\">3. <strong>Over the past four weeks</strong>, when you attempted sexual intercourse, how often were you able to penetrate (enter) your partner?</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 0 = Did not attempt intercourse</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 1 = Almost never or never</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 2 = A few times (much less than half the time)</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 3 = Sometimes (about half the time)</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 4 = Most times (much more than half the time)</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 5 = Almost always or always</td> </tr> <tr> <td class=\"indent1\">4. <strong>Over the past four weeks</strong>, during sexual intercourse, <strong>how often</strong> were you able to maintain your erection after you had penetrated (entered) your partner?</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 0 = Did not attempt intercourse</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 1 = Almost never or never</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 2 = A few times (much less than half the time)</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 3 = Sometimes (about half the time)</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 4 = Most times (much more than half the time)</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 5 = Almost always or always</td> </tr> <tr> <td class=\"indent1\">5. <strong>Over the past four weeks</strong>, during sexual intercourse, <strong>how difficult</strong> was it to maintain your erection to completion of intercourse?</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 0 = Did not attempt intercourse</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 1 = Extremely difficult</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 2 = Very difficult</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 3 = Difficult</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 4 = Slightly difficult</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 5 = Not difficult</td> </tr> <tr> <td class=\"indent1\">6. <strong>Over the past four weeks</strong>, how many times have you attempted sexual intercourse?</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 0 = No attempts</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 1 = One to two attempts</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 2 = Three to four attempts</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 3 = Five to six attempts</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 4 = 7 to 10 attempts</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 5 = 11 or more attempts</td> </tr> <tr> <td class=\"indent1\">7. <strong>Over the past four weeks</strong>, when you attempted sexual intercourse, how often was it satisfactory for you?</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 0 = Did not attempt intercourse</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 1 = Almost never or never</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 2 = A few times (much less than half the time)</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 3 = Sometimes (about half the time)</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 4 = Most times (much more than half the time)</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 5 = Almost always or always</td> </tr> <tr> <td class=\"indent1\">8. <strong>Over the past four weeks</strong>, when you attempted sexual intercourse, how much have you enjoyed sexual intercourse?</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 0 = No intercourse</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 1 = No enjoyment</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 2 = Not very enjoyable</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 3 = Fairly enjoyable</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 4 = Highly enjoyable</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 5 = Very highly enjoyable</td> </tr> <tr> <td class=\"indent1\">9. <strong>Over the past four weeks</strong>, when you had sexual stimulation or intercourse, how often did you ejaculate?</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 0 = No sexual stimulation/intercourse</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 1 = Almost never or never</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 2 = A few times (much less than half the time)</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 3 = Sometimes (about half the time)</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 4 = Most times (much more than half the time)</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 5 = Almost always or always</td> </tr> <tr> <td class=\"indent1\">10. <strong>Over the past four weeks</strong>, when you had sexual stimulation or intercourse, how often did you have the feeling of orgasm or climax?</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 0 = No sexual stimulation/intercourse</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 1 = Almost never or never</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 2 = A few times (much less than half the time)</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 3 = Sometimes (about half the time)</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 4 = Most times (much more than half the time)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 5 = Almost always or always</td> </tr> <tr> <td class=\"subtitle1_single\">The next&nbsp;five questions ask about sexual desire. Let's define sexual desire as a feeling that may include wanting to have a sexual experience (for example, masturbation or intercourse), thinking about having sex, or feeling frustrated due to lack of sex.</td> </tr> <tr> <td class=\"indent1\">11. <strong>Over the past four weeks</strong>, how often have you felt <strong>sexual desire</strong>?</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 1 = Almost never or never</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 2 = A few times (much less than half the time)</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 3 = Sometimes (about half the time)</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 4 = Most times (much more than half the time)</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 5 = Almost always or always</td> </tr> <tr> <td class=\"indent1\">12. <strong>Over the past four weeks</strong>, how would you rate your level of <strong>sexual desire</strong>?</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 1 = Very low or not at all</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 2 = Low</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 3 = Moderate</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 4 = High</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 5 = Very high</td> </tr> <tr> <td class=\"indent1\">13. <strong>Over the past four weeks</strong>, how satisfied have you been with your overall <strong>sex life</strong>?</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 1 = Very dissatisfied</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 2 = Moderately dissatisfied</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 3 = About equally satisfied and dissatisfied</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 4 = Moderately satisfied</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 5 = Very satisfied</td> </tr> <tr> <td class=\"indent1\">14. <strong>Over the past four weeks</strong>, how satisfied have you been with your <strong>sexual relationship</strong> with your partner?</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 1 = Very dissatisfied</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 2 = Moderately dissatisfied</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 3 = About equally satisfied and dissatisfied</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 4 = Moderately satisfied</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 5 = Very satisfied</td> </tr> <tr> <td class=\"indent1\">15. <strong>Over the past four weeks</strong>, how do you rate your <strong>confidence</strong> that you can get and keep an erection?</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 1 = Very low</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 2 = Low</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 3 = Moderate</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 4 = High</td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> 5 = Very high</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Rosen RC, Riley A, Wagner G, et al. The international index of erectile dysfunction (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49:822. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98030 Version 2.0</div></div></div>"},"98036":{"type":"graphic_table","displayName":"Pediatric causes of hypokalemia","title":"Pediatric causes of hypokalemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pediatric causes of hypokalemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Gastrointestinal</td> </tr> <tr> <td class=\"subtitle2_single\">Increased losses (diarrhea, vomiting, nasogastric drainage)</td> </tr> <tr> <td class=\"subtitle2_single\">Decreased intake (anorexia, bulimia)</td> </tr> <tr> <td class=\"subtitle1_single\">Increased potassium intracellular uptake</td> </tr> <tr> <td class=\"subtitle2_single\">Alkalosis</td> </tr> <tr> <td class=\"subtitle2_single\">Increased insulin activity</td> </tr> <tr> <td class=\"subtitle2_single\">Beta adrenergic agents (eg, albuterol, epinephrine, dopamine)</td> </tr> <tr> <td class=\"subtitle2_single\">Periodic paralysis</td> </tr> <tr> <td class=\"indent2\">Genetic etiology</td> </tr> <tr> <td class=\"indent2\">Hyperthyroidism</td> </tr> <tr> <td class=\"subtitle2_single\">Other Drugs</td> </tr> <tr> <td class=\"indent2\">Barium</td> </tr> <tr> <td class=\"indent2\">Antipsychotic drugs</td> </tr> <tr> <td class=\"indent2\">Chloroquine</td> </tr> <tr> <td class=\"subtitle1_single\">Increased urinary losses</td> </tr> <tr> <td class=\"subtitle2_single\">Increased distal delivery of sodium to distal nephron</td> </tr> <tr> <td class=\"indent2\">Diuretics</td> </tr> <tr> <td class=\"indent2\">Osmotic diuretics (mannitol, hyperglycemia)</td> </tr> <tr> <td class=\"indent2\">Non-reabsorbed anions (elevated serum bicarbonate level)</td> </tr> <tr> <td class=\"indent2\">Tubular injury (Cisplatin)</td> </tr> <tr> <td class=\"subtitle2_single\">Types I and II renal tubular acidosis</td> </tr> <tr> <td class=\"subtitle2_single\">Increased mineralocorticoid activity</td> </tr> <tr> <td class=\"indent2\">Hyperaldosteronism due to hypovolemia</td> </tr> <tr> <td class=\"indent2\">Glucocorticoid remediable aldosteronism (GRA)</td> </tr> <tr> <td class=\"indent2\">Apparent mineralocorticoid excess (AME)</td> </tr> <tr> <td class=\"indent2\">Rare forms of congenital adrenal hyperplasia (17-alpha-hydroxylase deficiency and 11-beta-hydroxylase deficiency)</td> </tr> <tr> <td class=\"subtitle2_single\">Tubulopathies (Bartter syndrome, Gitelman syndrome)</td> </tr> <tr> <td class=\"subtitle2_single\">Amphotericin</td> </tr> <tr> <td class=\"subtitle2_single\">Enhanced sodium reabsorption (Liddle syndrome)</td> </tr> <tr> <td class=\"subtitle1_single\">Increased skin loss</td> </tr> <tr> <td class=\"subtitle2_single\">Cystic fibrosis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 98036 Version 1.0</div></div></div>"},"98037":{"type":"graphic_table","displayName":"Lab testing for pediatric hypokalemia of unknown etiology","title":"Laboratory testing for pediatric hypokalemia of unknown etiology","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory testing&nbsp;for pediatric hypokalemia of unknown etiology</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Blood tests</td> </tr> <tr> <td class=\"indent1\">Chemistries (sodium, potassium, chloride, bicarbonate, magnesium, creatinine)</td> </tr> <tr> <td class=\"indent1\">Venous pH</td> </tr> <tr> <td class=\"indent1\">Plasma renin activity</td> </tr> <tr> <td class=\"indent1\">Plasma aldosterone</td> </tr> <tr> <td class=\"subtitle1_single\">Urine tests</td> </tr> <tr> <td class=\"indent1\">Chemistries (sodium, potassium, chloride, calcium, creatinine)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 98037 Version 1.0</div></div></div>"},"98038":{"type":"graphic_figure","displayName":"Nomogram for survival of retroperitoneal soft tissue sarcoma","title":"Nomogram for survival of retroperitoneal soft tissue sarcoma","html":"<div class=\"graphic\"><div style=\"width: 793px\" class=\"figure\"><div class=\"ttl\">Nomogram for survival of retroperitoneal soft tissue sarcoma</div><div class=\"cntnt\"><img style=\"width:773px; height:496px;\" src=\"images/ONC/98038_Nmg_srv_rtrprt_sft_tss_srcm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The nomogram allows the user to obtain the seven-year OS probability corresponding to a patient's combination of covariates. For instance, locate the patient's tumor size and draw a line straight upward to the \"Points\" axis to determine the score associated with that size. Repeat the process for patient's age, FNCLCC grade, histologic subtype, multifocality, and extent of resection, then sum the scores achieved for each covariate and locate this sum on the \"Total Points\" axis. Draw a line straight down to the \"7-year OS\" axis to find the predicted probability.</div><div class=\"graphic_footnotes\">FNCLCC: French National Federation of the Centers for the Fight Against Cancer; SFT: solitary fibrous tumor; MPNST: malignant peripheral nerve sheath tumor; DD lipo: dedifferentiated liposarcoma; LMS: leiomyosarcoma; UPS: undifferentiated pleomorphic sarcoma; WD lipo: well-differentiated liposarcoma; OS overall survival.</div><div class=\"graphic_reference\">From: Gronchi A, Miceli R, Shurell E, et al. Outcome Prediction in Primary Resected Retroperitoneal Soft Tissue Sarcoma: Histology-Specific Overall Survival and Disease-Free Survival Nomograms Built on Major Sarcoma Center Data Sets. J Clin Oncol 2013; 31:1649-55. Reprinted with permission. Copyright &copy; 2013 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98038 Version 2.0</div></div></div>"},"98040":{"type":"graphic_table","displayName":"Pediatric causes of hypokalemia and acid-base disorders","title":"Pediatric causes of concomitant hypokalemia and acid-base disorders based on urinary potassium loss","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pediatric causes of concomitant hypokalemia and acid-base disorders based on urinary potassium loss</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">&nbsp;</td> <td class=\"subtitle1_single\">Low urinary potassium losses</td> <td class=\"subtitle1_single\">High urinary potassium losses</td> </tr> <tr> <td><strong>Metabolic acidosis</strong></td> <td>Diarrhea</td> <td> <p>Fanconi syndrome</p> <p>Cystinosis</p> <p>Types I and II RTA</p> Ketoacidosis</td> </tr> <tr> <td><strong>Metabolic alkalosis</strong></td> <td> <p>Vomiting</p> Chronic diuretic use</td> <td> <p><strong>With high blood pressure:</strong></p> <p class=\"indent1\">Hyperaldosteronism</p> <p><strong>With normal blood pressure:</strong></p> <p class=\"indent1\">Diuretics<br /> Vomiting<br /> Bartter syndrome<br /> Gitelman syndrome</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RTA: renal tubular acidosis.</div><div id=\"graphicVersion\">Graphic 98040 Version 1.0</div></div></div>"},"98041":{"type":"graphic_algorithm","displayName":"Diagnostic approach for etiology of pediatric hypokalemia","title":"Diagnostic approach to determine the etiology of pediatric hypokalemia","html":"<div class=\"graphic\"><div style=\"width: 695px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to determine the etiology of pediatric hypokalemia</div><div class=\"cntnt\"><img style=\"width:675px; height:527px;\" src=\"images/PEDS/98041_Dgnstc_etlgy_pdtrc_hypklm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">K: potassium; Cr: creatinine; GI: gastrointestinal; RTA: renal tubular acidosis; DKA: diabetic ketoacidosis; Aldo: aldosterone; AME: apparent mineralocorticoid excess; NG: nasogastric.</div><div id=\"graphicVersion\">Graphic 98041 Version 1.0</div></div></div>"},"98047":{"type":"graphic_figure","displayName":"DIC pathogenesis","title":"Pathogenesis of disseminated intravascular coagulation","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Pathogenesis of disseminated intravascular coagulation</div><div class=\"cntnt\"><img style=\"width:529px; height:510px;\" src=\"images/HEME/98047_DIC_pathogenesis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Text in blue refers to pathophysiologic processes; text in green denotes associated&nbsp;laboratory abnormalities. Refer to UpToDate topics on disseminated intravascular coagulation for additional details.</div><div class=\"graphic_footnotes\">NET: neutrophil extracellular trap; PT: prothrombin time; aPTT: activated partial thromboplastin time; FDPs: fibrin degradation products; dsDNA: double-stranded DNA;&nbsp;MAHA: microangiopathic hemolytic anemia.</div><div id=\"graphicVersion\">Graphic 98047 Version 3.0</div></div></div>"},"98055":{"type":"graphic_picture","displayName":"Celiac disease histology low power","title":"Celiac disease histology","html":"<div class=\"graphic\"><div style=\"width: 733px\" class=\"figure\"><div class=\"ttl\">Celiac disease histology</div><div class=\"cntnt\"><img style=\"width:713px; height:264px;\" src=\"images/GAST/98055_Celiac_diseas_hstlgy_lw_pwr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of a biopsy specimen from the third portion of the duodenum shows marked villous atrophy.</div><div class=\"graphic_reference\">Courtesy of Edward Uhlemann, MD.</div><div id=\"graphicVersion\">Graphic 98055 Version 1.0</div></div></div>"},"98056":{"type":"graphic_table","displayName":"Causes of magnesium depletion","title":"Causes of magnesium depletion","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of magnesium depletion</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"divider_bottom\" rowspan=\"6\"><strong>Gastrointestinal losses</strong></td> <td><strong>Diarrhea, malabsorption and steatorrhea, and small bowel bypass surgery</strong></td> </tr> <tr> <td><strong>Acute pancreatitis</strong></td> </tr> <tr> <td><strong>Medications</strong></td> </tr> <tr> <td class=\"indent2\">PPIs</td> </tr> <tr> <td><strong>Genetic disorders</strong></td> </tr> <tr> <td class=\"indent2 divider_bottom\">Intestinal hypomagnesemia with secondary hypocalcemia</td> </tr> <tr> <td rowspan=\"10\"><strong>Renal losses</strong></td> <td><strong>Medications</strong></td> </tr> <tr> <td class=\"indent2\"> <p>Diuretics (loop and thiazide)</p> <p>Antibiotics (aminoglycoside, amphotericin, pentamidine)</p> <p>Calcineurin inhibitors</p> <p>Cisplatin</p> Antibodies targeting epidermal growth factor (EGF) receptor (cetuximab, panitumumab, matuzumab)</td> </tr> <tr> <td><strong>Volume expansion</strong></td> </tr> <tr> <td><strong>Uncontrolled diabetes mellitus</strong></td> </tr> <tr> <td><strong>Alcoholism</strong></td> </tr> <tr> <td><strong>Hypercalcemia</strong></td> </tr> <tr> <td><strong>Acquired tubular dysfunction</strong></td> </tr> <tr> <td class=\"indent2\"> <p>Recovery from acute tubular necrosis</p> <p>Postobstructive diuresis</p> Post-renal transplantation</td> </tr> <tr> <td><strong>Genetic disorders</strong></td> </tr> <tr> <td class=\"indent2\"> <p>Bartter/Gitelman syndrome</p> <p>Familial hypomagnesemia with hypercalciuria and nephrocalcinosis</p> <p>Autosomal dominant isolated hypomagnesemia (Na-K-ATPase gamma subunit, Kv1.1 and cyclin M2 mutations)</p> <p>Autosomal recessive isolated hypomagnesemia (EGF mutation)</p> Renal malformations and early-onset diabetes mellitus (HNF1-beta mutation)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 98056 Version 1.0</div></div></div>"},"98057":{"type":"graphic_figure","displayName":"Anatomy and sequence of swallowing","title":"Anatomic structures and sequence of swallowing","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Anatomic structures and sequence of swallowing</div><div class=\"cntnt\"><img style=\"width:520px; height:658px;\" src=\"images/PEDS/98057_Anatomy_of_the_pharynx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Swallowing function can be evaluated with a videofluoroscopic swallow study (VFSS), which is interpreted in real time by a speech-language pathologist and/or radiologist with special training in the technique. The examiner assesses the duration of oral and pharyngeal transit time, characterizes pharyngeal motility, and observes for signs of swallowing abnormalities including pooling of material in the vallecula and pyriform sinuses, residue in the pharyngeal recesses, and aspiration into the tracheobronchial tree. Laryngeal penetration is noted when food or liquid extends below the laryngeal surface of the epiglottis. Deep laryngeal penetration is noted when food or liquid reaches the level of the vocal folds, and aspiration occurs when food or liquid extends below the vocal folds into the tracheobronchial tree.</div><div id=\"graphicVersion\">Graphic 98057 Version 2.0</div></div></div>"},"98058":{"type":"graphic_picture","displayName":"Biliary intraepithelial neoplasia, histologic appearance","title":"BilIN with varying degrees of cytologic atypia, ranging in severity from BilIN1 to BilIN3","html":"<div class=\"graphic\"><div style=\"width: 988px\" class=\"figure\"><div class=\"ttl\">BilIN with varying degrees of cytologic atypia, ranging in severity from BilIN1 to BilIN3</div><div class=\"cntnt\"><img style=\"width:968px; height:243px;\" src=\"images/ONC/98058_Blry_intrpthll_npls_hstlgy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) BilIN1: Flat or micropapillary architecture with basally located and relatively uniform nuclei (arrows).<br />(B) BilIN2: Pseudopapillary or micropapillary architecture with nuclear pseudostratification reaching the luminal surface (arrows). The nuclei demonstrate dysplastic nuclear changes, including enlargement, hyperchromasia, and irregular nuclear membrane. Some variations in nuclear sizes and shapes are seen (arrowheads).<br />(C) BilIN3: Pseudopapillary lesion, cytologically resembling carcinoma, but invasion through the basement membrane is absent. Loss of nuclear polarity resulting in cellular piling at luminal surface (arrows) and \"budding off\" of small clusters of cells in the lumen (arrowhead). The cells have cytologically malignant features with hyperchromasia, nuclear membrane irregularities, and large nuclei (dashed arrows).</div><div class=\"graphic_footnotes\">BilIN: biliary intraepithelial neoplasia.</div><div id=\"graphicVersion\">Graphic 98058 Version 1.0</div></div></div>"},"98059":{"type":"graphic_table","displayName":"PROMIS HRQOL domains, adult","title":"PROMIS health-related quality of life domains for adult patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">PROMIS health-related quality of life domains for adult patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Physical health</td> <td class=\"subtitle1\">Mental health</td> <td class=\"subtitle1\">Social health</td> </tr> <tr class=\"divider_bottom\"> <td><strong>PROMIS profile domains</strong></td> <td> <p>Physical function</p> <p>Pain intensity</p> <p>Pain interference</p> <p>Fatigue</p> Sleep disturbance</td> <td> <p>Depression</p> Anxiety</td> <td>Ability to participate in social roles and activities</td> </tr> <tr class=\"divider_bottom\"> <td><strong>PROMIS additional domains</strong></td> <td> <p>Pain behavior</p> <p>Pain quality</p> <p>Sleep-related impairment</p> <p>Sexual function and satisfaction</p> <p>Gastrointestinal symptoms</p> Dyspnea</td> <td> <p>Anger</p> <p>Cognitive function</p> <p>Alcohol use, consequences, and expectancies</p> <p>Smoking</p> <p>Substance abuse</p> <p>Psychosocial illness impact</p> Self-efficacy for managing chronic conditions</td> <td> <p>Satisfaction with social roles and activities</p> <p>Social support</p> <p>Social isolation</p> Companionship</td> </tr> <tr> <td><strong>PROMIS global health</strong></td> <td>Global physical health</td> <td colspan=\"2\">Global mental health</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PROMIS: Patient-Reported Outcomes Measurement Information System.</div><div class=\"graphic_reference\">&copy; 2008-2017 PROMIS Health Organization and PROMIS Cooperative Group. Reprinted with permission.</div><div id=\"graphicVersion\">Graphic 98059 Version 2.0</div></div></div>"},"98060":{"type":"graphic_table","displayName":"PROMIS HRQOL domains, pediatrics","title":"PROMIS health-related quality of life domains, pediatric patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">PROMIS health-related quality of life domains, pediatric patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Physical health</td> <td class=\"subtitle1\">Mental health</td> <td class=\"subtitle1\">Social health</td> </tr> <tr class=\"divider_bottom\"> <td><strong>PROMIS profile domains</strong></td> <td> <p>Mobility</p> <p>Upper extremity function</p> <p>Pain intensity</p> <p>Pain interference</p> Fatigue</td> <td> <p>Depressive symptoms</p> Anxiety</td> <td>Peer relationships</td> </tr> <tr class=\"divider_bottom\"> <td><strong>PROMIS additional domains</strong></td> <td> <p>Pain behavior</p> <p>Pain quality</p> <p>Physical activity</p> <p>Physical stress experiences</p> <p>Strength impact</p> <p>Asthma impact</p> </td> <td> <p>Anger</p> <p>Cognitive function</p> <p>Life satisfaction</p> <p>Meaning and purpose</p> <p>Positive affect</p> Psychological stress experiences</td> <td>Family relationships</td> </tr> <tr> <td><strong>PROMIS global health</strong></td> <td colspan=\"3\">Pediatric global health</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PROMIS: Patient-Reported Outcomes Measurement Information System.</div><div class=\"graphic_reference\">&copy; 2008-2017 PROMIS Health Organization and PROMIS Cooperative Group. Reprinted with permission.</div><div id=\"graphicVersion\">Graphic 98060 Version 2.0</div></div></div>"},"98061":{"type":"graphic_figure","displayName":"WaveCrest system","title":"WaveCrest system","html":"<div class=\"graphic\"><div style=\"width: 734px\" class=\"figure\"><div class=\"ttl\">WaveCrest system</div><div class=\"cntnt\"><img style=\"width:714px; height:399px;\" src=\"images/CARD/98061_WaveCrest_system.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2015 Coherex Medical, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98061 Version 1.0</div></div></div>"},"98064":{"type":"graphic_movie","displayName":"Fetal cardiac activity","title":"Fetal cardiac activity","html":"<div class=\"graphic normal\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">Fetal&nbsp;cardiac activity</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/OBGYN/98064_Embryoniccardiacactivvid.mp4\" style=\"width:640px;height:496px\"></div><img style=\"width:514px; height:363px;\" src=\"images/OBGYN/98064_Embryoniccardiacactivimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">10 week fetus. Heart rate&nbsp;is 160 beats/minute.</div><div class=\"graphic_reference\">Courtesy of Courtney Stephenson, MD, and Jolene Bryant.</div><div id=\"graphicVersion\">Graphic 98064 Version 2.0</div></div></div>"},"98065":{"type":"graphic_table","displayName":"IMWG criteria MGUS and related plasma-cell disorders","title":"International Myeloma Working Group diagnostic criteria and classification for monoclonal gammopathy of undetermined significance and related plasma-cell disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">International Myeloma Working Group diagnostic criteria and classification for monoclonal gammopathy of undetermined significance and related plasma-cell disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Definition</td> <td class=\"subtitle1\">Progression rate</td> <td class=\"subtitle1\">Primary progression events</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Non-IgM monoclonalgammopathy of undetermined significance</strong></td> <td> <p>Serum monoclonal protein (non-IgM type) &#60;30 g/L</p> <p>Clonal bone marrow plasma cells &#60;10%*</p> Absence of end-organ damage such as hypercalcemia, renal insufficiency, anemia, and bone lesions (CRAB) or amyloidosis that can be attributed to the plasma cell proliferative disorder</td> <td>1% per year</td> <td>Multiple myeloma, solitary plasmacytoma, immunoglobulin-related amyloidosis (AL, AHL, AH)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>IgM monoclonal gammopathy of undetermined significance</strong></td> <td> <p>Serum IgM monoclonal protein &#60;30 g/L</p> <p>Bone marrow lymphoplasmacytic infiltration &#60;10%</p> No evidence of anemia, constitutional symptoms, hyperviscosity, lymphadenopathy, hepatosplenomegaly, or other end-organ damage that can be attributed to the underlying lymphoproliferative disorder</td> <td>1.5% per year</td> <td>Waldenstr&#246;m macroglobulinemia, immunoglobulin-related amyloidosis (AL, AHL, AH)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Light-chain monoclonal gammopathy of undetermined significance</strong></td> <td> <p>Abnormal FLC ratio (&#60;0.26 or &#62;1.65)</p> <p>Increased level of the appropriate involved light chain (increased kappa FLC in patients with ratio &#62;1.65 and increased lambda FLC in patients with ratio &#60;0.26)</p> <p>No immunoglobulin heavy chain expression on immunofixation</p> <p>Absence of end-organ damage such as hypercalcemia, renal insufficiency, anemia, and bone lesions (CRAB) or amyloidosis that can be attributed to the plasma cell proliferative disorder</p> <p>Clonal bone marrow plasma cells &#60;10%</p> Urinary monoclonal protein &#60;500 mg/24 hours</td> <td>0.3% per year</td> <td>Light chain multiple myeloma, immunoglobulin light-chain amyloidosis</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Solitary plasmacytoma</strong></td> <td> <p>Biopsy-proven solitary lesion of bone or soft tissue with evidence of clonal plasma cells</p> <p>Normal bone marrow with no evidence of clonal plasma cells</p> <p>Normal skeletal survey and MRI (or CT) of spine and pelvis (except for the primary solitary lesion)</p> Absence of end-organ damage such as hypercalcemia, renal insufficiency, anemia, or bone lesions (CRAB) that can be attributed to a lymphoplasma cell proliferative disorder</td> <td>About 10% within three years</td> <td>Multiple myeloma</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Solitary plasmacytoma with minimal marrow involvement</strong><sup>&#182;</sup></td> <td> <p>Biopsy-proven solitary lesion of bone or soft tissue with evidence of clonal plasma cells</p> <p>Clonal bone marrow plasma cells &#60;10%</p> <p>Normal skeletal survey and MRI (or CT) of spine and pelvis (except for the primary solitary lesion)</p> Absence of end-organ damage such as hypercalcemia, renal insufficiency, anemia, or bone lesions (CRAB) that can be attributed to a lymphoplasma cell proliferative disorder</td> <td>60% (bone) or 20% (soft tissue) within three years</td> <td>Multiple myeloma</td> </tr> <tr class=\"divider_bottom\"> <td><strong>POEMS syndrome</strong><sup>&#916;</sup></td> <td> <p>Polyneuropathy</p> <p>Monoclonal plasma cell proliferative disorder (almost always lambda)</p> <p>Any one of the following three other major criteria:</p> <p class=\"indent1\">Sclerotic bone lesions<br /> Castleman's disease<br /> Elevated levels of VEGFA<sup>&#9674;</sup></p> <p>Any one of the following six minor criteria:</p> <p class=\"indent1\">Organomegaly (splenomegaly, hepatomegaly, or lymphadenopathy)<br /> Extravascular volume overload (edema, pleural effusion, or ascites)<br /> Endocrinopathy (adrenal, thyroid, pituitary, gonadal, parathyroid, pancreatic)<sup>&#167;</sup><br /> Skin changes (hyperpigmentation, hypertrichosis, glomeruloid hemangiomata, plethora, acrocyanosis, flushing, white nails)<br /> Papilledema<br /> Thrombocytosis/polycythemia</p> </td> <td>NA</td> <td>NA</td> </tr> <tr> <td><strong>Systemic AL amyloidosis</strong><sup>&#165;</sup><sup>&#135;</sup></td> <td> <p>Presence of an amyloid-related systemic syndrome (eg, renal, liver, heart, gastrointestinal tract, or peripheral nerve involvement)</p> <p>Positive amyloid staining by Congo red in any tissue (eg, fat aspirate, bone marrow, or organ biopsy)</p> <p>Evidence that amyloid is light-chain-related established by direct examination of the amyloid using mass spectrometry-based proteomic analysis, or immunoelectronmicroscopy, <strong>and</strong></p> Evidence of a monoclonal plasma cell proliferative disorder (serum or urine monoclonal protein, abnormal free light-chain ratio, or clonal plasma cells in the bone marrow)</td> <td>NA</td> <td>Some patients might develop multiple myeloma</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgM: immunoglobulin M; AL: immunoglobulin light-chain amyloidosis; AHL: immunoglobulin heavy and light-chain amyloidosis; AH: immunoglobulin heavy chain amyloidosis; FLC: free light chain. MRI: magnetic resonance imaging; CT: computed tomography; POEMS: polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes; VEGFA: vascular endothelial growth factor A; NA: not applicable.<br />* Bone marrow can be deferred in patients with low-risk monoclonal gammopathy of undetermined significance (IgG type, monoclonal protein &lt;15 g/L, normal free light-chain ratio) in whom there are no clinical features concerning for myeloma. <br />¶ Solitary plasmacytoma with 10% or more clonal plasma cells is regarded as multiple myeloma.<br />Δ Not every patient meeting these criteria will have POEMS syndrome; the features should have a temporal association with each other and no other attributable cause. Anemia or thrombocytopenia are distinctively unusual in this syndrome unless Castleman's disease is present.<br /><FONT class=lozenge>◊</FONT> The source data do not define an optimal cutoff value for considering elevated VEGFA level as a major criterion. We suggest that VEGFA measured in the serum or plasma should be at least three to four times higher than the normal reference range for the laboratory that is doing the testing to be regarded as a major criterion.<br />§ To regard endocrinopathy as a minor criterion, an endocrine disorder other than diabetes or hypothyroidism is required because these two disorders are common in the general population.<br />¥ Patients with AL amyloidosis who also meet criteria for multiple myeloma are considered to have both diseases.<br />‡ Approximately 2 to 3% of patients with AL amyloidosis will not meet the requirement for evidence.</div><div class=\"graphic_reference\">Reproduced from: Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15:e538. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98065 Version 1.0</div></div></div>"},"98068":{"type":"graphic_table","displayName":"ACE: Strategies for coping with smoking triggers","title":"ACE: Avoid, Change, Escape. Strategies for coping with smoking triggers.","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACE: Avoid, Change, Escape. Strategies for coping with smoking triggers.</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Strategy</td> <td class=\"subtitle1\">Helpful statements</td> <td class=\"subtitle1\">Helpful questions </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Avoid</strong> - staying away from high-risk environments</td> <td>As smokers prepare or try to quit, it is sometimes helpful to avoid people, places, and events that may tempt them to smoke.</td> <td> <p>What are the things that trigger you to smoke?</p> Which of these do you think you can avoid over the next week or so?</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Change</strong> - altering a high-risk situation</td> <td>Sometimes it's not possible to avoid the things that trigger smoking. But another option is to change the situation, even a little, so that you feel less tempted to smoke.</td> <td> <p>What are a couple of situations that trigger your smoking but that may be hard to avoid?</p> What can you do to change the situation to make smoking less tempting?</td> </tr> <tr> <td><strong>Escape</strong> - planning how to excuse oneself from high-risk situations</td> <td>Sometimes, situations catch you by surprise. Staying in the situation can make it too tempting to smoke. In these cases, another option may be to leave the situation.</td> <td> <p>Did you find yourself lately in a situation like this?</p> <p>What happened?</p> <p>Would leaving have been an option?</p> What would it be like to leave?</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 98068 Version 1.0</div></div></div>"},"98069":{"type":"graphic_figure","displayName":"Round ligament technique vaginal BSO","title":"Round ligament technique for vaginal salpingo-oophorectomy","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Round ligament technique for vaginal salpingo-oophorectomy</div><div class=\"cntnt\"><img style=\"width:530px; height:281px;\" src=\"images/OBGYN/98069_Round_ligament_technique_vaginal_BSO.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from: Mayo Foundation for Medical Education and Research.</div><div id=\"graphicVersion\">Graphic 98069 Version 1.0</div></div></div>"},"98070":{"type":"graphic_diagnosticimage","displayName":"Ovarian remnant pelvic mass CT","title":"Ovarian remnant after oophorectomy as pelvic mass: Computed tomography","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">Ovarian remnant after oophorectomy as pelvic mass: Computed tomography</div><div class=\"cntnt\"><img style=\"width:570px; height:370px;\" src=\"images/OBGYN/98070_Ovarian_rmnnt_plvc_mass_CT.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 98070 Version 1.0</div></div></div>"},"98071":{"type":"graphic_diagnosticimage","displayName":"Ovarian remnant US","title":"Ovarian remnant: Pelvic ultrasound","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">Ovarian remnant: Pelvic ultrasound</div><div class=\"cntnt\"><img style=\"width:570px; height:283px;\" src=\"images/OBGYN/98071_Ovarian_remnant_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transvaginal ultrasound reveals a multicystic lesion superior to the vaginal cuff in a patient who has had a previous bilateral salpingo-oophorectomy. Doppler studies reveal flow to the mass.</div><div id=\"graphicVersion\">Graphic 98071 Version 1.0</div></div></div>"},"98072":{"type":"graphic_diagnosticimage","displayName":"Ovarian remnant clomiphene","title":"Ovarian remnant: clomiphene provocation on ultrasound","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Ovarian remnant: clomiphene provocation on ultrasound</div><div class=\"cntnt\"><img style=\"width:580px; height:693px;\" src=\"images/OBGYN/98072_Ovarian_remnant_clomiphene.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Pelvic ultrasound of patient with ovarian remnant after oophorectomy, before administration of clomiphene citrate.<br />(B) After administration of clomiphene citrate, pelvic mass is detected.</div><div id=\"graphicVersion\">Graphic 98072 Version 1.0</div></div></div>"},"98073":{"type":"graphic_picture","displayName":"Ovarian remnant gross appearance","title":"Ovarian remnant: gross appearance","html":"<div class=\"graphic\"><div style=\"width: 637px\" class=\"figure\"><div class=\"ttl\">Ovarian remnant: gross appearance</div><div class=\"cntnt\"><img style=\"width:617px; height:375px;\" src=\"images/OBGYN/98073_Ovarian_remnant_grss_apprnc.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Kho RM, Magrina JF, Magtibay PM. Pathologic findings and outcomes of a minimally invasive approach to ovarian remnant syndrome. Fertil Steril 2007; 87:1005. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98073 Version 1.0</div></div></div>"},"98074":{"type":"graphic_picture","displayName":"Ovarian remnant surgical excision","title":"Ovarian remnant: surgical excision","html":"<div class=\"graphic\"><div style=\"width: 637px\" class=\"figure\"><div class=\"ttl\">Ovarian remnant: surgical excision</div><div class=\"cntnt\"><img style=\"width:617px; height:453px;\" src=\"images/OBGYN/98074_Ovarian_remnant_srgcl_excsn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Entering the retroperitoneum at the level of the pelvic brim where the infundibulopelvic ligament can be isolated from the ureter.</div><div class=\"graphic_reference\">Reproduced from: Kho RM, Magrina JF, Magtibay PM. Pathologic findings and outcomes of a minimally invasive approach to ovarian remnant syndrome. Fertil Steril 2007; 87:1005. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98074 Version 1.0</div></div></div>"},"98079":{"type":"graphic_picture","displayName":"Knodell marked interface hepatitis","title":"Knodell score: Marked interface hepatitis","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Knodell score: Marked interface hepatitis</div><div class=\"cntnt\"><img style=\"width:712px; height:524px;\" src=\"images/GAST/98079_Knodell_mrk_intrface_hptt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Marked interface hepatitis with &gt;50% of the portal tract circumference involved. Despite the mild portal inflammation, the entire portal tract circumference is eroded by inflammatory cells spilling over into the surrounding lobules (denoted by arrows).</div><div id=\"graphicVersion\">Graphic 98079 Version 1.0</div></div></div>"},"98083":{"type":"graphic_table","displayName":"Antibiotics for bacteriuria in pregnancy","title":"Antibiotics for asymptomatic bacteriuria and cystitis in pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antibiotics for asymptomatic bacteriuria and cystitis in pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antibiotic</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Duration</td> <td class=\"subtitle1\">Notes</td> </tr> <tr class=\"divider_bottom\"> <td>Nitrofurantoin</td> <td>100 mg orally every 12 hours</td> <td>Five to seven days</td> <td> <p>Does not achieve therapeutic levels in the kidneys so should not be used if pyelonephritis is suspected.</p> Avoid use during the first trimester and at term if other options are available.</td> </tr> <tr class=\"divider_bottom\"> <td>Amoxicillin</td> <td> <p>500 mg orally every 8 hours or</p> <p>875 mg orally every 12 hours</p> </td> <td>Three to seven days</td> <td>Resistance may limit its utility among gram-negative pathogens.</td> </tr> <tr class=\"divider_bottom\"> <td>Amoxicillin-clavulanate</td> <td>500 mg orally every 8 hours or <br /> 875 mg orally every 12 hours</td> <td>Three to seven days</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Cephalexin</td> <td>500 mg orally every 6 hours</td> <td>Three to seven days</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Cefpodoxime</td> <td>100 mg orally every 12 hours</td> <td>Three to seven days</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Fosfomycin</td> <td>3 g orally as single dose</td> <td>&nbsp;</td> <td>Does not achieve therapeutic levels in the kidneys so should not be used if pyelonephritis is suspected.</td> </tr> <tr> <td>Trimethoprim-sulfamethoxazole</td> <td>800/160 mg (one double strength tablet) every 12 hours</td> <td>Three days</td> <td>Avoid during the first trimester and at term.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The durations listed in the table are based on data from studies conducted in both nonpregnant and pregnant women.</div><div id=\"graphicVersion\">Graphic 98083 Version 5.0</div></div></div>"},"98088":{"type":"graphic_table","displayName":"Differential diagnosis of onchocerciasis","title":"Differential diagnosis of onchocerciasis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of onchocerciasis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Category of onchocercal skin disease</td> <td class=\"subtitle1\">Main differential diagnosis</td> <td class=\"subtitle1\">Distinguishing features and remarks</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Acute papular onchodermatitis (APOD)</td> <td>Miliaria</td> <td>APOD vesicles are larger and more widely scattered over the trunk, whereas miliaria is usually limited to flexural sites.</td> </tr> <tr class=\"divider_bottom\"> <td>Bites of <em>Simulium</em> and other insects</td> <td>These papules are small, closely clustered and many have a tangential punctum.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Chronic papular onchodermatitis (CPOD)</td> <td>Scabies*</td> <td>Involvement of extremities and presence of burrows (thin, grayish, reddish, or brownish lines that are 2 to 15 mm long) indicate scabies. Examine other family members.</td> </tr> <tr class=\"divider_bottom\"> <td>Eczema<sup>&#182;</sup></td> <td>Eczema is rarely limited to the buttocks, the commonest site for CPOD. The flat-topped papules of CPOD are characteristic.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Lichenified onchodermatitis (LOD)</td> <td>Lichenified eczema</td> <td class=\"divider_bottom\" rowspan=\"2\">Eczema and scabies tend to be symmetrical, unlike LOD which may be limited to one limb.</td> </tr> <tr class=\"divider_bottom\"> <td>Lichenification secondary to chronic scabies</td> </tr> <tr class=\"divider_bottom\"> <td>Atrophy</td> <td>Senile atrophy</td> <td>Atrophy associated with old age is usually generalised, whereas onchocercal atrophy may be limited to a particular region (e.g. the buttocks). Reserve a clinical diagnosis of onchocercal atrophy to patients &#60;50 years.</td> </tr> <tr> <td rowspan=\"2\">Depigmentation</td> <td>Other post-inflammatory/post-traumatic hypopigmentation</td> <td>The shins are common sites for trauma. Onchocercal depigmentation is often quite extensive and bilateral with \"spots\" of normally pigmented skin centred around hair follicles.</td> </tr> <tr> <td>Repigmenting vitiligo</td> <td>Vitiligo typically begins in an acrofacial distribution. Repigmentation of patches of vitiligo may give a \"spotty\" appearance initially.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Refer to the UpToDate topics on scabies, section on typical infestation, and the etiology and patient evaluation of pruritus.<br />¶ Refer to the UpToDate topic on the epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema).</div><div class=\"graphic_reference\">From: Murdoch ME, Hay RJ, Mackenzie CD, et al. A clinical classification and grading system of the cutaneous changes in onchocerciasis. Br J Dermatol 1993; 129:260. <A spellcheck=true href=\"http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2133.1993.tb11844.x/abstract\" target=_blank>http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2133.1993.tb11844.x/abstract</A>. Copyright © 1993 British Association of Dermatologists. Modified and reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <A spellcheck=true href=\"mailto:permissions@wiley.com\" target=_blank>permissions@wiley.com</A> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<A spellcheck=true href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 98088 Version 1.0</div></div></div>"},"98092":{"type":"graphic_table","displayName":"Indications to test for HCV infection","title":"Indications to test for hepatitis C virus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications to test for hepatitis C virus</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinical suspicion</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Clinical or biochemical evidence of chronic liver disease (eg, persistently elevated alanine aminotransferase)</li> <li>Extrahepatic manifestations of chronic HCV infection, including: <ul> <li>Porphyria cutanea tarda</li> <li>Mixed cryoglobulinemia</li> <li>Lichen planus</li> <li>Necrolytic acral erythema</li> <li>Unexplained arthritis or false positive rheumatoid factor</li> <li>Sj&#246;gren's syndrome/sicca symptoms</li> <li>Membranoproliferative glomerulonephritis</li> <li>Idiopathic thrombocytopenic purpura</li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">History of illicit injection or intranasal drug use, even if only once</td> </tr> <tr> <td class=\"subtitle1_single\">Receipt of potentially contaminated blood products or tissue</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Receipt of clotting factors made prior to the introduction of sensitive screening of the supply (1987 in the United States)</li> <li>Receipt of blood or organs prior to the introduction of sensitive screening of the supply (July 1992 in the United States)</li> <li>Receipt of blood from a donor later diagnosed with HCV</li> <li>Other risk for receipt of potentially contaminated blood products (eg, care in neonatal intensive care prior to sensitive screening)</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Belonging to a high prevalence group</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Born between 1945 and 1965 and living in the United States</li> <li>HIV-infected</li> <li>Men who have sex with men (MSM)</li> <li>Past or present use of chronic hemodialysis</li> <li>History of or present incarceration</li> <li>Residence in or immigration from a high prevalence region</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Other potential exposure to HCV</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Birth to HCV-infected mother (or international adoptee from a high prevalence region)</li> <li>Current sexual partnership with an HCV-infected individual</li> <li>Needle stick injury or mucosal exposure to HCV-infected blood</li> <li>Percutaneous exposure in unregulated setting</li> </ul> </td> </tr> <tr> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\"><strong>Potential for transmission (eg, planned organ donation)</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HCV: hepatitis C virus; HIV: human immunodeficiency virus.</div><div id=\"graphicVersion\">Graphic 98092 Version 8.0</div></div></div>"},"98097":{"type":"graphic_table","displayName":"METAVIR score","title":"METAVIR fibrosis and activity score","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">METAVIR fibrosis and activity score</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">METAVIR fibrosis score</td> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">METAVIR activity score</td> <td class=\"subtitle1\">&nbsp;</td> </tr> <tr> <td>No fibrosis</td> <td class=\"centered\">F0</td> <td>No activity</td> <td class=\"centered\">A0</td> </tr> <tr> <td>Portal fibrosis without septa</td> <td class=\"centered\">F1</td> <td>Mild activity</td> <td class=\"centered\">A1</td> </tr> <tr> <td>Portal fibrosis with few septa</td> <td class=\"centered\">F2</td> <td>Moderate activity</td> <td class=\"centered\">A2</td> </tr> <tr> <td>Portal fibrosis with numerous septa without cirrhosis</td> <td class=\"centered\">F3</td> <td>Severe activity</td> <td class=\"centered\">A3</td> </tr> <tr> <td>Cirrhosis</td> <td class=\"centered\">F4</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 29:15.</li>&#xD;&#xA;    <li>Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24:289.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 98097 Version 1.0</div></div></div>"},"98098":{"type":"graphic_diagnosticimage","displayName":"Iliac horns in nail-patella syndrome","title":"Bilateral iliac horns in a patient with nail-patella syndrome","html":"<div class=\"graphic\"><div style=\"width: 792px\" class=\"figure\"><div class=\"ttl\">Bilateral iliac horns in a patient with nail-patella syndrome</div><div class=\"cntnt\"><img style=\"width:772px; height:654px;\" src=\"images/PEDS/98098_Ilc_hrns_nl_ptll_syndrm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiograph showing bilateral iliac horns (arrow) in a patient with nail-patella syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: Clinical pediatric nephrology, 2nd ed, Kher KK, Schnaper HW, Makker SP (Eds), Informa UK Ltd, London 2007. Copyright &copy; 2007 Informa UK Ltd.</div><div id=\"graphicVersion\">Graphic 98098 Version 1.0</div></div></div>"},"98099":{"type":"graphic_table","displayName":"Ishak inflammation score","title":"Ishak score (modified Knodell score)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ishak score (modified Knodell score)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"80%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">A. Periportal or periseptal interface hepatitis (piecemeal necrosis)</td> <td class=\"subtitle1\">Score</td> </tr> <tr> <td>Mild (focal, few portal areas)</td> <td class=\"centered\">0</td> </tr> <tr> <td>Mild/moderate (focal, most portal areas)</td> <td class=\"centered\">1</td> </tr> <tr> <td>Moderate (continuous around &#60;50% of tracts or septa)</td> <td class=\"centered\">2</td> </tr> <tr> <td>Severe (continuous around &#60;50% of tracts or septa)</td> <td class=\"centered\">3</td> </tr> <tr> <td>Severe (continuous around &#60;50% tracts or septa)</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"subtitle1\">B. Confluent necrosis</td> <td class=\"subtitle1\">&nbsp;</td> </tr> <tr> <td>Absent</td> <td class=\"centered\">0</td> </tr> <tr> <td>Focal confluent necrosis</td> <td class=\"centered\">1</td> </tr> <tr> <td>Zone 3 necrosis in some areas</td> <td class=\"centered\">2</td> </tr> <tr> <td>Zone 3 necrosis in most areas</td> <td class=\"centered\">3</td> </tr> <tr> <td>Zone 3 necrosis + occasional portal-central bridging</td> <td class=\"centered\">4</td> </tr> <tr> <td>Zone 3 necrosis + multiple portal-central bridging</td> <td class=\"centered\">5</td> </tr> <tr> <td>Panacinar or multiacinar necrosis</td> <td class=\"centered\">6</td> </tr> <tr> <td class=\"subtitle1\">C. Focal (spotty) lytic necrosis, apoptosis, and focal inflammation</td> <td class=\"subtitle1\">&nbsp;</td> </tr> <tr> <td>Absent</td> <td class=\"centered\">0</td> </tr> <tr> <td>One focus or less per 10X objective</td> <td class=\"centered\">1</td> </tr> <tr> <td>Two to four foci per 10X objective</td> <td class=\"centered\">2</td> </tr> <tr> <td>5 to 10 foci per 10X objective</td> <td class=\"centered\">3</td> </tr> <tr> <td>More than 10 foci per 10X objective</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"subtitle1\">D. Portal inflammation</td> <td class=\"subtitle1\">&nbsp;</td> </tr> <tr> <td>None</td> <td class=\"centered\">0</td> </tr> <tr> <td>Mild, some or all portal areas</td> <td class=\"centered\">1</td> </tr> <tr> <td>Moderate, some or all portal areas</td> <td class=\"centered\">2</td> </tr> <tr> <td>Moderate/marked, all portal areas</td> <td class=\"centered\">3</td> </tr> <tr> <td>Marked, all portal areas</td> <td class=\"centered\">4</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 98099 Version 1.0</div></div></div>"},"98100":{"type":"graphic_picture","displayName":"Nail dysplasia: Nail-patella syndrome","title":"Nail dysplasia in a patient with nail-patella syndrome","html":"<div class=\"graphic\"><div style=\"width: 818px\" class=\"figure\"><div class=\"ttl\">Nail dysplasia in a patient with nail-patella syndrome</div><div class=\"cntnt\"><img style=\"width:798px; height:378px;\" src=\"images/PEDS/98100_Nl_dyspls_nl_ptll_syndrm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nail dysplasia in patients with nail-patella syndrome.<br />(A) Photograph demonstrating increasing severity of nail dysplasia from the thumb (most severely affected)&nbsp;to the fifth finger (least affected). There is also clinodactyly&nbsp;and swan neck deformity of the fifth finger.<br />(B) Close-up of nail dysplasia.</div><div class=\"graphic_reference\">Panel A reproduced with permission from: Clinical pediatric nephrology, 2nd ed, Kher KK, Schnaper HW, Makker SP (Eds), Informa UK Ltd, London 2007. Copyright &copy; 2007 Informa UK Ltd.<br />Panel B reproduced with permission from <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98100 Version 3.0</div></div></div>"},"98101":{"type":"graphic_table","displayName":"Ishak fibrosis stage","title":"Ishak staging: Architectural changes, fibrosis, cirrhosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ishak staging: Architectural changes, fibrosis, cirrhosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"80%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Change</td> <td class=\"subtitle1\">Score</td> </tr> <tr> <td>No fibrosis</td> <td class=\"centered\">0</td> </tr> <tr> <td>Fibrous expansion of some portal areas, with or without short fibrous septa</td> <td class=\"centered\">1</td> </tr> <tr> <td>Fibrous expansion of most portal areas, with or without short fibrous septa</td> <td class=\"centered\">2</td> </tr> <tr> <td>Fibrous expansion of most portal areas, with occasional portal to portal bridging</td> <td class=\"centered\">3</td> </tr> <tr> <td>Fibrous expansion of portal areas with marked bridging (portal to portal) as well as portal to central</td> <td class=\"centered\">4</td> </tr> <tr> <td>Marked bridging (portal to portal and/or portal to central) with occasional nodules (incomplete cirrhosis)</td> <td class=\"centered\">5</td> </tr> <tr> <td>Cirrhosis, probable or definite </td> <td class=\"centered\">6</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 98101 Version 1.0</div></div></div>"},"98102":{"type":"graphic_table","displayName":"Scheuer system hepatitis","title":"Scheuer system for scoring necroinflammatory activity and fibrosis in chronic hepatitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Scheuer system for scoring necroinflammatory activity and fibrosis in chronic hepatitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"26%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup width=\"26%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Grade</td> <td class=\"subtitle1\">Portal/periportal activity</td> <td class=\"subtitle1\">Lobular activity</td> <td class=\"subtitle1\">Grade</td> <td class=\"subtitle1\">Fibrosis</td> </tr> <tr> <td class=\"centered\">0</td> <td>None </td> <td>None</td> <td class=\"centered\">0</td> <td>None</td> </tr> <tr> <td class=\"centered\">1</td> <td>Minimal portal inflammation</td> <td>Inflammation but no necrosis</td> <td class=\"centered\">1</td> <td>Enlarged fibrotic portal tracts</td> </tr> <tr> <td class=\"centered\">2</td> <td>Mild piecemeal necrosis</td> <td>Focal necrosis or acidophil bodies</td> <td class=\"centered\">2</td> <td>Periportal or portal-portal septa but intact architecture</td> </tr> <tr> <td class=\"centered\">3</td> <td>Moderate piecemeal necrosis</td> <td>Severe focal cell damage</td> <td class=\"centered\">3</td> <td>Fibrosis with architectural distortion but no obvious cirrhosis</td> </tr> <tr> <td class=\"centered\">4</td> <td>Severe piecemeal necrosis</td> <td>Damage includes bridging necrosis</td> <td class=\"centered\">4</td> <td>Probable or definite cirrhosis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 98102 Version 1.0</div></div></div>"},"98103":{"type":"graphic_table","displayName":"Batts-Ludwig grading and staging","title":"Batts-Ludwig system for grading and staging hepatic inflammation and fibrosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Batts-Ludwig system for grading and staging hepatic inflammation and fibrosis</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Grading terminology</td> <td class=\"subtitle1\" colspan=\"2\">Criteria</td> </tr> <tr> <td class=\"centered\">Semiquantitative</td> <td>Descriptive</td> <td>Lymphocytic piecemeal necrosis</td> <td>Lobular inflammation and necrosis</td> </tr> <tr> <td class=\"centered\">0</td> <td>No activity</td> <td>None</td> <td>None</td> </tr> <tr> <td class=\"centered\">1</td> <td>Minimal activity</td> <td>Minimal, patchy</td> <td>Minimal: occasional spotty necrosis</td> </tr> <tr> <td class=\"centered\">2</td> <td>Mild activity</td> <td>Mild, involving some or all portal tracts</td> <td>Mild: little hepatocellular damage</td> </tr> <tr> <td class=\"centered\">3</td> <td>Moderate activity</td> <td>Moderate, involving all portal tracts</td> <td>Moderate:&nbsp; noticeable hepatocellular change</td> </tr> <tr> <td class=\"centered\">4</td> <td>Severe activity</td> <td>Severe, may have bridging necrosis</td> <td>Severe:&nbsp; prominent diffuse hepatocellular damage</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\">Semiquantitative</td> <td class=\"subtitle1\">Descriptive</td> <td class=\"subtitle1\">Criteria</td> </tr> <tr> <td class=\"centered\">0</td> <td>No fibrosis</td> <td>Normal connective tissue</td> </tr> <tr> <td class=\"centered\">1</td> <td>Portal fibrosis</td> <td>Fibrous portal expansion</td> </tr> <tr> <td class=\"centered\">2</td> <td>Periportal fibrosis</td> <td>Periportal or rare portal-portal septa</td> </tr> <tr> <td class=\"centered\">3</td> <td>Septal fibrosis</td> <td>Fibrous septa with architectural distortion; no obvious cirrhosis</td> </tr> <tr> <td class=\"centered\">4</td> <td>Cirrhosis</td> <td>Cirrhosis</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 98103 Version 1.0</div></div></div>"},"98104":{"type":"graphic_table","displayName":"Laennec stage cirrhosis","title":"Laennec staging of cirrhosis (METAVIR F4)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laennec staging of cirrhosis (METAVIR F4)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Laennec stage</td> <td class=\"subtitle1\">Criteria</td> </tr> <tr> <td class=\"centered\">4A</td> <td>Nodules enclosed by thin fibrous septa</td> </tr> <tr> <td class=\"centered\">4B</td> <td>Nodules enclosed by broad fibrous septa</td> </tr> <tr> <td class=\"centered\">4C</td> <td>Very broad fibrous septa with more than half of the biopsy comprised of micronodules</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 98104 Version 1.0</div></div></div>"},"98105":{"type":"graphic_table","displayName":"NASH grading and staging","title":"Nonalcoholic steatohepatitis grading and staging system","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nonalcoholic steatohepatitis grading and staging system</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Grade</td> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">&nbsp;</td> </tr> <tr> <td class=\"centered\">Mild (grade 1)</td> <td>Steatosis (predominantly macrovesicular) involving up to 66% of biopsy; may see occasional ballooned zone 3 hepatocytes; scattered intra-acinar polymorphonuclear cells, intra-acinar lymphocytes; no or mild portal chronic inflammation.</td> <td class=\"centered\">Stage I</td> <td>Zone 3 perisinusoidal/pericellular fibrosis; focally or extensively present.</td> </tr> <tr> <td class=\"centered\">Moderate (grade 2)</td> <td>Steatosis of any degree; ballooning of hepatocytes (predominantly zone 3) obvious; intra-acinar&nbsp;polymorphonuclear cells&nbsp;noted, may be associated with zone 3 pericellular fibrosis; portal and intra-acinar chronic inflammation noted, mild to moderate.</td> <td class=\"centered\">Stage II</td> <td>Zone 3 perisinusoidal/pericellular fibrosis with focal or extensive periportal fibrosis.</td> </tr> <tr> <td class=\"centered\">Severe (grade 3)</td> <td>Panacinar steatosis; ballooning and disarray obvious, predominantly in zone 3; intra-acinar inflammation noted as scattered polymorphonuclear cells, ballooned hepatocytes, mild chronic inflammation; portal chronic inflammation mild or moderate.</td> <td class=\"centered\">Stage III</td> <td>Zone 3 perisinusoidal/pericellular fibrosis and portal fibrosis with focal or extensive bridging fibrosis.</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td class=\"centered\">Stage IV</td> <td>Cirrhosis.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted by permission from Macmillan Publishers Ltd: American Journal of Gastroenterology. Brunt EM, Janney CG, DiBisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94:2467. Copyright &copy; 1999. <a href=\"http://www.nature.com/ajg\" spellcheck=\"true\" target=\"_blank\">www.nature.com/ajg</a>.</div><div id=\"graphicVersion\">Graphic 98105 Version 1.0</div></div></div>"},"98106":{"type":"graphic_picture","displayName":"Eruptive pseudoangiomatosis","title":"Eruptive pseudoangiomatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eruptive pseudoangiomatosis</div><div class=\"cntnt\"><img style=\"width:395px; height:267px;\" src=\"images/DERM/98106_Eruptive_pseudoangiomatosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Moise L Levy, MD.</div><div id=\"graphicVersion\">Graphic 98106 Version 1.0</div></div></div>"},"98133":{"type":"graphic_table","displayName":"Contributing issues to cancer-related fatigue","title":"Contributing issues to cancer-related fatigue","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contributing issues to cancer-related fatigue</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Cancer therapy</td> </tr> <tr> <td class=\"indent1\">Chemotherapy</td> </tr> <tr> <td class=\"indent1\">Biologics, molecularly targeted agents, hormone therapy</td> </tr> <tr> <td class=\"indent1\">Surgery</td> </tr> <tr> <td class=\"indent1\">Radiation therapy</td> </tr> <tr> <td class=\"subtitle1_single\">Symptom burden</td> </tr> <tr> <td class=\"indent1\">Pain</td> </tr> <tr> <td class=\"indent1\">Anxiety</td> </tr> <tr> <td class=\"indent1\">Depression</td> </tr> <tr> <td class=\"indent1\">Sleep dysfunction</td> </tr> <tr> <td class=\"subtitle1_single\">Anemia</td> </tr> <tr> <td class=\"subtitle1_single\">Medications</td> </tr> <tr> <td class=\"indent1\">Analgesics (opioids)</td> </tr> <tr> <td class=\"indent1\">Sedating agents (hypnotics, neuropathic agents, antiemetics, etc.)</td> </tr> <tr> <td class=\"indent1\">Beta-blockers</td> </tr> <tr> <td class=\"indent1\">Other drugs</td> </tr> <tr> <td class=\"indent1\">Drug-drug interactions</td> </tr> <tr> <td class=\"subtitle1_single\">Nutritional and fluid imbalances</td> </tr> <tr> <td class=\"indent1\">Weight loss</td> </tr> <tr> <td class=\"indent1\">Changes in caloric intake</td> </tr> <tr> <td class=\"indent1\">Fluid and electrolyte imbalances</td> </tr> <tr> <td class=\"indent1\">Gastrointestinal tract motility disorders</td> </tr> <tr> <td class=\"subtitle1_single\">Medical comorbidities</td> </tr> <tr> <td class=\"indent1\">Infection</td> </tr> <tr> <td class=\"indent1\">Cardiopulmonary disorders</td> </tr> <tr> <td class=\"indent1\">Connective tissue diseases</td> </tr> <tr> <td class=\"indent1\">Renal dysfunction</td> </tr> <tr> <td class=\"indent1\">Hepatic dysfunction</td> </tr> <tr> <td class=\"indent1\">Neurologic dysfunction</td> </tr> <tr> <td class=\"indent1\">Endocrinopathies</td> </tr> <tr> <td class=\"indent2\">Hypothyroidism</td> </tr> <tr> <td class=\"indent2\">Hypogonadism</td> </tr> <tr> <td class=\"indent2\">Diabetes mellitus</td> </tr> <tr> <td class=\"indent2\">Adrenal insufficiency</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 98133 Version 2.0</div></div></div>"},"98135":{"type":"graphic_table","displayName":"NAFLD activity score","title":"Nonalcoholic fatty liver disease activity score (NAS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nonalcoholic fatty liver disease activity score (NAS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Feature</td> <td class=\"subtitle1\">Points</td> <td class=\"subtitle1\">Criteria</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">A. Steatosis</td> <td class=\"centered\">0</td> <td>&#60;5%</td> </tr> <tr> <td class=\"centered\">1</td> <td>5 to 33%</td> </tr> <tr> <td class=\"centered\">2</td> <td>&#62;33 to 66%</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">3</td> <td>&#62;66%</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">B. Lobular inflammation</td> <td class=\"centered\">0</td> <td>None</td> </tr> <tr> <td class=\"centered\">1</td> <td>&#60;2 foci per 200X field</td> </tr> <tr> <td class=\"centered\">2</td> <td>2 to 4 foci per 200X field</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">3</td> <td>&#62;4 foci per 200X field</td> </tr> <tr> <td rowspan=\"3\">C. Ballooning</td> <td class=\"centered\">0</td> <td>None</td> </tr> <tr> <td class=\"centered\">1</td> <td>Few ballooning cells</td> </tr> <tr> <td class=\"centered\">2</td> <td>Many cells/prominent ballooning</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 98135 Version 1.0</div></div></div>"},"98136":{"type":"graphic_table","displayName":"Alcoholic hepatitis score","title":"Alcoholic hepatitis histologic score","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Alcoholic hepatitis histologic score</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"80%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Points</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Stage of fibrosis</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>No fibrosis or portal fibrosis </li> </ul> </td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Expansive fibrosis </li> </ul> </td> <td class=\"centered\">0</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Bridging fibrosis or cirrhosis </li> </ul> </td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Bilirubinostasis</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>No </li> </ul> </td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Hepatocellular only </li> </ul> </td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Canalicular or ductular </li> </ul> </td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Canalicular or ductular plus hepatocellular </li> </ul> </td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">PMN infiltration</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>No/mild </li> </ul> </td> <td class=\"centered\">2</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Severe </li> </ul> </td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Megamitochondria</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>No megamitochondria </li> </ul> </td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Megamitochondria </li> </ul> </td> <td class=\"centered\">0</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PMN: polymorphonuclear leukocytes.</div><div id=\"graphicVersion\">Graphic 98136 Version 1.0</div></div></div>"},"98137":{"type":"graphic_table","displayName":"Scheuer staging PBC","title":"The Scheuer staging system for primary biliary cholangitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The Scheuer staging system for primary biliary cholangitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Definition</td> </tr> <tr> <td class=\"centered\">1</td> <td>Florid duct lesions (chronic nonsuppurative destructive cholangitis)</td> </tr> <tr> <td class=\"centered\">2</td> <td>Proliferation of bile ductules</td> </tr> <tr> <td class=\"centered\">3</td> <td>Fibrosis or scarring</td> </tr> <tr> <td class=\"centered\">4</td> <td>Cirrhosis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Source: ​Scheuer P. Primary biliary cirrhosis. Proc R Soc Med 1967; 60:1257.</div><div id=\"graphicVersion\">Graphic 98137 Version 2.0</div></div></div>"},"98138":{"type":"graphic_table","displayName":"Ludwig staging PBC","title":"The Ludwig staging system for primary biliary cholangitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The Ludwig staging system for primary biliary cholangitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Definition</td> </tr> <tr> <td class=\"centered\">1</td> <td>Portal hepatitis</td> </tr> <tr> <td class=\"centered\">2</td> <td>Periportal hepatitis</td> </tr> <tr> <td class=\"centered\">3</td> <td>Bridging fibrosis or necrosis</td> </tr> <tr> <td class=\"centered\">4</td> <td>Cirrhosis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Source: Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978; 379:103.</div><div id=\"graphicVersion\">Graphic 98138 Version 2.0</div></div></div>"},"98139":{"type":"graphic_table","displayName":"Histologic score PSC","title":"Histologic scoring system for primary sclerosing cholangitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histologic scoring system for primary sclerosing cholangitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Definition</td> </tr> <tr> <td class=\"centered\">1</td> <td>Cholangitis or portal hepatitis</td> </tr> <tr> <td class=\"centered\">2</td> <td>Expansion of portal triads with fibrosis extending into the surrounding parenchyma</td> </tr> <tr> <td class=\"centered\">3</td> <td>Septal fibrosis and/or bridging fibrosis</td> </tr> <tr> <td class=\"centered\">4</td> <td>Cirrhosis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 98139 Version 1.0</div></div></div>"},"98165":{"type":"graphic_diagnosticimage","displayName":"CT of thoracic spine osteoblastoma","title":"Osteoblastoma of the thoracic spine on CT","html":"<div class=\"graphic\"><div style=\"width: 772px\" class=\"figure\"><div class=\"ttl\">Osteoblastoma of the thoracic spine on CT</div><div class=\"cntnt\"><img style=\"width:752px; height:387px;\" src=\"images/RADIOL/98165_CT_thrcc_spn_osteoblastoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 15-year-old male who presented with back pain and was found to have an osteoblastoma of the thoracic spine. Image A is an axial CT image of the thoracic spine demonstrating an expansile bony lesion centered within the posterior elements of the spine (arrow). Image B is a coronal section and image C, a sagittal section of the osteoblastoma (arrows).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Joseph Konrad, MD.</div><div id=\"graphicVersion\">Graphic 98165 Version 1.0</div></div></div>"},"98166":{"type":"graphic_diagnosticimage","displayName":"MRI thoracic spine osteoblastoma","title":"Thoracic spine osteoblastoma on MRI","html":"<div class=\"graphic\"><div style=\"width: 743px\" class=\"figure\"><div class=\"ttl\">Thoracic spine osteoblastoma on MRI</div><div class=\"cntnt\"><img style=\"width:723px; height:459px;\" src=\"images/RADIOL/98166_Thoracic_spin_osteoblastoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 15-year-old male who presented with back pain and was found to have an osteoblastoma of the thoracic spine. Image A is an axial MRI T2-weighted image of the thoracic spine demonstrating an expansile bony lesion with heterogeneous T2 hypointensity centered within the posterior elements of the spine (arrow). Image B is a sagittal precontrast T1-weighted MRI image of the lesion showing an isointense bony lesion (arrow). Image C is a coronal T1-weighted fat saturated post-contrast image demonstrating a heterogeneously enhancing expansile bony lesion (arrow).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Joseph Konrad, MD.</div><div id=\"graphicVersion\">Graphic 98166 Version 1.0</div></div></div>"},"98167":{"type":"graphic_diagnosticimage","displayName":"Radiograph osteoid osteoma of humerus","title":"Osteoid osteoma of the humerus on radiograph","html":"<div class=\"graphic\"><div style=\"width: 657px\" class=\"figure\"><div class=\"ttl\">Osteoid osteoma of the humerus on radiograph</div><div class=\"cntnt\"><img style=\"width:637px; height:464px;\" src=\"images/RADIOL/98167_Rdgrph_osteoid_osteoma_hmrs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 22-year-old male presented with right arm pain the in absence of trauma and was found to have an osteoid osteoma of the right proximal humerus. Image A is a coned down, magnified AP radiograph of the proximal right humerus that demonstrates a faint lytic lesion with central calcification and a sclerotic rim located within the humeral diaphysis (arrow). Image B is a coned down, magnified oblique radiograph of the lesion (arrow).</div><div class=\"graphic_reference\">Courtesy of Joseph Konrad, MD.</div><div id=\"graphicVersion\">Graphic 98167 Version 1.0</div></div></div>"},"98168":{"type":"graphic_algorithm","displayName":"Indications for AVR in patients with AS","title":"Indications for aortic valve replacement in patients with aortic stenosis","html":"<div class=\"graphic\"><div style=\"width: 684px\" class=\"figure\"><div class=\"ttl\">Indications for aortic valve replacement in patients with aortic stenosis</div><div class=\"cntnt\"><img style=\"width:664px; height:486px;\" src=\"images/CARD/98168_Indications_AVR_patients_AS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arrows show the decision pathways that result in a recommendation for AVR. Periodic monitoring is indicated for all patients in whom AVR is not yet indicated, including those with asymptomatic AS (stage D or C) and those with low gradient AS (stage D2 or D3) who do not meet the criteria for intervention.<br />For the strength of recommendations: Class I means the procedure/treatment should be performed/administered. Class IIa means it is reasonable to perform procedure/administer treatment. Class IIb means the procedure/treatment may be considered. Class III means that procedure or treatment is not useful/effective and may be harmful.<br />For the level of evidence: Level A means multiple populations evaluated; data derived from multiple randomized clinical trials or meta-analyses. Level B means limited populations evaluated; data derived from a single randomized trial or nonrandomized studies. Level C means very limited populations evaluated; only consensus opinion of experts, case studies, or standard of care.</div><div class=\"graphic_footnotes\">AS: aortic stenosis; AVA: aortic valve area; AVR: aortic valve replacement by either surgical or transcatheter approach; BP: blood pressure; DSE: dobutamine stress echocardiography; ETT: exercise treadmill test; LVEF: left ventricular ejection fraction; &Delta;P<sub>mean</sub>: mean pressure gradient; V<sub>max</sub>: maximum velocity.<br />* AVR should be considered with stage D3 AS only if valve obstruction is the most likely cause of symptoms, stroke volume index is &lt;35 mL/m<sup>2</sup>, indexed AVA is &le;0.6 cm<sup>2</sup>/m<sup>2</sup>, and data are recorded when the patient is normotensive (systolic BP &lt;140 mmHg).</div><div class=\"graphic_reference\">Reproduced from: Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:e57. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98168 Version 2.0</div></div></div>"},"98169":{"type":"graphic_figure","displayName":"Indications for AVR for chronic AR","title":"Indications for AVR for chronic AR","html":"<div class=\"graphic\"><div style=\"width: 754px\" class=\"figure\"><div class=\"ttl\">Indications for AVR for chronic AR</div><div class=\"cntnt\"><img style=\"width:734px; height:426px;\" src=\"images/CARD/98169_Indications_AVR_chronic_AR.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For the strength of recommendations: Class I means the procedure/treatment should be performed/administered. Class IIa means it is reasonable to perform the procedure/administer treatment. Class IIb means the procedure/treatment may be considered. Class III means that procedure or treatment is not useful/effective and may be harmful.<br />For the level of evidence: Level A means multiple populations evaluated; data derived from multiple randomized clinical trials or meta-analyses. Level B means limited populations evaluated; data derived from a single randomized trial or nonrandomized studies. Level C means very limited populations evaluated; only consensus opinion of experts, case studies, or standard of care.</div><div class=\"graphic_footnotes\">AR: aortic regurgitation; AVR: aortic valve replacement (valve repair may be appropriate in selected patients); ERO: effective regurgitant orifice; LV: left ventricular; LVEDD: left ventricular end-diastolic dimension; LVEF: left ventricular ejection fraction; LVESD: left ventricular end-systolic dimension; RF: regurgitant fraction; RVol: regurgitant volume.</div><div class=\"graphic_reference\">Reproduced from: Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:e57. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98169 Version 3.0</div></div></div>"},"98172":{"type":"graphic_figure","displayName":"Anticoagulation for prosthetic valves","title":"Anticoagulation for prosthetic valves","html":"<div class=\"graphic\"><div style=\"width: 906px\" class=\"figure\"><div class=\"ttl\">Anticoagulation for prosthetic valves</div><div class=\"cntnt\"><img style=\"width:886px; height:398px;\" src=\"images/CARD/98172_Anticoag_prosthetic_valves.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Risk factors include AF, previous thromboembolism, LV dysfunction, hypercoagulable condition, and older-generation mechanical AVR.<br />For the strength of recommendations: Class I means the procedure/treatment should be performed/administered. Class IIa means it is reasonable to perform the procedure/administer treatment. Class IIb means the procedure/treatment may be considered. Class III means that the procedure or treatment is not useful/effective and may be harmful.<br />For the level of evidence: Level A means multiple populations evaluated; data derived from multiple randomized clinical trials or meta-analyses. Level B means limited populations evaluated; data derived from a single randomized trial or nonrandomized studies. Level C means very limited populations evaluated; only consensus opinion of experts, case studies, or standard of care.</div><div class=\"graphic_footnotes\">AF: atrial fibrillation; ASA: aspirin; AVR: aortic valve replacement; INR: international normalized ratio; LMWH: low-molecular-weight heparin; MVR: mitral valve replacement; PO: by mouth; QD: every day; SC: subcutaneous; TAVR: transcatheter aortic valve replacement; UFH: unfractionated heparin; VKA: vitamin K antagonist.</div><div class=\"graphic_reference\">Reproduced from: Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:e57. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98172 Version 2.0</div></div></div>"},"98176":{"type":"graphic_table","displayName":"Cardiac and aortic sources of embolism","title":"Cardiac and aortic sources of embolism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cardiac and aortic sources of embolism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Cardiac</td> </tr> <tr> <td class=\"subtitle2_single\">Thrombus</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Left ventricle <ul> <li>Prior myocardial infarction </li> <li>Dilated cardiomyopathy with reduced cardiac output </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Left atrium <ul> <li>Atrial fibrillation or atrial flutter </li> <li>Valvular heart disease <ul> <li>Mitral stenosis </li> <li>Prosthetic valve (mitral or aortic) thrombosis </li> </ul> </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Systemic venous or right heart <ul> <li>Paradoxical embolization via right-to-left intracardiac shunt <ul> <li>Atrial septal defect </li> <li>Patent foramen ovale </li> <li>Atrial septal aneurysm </li> </ul> </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_single\">Non-thrombotic masses</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Tumor <ul> <li>Myxoma </li> <li>Papillary fibroelastoma </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Vegetation <ul> <li>Infectious endocarditis </li> <li>Noninfectious (marantic) endocarditis <ul> <li>Underlying malignancy </li> <li>Systemic inflammatory disease (ie, SLE, RA) </li> <li>Sepsis </li> <li>Severe burns </li> </ul> </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Mitral annular calcification </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Aortic</td> </tr> <tr> <td class=\"subtitle2_single\">Complex atheroma (protruding &#62;4 mm, mobile component, and/or plaque ulceration)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SLE: systemic lupus erythematosus; RA: rheumatoid arthritis.</div><div id=\"graphicVersion\">Graphic 98176 Version 1.0</div></div></div>"},"98177":{"type":"graphic_table","displayName":"Drugs inducing edema","title":"Drugs inducing peripheral edema​","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs inducing peripheral edema​</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Antihypertensive drugs</td> </tr> <tr> <td class=\"indent1\">Beta blockers </td> </tr> <tr> <td class=\"indent1\">Calcium channel blockers</td> </tr> <tr> <td class=\"indent1\">Clonidine</td> </tr> <tr> <td class=\"indent1\">Hydralazine</td> </tr> <tr> <td class=\"indent1\">Methyldopa</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Minoxidil</td> </tr> <tr> <td class=\"subtitle1_single\">Hormones</td> </tr> <tr> <td class=\"indent1\">Corticosteroids</td> </tr> <tr> <td class=\"indent1\">Estrogen</td> </tr> <tr> <td class=\"indent1\">Insulin&nbsp;</td> </tr> <tr> <td class=\"indent1\">Progesterone</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Testosterone</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td class=\"indent1\">Acyclovir</td> </tr> <tr> <td class=\"indent1\">Anticancer agents (cyclophosphamide, cyclosporine, cytosine arabinoside, docetaxel, granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, interferon-alfa, interleukin-2, interleukin-4, mithramycin)&nbsp;&nbsp;</td> </tr> <tr> <td class=\"indent1\">Antidepressants (monoamine oxidase inhibitors, trazodone) </td> </tr> <tr> <td class=\"indent1\">Antipsychotic phenothiazines (chlorpromazine, thioridazine, thiothixene, trifluoperazine)&nbsp;&nbsp;&nbsp;</td> </tr> <tr> <td class=\"indent1\">Nonsteroidal anti-inflammatory drugs</td> </tr> <tr> <td class=\"indent1\">Oral thiazolidinedione hypoglycemic agents (pioglitazone, rosiglitazone) </td> </tr> <tr> <td class=\"indent1\">Pramipexole</td> </tr> <tr> <td class=\"indent1\">Quinolone antibiotics</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 98177 Version 2.0</div></div></div>"},"98182":{"type":"graphic_picture","displayName":"Trichilemmoma histo","title":"Histopathologic features of trichilemmoma​","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Histopathologic features of trichilemmoma​</div><div class=\"cntnt\"><img style=\"width:726px; height:275px;\" src=\"images/DERM/98182_Trichilemmoma_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Trichilemmomas consist of lobular collections of keratinocytes with small nuclei and pink to pale cytoplasm. A rim of small, palisaded cells lines some areas of the tumor, and there are frequently areas of hypergranulosis resembling the koilocytic changes of&nbsp;human papillomavirus&nbsp;infection.<br />(A) H&amp;E 40x.<br />(B) H&amp;E 200x.</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98182 Version 2.0</div></div></div>"},"98185":{"type":"graphic_table","displayName":"Staging gestational troph neoplasia","title":"FIGO Staging of Gestational Trophoblastic Neoplasia (GTN) and modified WHO Prognostic Scoring System as adapted by FIGO","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">FIGO Staging of Gestational Trophoblastic Neoplasia (GTN) and modified WHO Prognostic Scoring System as adapted by FIGO</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td><strong>Stage I</strong></td> <td>Disease confined to the uterus</td> </tr> <tr> <td><strong>Stage II</strong></td> <td>GTN extends outside of the uterus, but is limited to the genital structures (adnexa, vagina)</td> </tr> <tr> <td><strong>Stage III</strong></td> <td>GTN extends to the lungs, with<br /> or<br /> without genital tract involvement</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Stage IV</strong></td> <td>All other metastatic sites</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">The stage should be followed by the sum of the risk factors (eg, III:5)</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Risk factor</td> <td class=\"subtitle1\">Score</td> <td class=\"subtitle1\" colspan=\"3\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2\">0</td> <td class=\"subtitle2\">1</td> <td class=\"subtitle2\">2</td> <td class=\"subtitle2\">4</td> </tr> <tr> <td>Age (years)</td> <td class=\"centered\">&#60;40</td> <td class=\"centered\">&#8805;40</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>Antecedent pregnancy</td> <td class=\"centered\">Mole</td> <td class=\"centered\">Abortion</td> <td class=\"centered\">Term</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>Interval (months)*</td> <td class=\"centered\">4</td> <td class=\"centered\">4 to 6</td> <td class=\"centered\">7 to 12</td> <td class=\"centered\">&#62;12</td> </tr> <tr> <td>Pretreatment serum hCG (mIU/mL)</td> <td class=\"centered\">&#60;10<sup>3</sup></td> <td class=\"centered\">10<sup>3</sup> to 10<sup>4</sup></td> <td class=\"centered\">10<sup>4</sup> to 10<sup>5</sup></td> <td class=\"centered\">&#62;10<sup>5</sup></td> </tr> <tr> <td>Largest tumor (including uterus)</td> <td class=\"centered\">&#60;3 cm</td> <td class=\"centered\">3 to 4 cm</td> <td class=\"centered\">&#8805;5 cm</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>Site of metastases</td> <td class=\"centered\">Lung</td> <td class=\"centered\">Spleen, kidney</td> <td class=\"centered\">GI tract</td> <td class=\"centered\">Brain, liver</td> </tr> <tr> <td>Number of metastases</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">1 to 4</td> <td class=\"centered\">5 to 8</td> <td class=\"centered\">&#62;8</td> </tr> <tr> <td>Prior failed chemotherapy</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">Single drug</td> <td class=\"centered\">&#8805;2 drugs</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FIGO: International Federation of Gynecology and Obstetrics; WHO: World Health Organization; hCG: human chorionic gonadotropin.<br />* Interval (in months) between end of antecedent pregnancy and start of chemotherapy.</div><div class=\"graphic_reference\">Original figure modified for this publication. Berkowitz RS, Goldstein DP. Current management of gestational trophoblastic diseases. Gynecol Oncol 2009; 112:654. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98185 Version 3.0</div></div></div>"},"98209":{"type":"graphic_algorithm","displayName":"Algorithm: Angioedema in urgent care settings","title":"Algorithm for evaluation and management of angioedema in the urgent care setting","html":"<div class=\"graphic\"><div style=\"width: 1053px\" class=\"figure\"><div class=\"ttl\">Algorithm for evaluation and management of angioedema in the urgent care setting</div><div class=\"cntnt\"><img style=\"width:1033px; height:735px;\" src=\"images/ALLRG/98209_Angioedema_urgent_care_sett.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ENT: ear, nose, and throat or otolaryngology; ACE: angiotensin-converting enzyme; C4: complement component 4.</div><div class=\"graphic_reference\">Modified from: Jaiganesh T, Wiese M, Hollingsworth J, et al. Acute angioedema: Recognition and management in the emergency department. Eur J Emerg Med 2013; 20:10.</div><div id=\"graphicVersion\">Graphic 98209 Version 1.0</div></div></div>"},"98212":{"type":"graphic_table","displayName":"Cutaneous adnexal tumors","title":"Cutaneous adnexal tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cutaneous adnexal tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Sweat gland tumors, benign</td> <td class=\"subtitle1\">Derivation</td> <td class=\"subtitle1\">Genetic abnormalities</td> </tr> <tr> <td>Poroma (classic poroma, hidroacanthoma simplex, dermal duct tumor)</td> <td>Eccrine or apocrine</td> <td>LOH in <em>APC</em></td> </tr> <tr> <td>Hidradenoma</td> <td>Eccrine or apocrine</td> <td>t(11;19) <em>MAML2</em>;<em>MECT1</em></td> </tr> <tr> <td>Hidradenoma papilliferum</td> <td>Anogenital apocrine</td> <td>&nbsp;</td> </tr> <tr> <td>Spiradenoma/cylindroma</td> <td>Eccrine or apocrine</td> <td><em>CYLD</em> mutation/LOH</td> </tr> <tr> <td>Mixed tumor</td> <td>Sweat duct +/&ndash; follicular</td> <td>&nbsp;</td> </tr> <tr> <td>Syringofibroadenoma</td> <td>Eccrine</td> <td>&nbsp;</td> </tr> <tr> <td>Syringoma</td> <td>Eccrine or apocrine</td> <td>&nbsp;</td> </tr> <tr> <td>Syringocystadenoma papilliferum</td> <td>Apocrine</td> <td>9p21 deletion; 9q22 LOH</td> </tr> <tr> <td>Tubular/Papillary adenoma</td> <td>Eccrine or apocrine</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle1\">Sweat gland tumors, malignant</td> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">&nbsp;</td> </tr> <tr> <td>Porocarcinoma</td> <td>Eccrine or apocrine</td> <td>&nbsp;</td> </tr> <tr> <td>(Aggressive) digital papillary adenocarcinoma</td> <td>Eccrine or apocrine</td> <td>&nbsp;</td> </tr> <tr> <td>Adenoid cystic carcinoma</td> <td>Eccrine or apocrine</td> <td>&nbsp;</td> </tr> <tr> <td>Apocrine adenocarcinoma</td> <td>Apocrine</td> <td>&nbsp;</td> </tr> <tr> <td>Syringomatous carcinoma</td> <td>Eccrine or apocrine</td> <td>&nbsp;</td> </tr> <tr> <td>Hidradenocarcinoma</td> <td>Eccrine or apocrine</td> <td>&nbsp;</td> </tr> <tr> <td>Malignant mixed tumor</td> <td>Eccrine or apocrine</td> <td>&nbsp;</td> </tr> <tr> <td>Cylindrocarcinoma/Spiradenocarcinoma</td> <td>Eccrine or apocrine</td> <td><em>CYLD</em> mutation/LOH</td> </tr> <tr> <td>Mucinous carcinoma</td> <td>Eccrine or apocrine</td> <td>&nbsp;</td> </tr> <tr> <td>Microcystic adnexal carcinoma</td> <td>Sweat duct and follicular</td> <td>&nbsp;</td> </tr> <tr> <td>Extramammary Paget disease</td> <td>Multiple possibilities</td> <td>Chr 19 and X amplification; 10q loss</td> </tr> <tr> <td class=\"subtitle1\">Follicular and sebaceous tumors, benign</td> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">&nbsp;</td> </tr> <tr> <td>Trichoblastoma/trichoepithelioma</td> <td>Follicular</td> <td><em>CTNNB1</em>, <em>CYLD</em>, and <em>PTCH1</em> mutation</td> </tr> <tr> <td>Trichofolliculoma</td> <td>Follicular</td> <td>&nbsp;</td> </tr> <tr> <td>Panfolliculoma</td> <td>Follicular</td> <td>&nbsp;</td> </tr> <tr> <td>Proliferating follicular-cystic acanthoma (proliferating pilar tumor)</td> <td>Follicular (outer root sheath)</td> <td>&nbsp;</td> </tr> <tr> <td>Trichilemmoma</td> <td>Follicular (outer root sheath)</td> <td><em>HRAS</em>, <em>PTEN</em> mutation</td> </tr> <tr> <td>Trichoadenoma</td> <td>Follicular (infundibulum)</td> <td>&nbsp;</td> </tr> <tr> <td>Tumor of the follicular infundibulum</td> <td>Follicular (isthmus)</td> <td>&nbsp;</td> </tr> <tr> <td>Pilar sheath acanthoma</td> <td>Follicular (isthmus/infundibulum)</td> <td>&nbsp;</td> </tr> <tr> <td>Pilomatricoma</td> <td>Follicular (matrix)</td> <td><em>CTNNB1</em> mutation; trisomy 18</td> </tr> <tr> <td>Sebaceous adenoma</td> <td>Sebaceous gland</td> <td><em>LEF1</em>, <em>MLH1</em>, <em>MSH2</em>, <em>MSH6</em> mutation</td> </tr> <tr> <td>Sebaceoma</td> <td>Sebaceous gland</td> <td><em>LEF1</em>, <em>MLH1</em>, <em>MSH2</em>, <em>MSH6</em> mutation</td> </tr> <tr> <td>Fibrofolliculoma/trichodiscoma</td> <td>Sebaceous mantle</td> <td><em>FLCN</em> mutation</td> </tr> <tr> <td class=\"subtitle1\">Follicular and sebaceous tumors, malignant</td> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">&nbsp;</td> </tr> <tr> <td>Trichoblastic carcinoma</td> <td>Follicular</td> <td>&nbsp;</td> </tr> <tr> <td>Trichilemmal carcinoma</td> <td>Follicular (outer root sheath)</td> <td>&nbsp;</td> </tr> <tr> <td>Pilomatrix (matrical) carcinoma</td> <td>Follicular (matrix)</td> <td><em>CTNNB1</em> mutation</td> </tr> <tr> <td>Sebaceous carcinoma</td> <td>Sebaceous</td> <td><em>LEF1</em>, <em>MLH1</em>, <em>MSH2</em>, <em>MSH6</em> mutation</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LOH: Loss of heterozigosity.</div><div id=\"graphicVersion\">Graphic 98212 Version 1.0</div></div></div>"},"98213":{"type":"graphic_picture","displayName":"Trichoepithelioma","title":"Trichoepithelioma","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Trichoepithelioma</div><div class=\"cntnt\"><img style=\"width:712px; height:670px;\" src=\"images/DERM/98213_Trichoepithelioma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cutaneous adnexal tumors present in a relatively non-specific pattern with pink, translucent, or slightly blue papules with variable amounts of telangiectasia. Biopsy of this lesion revealed a trichoepithelioma.</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98213 Version 2.0</div></div></div>"},"98214":{"type":"graphic_picture","displayName":"Syringoma histo","title":"Histologic features of syringoma","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Histologic features of syringoma</div><div class=\"cntnt\"><img style=\"width:712px; height:532px;\" src=\"images/DERM/98214_Syringoma_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Syringomas are characterized by numerous small collections of epithelial cells with central duct formation and associated fibrotic stroma (H&amp;E 100x).</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98214 Version 2.0</div></div></div>"},"98215":{"type":"graphic_table","displayName":"Rehabilitation plan for quadriceps muscle strain","title":"Rehabilitation plan for quadriceps muscle strain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rehabilitation plan for quadriceps muscle strain</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Goals</td> <td class=\"subtitle1\">Treatment</td> <td class=\"subtitle1\">Progression</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">1</td> <td> <ul> <li>Restore motion </li> <li>Limit swelling </li> </ul> </td> <td> <ul> <li>RICE </li> <li>OTC analgesics (eg, NSAIDs) </li> <li>Gentle passive or assisted knee flexion </li> <li>Limited weightbearing </li> </ul> </td> <td> <ul> <li>First 48 hours after injury </li> <li>Swelling stabilized </li> <li>ROM stabilized </li> <li>Tolerating at least partial weightbearing </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">2</td> <td> <ul> <li>Achieve full ROM </li> <li>Restore strength and cardiovascular fitness </li> </ul> </td> <td> <ul> <li>Soft tissue therapy by physical therapist or athletic trainer (if available) </li> <li>Quadriceps stretching with prone knee flexion </li> <li>Eccentric strengthening of quadriceps with progression of resistance and motion arc (eg, reverse leg extensions starting at 3 sets of 10 reps&nbsp;and low resistance) </li> <li>Isotonic strengthening (eg, leg extension exercises) </li> </ul> </td> <td> <ul> <li>Full passive ROM </li> <li>Full weightbearing </li> <li>Performs 3 sets of 10 single leg hops pain free </li> <li>Ideally, can perform 3 sets of 20 single leg squats with good form </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">3</td> <td> <ul> <li>Return to running and/or kicking </li> </ul> </td> <td> <ul> <li>Jogging for 10 minutes x 2 sets </li> <li>Running at 60% maximum strides for 80 m intervals &ndash; 3 sets of 5 reps </li> <li>Sprinting at 90% maximum speed for 30 m intervals &ndash; 3 sets of 5 reps </li> <li>Initiation of kicking activities over short distance with lighter ball </li> <li>Advancing isotonic leg extension resistance and motion arc </li> </ul> </td> <td> <ul> <li>Completion of all stages without recurrence of significant pain or exacerbation of symptoms immediately following routines </li> </ul> </td> </tr> <tr> <td class=\"centered\">4</td> <td> <ul> <li>Sport specific activities </li> </ul> </td> <td> <ul> <li>100% sprint over 60 to 80 m </li> <li>Shuttle runs </li> <li>Figure-of-8 sprints</li> <li>Full kicking with game ball </li> <li>Plyometric activities (eg, box jumps) </li> </ul> </td> <td> <ul> <li>Successful completion of sports related activities </li> <li>Observed full function without deficit or compensation and without setback in symptoms following completion of training </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NSAIDs: nonsteroidal antiinflammatory drugs; OTC: over-the-counter; reps: repetitions; RICE: rest, ice, compression, elevation; ROM: range of motion.</div><div class=\"graphic_reference\">Courtesy of Timothy Von Fange, MD.</div><div id=\"graphicVersion\">Graphic 98215 Version 1.0</div></div></div>"},"98216":{"type":"graphic_table","displayName":"Rehabilitation plan for quadriceps or patellar tendinopathy","title":"Rehabilitation plan for quadriceps or patellar tendinopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rehabilitation plan for quadriceps or patellar tendinopathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Goals</td> <td class=\"subtitle1\">Treatment</td> <td class=\"subtitle1\">Progression</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">1</td> <td> <ul> <li>Tendon load reduction (ie, no jumping or running) </li> <li>Correct biomechanical errors </li> <li>Adapt playing surface </li> </ul> </td> <td> <ul> <li>Transverse friction massage </li> <li>Relative rest from offending activity </li> <li>Improve flexibility of quadriceps, hamstrings, IT band, gastrocnemius/soleus complex </li> <li>Eccentric quadriceps activity partial weight bearing performed twice daily </li> <li>\"Around the World Leg Raises\" </li> </ul> </td> <td> <ul> <li>Performs 3 sets of 15 reps eccentric quadriceps activity at full body weight without pain </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">2</td> <td> <ul> <li>Symmetric lower extremity biomechanics </li> <li>Increase strength </li> <li>Cardiovascular fitness </li> </ul> </td> <td> <ul> <li>Upright eccentric decline squat to 60 degrees knee flexion </li> <li>Perform twice daily to 3 sets of 15 </li> <li>Progress from bilateral to single leg, then to single leg with added weight </li> <li>Continue \"Around the World Leg Raises\" and stretching programs </li> <li>Stationary biking or pool jogging at tolerated exertion levels </li> </ul> </td> <td> <ul> <li>Performs 3 sets of 15 single leg decline eccentric squats with 110% BW (ie, BW + added weight) without pain </li> <li>Other conditioning activities performed pain free </li> </ul> </td> </tr> <tr> <td class=\"centered\">3</td> <td> <ul> <li>Return to running and jumping </li> </ul> </td> <td> <ul> <li>Drop squats 3 sets of 20 reps </li> <li>Eccentric step downs from 4 to 8 inch (10 to 20 cm) heights, 3 sets of 15 reps </li> <li>Drop jumps from 4 to 8 inch (10 to 20 cm) heights, 3 sets of 20 reps&nbsp;</li> <li>Other sports specific activities such as shuttle or figure-of-8 runs </li> </ul> </td> <td> <ul> <li>3 sets of 20 drop jumps from 8 inch (20 cm) height without pain </li> <li>Observed sporting activities without deficit or compensation and no setback in symptoms following completion of training </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BW: body weight; IT: iliotibial; reps: repetitions.</div><div class=\"graphic_reference\">Adapted from: Rutland M, O'Connell D, Brism&eacute;e JM, et al. Evidence Supported Rehabilitation of Patellar Tendonopathy. N Am J Sports Phys Ther 2010; 5:166.</div><div id=\"graphicVersion\">Graphic 98216 Version 1.0</div></div></div>"},"98217":{"type":"graphic_table","displayName":"ICSD-3 criteria for Kleine-Levin syndrome","title":"The International Classification of Sleep Disorders (ICSD)-3 criteria for Kleine-Levin syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The International Classification of Sleep Disorders (ICSD)-3 criteria for Kleine-Levin syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Diagnostic criteria</td> </tr> <tr> <td class=\"subtitle2_single\">Criteria A-E must be met</td> </tr> <tr> <td class=\"indent1\">A. The patient experiences at least two recurrent episodes of excessive sleepiness and sleep duration, each persisting for two days to five weeks.</td> </tr> <tr> <td class=\"indent1\">B. Episodes recur usually more than once a year and at least once every 18 months.</td> </tr> <tr> <td class=\"indent1\">C. The patient has normal alertness, cognitive function, behavior, and mood between episodes.</td> </tr> <tr> <td class=\"indent1\">D. The patient must demonstrate at least <em>one</em> of the following during episodes: <ol> <li>Cognitive dysfunction. </li> <li>Altered perception. </li> <li>Eating disorder (anorexia or hyperphagia). </li> <li>Disinhibited behavior (such as hypersexuality). </li> </ol> </td> </tr> <tr> <td class=\"indent1\">E. The hypersomnolence and related symptoms are not better explained by another sleep disorder, other medical, neurologic, or psychiatric disorder (especially bipolar disorder), or use of drugs or medications.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: American Academy of Sleep Medicine. The International Classification of Sleep Disorders, 3rd ed, Chicago, IL 2014. Copyright &copy; 2014 American Academy of Sleep Medicine. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98217 Version 1.0</div></div></div>"},"98219":{"type":"graphic_table","displayName":"Treatment trials in patients with Kleine-Levin syndrome","title":"Spectrum of reported responses to various treatment trials in patients with Kleine-Levin syndrome (KLS)*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Spectrum of reported responses to various treatment trials in patients with Kleine-Levin syndrome (KLS)*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"4\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Treatment</td> <td class=\"subtitle1\">N</td> <td class=\"subtitle1\">Clear benefit</td> <td class=\"subtitle1\">Partial effect</td> <td class=\"subtitle1\">No effect or worse</td> </tr> <tr> <td><strong>Stimulants</strong></td> <td class=\"centered\">148</td> <td class=\"centered\">13%</td> <td class=\"centered\">17%</td> <td class=\"centered\">70%</td> </tr> <tr> <td class=\"indent1\">Modafinil</td> <td class=\"centered\">45</td> <td class=\"centered\">0%</td> <td class=\"centered\">20%</td> <td class=\"centered\">80%</td> </tr> <tr> <td class=\"indent1\">Methylphenidate</td> <td class=\"centered\">37</td> <td class=\"centered\">8%</td> <td class=\"centered\">14%</td> <td class=\"centered\">78%</td> </tr> <tr> <td class=\"indent1\">Amantadine</td> <td class=\"centered\">24</td> <td class=\"centered\">12%</td> <td class=\"centered\">29%</td> <td class=\"centered\">58%</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Amphetamines</td> <td class=\"centered\">31</td> <td class=\"centered\">39%</td> <td class=\"centered\">16%</td> <td class=\"centered\">45%</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Lithium</strong></td> <td class=\"centered\">59</td> <td class=\"centered\">24%</td> <td class=\"centered\">22%</td> <td class=\"centered\">54%</td> </tr> <tr> <td><strong>Antidepressants</strong></td> <td class=\"centered\">60</td> <td class=\"centered\">3%</td> <td class=\"centered\">8%</td> <td class=\"centered\">88%</td> </tr> <tr> <td class=\"indent1\">Sertraline</td> <td class=\"centered\">17</td> <td class=\"centered\">0%</td> <td class=\"centered\">0%</td> <td class=\"centered\">100%</td> </tr> <tr> <td class=\"indent1\">Fluoxetine</td> <td class=\"centered\">16</td> <td class=\"centered\">0%</td> <td class=\"centered\">19%</td> <td class=\"centered\">81%</td> </tr> <tr> <td class=\"indent1\">Bupropion</td> <td class=\"centered\">4</td> <td class=\"centered\">0%</td> <td class=\"centered\">50%</td> <td class=\"centered\">50%</td> </tr> <tr> <td class=\"indent1\">Melatonin</td> <td class=\"centered\">16</td> <td class=\"centered\">0%</td> <td class=\"centered\">19%</td> <td class=\"centered\">81%</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Phototherapy</td> <td class=\"centered\">9</td> <td class=\"centered\">0%</td> <td class=\"centered\">11%</td> <td class=\"centered\">89%</td> </tr> <tr> <td><strong>Antipsychotics</strong></td> <td class=\"centered\">51</td> <td class=\"centered\">6%</td> <td class=\"centered\">6%</td> <td class=\"centered\">88%</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Risperidone</td> <td class=\"centered\">8</td> <td class=\"centered\">0%</td> <td class=\"centered\">37%</td> <td class=\"centered\">63%</td> </tr> <tr> <td><strong>Antiepileptic drugs</strong></td> <td class=\"centered\">81</td> <td class=\"centered\">8%</td> <td class=\"centered\">9%</td> <td class=\"centered\">83%</td> </tr> <tr> <td class=\"indent1\">Carbamazepine</td> <td class=\"centered\">41</td> <td class=\"centered\">10%</td> <td class=\"centered\">7%</td> <td class=\"centered\">83%</td> </tr> <tr> <td class=\"indent1\">Valproate</td> <td class=\"centered\">17</td> <td class=\"centered\">6%</td> <td class=\"centered\">19%</td> <td class=\"centered\">75%</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Benzodiazepines</td> <td class=\"centered\">30</td> <td class=\"centered\">0%</td> <td class=\"centered\">3%</td> <td class=\"centered\">97%</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Electroconvulsive therapy</strong></td> <td class=\"centered\">5</td> <td class=\"centered\">0%</td> <td class=\"centered\">0%</td> <td class=\"centered\">100%</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Immunoglobulins</strong></td> <td class=\"centered\">3</td> <td class=\"centered\">0%</td> <td class=\"centered\">33%</td> <td class=\"centered\">66%</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Acyclovir</strong></td> <td class=\"centered\">2</td> <td class=\"centered\">0%</td> <td class=\"centered\">0%</td> <td class=\"centered\">100%</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Corticosteroids</strong></td> <td class=\"centered\">2</td> <td class=\"centered\">0%</td> <td class=\"centered\">0%</td> <td class=\"centered\">100%</td> </tr> <tr> <td><strong>Vitamin supplements</strong></td> <td class=\"centered\">24</td> <td class=\"centered\">0%</td> <td class=\"centered\">0%</td> <td class=\"centered\">100%</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Effects of 508 treatment trials in 176 KLS patients. Combined results of a meta-analysis<sup>[1]</sup> and a large survey of new patients<sup>[2]</sup> are presented.</div><div class=\"graphic_footnotes\">* It should be noted that these results are based on patients' subjective reports and are to be compared with \"No treatment,\" which had been calculated in 32 patients to have \"clear effect\" in 16%, \"partial effect\" in 34%, and \"no effect\" in 50%.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Arnulf I, Zeitzer JM, File J, et al. Kleine-Levin syndrome: A systematic review of 186 cases in the literature. Brain 2005; 128:2763.</li>&#xD;&#xA;    <li>Arnulf I, Lin L, Gadoth N, et al. Kleine-Levin syndrome: A systematic study of 108 patients. Ann Neurol 2008; 63:482.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 98219 Version 1.0</div></div></div>"},"98221":{"type":"graphic_figure","displayName":"Superficial muscles of the pelvis, thigh, knee","title":"Superficial muscles of the pelvis, thigh, knee","html":"<div class=\"graphic\"><div style=\"width: 509px\" class=\"figure\"><div class=\"ttl\">Superficial muscles of the pelvis, thigh, knee</div><div class=\"cntnt\"><img style=\"width:489px; height:734px;\" src=\"images/EM/98221_Antvwsprfcmslplvthgkn.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists. Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 98221 Version 5.0</div></div></div>"},"98222":{"type":"graphic_figure","displayName":"Superficial muscles of pelvis, thigh, knee: Lateral view","title":"Superficial muscles of pelvis, thigh, knee: Lateral view","html":"<div class=\"graphic\"><div style=\"width: 630px\" class=\"figure\"><div class=\"ttl\">Superficial muscles of pelvis, thigh, knee: Lateral view</div><div class=\"cntnt\"><img style=\"width:610px; height:754px;\" src=\"images/EM/98222_Ltrsprfimsclplvsthghkn.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists. Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 98222 Version 4.0</div></div></div>"},"98223":{"type":"graphic_figure","displayName":"Deep muscles of pelvis, thigh, knee: Anterior view","title":"Deep muscles of pelvis, thigh, knee: Anterior view","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Deep muscles of pelvis, thigh, knee: Anterior view</div><div class=\"cntnt\"><img style=\"width:483px; height:707px;\" src=\"images/EM/98223_Antrvwdpmsclplvthghkn.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists. Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 98223 Version 4.0</div></div></div>"},"98224":{"type":"graphic_figure","displayName":"Deep muscles of the pelvis, thigh, knee: Lateral view","title":"Deep muscles of the pelvis, thigh, knee: Lateral view","html":"<div class=\"graphic\"><div style=\"width: 643px\" class=\"figure\"><div class=\"ttl\">Deep muscles of the pelvis, thigh, knee: Lateral view</div><div class=\"cntnt\"><img style=\"width:623px; height:769px;\" src=\"images/EM/98224_Ltrlvwdpmsclplvthghkn.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists. Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 98224 Version 3.0</div></div></div>"},"98225":{"type":"graphic_figure","displayName":"Rectus femoris","title":"Rectus femoris","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Rectus femoris</div><div class=\"cntnt\"><img style=\"width:586px; height:713px;\" src=\"images/EM/98225_Rectusfemoris.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists. Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 98225 Version 3.0</div></div></div>"},"98226":{"type":"graphic_figure","displayName":"Surface anatomy of the thigh","title":"Surface anatomy of the thigh","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Surface anatomy of the thigh</div><div class=\"cntnt\"><img style=\"width:477px; height:727px;\" src=\"images/EM/98226_Surfaceanatomythigh.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Clinically Oriented Anatomy, 7th ed, Moore KL, Dalley AF, Agur AM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 98226 Version 3.0</div></div></div>"},"98227":{"type":"graphic_picture","displayName":"Hidroacanthoma simplex histo","title":"Histologic features of hidroacanthoma simplex​","html":"<div class=\"graphic\"><div style=\"width: 744px\" class=\"figure\"><div class=\"ttl\">Histologic features of hidroacanthoma simplex​</div><div class=\"cntnt\"><img style=\"width:724px; height:670px;\" src=\"images/DERM/98227_Hidroacanthom_simplex_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Intraepidermal poroma (hidroacanthoma simplex) consists of well-demarcated collections of poroid cells within the epidermis (H&amp;E 40x).<br />(B) Hidroacanthoma simplex resemble seborrheic keratosis histopathologically, but are distinguished by the presence of ducts within the neoplasm (H&amp;E 200x).</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98227 Version 2.0</div></div></div>"},"98228":{"type":"graphic_figure","displayName":"Muscles of anterior thigh - Extensors of the knee","title":"Muscles of anterior thigh: Extensors of the knee","html":"<div class=\"graphic\"><div style=\"width: 688px\" class=\"figure\"><div class=\"ttl\">Muscles of anterior thigh: Extensors of the knee</div><div class=\"cntnt\"><img style=\"width:668px; height:626px;\" src=\"images/EM/98228_Msclantrrthghextnsrkn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">* The spinal cord segmental innervation is indicated (eg, \"L1, L2, L3\" means that the nerves supplying the quadriceps femoris are derived from the first three lumbar segments of the spinal cord). Numbers in boldface (L3, L4) indicate the main segmental innervation. Damage to one or more of the listed spinal cord segments or to the motor nerve roots arising from them results in paralysis of the muscles concerned.</div><div class=\"graphic_reference\">Reproduced with permission from: Clinically Oriented Anatomy, 7th ed, Moore KL, Dalley AF, Agur AM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 98228 Version 3.0</div></div></div>"},"98229":{"type":"graphic_picture","displayName":"Poroma histo","title":"Histologic features of classic poroma","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">Histologic features of classic poroma</div><div class=\"cntnt\"><img style=\"width:715px; height:371px;\" src=\"images/DERM/98229_Poroma histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Classic poromas form nodular collections of poroid keratinocytes in the upper dermis that connect with the overlying epidermis in multiple areas. Ductal differentiation is focally present (H&amp;E 40x).</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98229 Version 2.0</div></div></div>"},"98230":{"type":"graphic_picture","displayName":"Poroma dermal duct histo","title":"Histologic features of poroma, dermal duct variant","html":"<div class=\"graphic\"><div style=\"width: 662px\" class=\"figure\"><div class=\"ttl\">Histologic features of poroma, dermal duct variant</div><div class=\"cntnt\"><img style=\"width:642px; height:711px;\" src=\"images/DERM/98230_Poroma_dermal_duct_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The dermal duct variant of poroma consists of numerous small to medium-sized collections of poroid cells in the dermis (H&amp;E 40x).</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98230 Version 2.0</div></div></div>"},"98231":{"type":"graphic_picture","displayName":"Poroid hidradenoma histo","title":"Histologic features of poroid hidradenoma","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Histologic features of poroid hidradenoma</div><div class=\"cntnt\"><img style=\"width:710px; height:533px;\" src=\"images/DERM/98231_Poroid_hidradenoma_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Poroid hidradenoma consists of one or more large dermal nodules of poroid cells with ductal differentiation (H&amp;E 20x).</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98231 Version 2.0</div></div></div>"},"98232":{"type":"graphic_picture","displayName":"Porocarcinoma histo","title":"Histologic features of porocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Histologic features of porocarcinoma</div><div class=\"cntnt\"><img style=\"width:710px; height:533px;\" src=\"images/DERM/98232_Porocarcinoma_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Porocarcinoma is a rare tumor composed of keratinocytes with atypical nuclei present in a poorly circumscribed, infiltrative growth pattern. Necrosis and mitotic activity can be present in both poroma and porocarcinoma, although they typically occur in greater amount in the latter. This porocarcinoma arose within a preexistent poroma (well-circumscribed aggregations of small poroid keratinocytes in the upper portion of the figure). (H&amp;E100x).</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98232 Version 2.0</div></div></div>"},"98233":{"type":"graphic_picture","displayName":"Spiradenoma","title":"Spiradenoma","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Spiradenoma</div><div class=\"cntnt\"><img style=\"width:710px; height:531px;\" src=\"images/DERM/98233_Spiradenoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spiradenomas present as shiny pink to red papules or nodules, typically on the head and neck region. This example from the scalp has prominent telangiectatic vessels.</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98233 Version 2.0</div></div></div>"},"98234":{"type":"graphic_picture","displayName":"Cylindroma histo","title":"Histologic features of cylindroma","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Histologic features of cylindroma</div><div class=\"cntnt\"><img style=\"width:513px; height:721px;\" src=\"images/DERM/98234_Cylindroma_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Cylindromas contain many small islands of basaloid keratinocytes closely opposed to one another in a pattern resembling the pieces of a jigsaw puzzle (H&amp;E 40x).<br />(B) Prominent pink, hyalinzed basement membrane substance surrounds the individual tumor aggregations and is present in drop-like fashion between the keratinocytes. Ductal differentiation is present (H&amp;E 200x).</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98234 Version 2.0</div></div></div>"},"98235":{"type":"graphic_picture","displayName":"Spiradenoma histo","title":"Histologic features of spiradenoma","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Histologic features of spiradenoma</div><div class=\"cntnt\"><img style=\"width:712px; height:532px;\" src=\"images/DERM/98235_Spiradenoma_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spiradenomas lie on a spectrum with cylindromas, but are composed of larger nodular aggregations of basaloid keratinocytes instead of small ones. Prominent deposition of basement membrane material and duct formation is present in both spiradenoma and cylindroma (H&amp;E 40x).</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98235 Version 2.0</div></div></div>"},"98236":{"type":"graphic_picture","displayName":"Mixed tumor skin","title":"Mixed tumor of the skin (chondroid syringoma)","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Mixed tumor of the skin (chondroid syringoma)</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/98236_Mixed_tumor_skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chondroid syringoma presenting as an asymptomatic firm nodule in the nasolabial fold.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98236 Version 1.0</div></div></div>"},"98237":{"type":"graphic_picture","displayName":"Mixed tumor histo","title":"Histologic features of mixed tumor of the skin (chondroid syringoma)","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Histologic features of mixed tumor of the skin (chondroid syringoma)</div><div class=\"cntnt\"><img style=\"width:712px; height:534px;\" src=\"images/DERM/98237_Mixed_tumor_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cutaneous mixed tumors have an epithelial and stromal component. The stromal component typically has areas with abundant mucin and can have a chondroid appearance as depicted in this case. Mixed tumors can show apocrine or eccrine differentiation, and they frequently have a prominent myoepithelial component. The epithelial component in this example is minimal, but can be confirmed with a keratin stain (H&amp;E 100x).</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98237 Version 2.0</div></div></div>"},"98238":{"type":"graphic_diagnosticimage","displayName":"CT scan of posthysterectomy pelvic abscess","title":"Posthysterectomy pelvic abscess on CT scan","html":"<div class=\"graphic\"><div style=\"width: 581px\" class=\"figure\"><div class=\"ttl\">Posthysterectomy pelvic abscess on CT scan</div><div class=\"cntnt\"><img style=\"width:561px; height:517px;\" src=\"images/RADIOL/98238_CT_scn_pst_hystrc_plvc_absc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) An axial CT scan through the pelvis following hysterectomy shows a large gas-containing (arrows) infected hematoma (arrow heads) in the postoperative bed. <br />(B) Image B is a coronal reconstruction and shows the abscess (between arrowheads) above the bladder (asterisk). Gas is noted in the abscess (arrows). <br />(C) Image C is a sagittal reconstruction of the CT scan and shows the abscess (between arrowheads) above the vagina (arrow).<br />(D) Image D shows a percutaneous pigtail drainage catheter (arrow) in the decompressed abscess (between arrowheads).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 98238 Version 2.0</div></div></div>"},"98239":{"type":"graphic_picture","displayName":"Syringofibroadenoma histo","title":"Histologic features of syringofibroadenoma","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Histologic features of syringofibroadenoma</div><div class=\"cntnt\"><img style=\"width:712px; height:534px;\" src=\"images/DERM/98239_Syringofibroadenoma_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Syringofibroadenoma exhibits a unique pattern of thin interconnecting strands of keratinocytes extending from the epidermis into the dermis. Small ducts are present in the strands in variable numbers (H&amp;E 40x).</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98239 Version 2.0</div></div></div>"},"98240":{"type":"graphic_picture","displayName":"Syringocystadenoma histo","title":"Syringocystadenoma papilliferum","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">Syringocystadenoma papilliferum</div><div class=\"cntnt\"><img style=\"width:715px; height:409px;\" src=\"images/DERM/98240_Syringocystadenoma_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Syringocystadenoma papilliferum is a superficial adnexal tumor. Cuboidal and columnar keratinocytes form interconnecting ducts that interrupt the normal epidermis and extend into the dermis. Papillary projections into duct lumens and decapitation secretion are typical. An inflammatory infiltrate rich in plasma cells surrounds the proliferation. Syringocystadenoma papilliferum often arise within a nevus sebaceus, as is the case in this example (H&amp;E 40x).</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98240 Version 2.0</div></div></div>"},"98241":{"type":"graphic_picture","displayName":"Hidradenoma papilliferum","title":"Hidradenoma papilliferum","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Hidradenoma papilliferum</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/98241_Hidradenoma_papilliferum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hidradenoma papilliferum presenting as a solitary, skin-colored nodule on the vulva.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98241 Version 1.0</div></div></div>"},"98242":{"type":"graphic_diagnosticimage","displayName":"MDCT visualization of iliofemoral vasculature","title":"Multidetector computed tomography visualization of iliofemoral vasculature","html":"<div class=\"graphic\"><div style=\"width: 772px\" class=\"figure\"><div class=\"ttl\">Multidetector computed tomography visualization of iliofemoral vasculature</div><div class=\"cntnt\"><img style=\"width:752px; height:325px;\" src=\"images/CARD/98242_MDCT_vsulztn_ilfmrl_vscltr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Three-dimensional, volume-rendered image of the iliofemoral vessels and boney pelvis. This reconstruction provides landmarks to display the site of minimal luminal diameter.<br />(B) Curved MPR of the right iliofemoral system in an 84-year-old male with severe aortic stenosis. The curved MPR demonstrates elongation of the arterial system and allows for assessment of luminal diameter and degree of encroachment by calcified plaque in multiple projections.</div><div class=\"graphic_footnotes\">MPR: multiplanar reformat.</div><div class=\"graphic_reference\">Reproduced from: Bloomfield GS, Gillam LD, Hahn RT, et al. A practical guide to multimodality imaging of transcatheter aortic valve replacement. JACC Cardiovasc Imaging 2012; 5:441. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98242 Version 3.0</div></div></div>"},"98243":{"type":"graphic_figure","displayName":"Anatomy of the aortic valvular complex","title":"Anatomy of the aortic valvular complex","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Anatomy of the aortic valvular complex</div><div class=\"cntnt\"><img style=\"width:496px; height:727px;\" src=\"images/CARD/98243_Anataorticvalvularcomplx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The three-dimensional aortic root contains three elliptical rings and one crown-like ring that together form an oval-shaped three-pronged coronet with three anchor points at the nadir of each aortic cusp. The \"aortic annulus\" is measured at the virtual ring formed by the basal attachments of the aortic cusps.</div><div class=\"graphic_footnotes\">VA: ventriculoarterial; A-M: aortic-mitral.</div><div class=\"graphic_reference\">From: Piazza N, de Jaegere P, Schultz C, et al. Anatomy of the aortic valvar complex and its implications for transcatheter implantation of the aortic valve. Circ Cardiovasc Interv 2008; 1:74. DOI: <a href=\"http://circinterventions.ahajournals.org/content/1/1/74.long\" target=\"_blank\">10.1161/CIRCINTERVENTIONS.108.780858</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2008 American Heart Association. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 98243 Version 2.0</div></div></div>"},"98244":{"type":"graphic_diagnosticimage","displayName":"Biplane echo sagittal plane bisects aortic annulus","title":"Biplane echocardiographic imaging identifies the sagittal imaging plane that bisects the largest dimension of the aortic annulus","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Biplane echocardiographic imaging identifies the sagittal imaging plane that bisects the largest dimension of the aortic annulus</div><div class=\"cntnt\"><img style=\"width:520px; height:594px;\" src=\"images/CARD/98244_Bpln_sgttl_bscts_artc_annls.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Biplane transthoracic imaging shows the sagittal (A) and corresponding transverse (B) plane. The large, vertical arrows define the imaging plane for the orthogonal view. The smaller, angled arrow shows the appropriate annular measurement in the on-axis sagittal plane.<br />Biplane transesophageal imaging shows the sagittal (C) and corresponding transverse (D) plane. Smaller, angled arrow in panel C shows the appropriate annular measurement in the on-axis sagittal plane.</div><div class=\"graphic_reference\">Reproduced from: Bloomfield GS, Gillam LD, Hahn RT, et al. A practical guide to multimodality imaging of transcatheter aortic valve replacement. JACC Cardiovasc Imaging 2012; 5:441. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98244 Version 2.0</div></div></div>"},"98245":{"type":"graphic_picture","displayName":"Hidradenoma histo","title":"Histologic features of hidradenoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histologic features of hidradenoma</div><div class=\"cntnt\"><img style=\"width:405px; height:722px;\" src=\"images/DERM/98245_Hidradenoma_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Hidradenomas can exhibit both eccrine and apocrine differentiation and are characterized by large, nodular collections of keratinocytes with variable duct formation (H&amp;E 40x).<br />(B) A variety of hidradenomas have been described. The pale/clear cell variant is composed of a preponderance of keratinocytes with abundant pale cytoplasm (H&amp;E 200x).</div><div id=\"graphicVersion\">Graphic 98245 Version 1.0</div></div></div>"},"98246":{"type":"graphic_diagnosticimage","displayName":"Measurement of the aortic annulus using MDCT","title":"Measurement of the aortic annulus using multidetector computed tomography","html":"<div class=\"graphic\"><div style=\"width: 794px\" class=\"figure\"><div class=\"ttl\">Measurement of the aortic annulus using multidetector computed tomography</div><div class=\"cntnt\"><img style=\"width:774px; height:303px;\" src=\"images/CARD/98246_Msurmn_artc_annls_usng_MDCT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Coronal plane view through the long axis of the LVOT. The longer dimension of the aortic annulus is depicted by the arrow.<br />(B) Sagittal plane view through the long axis of the LVOT. The shorter dimension of the annulus is depicted by the arrow.<br />(C) Transverse plane reconstructed using the double oblique technique of multiplanar reconstruction.</div><div class=\"graphic_footnotes\">LVOT: left ventricular outflow tract.</div><div class=\"graphic_reference\">Reproduced from: Bloomfield GS, Gillam LD, Hahn RT, et al. A practical guide to multimodality imaging of transcatheter aortic valve replacement. JACC Cardiovasc Imaging 2012; 5:441. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98246 Version 2.0</div></div></div>"},"98247":{"type":"graphic_figure","displayName":"Close proximity of the aortic annulus and mitral valve apparatus","title":"Anatomical display of the close proximity of the aortic annulus and the mitral valve apparatus","html":"<div class=\"graphic\"><div style=\"width: 642px\" class=\"figure\"><div class=\"ttl\">Anatomical display of the close proximity of the aortic annulus and the mitral valve apparatus</div><div class=\"cntnt\"><img style=\"width:622px; height:400px;\" src=\"images/CARD/98247_Clseprxaortcannulusmtrl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With the aortic root opened from the ventricular aspect, the continuity of the interleaflet triangles, the fibrous trigones, and the membranous septum are seen.</div><div class=\"graphic_footnotes\">A-M: aortic-mitral.</div><div class=\"graphic_reference\">From: Piazza N, de Jaegere P, Schultz C, et al. Anatomy of the aortic valvar complex and its implications for transcatheter implantation of the aortic valve. Circ Cardiovasc Interv 2008; 1:74. DOI: <a href=\"http://circinterventions.ahajournals.org/content/1/1/74.long\" target=\"_blank\">10.1161/CIRCINTERVENTIONS.108.780858</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2008 American Heart Association. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 98247 Version 3.0</div></div></div>"},"98248":{"type":"graphic_table","displayName":"Chemotherapy outcomes for high-risk GTN","title":"Results of chemotherapy in 90 patients with high-risk stage II and III gestational trophoblastic neoplasia (GTN) (New England Trophoblastic Disease Center, July 1965 to December 2013)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Results of chemotherapy in 90 patients with high-risk stage II and III gestational trophoblastic neoplasia (GTN) (New England Trophoblastic Disease Center, July 1965 to December 2013)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Treatment</td> <td class=\"subtitle1\">Number of patients</td> <td class=\"subtitle1\">Remissions (%)</td> </tr> <tr> <td class=\"divider_bottom centered\" rowspan=\"3\">II</td> <td>&nbsp;</td> <td class=\"centered\">16</td> <td class=\"centered\">16 (100)</td> </tr> <tr> <td class=\"centered\">Primary</td> <td class=\"centered\">11</td> <td class=\"centered\">11 (68.9)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">Second-line</td> <td class=\"centered\">5</td> <td class=\"centered\">5 (31.1)</td> </tr> <tr> <td class=\"divider_bottom centered\" rowspan=\"3\">III</td> <td>&nbsp;</td> <td class=\"centered\">74</td> <td class=\"centered\">71 (95.9)</td> </tr> <tr> <td class=\"centered\">Primary</td> <td class=\"centered\">59</td> <td class=\"centered\">59 (79.7)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">Second-line</td> <td class=\"centered\">15</td> <td class=\"centered\">12 (16.3)</td> </tr> <tr> <td class=\"centered\" rowspan=\"3\">Total</td> <td>&nbsp;</td> <td class=\"centered\">90</td> <td class=\"centered\">87 (96.7)</td> </tr> <tr> <td class=\"centered\">Primary</td> <td class=\"centered\">70</td> <td class=\"centered\">70 (77.8)</td> </tr> <tr> <td class=\"centered\">Second-line</td> <td class=\"centered\">20</td> <td class=\"centered\">17 (18.9)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 98248 Version 1.0</div></div></div>"},"98249":{"type":"graphic_diagnosticimage","displayName":"Determination of aortic plane pre-procedural CT and angiography","title":"Determination of the aortic plane using pre-procedural CT scan and angiography","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Determination of the aortic plane using pre-procedural CT scan and angiography</div><div class=\"cntnt\"><img style=\"width:726px; height:242px;\" src=\"images/CARD/98249_Dtrm_artc_pln_prprcd_CT_ang.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Three-dimensional CT reconstruction demonstrating the aortic plane running from right anterior oblique (RAO) caudal to left anterior oblique (LAO) cranial angles.<br />(B, C) Aortic root injection in LAO (B) and RAO (C) views demonstrates the aortic valve plane with location of each leaflet, respectively.</div><div class=\"graphic_footnotes\">CT: computed tomography; NCC: noncoronary cusp; LCC: left coronary cusp; RCC: right coronary cusp.</div><div class=\"graphic_reference\">Reproduced from: Bloomfield GS, Gillam LD, Hahn RT, et al. A practical guide to multimodality imaging of transcatheter aortic valve replacement. JACC Cardiovasc Imaging 2012; 5:441. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98249 Version 2.0</div></div></div>"},"98250":{"type":"graphic_diagnosticimage","displayName":"Echo dilatation decrease paravalvular regurgitation","title":"Echocardiography-guided post-deployment balloon dilatation to decrease paravalvular regurgitation","html":"<div class=\"graphic\"><div style=\"width: 691px\" class=\"figure\"><div class=\"ttl\">Echocardiography-guided post-deployment balloon dilatation to decrease paravalvular regurgitation</div><div class=\"cntnt\"><img style=\"width:671px; height:731px;\" src=\"images/CARD/98250_Ech_dlttn_dcrs_prvlvlr_rgrg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Color Doppler imaging just after transcatheter heart valve deployment shows moderate paravalvular regurgitation (arrows).<br />(B) Following repeat balloon dilatation, the aortic regurgitation is mild.</div><div class=\"graphic_reference\">Reproduced from: Bloomfield GS, Gillam LD, Hahn RT, et al. A practical guide to multimodality imaging of transcatheter aortic valve replacement. JACC Cardiovasc Imaging 2012; 5:441. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98250 Version 1.0</div></div></div>"},"98251":{"type":"graphic_figure","displayName":"Grading criteria for paravalvular AR","title":"Grading criteria for paravalvular aortic regurgitation","html":"<div class=\"graphic\"><div style=\"width: 631px\" class=\"figure\"><div class=\"ttl\">Grading criteria for paravalvular aortic regurgitation</div><div class=\"cntnt\"><img style=\"width:611px; height:345px;\" src=\"images/CARD/98251_Grading_criteria_prvlvlr_AR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Schematic and illustrated representation of the short axis view at the level of the aortic valve by echocardiography. Image credit: CC Patrick J. Lynch and C. Carl Jaffe, Yale University, 2006.<br />(B) Echocardiographic and schematic illustrations of the short axis view of the aortic valve. Paravalvular AR can be graded according to the circumferential extent of the regurgitant jet. Paravalvular AR can be graded as mild, moderate, or severe based on a circumferential extent of &lt;10%, 10 to 20, or &gt;20%, respectively. Leon MB, Piazza N, Nikolsky E, et al. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol 2011; 57:253-69.</div><div class=\"graphic_footnotes\">AR: aortic regurgitation.</div><div class=\"graphic_reference\">Reproduced from: Bloomfield GS, Gillam LD, Hahn RT, et al. A practical guide to multimodality imaging of transcatheter aortic valve replacement. JACC Cardiovasc Imaging 2012; 5:441. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98251 Version 2.0</div></div></div>"},"98252":{"type":"graphic_table","displayName":"Chemotherapy outcomes in stage IV GTN","title":"Results of chemotherapy in 39 patients with stage IV gestational trophoblastic neoplasia (New England Trophoblastic Disease Center, July 1965 to December 2013)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Results of chemotherapy in 39 patients with stage IV gestational trophoblastic neoplasia (New England Trophoblastic Disease Center, July 1965 to December 2013)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Time period</td> <td class=\"subtitle1\">Total number of patients</td> <td class=\"subtitle1\">Remissions (%)</td> </tr> <tr> <td class=\"centered\">1965 to 1975</td> <td class=\"centered\">20</td> <td class=\"centered\">6 (30)</td> </tr> <tr> <td class=\"centered\">1976 to 2013</td> <td class=\"centered\">19</td> <td class=\"centered\">16 (84)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 98252 Version 1.0</div></div></div>"},"98253":{"type":"graphic_picture","displayName":"Seabather's eruption","title":"Seabather's eruption","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Seabather's eruption</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/ID/98253_Seabathers_eruption.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous papules on the trunk.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98253 Version 1.0</div></div></div>"},"98254":{"type":"graphic_picture","displayName":"Seabather's eruption on chest","title":"Seabather's eruption","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Seabather's eruption</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/ID/98254_Seabathers_eruption_chest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous papules on the breasts and trunk. The papules are primarily located in areas covered by a bathing suit.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98254 Version 1.0</div></div></div>"},"98255":{"type":"graphic_picture","displayName":"Pseudomonas folliculitis","title":"<em>Pseudomonas </em>folliculitis (hot tub folliculitis)","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\"><em>Pseudomonas </em>folliculitis (hot tub folliculitis)</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/ID/98255_Pseudomonas_folliculitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous papules and pustules.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98255 Version 1.0</div></div></div>"},"98256":{"type":"graphic_picture","displayName":"Pseudomonas folliculitis scattered papules","title":"<em>Pseudomonas</em> folliculitis (hot tub folliculitis)","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\"><em>Pseudomonas</em> folliculitis (hot tub folliculitis)</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/ID/98256_Psdmn_fllclts_scttrd_ppls.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous papules and small pustules on the trunk.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98256 Version 1.0</div></div></div>"},"98257":{"type":"graphic_picture","displayName":"Cysticercosis","title":"Cysticercosis","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Cysticercosis</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/ID/98257_Cysticercosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subcutaneous nodule secondary to cysticercosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98257 Version 1.0</div></div></div>"},"98258":{"type":"graphic_figure","displayName":"Modes of death based on heart failure severity","title":"Modes of death based on heart failure severity","html":"<div class=\"graphic\"><div style=\"width: 642px\" class=\"figure\"><div class=\"ttl\">Modes of death based on heart failure severity</div><div class=\"cntnt\"><img style=\"width:622px; height:310px;\" src=\"images/CARD/98258_Mode_death_heart_fail_sev.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">As the severity of heart failure symptoms worsens, the mode of death is less likely to be arrhythmic sudden cardiac death and more likely to be due to heart failure.</div><div class=\"graphic_footnotes\">NYHA: New York Heart Association; CHF: congestive heart failure.</div><div id=\"graphicVersion\">Graphic 98258 Version 2.0</div></div></div>"},"98259":{"type":"graphic_table","displayName":"Summary of MADIT I, MADIT II, and MUSTT trials","title":"Summary of MADIT I, MADIT II, and MUSTT trials","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of MADIT I, MADIT II, and MUSTT trials</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"24%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">MADIT I</td> <td class=\"subtitle1\">MUSTT</td> <td class=\"subtitle1\">MADIT II</td> </tr> <tr> <td><strong>Study duration</strong></td> <td class=\"centered\">12/90 to 3/96</td> <td class=\"centered\">11/90 to 10/96</td> <td class=\"centered\">7/97 to 11/01</td> </tr> <tr> <td><strong>Patients enrolled</strong></td> <td class=\"centered\">196</td> <td class=\"centered\">704</td> <td class=\"centered\">1232</td> </tr> <tr> <td><strong>Prematurely terminated</strong></td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> </tr> <tr> <td><strong>MI to qualify</strong></td> <td class=\"centered\">&#8805;3 weeks</td> <td class=\"centered\">&#8805;4 days</td> <td class=\"centered\">&#8805;1 month</td> </tr> <tr> <td><strong>PTCA</strong></td> <td class=\"centered\">&#62;3 months</td> <td class=\"centered\">&#8805;4 days</td> <td class=\"centered\">&#8805;3 months</td> </tr> <tr> <td><strong>CABG</strong></td> <td class=\"centered\">&#62;2 months</td> <td class=\"centered\">&#8805;4 days</td> <td class=\"centered\">&#8805;3 months</td> </tr> <tr> <td><strong>Age, mean</strong></td> <td class=\"centered\">63 years</td> <td class=\"centered\">67 years</td> <td class=\"centered\">~64 years</td> </tr> <tr> <td><strong>Percent women</strong></td> <td class=\"centered\">8%</td> <td class=\"centered\">10%</td> <td class=\"centered\">~15%</td> </tr> <tr> <td><strong>Ejection fraction, mean</strong></td> <td class=\"centered\">26%</td> <td class=\"centered\">30%</td> <td class=\"centered\">23%</td> </tr> <tr> <td><strong>Beta blocker usage</strong></td> <td class=\"centered\">18%</td> <td class=\"centered\">40%</td> <td class=\"centered\">70%</td> </tr> <tr> <td><strong>ACE inhibitor usage</strong></td> <td class=\"centered\">58%</td> <td class=\"centered\">75%</td> <td class=\"centered\">~69%</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MI: myocardial infarction; PTCA: percutaneous transluminal coronary angioplasty; CABG: coronary artery bypass grafting; ACE: angiotensin-converting enzyme.</div><div id=\"graphicVersion\">Graphic 98259 Version 2.0</div></div></div>"},"98261":{"type":"graphic_table","displayName":"Summary of primary prevention ICD trials","title":"Summary of primary prevention implantable cardioverter-defibrillator (ICD) trials","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of primary prevention implantable cardioverter-defibrillator&nbsp;(ICD) trials</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Study:</td> <td class=\"subtitle1\">MADIT I</td> <td class=\"subtitle1\">MUSTT</td> <td class=\"subtitle1\">MADIT II</td> <td class=\"subtitle1\">Definite</td> <td class=\"subtitle1\">SCD-HeFT</td> <td class=\"subtitle1\">Companion</td> <td class=\"subtitle1\">DANISH&nbsp;</td> </tr> <tr> <td><strong>Years</strong></td> <td class=\"centered\">1991-96</td> <td class=\"centered\">1990-96</td> <td class=\"centered\">1997-2001</td> <td class=\"centered\">1998-2003</td> <td class=\"centered\">1997-2003</td> <td class=\"centered\">2000-02</td> <td class=\"centered\">2008-14&nbsp;</td> </tr> <tr> <td><strong>Patients</strong></td> <td class=\"centered\">196</td> <td class=\"centered\">704</td> <td class=\"centered\">1232</td> <td class=\"centered\">458</td> <td class=\"centered\">2521</td> <td class=\"centered\">1520</td> <td class=\"centered\">&nbsp;1116</td> </tr> <tr> <td><strong>Follow-up (months)</strong></td> <td class=\"centered\">27</td> <td class=\"centered\">39</td> <td class=\"centered\">20</td> <td class=\"centered\">29</td> <td class=\"centered\">45</td> <td class=\"centered\">16</td> <td class=\"centered\">68&nbsp;</td> </tr> <tr> <td><strong>CAD</strong></td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No&nbsp;</td> </tr> <tr> <td><strong>Nonischemic</strong></td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> <td class=\"centered\">&nbsp;Yes</td> </tr> <tr> <td><strong>LVEF</strong></td> <td class=\"centered\">&#8804;35%</td> <td class=\"centered\">&#8804;40%</td> <td class=\"centered\">&#8804;30%</td> <td class=\"centered\">&#8804;35%</td> <td class=\"centered\">&#8804;35%</td> <td class=\"centered\">&#8804;35%</td> <td class=\"centered\">&#8804;35%&nbsp;</td> </tr> <tr> <td><strong>NYHA</strong></td> <td class=\"centered\">I,II,III</td> <td class=\"centered\">I,II,III</td> <td class=\"centered\">I,II,III(IV)</td> <td class=\"centered\">I,II,III</td> <td class=\"centered\">II,III</td> <td class=\"centered\">III,IV</td> <td class=\"centered\">II,III(also&nbsp;IV if CRT planned)&nbsp;</td> </tr> <tr> <td><strong>EPS</strong></td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">No&nbsp;</td> </tr> <tr> <td><strong>BB (%)</strong></td> <td class=\"centered\">18%</td> <td class=\"centered\">40%</td> <td class=\"centered\">70%</td> <td class=\"centered\">85%</td> <td class=\"centered\">69%</td> <td class=\"centered\">67%</td> <td class=\"centered\">92%&nbsp;</td> </tr> <tr> <td><strong>ACE (%)</strong></td> <td class=\"centered\">58%</td> <td class=\"centered\">75%</td> <td class=\"centered\">~69%</td> <td class=\"centered\">86%</td> <td class=\"centered\">85%</td> <td class=\"centered\">69%</td> <td class=\"centered\">97%&nbsp;(ACE or ARB)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CAD: coronary artery disease; LVEF: left ventricular ejection fraction; NYHA: New York Heart Association; CRT: cardiac resynchronization therapy; EPS: electrophysiology studies; BB: beta blocker; ACE: angiotensin converting enzyme inhibitor; ARB: angiotensin II receptor blocker.</div><div id=\"graphicVersion\">Graphic 98261 Version 4.0</div></div></div>"},"98262":{"type":"graphic_figure","displayName":"Surface anatomy of the leg: Lateral view","title":"Surface anatomy of the leg: Lateral view","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Surface anatomy of the leg: Lateral view</div><div class=\"cntnt\"><img style=\"width:485px; height:377px;\" src=\"images/EM/98262_Lateralviewsrfcantmylg.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Clinically Oriented Anatomy, 7th ed, Moore KL, Dalley AF, Agur AM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 98262 Version 3.0</div></div></div>"},"98264":{"type":"graphic_figure","displayName":"Collateral ligaments of knee: Lateral view","title":"Collateral ligaments of knee: Lateral view","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Collateral ligaments of knee: Lateral view</div><div class=\"cntnt\"><img style=\"width:473px; height:569px;\" src=\"images/EM/98264_Lateralviewclltrllgmnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Clinically Oriented Anatomy, 7th ed, Moore KL, Dalley AF, Agur AM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 98264 Version 3.0</div></div></div>"},"98269":{"type":"graphic_diagnosticimage","displayName":"MRI of hydrocephalus in TB meningitis","title":"Hydrocephalus in TB meningitis on MRI","html":"<div class=\"graphic\"><div style=\"width: 745px\" class=\"figure\"><div class=\"ttl\">Hydrocephalus in TB meningitis on MRI</div><div class=\"cntnt\"><img style=\"width:725px; height:295px;\" src=\"images/RADIOL/98269_MRI_hydrocephalus_TB_mnngts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A T1-weighted MRI of the brain in the sagittal projection shows hydrocephalus of the lateral ventricle (asterisk) and fourth ventricle (arrow). Image B is a FLAIR sequence in axial projection and shows moderate hydrocephalus of the lateral ventricles (asterisks) with trans-ependymal edema (arrows), and diffuse cerebral edema and effacement of the sulci (arrowhead). Image C is a FLAIR sequence showing hydrocephalus of the third ventricle (asterisk), transependymal edema (arrows), and effacement of the sulci (arrowhead) indicating cerebral edema.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; TB: tuberculous.</div><div class=\"graphic_reference\">Courtesy of Asim Mian, MD and Glenn Barest, MD.</div><div id=\"graphicVersion\">Graphic 98269 Version 1.0</div></div></div>"},"98270":{"type":"graphic_diagnosticimage","displayName":"MRI of meningeal enhancement in TB meningitis","title":"Meningeal enhancement in TB meningitis on MRI","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Meningeal enhancement in TB meningitis on MRI</div><div class=\"cntnt\"><img style=\"width:754px; height:478px;\" src=\"images/RADIOL/98270_MRI_mnngl_enhncmnt_TB_mnngt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image A is T1-weighted sequence following contrast and shows extensive basilar meningeal enhancement (arrows). Image B is also a contrast-enhanced study showing meningeal enhancement (arrows).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; TB: tuberculous.</div><div class=\"graphic_reference\">Courtesy of Asim Mian, MD and Glenn Barest, MD.</div><div id=\"graphicVersion\">Graphic 98270 Version 2.0</div></div></div>"},"98271":{"type":"graphic_diagnosticimage","displayName":"Chest radiograph and CT of the Westermark sign","title":"Chest radiograph and CT of the Westermark sign","html":"<div class=\"graphic\"><div style=\"width: 731px\" class=\"figure\"><div class=\"ttl\">Chest radiograph and CT of the Westermark sign</div><div class=\"cntnt\"><img style=\"width:711px; height:327px;\" src=\"images/RADIOL/98271_Xray_CT_Westermark_sign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Westermark sign in a patient with occlusive pulmonary embolism.<br />(A) Chest radiograph magnified A-P view shows a region of oligemia in the left lower lung (asterisk).<br />(B) Chest CT shows a large&nbsp;thrombus&nbsp;in the left main pulmonary artery (arrow).</div><div class=\"graphic_footnotes\">A-P: anteroposterior; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 98271 Version 2.0</div></div></div>"},"98272":{"type":"graphic_table","displayName":"Rehabilitation scheme for isolated low-grade LCL injuries","title":"Rehabilitation scheme for isolated low-grade LCL injuries","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rehabilitation scheme for isolated low-grade LCL injuries</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Time frame</td> <td class=\"subtitle1\">Grade 1 sprain</td> <td class=\"subtitle1\">Grade 2 sprain</td> </tr> <tr class=\"divider_bottom\"> <td>Week 1</td> <td> <ul> <li>Relative rest, ice, compression </li> <li>Crutches as needed and hinged brace protection </li> <li>ROM exercise </li> </ul> </td> <td> <ul> <li>Relative rest, ice, compression </li> <li>Crutches as needed; brief immobilization (2 to 3 weeks) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Week 2</td> <td> <ul> <li>ROM and stretching exercises </li> <li>Begin light quadriceps and hamstring strength exercises while wearing hinged brace </li> </ul> </td> <td> <ul> <li>Hinged brace worn during all weightbearing activities; knee motion restricted to between 20 and 90 degrees </li> <li>NWB ROM exercises </li> <li>Light strength and aerobic exercises </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Weeks 3-5</td> <td> <ul> <li>Gradual progression of strength exercises </li> <li>Light aerobic exercise while wearing hinged brace </li> <li>Gradual progression to sport-specific exercises and return to sport </li> </ul> </td> <td> <ul> <li>Use hinged brace that permits full ROM </li> <li>Progress to full weightbearing </li> <li>Gradual progression of ROM exercises </li> <li>Gradual progression of strength and aerobic exercises </li> <li>Balance training </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Weeks 6-10</td> <td> <ul> <li>N/A </li> </ul> </td> <td> <ul> <li>Continue strength exercises </li> <li>Progress to light jogging; gradually introduce cutting movements </li> <li>Balance training </li> </ul> </td> </tr> <tr> <td>Weeks 11-16</td> <td> <ul> <li>N/A </li> </ul> </td> <td> <ul> <li>Progressive plyometric training </li> <li>Gradual progression to sport-specific exercises and return to sport </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">N/A: not applicable; NWB: non-weightbearing; ROM: range of motion.</div><div id=\"graphicVersion\">Graphic 98272 Version 1.0</div></div></div>"},"98273":{"type":"graphic_table","displayName":"Success at finding an occult neuroendocrine tumor by surgery","title":"Success at identifying an occult primary neuroendocrine tumor by surgical exploration","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Success at identifying an occult primary neuroendocrine tumor by surgical exploration</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Author, year</td> <td class=\"subtitle1\">Number of unknown primary tumors</td> <td class=\"subtitle1\">Primary site identified, number</td> <td class=\"subtitle1\">Location of primary site</td> </tr> <tr> <td>Boudreaux JP, 2005<sup>[1]</sup></td> <td class=\"centered\">22</td> <td class=\"centered\">17 (77.3%)</td> <td>Not specified</td> </tr> <tr> <td>Wang SC, 2010<sup><span style=\"font-size: 13px;\">[2]</span></sup></td> <td class=\"centered\">15</td> <td class=\"centered\">13 (86.7%)&nbsp;</td> <td>12 ileum, 1 jejunum</td> </tr> <tr> <td>Massimo KP, 2012<sup><span style=\"font-size: 13px;\">[3]</span></sup></td> <td class=\"centered\">52</td> <td class=\"centered\">39 (75%)</td> <td>Most in small intestine</td> </tr> <tr> <td>Bartlett EK, 2013<sup><span style=\"font-size: 13px;\">[4]</span></sup></td> <td class=\"centered\">28</td> <td class=\"centered\">25 (89.3%)&nbsp;</td> <td>10 terminal ileum, 12 other small intestine</td> </tr> <tr> <td>Wang Y, 2013<sup>[5]</sup></td> <td class=\"centered\">26</td> <td class=\"centered\">26 (100%)</td> <td>23 ileum, 3 pancreas</td> </tr> <tr> <td>Total</td> <td class=\"centered\">143</td> <td class=\"centered\">120 (83.9%)</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Elevated levels of urinary 5-hydroxyindoleacetic acid or plasma 5-hydroxyindoleacetic acid also suggests a small intestine primary. Evidence is accumulating at experienced centers showing that most (83.9%) unknown primary tumors are found in the small intestine, in particular the ileum, by surgical exploration.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Boudreaux JP, Putty B, Grey DJ, et al. Surgical treatment of advanced-stage carcinoid tumors: lessons learned. Ann Surg 2005; 241:839.</LI>&#xD;&#xA;<LI>Wang SC, Parekh JR, Zuraek MB, et al. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg 2010; 145:276.</LI>&#xD;&#xA;<LI>Massimino KP, Han E, Pommier SJ, Pommier&nbsp;RF. Laparoscopic surgical exploration is an effective strategy for locating occult primary neuroendocrine tumors. Am J Surg 2012; 203:628.</LI>&#xD;&#xA;<LI>Bartlett EK, Roses RE, Gupta M, et al. Surgery for metastatic neuroendocrine tumors with occult primaries. J Surg Res 2013; 184:221.</LI>&#xD;&#xA;<LI>Wang Y, Rau J, Diebold AE, et al. Neuroendocrine tumors (NETs)of unknown primary: is early surgical exploration and aggressive debulking justifiable? (abstract). Poster presented at the North American Neuroendocrine Tumor Society 2013 Neuroendocrine Tumor Symposium: October 4, 2013; Charleston, SC.</LI></OL>Reproduced with permission from: Bergsland EK, Nakakura EK. Neuroendocrine Tumors of Unknown Primary: Is the Primary Site Really Not Known? JAMA Surg 2014; 149:889. Copyright © 2014 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98273 Version 4.0</div></div></div>"},"98278":{"type":"graphic_picture","displayName":"Sporotrichosis","title":"Sporotrichosis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Sporotrichosis</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/98278_Sporotrichosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nodular lymphangitis in sporotrichosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98278 Version 1.0</div></div></div>"},"98279":{"type":"graphic_picture","displayName":"Tubular adenoma histo","title":"Histologic features of tubular adenoma of the skin","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Histologic features of tubular adenoma of the skin</div><div class=\"cntnt\"><img style=\"width:484px; height:726px;\" src=\"images/DERM/98279_Tubular_adenoma_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Tubular adenomas are benign sweat gland tumors with prominent ductal differentiation (H&amp;E 20x).<br />(B) Multiple collections of keratinocytes with central ducts form tubular structures that may have papillary projections in their cystically-dilated lumens (H&amp;E 100x).</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98279 Version 2.0</div></div></div>"},"98280":{"type":"graphic_picture","displayName":"Gnathostomiasis","title":"Gnathostomiasis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Gnathostomiasis</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/ID/98280_Gnathostomiasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Serpiginous erythematous plaque on the trunk of a patient with gnathostomiasis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98280 Version 1.0</div></div></div>"},"98282":{"type":"graphic_picture","displayName":"Myiasis","title":"Myiasis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Myiasis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/ID/98282_Myiasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nodule containing fly larva. Note the central punctum.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98282 Version 1.0</div></div></div>"},"98283":{"type":"graphic_picture","displayName":"Myiasis with larva","title":"Myiasis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Myiasis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/ID/98283_Myiasis_with_larva.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fly larva protruding from erythematous nodule in skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98283 Version 1.0</div></div></div>"},"98284":{"type":"graphic_picture","displayName":"Tungiasis","title":"Tungiasis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Tungiasis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/ID/98284_Tungiasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Papule containing a female sand flea <em>(Tunga penetran</em>s) on the distal toe.</div><div class=\"graphic_reference\">Reproduced with permission from: <A spellcheck=true href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98284 Version 1.0</div></div></div>"},"98285":{"type":"graphic_picture","displayName":"Adenoid cystic carcinoma histo","title":"Histologic features of adenoid cystic carcinoma of the skin","html":"<div class=\"graphic\"><div style=\"width: 731px\" class=\"figure\"><div class=\"ttl\">Histologic features of adenoid cystic carcinoma of the skin</div><div class=\"cntnt\"><img style=\"width:711px; height:533px;\" src=\"images/DERM/98285_Adenoid_cystc_carcinm_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The hallmark histopathologic finding in adenoid cystic carcinoma is a cribriform architecture in which multiple circular collections of mucin form within tumor aggregations in a sieve-like pattern (H&amp;E 100x).</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98285 Version 2.0</div></div></div>"},"98286":{"type":"graphic_picture","displayName":"Microcystic adnexal carcinoma histo","title":"Histologic features of microcystic adnexal carcinoma","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Histologic features of microcystic adnexal carcinoma</div><div class=\"cntnt\"><img style=\"width:480px; height:722px;\" src=\"images/DERM/98286_Micrcystc_adnxl_crcnm_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Microcystic adnexal carcinoma (MAC) is a locally aggressive adnexal carcinoma with divergent differentiation. Follicular differentiation in the form of keratin (horn) cysts is present in the superficial dermis (H&amp;E 20x).<br />(B) Deeper in the dermis, smaller aggregations of keratinocytes with sweat duct formation infiltrate between deep dermal collagen and into the subcutis. Dystrophic calcium deposition (fragmented purple material) is common (H&amp;E 100x).</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98286 Version 2.0</div></div></div>"},"98287":{"type":"graphic_picture","displayName":"Digital papillary adenocarcinoma histo","title":"Histologic features of digital papillary adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Histologic features of digital papillary adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:484px; height:724px;\" src=\"images/DERM/98287_Dgl_ppllry_adncrcnm_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Digital papillary adenocarcinomas have a multi-nodular growth pattern with ductal differentiation. Cystically-dilated areas are frequently present (H&amp;E 40x).<br />(B) Papillary projections into dilated ductal spaces are a characteristic finding. This example shows numerous mitotic figures, crowding of tumor nuclei, and prominent cytologic atypia (H&amp;E 200x).</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98287 Version 2.0</div></div></div>"},"98290":{"type":"graphic_picture","displayName":"Extramammary Paget disease histo","title":"Histopathologic features of extramammary Paget disease","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">Histopathologic features of extramammary Paget disease</div><div class=\"cntnt\"><img style=\"width:716px; height:461px;\" src=\"images/DERM/98290_Extrmmmry_Paget_disea_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extramammary Paget disease (EMPD) is characterized by large keratinocytes with abundant pale pink cytoplasm and large oval nuclei (pagetoid cytomorphology) that form nests in the epidermis. Solitary tumor cells can also be seen in the upper epidermis between the normal epidermal keratinocytes (pagetoid architecture). Duct formation is helpful in identifying the tumor, but is not always evident (H&amp;E 200x).</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98290 Version 2.0</div></div></div>"},"98291":{"type":"graphic_picture","displayName":"Trichoblastoma histo","title":"Histologic features of trichoblastoma","html":"<div class=\"graphic\"><div style=\"width: 745px\" class=\"figure\"><div class=\"ttl\">Histologic features of trichoblastoma</div><div class=\"cntnt\"><img style=\"width:725px; height:776px;\" src=\"images/DERM/98291_Trichoblastoma_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Trichoblastomas have large islands of basaloid keratinocytes with an associated hypercellular, fibrotic stroma (H&amp;E 40x).<br />(B) Peripheral palisading of the outermost keratinocytes is present, and dense collections of mesenchymal cells directly adjacent to the basaloid keratinocytes (papillary mesenchymal body) are identifiable (arrowhead) (H&amp;E 200x).</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98291 Version 2.0</div></div></div>"},"98292":{"type":"graphic_picture","displayName":"Trichoadenoma histo","title":"Histologic features of trichoadenoma","html":"<div class=\"graphic\"><div style=\"width: 677px\" class=\"figure\"><div class=\"ttl\">Histologic features of trichoadenoma</div><div class=\"cntnt\"><img style=\"width:657px; height:710px;\" src=\"images/DERM/98292_Trichoadenoma_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Trichoadenomas are benign follicular tumors with multiple cystic structures of varying size in the dermis (H&amp;E 40x).</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98292 Version 2.0</div></div></div>"},"98294":{"type":"graphic_picture","displayName":"Trichofolliculoma histo","title":"Histologic features of trichofolliculoma​","html":"<div class=\"graphic\"><div style=\"width: 648px\" class=\"figure\"><div class=\"ttl\">Histologic features of trichofolliculoma​</div><div class=\"cntnt\"><img style=\"width:628px; height:712px;\" src=\"images/DERM/98294_Trichofolliculoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Trichofolliculoma has a central dilated hair follicle from which multiple small vellus hair follicles emanate (H&amp;E 40x).</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98294 Version 3.0</div></div></div>"},"98295":{"type":"graphic_picture","displayName":"Trichodiscoma histo","title":"Histologic features of trichodiscoma","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Histologic features of trichodiscoma</div><div class=\"cntnt\"><img style=\"width:712px; height:466px;\" src=\"images/DERM/98295_Trichodiscoma_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Trichodiscoma is composed of a central zone of spindled fibroblasts with mucin deposition (bluish substance) and a rim of surrounding sebaceous glands arranged in what has been described as a mitt-like pattern (H&amp;E 20x).</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98295 Version 2.0</div></div></div>"},"98296":{"type":"graphic_picture","displayName":"Fibrofolliculoma histo","title":"Histologic features of fibrofolliculoma","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Histologic features of fibrofolliculoma</div><div class=\"cntnt\"><img style=\"width:712px; height:501px;\" src=\"images/DERM/98296_Fibrofolliculoma_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fibrofolliculoma has cystically-dilated follicular infundibula from which thin strands of keratinocytes radiate. Sebaceous glands can be found attached to the thin strands in some areas. A variably fibrotic and mucinous stroma is present (H&amp;E 100x).</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98296 Version 2.0</div></div></div>"},"98297":{"type":"graphic_picture","displayName":"Tumor follicular infundibulum histo","title":"Histologic features of tumor of the follicular infundibulum","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">Histologic features of tumor of the follicular infundibulum</div><div class=\"cntnt\"><img style=\"width:715px; height:224px;\" src=\"images/DERM/98297_Tumor_fllclr_infndblm_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tumor of the follicular infundibulum has a horizontal orientation to the tumor that parallels the epidermis. Keratinocytes with pale pink cytoplasm that contrast sharply with the darker pink epidermal keratinocytes descend from and reconnect with the undersurface of the epidermis. Small cyst and duct-like structures are focally present (H&amp;E 40x).</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98297 Version 2.0</div></div></div>"},"98298":{"type":"graphic_picture","displayName":"Pilomatricoma histo","title":"Histologic features of pilomatricoma​","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Histologic features of pilomatricoma​</div><div class=\"cntnt\"><img style=\"width:479px; height:720px;\" src=\"images/DERM/98298_Pilomatricoma_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Pilomatricoma is a well-circumscribed proliferation with basaloid keratinocytes resembling those seen in the hair bulb/matrix that transition into large masses of pink keratin material with focal calcification (H&amp;E 20x).<br />(B) The basaloid matrical cells abruptly keratinize into large collections of pink keratinocytes without nuclei (shadow cells) (H&amp;E 200x).</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98298 Version 2.0</div></div></div>"},"98299":{"type":"graphic_picture","displayName":"Pilomatricoma","title":"Pilomatricoma","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Pilomatricoma</div><div class=\"cntnt\"><img style=\"width:712px; height:551px;\" src=\"images/DERM/98299_Pilomatricoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pilomatricomas present as firm nodules in the skin with varying degrees of pink, blue, and white color. Ulceration with extrusion of calcified material can occasionally be seen.</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98299 Version 2.0</div></div></div>"},"98300":{"type":"graphic_picture","displayName":"Proliferating pilar tumor histo","title":"Histologic features of proliferating cystic acanthoma (proliferating pilar tumor)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histologic features of proliferating cystic acanthoma (proliferating pilar tumor)</div><div class=\"cntnt\"><img style=\"width:416px; height:722px;\" src=\"images/DERM/98300_Prolifert_pilar_tumor_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Proliferating cystic acanthoma (proliferating pilar tumor) consists of multiple small to large interconnecting collections of keratinocytes with abundant pink cytoplasm that cornify centrally without a granular layer. Central calcification is often present. Cytologic atypia is minimal in this case.<br />(A) H&amp;E 20x.<br />(B) H&amp;E 100x.</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98300 Version 2.0</div></div></div>"},"98301":{"type":"graphic_picture","displayName":"Sebaceous hyperplasia histo","title":"Histologic features of sebaceous hyperplasia","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">Histologic features of sebaceous hyperplasia</div><div class=\"cntnt\"><img style=\"width:716px; height:331px;\" src=\"images/DERM/98301_Sebaceous_hyperplasia_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sebaceous hyperplasia has multiple enlarged but otherwise normal sebaceous glands present around a dilated follicle or follicles in the upper dermis (H&amp;E 20x).</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98301 Version 2.0</div></div></div>"},"98302":{"type":"graphic_picture","displayName":"Sebaceous adenoma histo","title":"Histologic features of sebaceous adenoma​","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Histologic features of sebaceous adenoma​</div><div class=\"cntnt\"><img style=\"width:712px; height:412px;\" src=\"images/DERM/98302_Sebaceous_adenoma_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sebaceous adenomas can have overlapping histopathologic features with sebaceous hyperplasia, but typically lack a central follicle and often connect directly to the epidermis. Architecturally, sebaceous adenomas have a more disorganized appearance than sebaceous hyperplasia, with more basaloid germinative sebocytes (H&amp;E 40x).</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98302 Version 2.0</div></div></div>"},"98303":{"type":"graphic_picture","displayName":"Sebaceoma histo","title":"Histologic features of sebaceoma","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Histologic features of sebaceoma</div><div class=\"cntnt\"><img style=\"width:560px; height:722px;\" src=\"images/DERM/98303_Sebaceoma_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sebaceoma is a variant of sebaceous adenoma that is typically located deeper in the dermis and has a predominance of germinative sebocytes over mature, lipidized sebocytes.<br />(A) H&amp;E 20x.<br />(B) H&amp;E 200x.</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98303 Version 2.0</div></div></div>"},"98304":{"type":"graphic_picture","displayName":"Sebaceous carcinoma histo","title":"Histologic features of sebaceous carcinoma","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Histologic features of sebaceous carcinoma</div><div class=\"cntnt\"><img style=\"width:480px; height:722px;\" src=\"images/DERM/98304_Sebaceous_carcinoma_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sebaceous carcinomas have variable numbers of fully lipidized sebocytes. They are characterized by an infiltrative growth pattern, cytologic atypia, and mitotic figures.<br />(A) H&amp;E 20x.<br />(B) H&amp;E 100x.</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98304 Version 2.0</div></div></div>"},"98305":{"type":"graphic_picture","displayName":"Brooke-Spiegler syndrome","title":"Brooke-Spiegler syndrome","html":"<div class=\"graphic\"><div style=\"width: 744px\" class=\"figure\"><div class=\"ttl\">Brooke-Spiegler syndrome</div><div class=\"cntnt\"><img style=\"width:724px; height:376px;\" src=\"images/DERM/98305_Brooke_spiegler_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Adolescent patient with Brooke-Spiegler syndrome. This patient already has &gt;50 papules on the temple and cheek ranging from 1 to 6 mm in size.<br />(B) As patients with Brooke-Spiegler syndrome age, their adnexal tumors may increase in size to over 1 cm in size and develop prominent telangiectasias.</div><div class=\"graphic_reference\">Courtesy of Jeffrey P North, MD.</div><div id=\"graphicVersion\">Graphic 98305 Version 1.0</div></div></div>"},"98306":{"type":"graphic_picture","displayName":"Cowden syndrome","title":"Cowden syndrome​","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Cowden syndrome​</div><div class=\"cntnt\"><img style=\"width:712px; height:633px;\" src=\"images/DERM/98306_Cowden_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient with Cowden syndrome has numerous dome-shaped to verrucous pink papules on the face, several of which were biopsied and diagnosed as trichilemmomas.</div><div id=\"graphicVersion\">Graphic 98306 Version 1.0</div></div></div>"},"98312":{"type":"graphic_diagnosticimage","displayName":"Chest radiograph Williams-Campbell","title":"Chest radiograph of bronchiectasis in Williams-Campbell Syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of bronchiectasis in Williams-Campbell Syndrome</div><div class=\"cntnt\"><img style=\"width:440px; height:390px;\" src=\"images/PULM/98312_Chst_rdgrph_Williams_Cmpbll.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest computed tomogram&nbsp;of a patient with&nbsp;Williams-Campbell syndrome showing cystic bronchiectasis (arrow) and dilation of medium caliber airways. In Williams-Campbell syndrome, generalized tracheobronchomalacia is caused by deficient cartilage in the 4th to 6th order bronchi.</div><div id=\"graphicVersion\">Graphic 98312 Version 1.0</div></div></div>"},"98313":{"type":"graphic_table","displayName":"Human papillomavirus (HPV) tests","title":"Human papillomavirus (HPV) tests","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Human papillomavirus (HPV) tests</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup span=\"2\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Number of HPV identified</td> <td class=\"subtitle1\">HPV types identified</td> <td class=\"subtitle1\">Results*</td> </tr> <tr> <td>Hybrid Capture 2</td> <td>13</td> <td>16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68 (not 66)</td> <td>Pooled result</td> </tr> <tr> <td>Cervista HPV HR test<sup>&#182;</sup></td> <td>14</td> <td>16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68</td> <td>Pooled result</td> </tr> <tr> <td rowspan=\"2\">cobas HPV test<sup>&#916;</sup></td> <td rowspan=\"2\">14</td> <td>16, 18</td> <td>Specific for 16/18</td> </tr> <tr> <td>31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68</td> <td>Pooled result for other 12 subtypes</td> </tr> <tr> <td>Aptima mRNA test<sup>&#9674;</sup></td> <td>14</td> <td>16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68</td> <td>Pooled result</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FDA: US Food and Drug Administration; HPV: human papillomavirus.<br />* Pooled result: Positive result for any of the HPV types, not specific for any one type.<br />¶ The Cervista 16/18 specifically detects HPV 16 and 18. It is FDA-approved for use in women ≥30 years as a follow-up to a positive Cervista HPV HR test or in women any age with borderline cytology results.<br />Δ FDA approved for use alone as primary screening in women 25 years and older.<br /><FONT class=lozenge>◊</FONT> The Aptima HPV 16 18/45 specifically detects HPV 16, 18, and/or 45. It is FDA-approved for use in women ≥30 years as a follow-up to a positive Aptima mRNA test or in women ≥21 years as a follow-up to a borderline cytology result.</div><div id=\"graphicVersion\">Graphic 98313 Version 3.0</div></div></div>"},"98314":{"type":"graphic_table","displayName":"HCT characteristics and infectious risk","title":"Effect of transplant characteristics on infectious risk in hematopoietic cell transplant recipients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Effect of transplant characteristics on infectious risk in hematopoietic cell transplant recipients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Transplant parameter</td> <td class=\"subtitle1\">Effect on host barriers and immunity</td> <td class=\"subtitle1\">Infectious consequences</td> </tr> <tr> <td>Type of transplant</td> <td>Allogeneic: slower B and T cell immune reconstitution</td> <td>Greater risk for infections of all types, but especially invasive fungal and herpesvirus infections; longer interval of risk</td> </tr> <tr> <td>Type of allogeneic donor</td> <td>Unrelated or mismatched donor: slower B and T cell immune reconstitution</td> <td>Greater risk for infections of all types, but especially invasive fungal and herpesvirus infections; longer interval of risk</td> </tr> <tr> <td>Type of stem cell graft</td> <td> <p>Peripheral blood: faster neutrophil engraftment, more chronic GVHD</p> Cord blood: slower neutrophil engraftment, less GVHD, slower B and T cell immune reconstitution</td> <td>Different risks for infections associated with neutropenia and GVHD</td> </tr> <tr> <td>Stem cell graft manipulation</td> <td>T cell depletion: greater risk for graft rejection, slower B and T cell immune reconstitution</td> <td>Greater risk for neutropenic infections, lower risk for infections associated with chronic GVHD, greater and longer risk for herpesvirus and invasive fungal infections</td> </tr> <tr> <td>Conditioning regimen</td> <td>Intensive regimens: more mucosal injury, shorter time to neutropenia and longer period of neutropenia</td> <td>Greater risk for neutropenic infections, especially neutropenic enterocolitis (typhlitis)</td> </tr> <tr> <td>Immunosuppressive regimen (allogeneic)</td> <td> <p>ATG: more profound deficiency of T cell immunity</p> Methotrexate: more mucosal injury, longer time to neutrophil recovery</td> <td>Greater risk for invasive fungal and herpesvirus infections</td> </tr> <tr> <td>Central venous catheter</td> <td>Breach in skin barrier</td> <td>Greater risk for bacterial and (less frequently) fungal infections</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ATG: antithymocyte globulin; GVHD: graft-versus-host disease.</div><div class=\"graphic_reference\">Reproduced from: Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Infect Dis Clin North Am 2010; 24:257. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98314 Version 1.0</div></div></div>"},"98319":{"type":"graphic_table","displayName":"EMA-CO for GTN","title":"Etoposide, methotrexate, plus dactinomycin followed by cyclophosphamide and vincristine (EMA-CO) for gestational trophoblastic neoplasia (GTN)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etoposide, methotrexate, plus dactinomycin followed by cyclophosphamide and vincristine (EMA-CO) for gestational trophoblastic neoplasia (GTN)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Time</td> <td class=\"subtitle1\">Treatment</td> </tr> <tr> <td class=\"divider_bottom centered\" rowspan=\"4\">Day 1</td> <td>Etoposide 100 mg/m<sup>2</sup> by IV infusion in 200 mL of normal saline over 30 minutes</td> </tr> <tr> <td>Dactinomycin 0.5 mg IV push</td> </tr> <tr> <td>Methotrexate 100 mg/m<sup>2</sup> IV bolus followed by</td> </tr> <tr class=\"divider_bottom\"> <td>Methotrexate 200 mg/m<sup>2</sup> by IV infusion over 12 hours</td> </tr> <tr> <td class=\"divider_bottom centered\" rowspan=\"3\">Day 2</td> <td>Etoposide 100 mg/m<sup>2</sup> by IV infusion in 200 mL of normal saline over 30 minutes</td> </tr> <tr> <td>Dactinomycin 0.5 mg IV push</td> </tr> <tr class=\"divider_bottom\"> <td>Leucovorin 15 mg IM or orally every 12 hours for four doses beginning 24 hours after starting methotrexate</td> </tr> <tr> <td class=\"centered\" rowspan=\"2\">Day 8</td> <td>Cyclophosphamide 600 mg/m<sup>2</sup> IV in normal saline</td> </tr> <tr> <td>Vincristine 1 mg/m<sup>2</sup> IV push</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous; IM: intramuscular.</div><div class=\"graphic_reference\">Reproduced with permission from: Lurain JR, Singh DK, Schink JC. Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy. J Reprod Med 2006; 51:767. Copyright &copy; 2006 Journal of Reproductive Medicine, Inc.</div><div id=\"graphicVersion\">Graphic 98319 Version 1.0</div></div></div>"},"98320":{"type":"graphic_table","displayName":"EMA-EP for GTN","title":"Etoposide, methotrexate, plus dactinomycin followed by etoposide and cisplatin (EMA-EP) for gestational trophoblastic neoplasia (GTN)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etoposide, methotrexate, plus dactinomycin followed by etoposide and cisplatin (EMA-EP) for gestational trophoblastic neoplasia (GTN)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Time</td> <td class=\"subtitle1\">Treatment</td> </tr> <tr> <td>Day 1</td> <td> <p>Etoposide 100 mg/m<sup>2</sup> by IV infusion in 200 mL of normal saline over 30 minutes</p> <p>Dactinomycin 0.5 mg IV push</p> <p>Methotrexate 100 mg/m<sup>2</sup> IV bolus followed by</p> Methotrexate 200 mg/m<sup>2</sup> by IV infusion over 12 hours</td> </tr> <tr> <td>Day 2</td> <td> <p>Etoposide 100 mg/m<sup>2</sup> by IV infusion in 200 mL of normal saline over 30 minutes</p> <p>Dactinomycin 0.5 mg IV push</p> Leucovorin* 15 mg IM or orally every 12 hours for four doses beginning 24 hours after starting methotrexate</td> </tr> <tr> <td>Day 8</td> <td> <p>Cisplatin 60 mg/m<sup>2</sup> IV</p> Etoposide 100 mg/m<sup>2</sup> by IV infusion in 200 mL of normal saline over 30 minutes</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous; IM: intramuscular.<br />* Also known as folinic acid.</div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Bower M, Newlands ES, Holden L, et al. EMA-CO for high-risk gestational trophoblastic neoplasia. J Clin Oncol 1997; 15:2636.</li>&#xD;&#xA;    <li>Ghaemmaghami F, Modares M, Arab M, et al. EMA-EP regimen, as firstline multiple agent chemotherapy in high-risk GTT patients (stage II-IV). Int J Gynecol Cancer 2004; 14:360.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 98320 Version 1.0</div></div></div>"},"98321":{"type":"graphic_picture","displayName":"Mucus impaction of ETT","title":"Mucus impaction of the endotracheal tube","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Mucus impaction of the endotracheal tube</div><div class=\"cntnt\"><img style=\"width:485px; height:725px;\" src=\"images/PULM/98321_Mucus_impaction_ETT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 39-year-old man with a history of alcohol abuse, morbid obesity, and obstructive sleep apnea was admitted to the ICU with multilobar pneumonia and respiratory failure. On ICU day 3, peak airway pressures were elevated and manual ventilation was difficult. A suction catheter could not be passed through the oral endotracheal tube (8 mm inner diameter). He was awakened from sedation and the endotracheal tube was removed. The endotracheal tube was noted to be almost completely obstructed with thick, purulent secretions. He required reintubation and eventual tracheostomy.</div><div id=\"graphicVersion\">Graphic 98321 Version 1.0</div></div></div>"},"98322":{"type":"graphic_figure","displayName":"Evaluation and management CAD patients undergoing valve surgery","title":"Evaluation and management of coronary artery disease in patients undergoing valve surgery","html":"<div class=\"graphic\"><div style=\"width: 802px\" class=\"figure\"><div class=\"ttl\">Evaluation and management of coronary artery disease in patients undergoing valve surgery</div><div class=\"cntnt\"><img style=\"width:782px; height:484px;\" src=\"images/CARD/98322_Eval_mang_CAD_valve_surgery.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For the strength of recommendations: Class I means the procedure/treatment should be performed/administered. Class IIa means it is reasonable to perform the procedure/administer treatment. Class IIb means the procedure/treatment may be considered. Class III means that the procedure or treatment is not useful/effective and may be harmful.<br />For the level of evidence: Level A means multiple populations evaluated; data derived from multiple randomized clinical trials or meta-analyses. Level B means limited populations evaluated; data derived from a single randomized trial or nonrandomized studies. Level C means very limited populations evaluated; only consensus opinion of experts, case studies, or standard of care.</div><div class=\"graphic_footnotes\">CABG: coronary artery bypass graft; CAD: coronary artery disease; CT: computed tomography; IE: infective endocarditis; LV: left ventricular; PCI: percutaneous coronary intervention.</div><div class=\"graphic_reference\">Reproduced from: Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:e57. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98322 Version 2.0</div></div></div>"},"98323":{"type":"graphic_picture","displayName":"Cuff leak","title":"Cuff leak from the endotracheal tube","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Cuff leak from the endotracheal tube</div><div class=\"cntnt\"><img style=\"width:532px; height:713px;\" src=\"images/PULM/98323_Cuff_leak.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 56-year-old woman with advanced multiple sclerosis was admitted with pyelonephritis, septic shock, and respiratory failure. She was trans-laryngeally intubated with a 7.5 mm inner diameter endotracheal tube through the mouth. Her course was characterized by hyperactive delirium and agitation. On ICU day 4, the exhaled tidal volume was noted to be less than the set tidal volume on volume assist-control ventilation, and the pilot balloon was soft despite multiple insufflations of air. She was sedated with midazolam and she was reintubated using a tube changing catheter. Examination of the first endotracheal tube revealed that the pilot balloon tube was compromised, likely from the patient repeatedly biting on it (arrow).</div><div id=\"graphicVersion\">Graphic 98323 Version 1.0</div></div></div>"},"98324":{"type":"graphic_figure","displayName":"Indications for intervention for rheumatic MS","title":"Indications for intervention for rheumatic MS","html":"<div class=\"graphic\"><div style=\"width: 758px\" class=\"figure\"><div class=\"ttl\">Indications for intervention for rheumatic MS</div><div class=\"cntnt\"><img style=\"width:738px; height:470px;\" src=\"images/CARD/98324_Intervention_rheumatic_MS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For the strength of recommendations: Class I means the procedure/treatment should be performed/administered. Class IIa means it is reasonable to perform the procedure/administer treatment. Class IIb means the procedure/treatment may be considered. Class III means that procedure or treatment is not useful/effective and may be harmful.<br />For the level of evidence: Level A means multiple populations evaluated; data derived from multiple randomized clinical trials or meta-analyses. Level B means limited populations evaluated; data derived from a single randomized trial or nonrandomized studies. Level C means very limited populations evaluated; only consensus opinion of experts, case studies, or standard of care.</div><div class=\"graphic_footnotes\">AF: atrial fibrillation; LA: left atrial; MR: mitral regurgitation; MS: mitral stenosis; MVA: mitral valve area; MVR: mitral valve surgery (repair or replacement); NYHA: New York Heart Association; PCWP: pulmonary capillary wedge pressure; PMBC: percutaneous mitral balloon commissurotomy; T&frac12;: pressure half-time.</div><div class=\"graphic_reference\">Reproduced from: Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:e57. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98324 Version 2.0</div></div></div>"},"98325":{"type":"graphic_figure","displayName":"Indications for surgery for MR","title":"Indications for surgery for MR","html":"<div class=\"graphic\"><div style=\"width: 816px\" class=\"figure\"><div class=\"ttl\">Indications for surgery for MR</div><div class=\"cntnt\"><img style=\"width:796px; height:520px;\" src=\"images/CARD/98325_Indications_surgery_MR.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For the strength of recommendations: Class I means procedure/treatment should be performed/administered. Class IIa means it is reasonable to perform procedure/administer treatment. Class IIb means the procedure/treatment may be considered. Class III means that procedure or treatment is not useful/effective and may be harmful.<br />For the level of evidence: Level A means multiple populations evaluated; data derived from multiple randomized clinical trials or meta-analyses. Level B means limited populations evaluated; data derived from a single randomized trial or nonrandomized studies. Level C means very limited populations evaluated; only consensus opinion of experts, case studies, or standard of care.</div><div class=\"graphic_footnotes\">AF: atrial fibrillation; CAD: coronary artery disease; CRT: cardiac resynchronization therapy; ERO: effective regurgitant orifice; HF: heart failure; LV: left ventricular; LVEF: left ventricular ejection fraction; LVESD: left ventricular end-systolic dimension; MR: mitral regurgitation, MV: mitral valve; MVR: mitral valve replacement; NYHA: New York Heart Association; PASP: pulmonary artery systolic pressure; RF: regurgitant fraction; RVol: regurgitant volume; Rx: therapy.<br />* Mitral valve repair is preferred over MVR when possible.</div><div class=\"graphic_reference\">Reproduced from: Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:e57. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98325 Version 2.0</div></div></div>"},"98326":{"type":"graphic_figure","displayName":"Indications for surgery for TR","title":"Indications for surgery for TR","html":"<div class=\"graphic\"><div style=\"width: 852px\" class=\"figure\"><div class=\"ttl\">Indications for surgery for TR</div><div class=\"cntnt\"><img style=\"width:832px; height:344px;\" src=\"images/CARD/98326_Indications_surgery_TR.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For the strength of recommendations: Class I means procedure/treatment should be performed/administered. Class IIa means it is reasonable to perform procedure/administer treatment. Class IIb means the procedure/treatment may be considered. Class III means that procedure or treatment is not useful/effective and may be harmful.<br />For the level of evidence: Level A means multiple populations evaluated; data derived from multiple randomized clinical trials or meta-analyses. Level B means limited populations evaluated; data derived from a single randomized trial or nonrandomized studies. Level C means very limited populations evaluated; only consensus opinion of experts, case studies, or standard of care.</div><div class=\"graphic_footnotes\">LV: left ventricular; PHTN: pulmonary hypertension; RV: right ventricular; TA: tricuspid annular; TR: tricuspid regurgitation; TTE: transthoracic echocardiogram; TV: tricuspid valve; TVR: tricuspid valve replacement.<br />* TA dilation is defined by &gt;40 mm on TTE (&gt;21 mm/m<sup>2</sup>) or &gt;70 mm on direct intraoperative measurement.</div><div class=\"graphic_reference\">Reproduced from: Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:e57. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98326 Version 2.0</div></div></div>"},"98327":{"type":"graphic_figure","displayName":"Pott's shunt","title":"Pott's shunt","html":"<div class=\"graphic\"><div style=\"width: 609px\" class=\"figure\"><div class=\"ttl\">Pott's shunt</div><div class=\"cntnt\"><img style=\"width:589px; height:671px;\" src=\"images/CARD/98327_Potts_shunt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic image demonstrating a Pott's shunt, which is surgical communication created between the descending thoracic aorta and the left pulmonary artery.</div><div class=\"graphic_reference\">Courtesy of Heidi Connolly, MD and Jonathan Johnson, MD. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98327 Version 1.0</div></div></div>"},"98328":{"type":"graphic_figure","displayName":"Waterston shunt","title":"Waterston shunt","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Waterston shunt</div><div class=\"cntnt\"><img style=\"width:582px; height:651px;\" src=\"images/CARD/98328_Waterston_shunt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Waterston shunt is surgical communication created between the ascending aorta and right pulmonary artery.</div><div class=\"graphic_reference\">Courtesy of Heidi Connolly, MD and Jonathan Johnson, MD. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98328 Version 1.0</div></div></div>"},"98330":{"type":"graphic_figure","displayName":"A multiple time-series study","title":"A multiple time-series study","html":"<div class=\"graphic\"><div style=\"width: 599px\" class=\"figure\"><div class=\"ttl\">A multiple time-series study</div><div class=\"cntnt\"><img style=\"width:579px; height:481px;\" src=\"images/PC/98330_A_multiple_time-series_study.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Change in cervical cancer mortality rates according to year organized Pap smear screening programs were implemented and targeted coverage. Arrows mark the year coverage was achieved for each country.</div><div class=\"graphic_reference\">Reproduced from: Laara E, Day NE, Hakama M. Trends in mortality from cervical cancer in Nordic countries: association with organized screening programmes. Lancet 1987;1(8544):1247. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98330 Version 2.0</div></div></div>"},"98332":{"type":"graphic_picture","displayName":"Pityriasis rosea - hyperpigmented","title":"Pityriasis rosea","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Pityriasis rosea</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/98332_Pityriasis_rosea_hyprpgmnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented oval plaques on the trunk in a \"Christmas tree\" distribution.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98332 Version 1.0</div></div></div>"},"98333":{"type":"graphic_picture","displayName":"Pityriasis rosea on back","title":"Pityriasis rosea","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Pityriasis rosea</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/98333_Pityriasis_rosea_back.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous, scaly papules and plaques on the trunk in a \"Christmas tree\" distribution.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98333 Version 1.0</div></div></div>"},"98334":{"type":"graphic_picture","displayName":"Pityriasis rosea papules and plaques","title":"Pityriasis rosea","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Pityriasis rosea</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/98334_Pityriasis_rosea_ppl_plq.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous and hyperpigmented papules and plaques on the neck and face.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98334 Version 1.0</div></div></div>"},"98335":{"type":"graphic_picture","displayName":"Pityriasis rosea close view","title":"Pityriasis rosea","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Pityriasis rosea</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/98335_Pityriasis_rosea_close_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous plaques with scale. The small plaque on the left demonstrates the classic collarette of scale associated with pityriasis rosea.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98335 Version 1.0</div></div></div>"},"98336":{"type":"graphic_picture","displayName":"Pityriasis rosea inguinal","title":"Pityriasis rosea","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Pityriasis rosea</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/98336_Pityriasis_rosea_inguinal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous, scaly plaques with peripheral scale in the inguinal region.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98336 Version 1.0</div></div></div>"},"98338":{"type":"graphic_picture","displayName":"Pityriasis rosea pathology","title":"Pityriasis rosea","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Pityriasis rosea</div><div class=\"cntnt\"><img style=\"width:590px; height:524px;\" src=\"images/DERM/98338_Pityriasisroseapathology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Superficial perivascular infiltrate of lymphocytes and extravasated erythrocytes that extend to the epidermis, where there is moderate acanthosis, spongiosis, decreased granular layer, and mounds of parakeratosis.</div><div class=\"graphic_reference\">Reproduced with permission from: Mobini N, Caire ST, Hu S, Kamino H. Noninfectious erythematous, papular, and squamous diseases. In: Lever's histopathology of the skin, 11th ed, Elder DE, Elenitsas R, Johnson B Jr, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2014. Copyright &copy; 2014 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 98338 Version 3.0</div></div></div>"},"98339":{"type":"graphic_picture","displayName":"Septal hematoma after nasal trauma","title":"Septal hematoma following nasal trauma","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Septal hematoma following nasal trauma</div><div class=\"cntnt\"><img style=\"width:712px; height:276px;\" src=\"images/EM/98339_Septal_hematom_aftr_nsl_trm.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Glenn Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 98339 Version 1.0</div></div></div>"},"98341":{"type":"graphic_picture","displayName":"Eastern coral snake","title":"<em>Micrurus fulvius fulvius</em> (eastern coral snake)","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\"><em>Micrurus fulvius fulvius</em> (eastern coral snake)</div><div class=\"cntnt\"><img style=\"width:700px; height:524px;\" src=\"images/EM/98341_Eastern_coral_snake.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The eastern coral snake is natively distributed in the United States from North Carolina south to Florida and then along the gulf coast to Texas, including southern parts of Alabama, Mississippi, and Louisiana. It has yellow bands next to black bands as shown which is different from other US snakes that are not venomous (eg, corn snake or king snake) which have red bands next to black bands.</div><div class=\"graphic_reference\">Image created by Mike Cardwell. Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98341 Version 1.0</div></div></div>"},"98356":{"type":"graphic_diagnosticimage","displayName":"Standard radiography series for shoulder ","title":"Standard radiography series for shoulder","html":"<div class=\"graphic\"><div style=\"width: 741px\" class=\"figure\"><div class=\"ttl\">Standard radiography series for shoulder</div><div class=\"cntnt\"><img style=\"width:721px; height:318px;\" src=\"images/RADIOL/98356_Radiograph_stndrd_shldr_srs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiograph in conventional A-P projection (A) shows overlap (arrow) of humeral head (h) with the glenoid (g). Image B is a Grashey projection and provides a clear view of the joint space (arrow). Image C is a lateral Y view and shows the humeral head (arrowheads) symmetrically positioned in the center of the \"Y\" of the scapula (dashed arrow).</div><div class=\"graphic_footnotes\">A-P: anteroposterior.</div><div id=\"graphicVersion\">Graphic 98356 Version 2.0</div></div></div>"},"98357":{"type":"graphic_diagnosticimage","displayName":"Radiograph normal shoulder with internal and external rotation","title":"Normal shoulder with internal and external rotation on radiograph","html":"<div class=\"graphic\"><div style=\"width: 679px\" class=\"figure\"><div class=\"ttl\">Normal shoulder with internal and external rotation on radiograph</div><div class=\"cntnt\"><img style=\"width:659px; height:320px;\" src=\"images/RADIOL/98357_Rdgr_nrml_shldr_intr_extrnl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An A-P radiograph with internal rotation (A) shows the position of the greater tuberosity (arrow). With external rotation (B), the greater tuberosity becomes more obvious (arrow).</div><div class=\"graphic_footnotes\">A-P: anteroposterior.</div><div id=\"graphicVersion\">Graphic 98357 Version 1.0</div></div></div>"},"98362":{"type":"graphic_figure","displayName":"Hypercontractility restricted to the LES","title":"Hypercontractility restricted to the lower esophageal sphincter","html":"<div class=\"graphic\"><div style=\"width: 714px\" class=\"figure\"><div class=\"ttl\">Hypercontractility restricted to the lower esophageal sphincter</div><div class=\"cntnt\"><img style=\"width:694px; height:676px;\" src=\"images/GAST/98362_Hyprcntrctlty_rstrct_LES.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hypercontractility restricted to the LES (panel A). Including the LES in the DCI measurement (dashed box) meets the criterion for hypercontractility, whereas excluding it would result in this being called normal. In the case of a marginal DCI (panel B), including LES in the DCI measurement also results in categorizing the swallow as hypercontractile instead of normal.</div><div class=\"graphic_footnotes\">LES: lower esophageal sphincter; DCI: distal contractile integral; s: seconds.</div><div class=\"graphic_reference\">From: Kahrilas PJ, Bredenoord AJ, Fox M, et al, and The International High Resolution Manometry Working Group. The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil 2015; 27:160. <a href=\"http://onlinelibrary.wiley.com/doi/10.1111/nmo.12477/abstract\" spellcheck=\"true\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1111/nmo.12477/abstract</a>. Copyright &copy; 2015. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\" spellcheck=\"true\" target=\"_blank\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" spellcheck=\"true\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 98362 Version 1.0</div></div></div>"},"98363":{"type":"graphic_figure","displayName":"Phases of throwing","title":"Phases of throwing","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Phases of throwing</div><div class=\"cntnt\"><img style=\"width:726px; height:348px;\" src=\"images/EM/98363_Phases_pitching.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The biomechanics of throwing are often separated into the following six phases: Windup; Stride (sometimes called early cocking); Cocking (sometimes called late cocking); Acceleration; Deceleration; and, Follow-through. A smooth transition from one phase to the next maximizes the velocity of the object thrown, while reducing the risk of injury. <br /></div><div class=\"graphic_reference\">Reproduced from: DiGiovine NM, Jobe FW, Pink M, Perry J. An electromyographic analysis of the upper extremity in pitching. J Shoulder Elbow Surg 1992 1:15. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98363 Version 3.0</div></div></div>"},"98367":{"type":"graphic_picture","displayName":"Panfolliculoma histo","title":"Histologic features of panfolliculoma","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Histologic features of panfolliculoma</div><div class=\"cntnt\"><img style=\"width:726px; height:549px;\" src=\"images/DERM/98367_Panfolliculomahisto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Solid aggregates in the dermis (H&amp;E 20x).<br />(B) Aggregates with follicular differentiation. Note the fibrous stroma (H&amp;E 100x).<br />(C) Aggregates composed of germinative cells, matrical cells, and cells with inner sheath differentiation (H&amp;E 400x).<br />(D) Cells with eosinophilic trichohyalin granules and associated blue-gray corneocytes, indicating inner sheath differentiation. Rudimentary papilla and inner sheath differentiation was evident (H&amp;E 200x).</div><div class=\"graphic_reference\">From: Shan SJ, Guo Y. Panfolliculoma and histopathologic variants: a study of 19 cases. Am J Dermatopathol 2014; 36:965. DOI: <a href=\"http://journals.lww.com/amjdermatopathology/pages/articleviewer.aspx?year=2014&amp;issue=12000&amp;article=00004&amp;type=abstract\" spellcheck=\"true\" target=\"_blank\">10.1097/DAD.0000000000000108</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2008 International Society of Dermatopathology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 98367 Version 2.0</div></div></div>"},"98371":{"type":"graphic_picture","displayName":"Trichilemmal carcinoma histo","title":"Histopathologic features of trichilemmal carcinoma","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Histopathologic features of trichilemmal carcinoma</div><div class=\"cntnt\"><img style=\"width:726px; height:273px;\" src=\"images/DERM/98371_Trichilemmalcarcinomhisto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Hematoxylin and eosin (original magnification x20), view showing lobular proliferation of atypical keratinocytes with areas of peripheral palisading of basaloid cells. The spinous layer shows broad areas of pale staining cells with areas of abrupt keratinization.<br />(B) Hematoxylin and eosin (original magnification x40), view showing enlarged keratinocytes with pleomorphic nuclei, and abundant mitotic activity, including atypical mitoses.</div><div class=\"graphic_reference\">From: Hamman MS, Brian Jiang SI. Management of trichilemmal carcinoma: an update and comprehensive review of the literature. Dermatol Surg 2014; 40:711. DOI: <a href=\"http://journals.lww.com/dermatologicsurgery/pages/articleviewer.aspx?year=2014&amp;issue=07000&amp;article=00001&amp;type=abstract\" spellcheck=\"true\" target=\"_blank\">10.1111/dsu.0000000000000002</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2014 American Society for Dermatologic Surgery. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 98371 Version 2.0</div></div></div>"},"98373":{"type":"graphic_table","displayName":"Symptoms of mast cell activation","title":"Symptoms of mast cell activation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms of mast cell activation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Flushing</td> </tr> <tr> <td>Pruritus</td> </tr> <tr> <td>Urticaria</td> </tr> <tr> <td>Angioedema</td> </tr> <tr> <td>Nasal congestion, rhinorrhea</td> </tr> <tr> <td>Wheezing, bronchospastic cough</td> </tr> <tr> <td>Headache</td> </tr> <tr> <td>Fatigue*</td> </tr> <tr> <td>Lethargy, memory and concentration problems*</td> </tr> <tr> <td>Diarrhea</td> </tr> <tr> <td>Gastric hyperacidity</td> </tr> <tr> <td>Abdominal cramping</td> </tr> <tr> <td>Nausea +/&ndash; vomiting</td> </tr> <tr> <td>Hypotension</td> </tr> <tr> <td>Tachycardia</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The symptoms of mast cell activation result from the physiologic actions of the chemical mediators released by mast cells. In patients with mast cell activation syndromes, combinations of these symptoms affecting two or more organ systems occur episodically.</div><div class=\"graphic_footnotes\">* Subjective complaints that should be accompanied by symptoms or signs affecting at least two other organ systems to prompt an evaluation for a mast cell disorder. </div><div id=\"graphicVersion\">Graphic 98373 Version 2.0</div></div></div>"},"98389":{"type":"graphic_picture","displayName":"Sebaceous hyperplasia nose","title":"Sebaceous hyperplasia","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Sebaceous hyperplasia</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/98389_Sebaceous_hyperplasia_nose.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sebaceous hyperplasia presenting as small, umbilicated brownish papules on the nose and central face of this patient.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98389 Version 1.0</div></div></div>"},"98390":{"type":"graphic_picture","displayName":"Sebaceous hyperplasia cheek","title":"Sebaceous hyperplasia","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Sebaceous hyperplasia</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/98390_Sebaceous_hyperplasia_cheek.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sebaceous hyperplasia presenting with multiple flesh-colored or yellowish papules on the cheek.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98390 Version 1.0</div></div></div>"},"98391":{"type":"graphic_figure","displayName":"Blalock-Taussig shunt","title":"Blalock-Taussig shunt","html":"<div class=\"graphic\"><div style=\"width: 900px\" class=\"figure\"><div class=\"ttl\">Blalock-Taussig shunt</div><div class=\"cntnt\"><img style=\"width:880px; height:410px;\" src=\"images/CARD/98391_Rsk_fct_CIPN_nrtxc_drg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right-sided&nbsp;classic Blalock-Taussig (BT) shunt (left image) and right-sided&nbsp;modified BT shunt (right image); the latter uses a Dacron tube to create the communication between the subclavian artery and pulmonary artery. In the current era, the modified BT is preferred. The shunt acts to increase pulmonary artery blood flow and saturation and is performed as a palliative procedure in cyanotic patients with reduced pulmonary blood flow. These shunts can be performed on either the left or right side.</div><div class=\"graphic_reference\">Courtesy of Heidi Connolly, MD and Jonathan Johnson, MD. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98391 Version 2.0</div></div></div>"},"98392":{"type":"graphic_table","displayName":"Causes elevated LDH","title":"Causes of an elevated serum lactate dehydrogenase level","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of an elevated serum lactate dehydrogenase level</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td><strong>Cardiac</strong></td> <td>Myocyte injury <ul class=\"decimal_heading\"> <li>Demand ischemia </li> <li>Trauma, cardiovascular surgery </li> <li>Toxins </li> <li>Infection (myocarditis, rheumatic fever) </li> <li>Drugs (alcohol, chemotherapy, cocaine, methysergide, carbon monoxide) </li> </ul> <p>&nbsp;</p> Hepatic congestion <ul class=\"decimal_heading\"> <li>Heart failure </li> </ul> <p>&nbsp;</p> Hemolysis <ul class=\"decimal_heading\"> <li>Prosthetic valves </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Central nervous system disorders</strong></td> <td> <ul> <li>Bacterial meningitis </li> <li>Cerebral hemorrhage </li> <li>Cerebral venous thrombosis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Drug-induced</strong></td> <td> <ul> <li>Neuroleptic agents (neuroleptic malignant syndrome) </li> <li>Withdrawal of L-Dopa or dopamine agonist </li> <li>Serotonin syndrome </li> <li>Malignant hyperthermia </li> <li>Recreational drugs </li> <li>Myopathies (colchicine, antimalarials, cholesterol-lowering drugs, cocaine, alcohol, glucocorticoid) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Endocrine</strong></td> <td> <ul> <li>Hypothyroidism </li> <li>Acromegaly </li> <li>Cushing's syndrome </li> <li>Diabetic muscle infarction </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Gastrointestinal</strong></td> <td> <ul> <li>Acute pancreatitis </li> <li>Intestinal obstruction </li> <li>Early acute hepatitis </li> <li>Ischemic hepatitis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Hematologic</strong></td> <td>Hemolytic anemias <ul class=\"decimal_heading\"> <li>Inherited (spherocytosis, sickle cell disease, deficiency of red blood cell enzymes) </li> <li>Acquired (microangiopathic hemolytic anemia, PNH, immune hemolysis) </li> </ul> <p>&nbsp;</p> Ineffective erythropoiesis <ul class=\"decimal_heading\"> <li>Pernicious anemia, folic acid deficiency </li> <li>Iron deficiency </li> <li>Primary myelofibrosis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Infection</strong></td> <td> <ul> <li>Pneumocystis pneumonia (late) </li> <li>Tuberculosis </li> <li>Malaria </li> <li>Parasitic </li> <li>Legionnaires disease </li> <li>Histoplasmosis </li> <li>Toxoplasmosis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Malignancy</strong></td> <td> <ul> <li>Leukemias </li> <li>Lymphomas </li> <li>Solid tumors (testicular germ cell tumors) </li> <li>Tumor lysis syndrome (large tumor burden) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Neuromuscular</strong></td> <td> <ul> <li>Myopathies (inherited, acquired, drug) </li> <li>Periodic paralyses </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Pregnancy</strong></td> <td> <ul> <li>Preeclampsia </li> <li>Adnexal mass in pregnancy </li> <li>HELLP syndrome </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Pulmonary</strong></td> <td> <ul> <li>Pulmonary embolism, infarction </li> <li>Pulmonary alveolar proteinosis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Renal</strong></td> <td> <ul> <li>Renal infarction </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Rheumatologic</strong></td> <td> <ul> <li>Dermatomyositis </li> <li>MCTD </li> <li>Rheumatoid arthritis </li> <li>Scleroderma </li> <li>Sj&#246;gren's syndrome </li> <li>SLE </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Trauma</strong></td> <td> <ul> <li>Rhabdomyolysis </li> <li>Surgery </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Vasculitis</strong></td> <td> <ul> <li>Polyarteritis nodosa </li> <li>Eosinophilic granulomatosis with polyangiitis (Churg-Strauss vasculitis) </li> <li>Granulomatosis with polyangiitis [Wegener's] </li> <li>Beh&#231;et's syndrome</li> <li>Sarcoidosis </li> </ul> </td> </tr> <tr> <td><strong>Idiosyncratic LDH elevation</strong></td> <td>The presence of macro-LDH (LDH combined with an immunoglobulin), not associated with any symptoms or particular disease</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PNH: paroxysmal nocturnal hemoglobinuria; HELLP: hemolysis, elevated liver enzymes, low platelets; MCTD: mixed connective tissue disease; SLE: systemic lupus erythematosus; LDH: lactate dehydrogenase.</div><div id=\"graphicVersion\">Graphic 98392 Version 2.0</div></div></div>"},"98393":{"type":"graphic_table","displayName":"Factor replacement for RICDs","title":"Factor replacement products for bleeding or surgery in patients with rare inherited coagulation factor deficiencies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factor replacement products for bleeding or surgery in patients with rare inherited coagulation factor deficiencies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Deficient factor</td> <td class=\"subtitle1\">Major bleeding/surgery (treat until healing is complete)</td> <td class=\"subtitle1\">Minor bleeding/surgery (treat for two to three days)</td> <td class=\"subtitle1\">Prophylaxis</td> </tr> <tr> <td> <p>XIII</p> Target level &#62;5%</td> <td> <p>rFXIII A-subunit: 35 international units/kg</p> <p>FXIII concentrate: 10 to 20 international units/kg</p> <p>FFP: 15 to 20 mL/kg</p> Cryoprecipitate: 1 bag/10 kg</td> <td> <p>rFXIII A-subunit: 35 international units/kg</p> <p>FXIII concentrate: 10 to 20 international units/kg</p> <p>FFP: 15 to 20 mL/kg</p> Cryoprecipitate: 1 bag/10 kg</td> <td> <p>rFXIII A-subunit: 35 international units/kg</p> <p>FXIII concentrate: 10 to 20 international units/kg</p> <p>FFP: 15 to 20 mL/kg</p> Cryoprecipitate: 1 bag/10 kg</td> </tr> <tr> <td> <p>X</p> Target level &#62;20%</td> <td> <p>FX concentrate: 25 international units/kg&nbsp;</p> <p>PCC (3 or 4 factor): 20 to 30 international units/kg</p> FFP: 15 to 20 mL/kg</td> <td> <p>FX concentrate: 25 international units/kg&nbsp;</p> <p>FFP: 15 to 20 mL/kg</p> </td> <td> <p>&nbsp;FX concentrate: 25 international units/kg</p> <p>PCC (3 or 4 factor)</p> FFP: 15 to 20 mL/kg</td> </tr> <tr> <td> <p>VII</p> Target level &#62;20%</td> <td> <p>rFVIIa: 15 to 30 mcg/kg</p> <p>FVII concentrate: 30 to 40 international units/kg</p> <p>PCC (4 factor): 20 to 30 international units/kg</p> FFP: 15 to 20 mL/kg</td> <td> <p>rFVIIa: 15 to 30 mcg/kg</p> <p>FVII concentrate: 30 to 40 international units/kg</p> FFP: 15 to 20 mL/kg</td> <td> <p>rFVIIa</p> FVII concentrate: 30 to 40 international units/kg</td> </tr> <tr> <td> <p>V</p> Target level &#62;20%</td> <td>FFP: 15 to 20 mL/kg</td> <td>FFP: 15 to 20 mL/kg</td> <td>FFP: 15 to 20 mL/kg</td> </tr> <tr> <td> <p>II</p> Target level &#62;30%</td> <td> <p>PCC (3 or 4 factor): 20 to 30 international units/kg</p> FFP: 15 to 20 mL/kg</td> <td>FFP: 15 to 20 mL/kg</td> <td>FFP: 15 to 20 mL/kg</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table serves as a general guide but does not substitute for clinical judgment in the management of bleeding; early involvement of a hemophilia treatment center or a clinician with expertise in managing coagulation factor deficiencies is advised. Dose adjustments may be required depending on&nbsp;severity of&nbsp;bleeding and factor activity&nbsp;levels. PCCs generally are not used in cases of minor bleeding or minor surgery due to their potential prothrombotic risks. Refer to UpToDate topics on rare coagulation disorders for further details including dosing intervals; indications for prophylaxis; other potential therapies; potential risks and complications of therapy; and other aspects of management.</div><div class=\"graphic_footnotes\">rFXIII A-subunit: recombinant factor XIII A-subunit; FFP: fresh frozen plasma; PCC: prothrombin complex concentrate; rFVIIa: recombinant activated factor VII.</div><div class=\"graphic_reference\">Adapted from: Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004; 104:1243.</div><div id=\"graphicVersion\">Graphic 98393 Version 2.0</div></div></div>"},"98394":{"type":"graphic_table","displayName":"Recommendations for AR intervention","title":"Summary of recommendations for aortic regurgitation intervention","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of recommendations for aortic regurgitation intervention</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Recommendations</td> <td class=\"subtitle1\">Class of recommendation</td> <td class=\"subtitle1\">Level of evidence</td> </tr> <tr> <td>AVR is indicated for symptomatic patients with severe AR regardless of LV systolic function (stage D)</td> <td class=\"centered\">I</td> <td class=\"centered\">B</td> </tr> <tr> <td>AVR is indicated for asymptomatic patients with chronic severe AR and LV systolic dysfunction (LVEF &#60;50%) (stage C2)</td> <td class=\"centered\">I</td> <td class=\"centered\">B</td> </tr> <tr> <td>AVR is indicated for patients with severe AR (stage C or D) while undergoing cardiac surgery for other indications</td> <td class=\"centered\">I</td> <td class=\"centered\">C</td> </tr> <tr> <td>AVR is reasonable for asymptomatic patients with severe AR with normal LV systolic function (LVEF &#8805;50%) but with LVESD &#62;50 mm (stage C2)</td> <td class=\"centered\">IIa</td> <td class=\"centered\">B</td> </tr> <tr> <td>AVR is reasonable in patients with moderate AR (stage B) who are undergoing other cardiac surgery</td> <td class=\"centered\">IIa</td> <td class=\"centered\">C</td> </tr> <tr> <td>AVR may be considered for asymptomatic patients with severe AR and normal LV systolic function (LVEF &#8805;50%, stage C) but with progressive severe LV dilation (LVEDD &#62;65 mm) if surgical risk is low*</td> <td class=\"centered\">IIb</td> <td class=\"centered\">C</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For the strength of recommendations: Class I means the procedure/treatment should be performed/administered. Class IIa means it is reasonable to perform the procedure/administer treatment. Class IIb means the procedure/treatment may be considered. Class III means that the procedure or treatment is not useful/effective and may be harmful.<br />For the level of evidence: Level A means multiple populations evaluated; data derived from multiple randomized clinical trials or meta-analyses. Level B means limited populations evaluated; data derived from a single randomized trial or nonrandomized studies. Level C means very limited populations evaluated; only consensus opinion of experts, case studies, or standard of care.</div><div class=\"graphic_footnotes\">AR: aortic regurgitation; AVR: aortic valve replacement; LV: left ventricular; LVEDD: left ventricular end-diastolic dimension; LVEF: left ventricular ejection fraction; LVESD: left ventricular end-systolic dimension.<br />* Particularly in the setting of progressive LV enlargement.</div><div class=\"graphic_reference\">Original figure modified for this publication. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:e57. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98394 Version 3.0</div></div></div>"},"98396":{"type":"graphic_table","displayName":"Recommendations for MS intervention","title":"Summary of recommendations for mitral stenosis intervention","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of recommendations for mitral stenosis intervention</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Recommendations</td> <td class=\"subtitle1\">Class of recommendation</td> <td class=\"subtitle1\">Level of evidence</td> </tr> <tr> <td>PMBC is recommended for symptomatic patients with severe MS (MVA &#8804;1.5 cm<sup>2</sup>, stage D) and favorable valve morphology in the absence of contraindications</td> <td class=\"centered\">I</td> <td class=\"centered\">A</td> </tr> <tr> <td>Mitral valve surgery is indicated in severely symptomatic patients (NYHA class III/IV) with severe MS (MVA &#8804;1.5 cm<sup>2</sup>, stage D) who are not high risk for surgery and who are not candidates for or failed previous PMBC</td> <td class=\"centered\">I</td> <td class=\"centered\">B</td> </tr> <tr> <td>Concomitant mitral valve surgery is indicated for patients with severe MS (MVA &#8804;1.5 cm<sup>2</sup>, stage C or D) undergoing other cardiac surgery</td> <td class=\"centered\">I</td> <td class=\"centered\">C</td> </tr> <tr> <td>PMBC is reasonable for asymptomatic patients with very severe MS (MVA &#8804;1.0 cm<sup>2</sup>, stage C) and favorable valve morphology in the absence of contraindications</td> <td class=\"centered\">IIa</td> <td class=\"centered\">C</td> </tr> <tr> <td>Mitral valve surgery is reasonable for severely symptomatic patients (NYHA class III/IV) with severe MS (MVA &#8804;1.5 cm<sup>2</sup>, stage D), provided there are other operative indications</td> <td class=\"centered\">IIa</td> <td class=\"centered\">C</td> </tr> <tr> <td>PMBC may be considered for asymptomatic patients with severe MS (MVA &#8804;1.5 cm<sup>2</sup>, stage C) and favorable valve morphology who have new onset of AF in the absence of contraindications</td> <td class=\"centered\">IIb</td> <td class=\"centered\">C</td> </tr> <tr> <td>PMBC may be considered for symptomatic patients with MVA &#62;1.5 cm<sup>2</sup> if there is evidence of hemodynamically significant MS during exercise</td> <td class=\"centered\">IIb</td> <td class=\"centered\">C</td> </tr> <tr> <td>PMBC may be considered for severely symptomatic patients (NYHA class III/IV) with severe MS (MVA &#8804;1.5 cm<sup>2</sup>, stage D) who have suboptimal valve anatomy and are not candidates for surgery or at high risk for surgery</td> <td class=\"centered\">IIb</td> <td class=\"centered\">C</td> </tr> <tr> <td>Concomitant mitral valve surgery may be considered for patients with moderate MS (MVA 1.6 to 2.0 cm<sup>2</sup>) undergoing other cardiac surgery</td> <td class=\"centered\">IIb</td> <td class=\"centered\">C</td> </tr> <tr> <td>Mitral valve surgery and excision of the left atrial appendage may be considered for patients with severe MS (MVA &#8804;1.5 cm<sup>2</sup>, stages C and D) who have had recurrent embolic events while receiving adequate anticoagulation</td> <td class=\"centered\">IIb</td> <td class=\"centered\">C</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For the strength of recommendations: Class I means the procedure/treatment should be performed/administered. Class IIa means it is reasonable to perform the procedure/administer treatment. Class IIb means the procedure/treatment may be considered. Class III means that the procedure or treatment is not useful/effective and may be harmful.<br />For the level of evidence: Level A means multiple populations evaluated; data derived from multiple randomized clinical trials or meta-analyses. Level B means limited populations evaluated; data derived from a single randomized trial or nonrandomized studies. Level C means very limited populations evaluated; only consensus opinion of experts, case studies, or standard of care.</div><div class=\"graphic_footnotes\">AF: atrial fibrillation; MS: mitral stenosis; MVA: mitral valve area; NYHA: New York Heart Association; PMBC: percutaneous mitral balloon commissurotomy.</div><div class=\"graphic_reference\">Reproduced from: Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:e57. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98396 Version 2.0</div></div></div>"},"98397":{"type":"graphic_table","displayName":"Summary of recommendations for chronic primary MR","title":"Summary of recommendations for chronic primary MR","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of recommendations for chronic primary MR</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Recommendations</td> <td class=\"subtitle1\">Class of recommendation</td> <td class=\"subtitle1\">Level of evidence</td> </tr> <tr> <td>MV surgery is recommended for symptomatic patients with chronic severe primary MR (stage D) and LVEF &#62;30%</td> <td class=\"centered\">I</td> <td class=\"centered\">B</td> </tr> <tr> <td>MV surgery is recommended for asymptomatic patients with chronic severe primary MR and LV dysfunction (LVEF 30 to 60% and/or LVESD &#8805;40 mm, stage C2)</td> <td class=\"centered\">I</td> <td class=\"centered\">B</td> </tr> <tr> <td>MV repair is recommended in preference to MVR when surgical treatment is indicated for patients with chronic severe primary MR limited to the posterior leaflet</td> <td class=\"centered\">I</td> <td class=\"centered\">B</td> </tr> <tr> <td>MV repair is recommended in preference to MVR when surgical treatment is indicated for patients with chronic severe primary MR involving the anterior leaflet or both leaflets when a successful and durable repair can be accomplished</td> <td class=\"centered\">I</td> <td class=\"centered\">B</td> </tr> <tr> <td>Concomitant MV repair or replacement is indicated in patients with chronic severe primary MR undergoing cardiac surgery for other indications</td> <td class=\"centered\">I</td> <td class=\"centered\">B</td> </tr> <tr> <td>MV repair is reasonable in asymptomatic patients with chronic severe primary MR (stage C1) with preserved LV function (LVEF &#62;60% and LVESD &#60;40 mm) in whom the likelihood of a successful and durable repair without residual MR is &#62;95% with an expected mortality rate of &#60;1% when performed at a Heart Valve Center of Excellence</td> <td class=\"centered\">IIa</td> <td class=\"centered\">B</td> </tr> <tr> <td>MV repair is reasonable for asymptomatic patients with chronic severe nonrheumatic primary MR (stage C1) and preserved LV function in whom there is a high likelihood of a successful and durable repair with 1) new onset of AF or 2) resting pulmonary hypertension (pulmonary artery systolic pressure &#62;50 mmHg)</td> <td class=\"centered\">IIa</td> <td class=\"centered\">B</td> </tr> <tr> <td>Concomitant MV repair is reasonable in patients with chronic moderate primary MR (stage B) undergoing cardiac surgery for other indications</td> <td class=\"centered\">IIa</td> <td class=\"centered\">C</td> </tr> <tr> <td>MV surgery may be considered in symptomatic patients with chronic severe primary MR and LVEF &#8804;30% (stage D)</td> <td class=\"centered\">IIb</td> <td class=\"centered\">C</td> </tr> <tr> <td>MV repair may be considered in patients with rheumatic mitral valve disease when surgical treatment is indicated if a durable and successful repair is likely or if the reliability of long-term anticoagulation management is questionable</td> <td class=\"centered\">IIb</td> <td class=\"centered\">B</td> </tr> <tr> <td>Transcatheter MV repair may be considered for severely symptomatic patients (NYHA class III/IV) with chronic severe primary MR (stage D) who have a reasonable life expectancy but a prohibitive surgical risk because of severe comorbidities</td> <td class=\"centered\">IIb</td> <td class=\"centered\">B</td> </tr> <tr> <td>MVR should not be performed for treatment of isolated severe primary MR limited to less than one-half of the posterior leaflet unless MV repair has been attempted and was unsuccessful</td> <td class=\"centered\">III: Harm</td> <td class=\"centered\">B</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For the strength of recommendations: Class I means the procedure/treatment should be performed/administered. Class IIa means it is reasonable to perform the procedure/administer treatment. Class IIb means the procedure/treatment may be considered. Class III means that the procedure or treatment is not useful/effective and may be harmful.<br />For the level of evidence: Level A means multiple populations evaluated; data derived from multiple randomized clinical trials or meta-analyses. Level B means limited populations evaluated; data derived from a single randomized trial or nonrandomized studies. Level C means very limited populations evaluated; only consensus opinion of experts, case studies, or standard of care.</div><div class=\"graphic_footnotes\">AF: atrial fibrillation; LV: left ventricular; LVEF: left ventricular ejection fraction; LVESD: left ventricular end-systolic dimension; MR: mitral regurgitation; MV: mitral valve; MVR: mitral valve replacement; NYHA: New York Heart Association.</div><div class=\"graphic_reference\">Reproduced from: Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:e57. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98397 Version 2.0</div></div></div>"},"98399":{"type":"graphic_picture","displayName":"Sebaceous adenoma","title":"Sebaceous adenoma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Sebaceous adenoma</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/98399_Sebaceous_adenoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sebaceous adenoma presenting as a solitary skin-colored, dome-shaped lesion with a central dell on the forehead of this patient.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98399 Version 1.0</div></div></div>"},"98401":{"type":"graphic_figure","displayName":"Geographical distribution of coral snakes in the Americas","title":"Geographical distribution of coral snakes (<em>Micrurus </em>species) in the Americas","html":"<div class=\"graphic\"><div style=\"width: 688px\" class=\"figure\"><div class=\"ttl\">Geographical distribution of coral snakes (<em>Micrurus </em>species) in the Americas</div><div class=\"cntnt\"><img style=\"width:668px; height:712px;\" src=\"images/EM/98401_Ggrphl_dstrbtn_crl_snk_Amrc.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Julian White, MB, BS, MD, FACMT. Reproduced with permission. Copyright &copy; 2014. This image may be used for strictly educational purposes in lectures, but any other use must be approved by the copyright holder. Unauthorized use of this image in any publication is strictly prohibited.</div><div id=\"graphicVersion\">Graphic 98401 Version 1.0</div></div></div>"},"98402":{"type":"graphic_picture","displayName":"Turban tumor","title":"Multiple cylindromas (turban tumor)","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Multiple cylindromas (turban tumor)</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/98402_Turban tumor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large, confluent tumors in this patient with Brooke-Spiegler syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98402 Version 1.0</div></div></div>"},"98403":{"type":"graphic_table","displayName":"Female Sexual Function Index (FSFI)","title":"Female Sexual Function Index (FSFI)*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Female Sexual Function Index (FSFI)*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Question</td> <td class=\"subtitle1\">Response options</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Q1: Over the past four weeks, how <strong>often</strong> did you feel sexual desire or interest?</td> <td>5 = Almost always or always</td> </tr> <tr> <td>4 = Most times (more than half the time)</td> </tr> <tr> <td>3 = Sometimes (about half the time)</td> </tr> <tr> <td>2 = A few times (less than half the time)</td> </tr> <tr class=\"divider_bottom\"> <td>1 = Almost never or never</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Q2: Over the past four weeks, how would you rate your <strong>level</strong> (degree) of sexual desire or interest?</td> <td>5 = Very high</td> </tr> <tr> <td>4 = High</td> </tr> <tr> <td>3 = Moderate</td> </tr> <tr> <td>2 = Low</td> </tr> <tr class=\"divider_bottom\"> <td>1 = Very low or none at all</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Q3: Over the past four weeks, how <strong>often</strong> did you feel sexually aroused (\"turned on\") during sexual activity or intercourse?</td> <td>0 = No sexual activity</td> </tr> <tr> <td>5 = Almost always or always</td> </tr> <tr> <td>4 = Most times (more than half the time)</td> </tr> <tr> <td>3 = Sometimes (about half the time)</td> </tr> <tr> <td>2 = A few times (less than half the time)</td> </tr> <tr class=\"divider_bottom\"> <td>1 = Almost never or never</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Q4: Over the past four weeks, how would you rate your <strong>level</strong> of sexual arousal (\"turn on\") during sexual activity or intercourse?</td> <td>0 = No sexual activity</td> </tr> <tr> <td>5 = Very high</td> </tr> <tr> <td>4 = High</td> </tr> <tr> <td>3 = Moderate</td> </tr> <tr> <td>2 = Low</td> </tr> <tr class=\"divider_bottom\"> <td>1 = Very low or none at all</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Q5: Over the past four weeks, how <strong>confident</strong> were you about becoming sexually aroused during sexual activity or intercourse?</td> <td>0 = No sexual activity</td> </tr> <tr> <td>5 = Very high confidence</td> </tr> <tr> <td>4 = High confidence</td> </tr> <tr> <td>3 = Moderate confidence</td> </tr> <tr> <td>2 = Low confidence</td> </tr> <tr class=\"divider_bottom\"> <td>1 = Very low or no confidence</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Q6: Over the past four weeks, how <strong>often</strong> have you been satisfied with your arousal (excitement) during sexual activity or intercourse?</td> <td>0 = No sexual activity</td> </tr> <tr> <td>5 = Almost always or always</td> </tr> <tr> <td>4 = Most times (more than half the time)</td> </tr> <tr> <td>3 = Sometimes (about half the time)</td> </tr> <tr> <td>2 = A few times (less than half the time)</td> </tr> <tr class=\"divider_bottom\"> <td>1 = Almost never or never</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Q7: Over the past four weeks, how <strong>often</strong> did you become lubricated (\"wet\") during sexual activity or intercourse?</td> <td>0 = No sexual activity</td> </tr> <tr> <td>5 = Almost always or always</td> </tr> <tr> <td>4 = Most times (more than half the time)</td> </tr> <tr> <td>3 = Sometimes (about half the time)</td> </tr> <tr> <td>2 = A few times (less than half the time)</td> </tr> <tr class=\"divider_bottom\"> <td>1 = Almost never or never</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Q8: Over the past four weeks, how <strong>difficult</strong> was it to become lubricated (\"wet\") during sexual activity or intercourse?</td> <td>0 = No sexual activity</td> </tr> <tr> <td>1 = Extremely difficult or impossible</td> </tr> <tr> <td>2 = Very difficult</td> </tr> <tr> <td>3 = Difficult</td> </tr> <tr> <td>4 = Slightly difficult</td> </tr> <tr class=\"divider_bottom\"> <td>5 = Not difficult</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Q9: Over the past four weeks, how often did you <strong>maintain</strong> your lubrication (\"wetness\") until completion of sexual activity or intercourse?</td> <td>0 = No sexual activity</td> </tr> <tr> <td>5 = Almost always or always</td> </tr> <tr> <td>4 = Most times (more than half the time)</td> </tr> <tr> <td>3 = Sometimes (about half the time)</td> </tr> <tr> <td>2 = A few times (less than half the time)</td> </tr> <tr class=\"divider_bottom\"> <td>1 = Almost never or never</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Q10: Over the past four weeks, how <strong>difficult</strong> was it to maintain your lubrication (\"wetness\") until completion of sexual activity or intercourse?</td> <td>0 = No sexual activity</td> </tr> <tr> <td>1 = Extremely difficult or impossible</td> </tr> <tr> <td>2 = Very difficult</td> </tr> <tr> <td>3 = Difficult</td> </tr> <tr> <td>4 = Slightly difficult</td> </tr> <tr class=\"divider_bottom\"> <td>5 = Not difficult</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Q11: Over the past four weeks, when you had sexual stimulation or intercourse, how <strong>often</strong> did you reach orgasm (climax)?</td> <td>0 = No sexual activity</td> </tr> <tr> <td>5 = Almost always or always</td> </tr> <tr> <td>4 = Most times (more than half the time)</td> </tr> <tr> <td>3 = Sometimes (about half the time)</td> </tr> <tr> <td>2 = A few times (less than half the time)</td> </tr> <tr class=\"divider_bottom\"> <td>1 = Almost never or never</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Q12: Over the past four weeks, when you had sexual stimulation or intercourse, how <strong>difficult</strong> was it for you to reach orgasm (climax)?</td> <td>0 = No sexual activity</td> </tr> <tr> <td>1 = Extremely difficult or impossible</td> </tr> <tr> <td>2 = Very difficult</td> </tr> <tr> <td>3 = Difficult</td> </tr> <tr> <td>4 = Slightly difficult</td> </tr> <tr class=\"divider_bottom\"> <td>5 = Not difficult</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Q13: Over the past four weeks, how <strong>satisfied</strong> were you with your ability to reach orgasm (climax) during sexual activity or intercourse?</td> <td>0 = No sexual activity</td> </tr> <tr> <td>5 = Very satisfied</td> </tr> <tr> <td>4 = Moderately satisfied</td> </tr> <tr> <td>3 = About equally satisfied and dissatisfied</td> </tr> <tr> <td>2 = Moderately dissatisfied</td> </tr> <tr class=\"divider_bottom\"> <td>1 = Very dissatisfied</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Q14: Over the past four weeks, how <strong>satisfied</strong> have you been with the amount of emotional closeness during sexual activity between you and your partner?</td> <td>0 = No sexual activity</td> </tr> <tr> <td>5 = Very satisfied</td> </tr> <tr> <td>4 = Moderately satisfied</td> </tr> <tr> <td>3 = About equally satisfied and dissatisfied</td> </tr> <tr> <td>2 = Moderately dissatisfied</td> </tr> <tr class=\"divider_bottom\"> <td>1 = Very dissatisfied</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Q15: Over the past four weeks, how <strong>satisfied</strong> have you been with your sexual relationship with your partner?</td> <td>5 = Very satisfied</td> </tr> <tr> <td>4 = Moderately satisfied</td> </tr> <tr> <td>3 = About equally satisfied and dissatisfied</td> </tr> <tr> <td>2 = Moderately dissatisfied</td> </tr> <tr class=\"divider_bottom\"> <td>1 = Very dissatisfied</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Q16: Over the past four weeks, how <strong>satisfied</strong> have you been with your overall sexual life?</td> <td>5 = Very satisfied</td> </tr> <tr> <td>4 = Moderately satisfied</td> </tr> <tr> <td>3 = About equally satisfied and dissatisfied</td> </tr> <tr> <td>2 = Moderately dissatisfied</td> </tr> <tr class=\"divider_bottom\"> <td>1 = Very dissatisfied</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Q17: Over the past four weeks, how <strong>often</strong> did you experience discomfort or pain during vaginal penetration?</td> <td>0 = Did not attempt intercourse</td> </tr> <tr> <td>1 = Almost always or always</td> </tr> <tr> <td>2 = Most times (more than half the time)</td> </tr> <tr> <td>3 = Sometimes (about half the time)</td> </tr> <tr> <td>4 = A few times (less than half the time)</td> </tr> <tr class=\"divider_bottom\"> <td>5 = Almost never or never</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Q18: Over the past four weeks, how <strong>often</strong> did you experience discomfort or pain following vaginal penetration?</td> <td>0 = Did not attempt intercourse</td> </tr> <tr> <td>1 = Almost always or always</td> </tr> <tr> <td>2 = Most times (more than half the time)</td> </tr> <tr> <td>3 = Sometimes (about half the time)</td> </tr> <tr> <td>4 = A few times (less than half the time)</td> </tr> <tr class=\"divider_bottom\"> <td>5 = Almost never or never</td> </tr> <tr> <td rowspan=\"6\">Q19: Over the past four weeks, how would you rate your <strong>level</strong> (degree) of discomfort or pain during or following vaginal penetration?</td> <td>0 = Did not attempt intercourse</td> </tr> <tr> <td>1 = Very high</td> </tr> <tr> <td>2 = High</td> </tr> <tr> <td>3 = Moderate</td> </tr> <tr> <td>4 = Low</td> </tr> <tr> <td>5 = Very low or none at all</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* For the complete FSFI questionnaire, instructions and scoring algorithm, please see <A href=\"http://www.fsfiquestionnaire.com/\" target=_blank>www.FSFIquestionnaire.com</A>, or contact Raymond Rosen Ph.D., (Department of Psychiatry: UMDNJ-Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, NJ 08854).</div><div class=\"graphic_reference\">Published in: Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000; 26:191. Reproduced with permission from Raymond Rosen, Ph.D.</div><div id=\"graphicVersion\">Graphic 98403 Version 1.0</div></div></div>"},"98404":{"type":"graphic_diagnosticimage","displayName":"Radiograph of lateral knee with degenerative joint disease","title":"Radiograph of lateral compartment of knee with degenerative joint disease","html":"<div class=\"graphic\"><div style=\"width: 598px\" class=\"figure\"><div class=\"ttl\">Radiograph of lateral compartment of knee with degenerative joint disease</div><div class=\"cntnt\"><img style=\"width:578px; height:376px;\" src=\"images/RADIOL/98404_Rdgr_DJD_ltrl_cmprtmnt_knee.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An A-P radiograph (A) of the left knee shows DJD of the lateral compartment with joint space narrowing (arrowhead) and marginal osteophytes (arrows). Image B is a magnified view showing joint space narrowing (arrowhead) and marginal osteophytes (arrows).</div><div class=\"graphic_footnotes\">A-P: anteroposterior.</div><div id=\"graphicVersion\">Graphic 98404 Version 1.0</div></div></div>"},"98416":{"type":"graphic_figure","displayName":"Pectineus","title":"Pectineus","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Pectineus</div><div class=\"cntnt\"><img style=\"width:522px; height:713px;\" src=\"images/EM/98416_Pectineus.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists. Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 98416 Version 3.0</div></div></div>"},"98417":{"type":"graphic_figure","displayName":"Adductor brevis","title":"Adductor brevis","html":"<div class=\"graphic\"><div style=\"width: 588px\" class=\"figure\"><div class=\"ttl\">Adductor brevis</div><div class=\"cntnt\"><img style=\"width:568px; height:713px;\" src=\"images/EM/98417_Adductorbrevis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists. Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 98417 Version 3.0</div></div></div>"},"98418":{"type":"graphic_figure","displayName":"Adductor longus","title":"Adductor longus","html":"<div class=\"graphic\"><div style=\"width: 577px\" class=\"figure\"><div class=\"ttl\">Adductor longus</div><div class=\"cntnt\"><img style=\"width:557px; height:715px;\" src=\"images/EM/98418_Adductorlongus.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists. Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 98418 Version 3.0</div></div></div>"},"98420":{"type":"graphic_figure","displayName":"Gracilis","title":"Gracilis","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Gracilis</div><div class=\"cntnt\"><img style=\"width:524px; height:713px;\" src=\"images/EM/98420_Gracilis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists. Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 98420 Version 3.0</div></div></div>"},"98421":{"type":"graphic_figure","displayName":"Adductor magnus","title":"Adductor magnus","html":"<div class=\"graphic\"><div style=\"width: 607px\" class=\"figure\"><div class=\"ttl\">Adductor magnus</div><div class=\"cntnt\"><img style=\"width:587px; height:713px;\" src=\"images/EM/98421_Adductormagnus.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists. Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 98421 Version 3.0</div></div></div>"},"98422":{"type":"graphic_table","displayName":"Older women with EOC","title":"Outcomes for older women with newly diagnosed ovarian cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Outcomes for older women with newly diagnosed ovarian cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Author</td> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Number of patients</td> <td class=\"subtitle1\">PFS (months)</td> <td class=\"subtitle1\">OS</td> <td class=\"subtitle1\">Postoperative mortality</td> <td class=\"subtitle1\">Postoperative complications</td> <td class=\"subtitle1\">Primary surgery</td> <td class=\"subtitle1\">NACT selected</td> </tr> <tr> <td>Marchetti, 1993</td> <td>&#8805;65 years</td> <td>29</td> <td>NA</td> <td>19.2 months</td> <td>3 (10.3%)</td> <td>NA</td> <td>28 (96.6%)</td> <td>1 (3.4%)</td> </tr> <tr> <td>Susini, 1999</td> <td>&#8805;70 years</td> <td>51</td> <td>NA</td> <td>NA</td> <td>NA</td> <td>NA</td> <td>51 (100%)</td> <td>Study exclusion</td> </tr> <tr> <td>Cloven, 1999</td> <td>&#8805;80 years</td> <td>18</td> <td>NA</td> <td>6 months</td> <td>2 (11.1%)</td> <td> <ul> <li>Cardiac: 7 (39%) </li> <li>Sepsis: 3 (16.7%) </li> <li>Pneumonia: 1 (5.6%) </li> </ul> </td> <td>16 (88.9%)</td> <td>3 (16.7%)</td> </tr> <tr> <td>Bruchim, 2002</td> <td>&#8805;70 years</td> <td>46</td> <td>NA</td> <td>NA</td> <td>2 (4.3%)</td> <td>NA</td> <td>25 (54.3%)</td> <td>13 (43.3%)</td> </tr> <tr> <td>Wright, 2004</td> <td>&#8805;70 years</td> <td>46</td> <td>NA</td> <td>NA</td> <td>0</td> <td> <ul> <li>ICU admission: 20% </li> <li>Infection: 8% </li> <li>Delirium: 5% </li> <li>Wound: 3% </li> <li>Ileus: 2% </li> <li>Arrhythmia: 2% </li> <li>VTE: 1% </li> </ul> </td> <td>46 (100%)</td> <td>Study exclusion</td> </tr> <tr> <td>Uyar, 2005</td> <td>&#8805;70 years</td> <td>131</td> <td>NA</td> <td> <p>70 to 79 years: 52 months</p> <p>&#8805;80 years: 36 months</p> p = 0.07</td> <td>NA</td> <td> <ul> <li>Overall: 23% </li> </ul> </td> <td>105 (80%)</td> <td>26 (20%)</td> </tr> <tr> <td>Alphs, 2006</td> <td>&#8805;75 years</td> <td>78</td> <td>NA</td> <td>19 months</td> <td>7 (9%)</td> <td> <ul> <li>Wound infection: 13 (16.7%) </li> <li>Ileus: 5 (6.4%) </li> </ul> </td> <td>78 (100%)</td> <td>Study exclusion</td> </tr> <tr> <td>Moore, 2008</td> <td>&#8805;80 years</td> <td>85</td> <td>NA</td> <td> <p>1&#176; surgery: two-year survival 51%</p> 1&#176; chemo: Two-year survival 27%</td> <td>9 (13%)</td> <td> <ul> <li>Cardiac: 17% </li> <li>Pulmonary: 26% </li> <li>GI: 22% </li> <li>Heme/infectious: 62% </li> <li>Mental status: 10% </li> <li>Surgical site: 23% </li> </ul> </td> <td>68 (80%)</td> <td>17 (20%)</td> </tr> <tr> <td>Moore, 2009</td> <td>&#8805;80 years</td> <td>39</td> <td>NA</td> <td>NA</td> <td>NA</td> <td>NA</td> <td>39 (100%)</td> <td>Study exclusion</td> </tr> <tr> <td>McLean, 2010</td> <td>&#8805;80 years</td> <td>34</td> <td>NA</td> <td>24 months</td> <td>0</td> <td> <ul> <li>Ileus: 29.4% </li> <li>Pneumonia: 6.1% </li> <li>Wound infection: 3.1% </li> <li>Sepsis: 3% </li> </ul> </td> <td>27 (79.4%)</td> <td>7 (20.6%)</td> </tr> <tr> <td>Chereau, 2011</td> <td>&#8805;70 years</td> <td>29</td> <td> <p>Two-year: 35%</p> Five-year: 23%</td> <td>Five-year: 55%</td> <td>1 (3.4%)</td> <td> <ul> <li>Overall: 3 (10%) </li> <li>Infection: 2 (7%) </li> <li>Febrile morbidity: 1 (3%) </li> <li>Pleural effusion: 1 (3%) </li> </ul> </td> <td>29 (100%)</td> <td>Study exclusion</td> </tr> <tr> <td>Langstraat, 2011</td> <td>&#8805;65 years</td> <td>280</td> <td>NA</td> <td>NA</td> <td>12 (4.3%)</td> <td>Overall: 32 (11.4%)</td> <td>280 (100%)</td> <td>Study exclusion</td> </tr> <tr> <td>Fanfani, 2012</td> <td>&#8805;65 years</td> <td>164</td> <td> <p>65 to 74 years: 12 months</p> &#8805;75 years: 21 months</td> <td>NA</td> <td>0</td> <td> <p>Overall:</p> <p>65 to 74 years: 11 (11.2%)</p> &#8805;75 years: 8 (25%)</td> <td>75 (45.7%)</td> <td>89 (54.3%)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PFS: progression-free survival; NA: not applicable, recorded, or extractable from the publication for this specific subset of patients; OS: overall survival; 1<sup>o</sup>: primary; ICU: intensive care unit; VTE: venous thromboembolism; GI: gastrointestinal; NACT: neoadjuvant chemotherapy.</div><div id=\"graphicVersion\">Graphic 98422 Version 1.0</div></div></div>"},"98458":{"type":"graphic_picture","displayName":"Syringoma periocular","title":"Syringoma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Syringoma</div><div class=\"cntnt\"><img style=\"width:700px; height:523px;\" src=\"images/DERM/98458_Syringoma_periocular.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Syringomas presenting as multiple small skin-colored papules in the periocular area.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98458 Version 1.0</div></div></div>"},"98460":{"type":"graphic_picture","displayName":"Syringoma neck 2","title":"Syringoma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Syringoma</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/98460_Syringomaneck2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Syringomas presenting as multiple small, skin-colored papules on the anterior neck.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98460 Version 2.0</div></div></div>"},"98461":{"type":"graphic_picture","displayName":"Poroma - palm","title":"Poroma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Poroma</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/98461_Poroma_palm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Poroma presenting as an erythematous papule on the palm.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98461 Version 2.0</div></div></div>"},"98462":{"type":"graphic_picture","displayName":"Poroma - palm 2","title":"Poroma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Poroma</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/98462_Poroma_palm_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Poroma presenting as a skin-colored papule on the palm.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98462 Version 1.0</div></div></div>"},"98463":{"type":"graphic_picture","displayName":"Poroma - leg","title":"Poroma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Poroma</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/98463_Poroma_leg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Poroma presenting as a skin-colored papule on the leg.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98463 Version 1.0</div></div></div>"},"98466":{"type":"graphic_picture","displayName":"Eosinophilic fasciitis groove sign","title":"Eosinophilic fasciitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eosinophilic fasciitis</div><div class=\"cntnt\"><img style=\"width:210px; height:605px;\" src=\"images/RHEUM/98466_Esnphlc_fscts_groove_sgn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Groove sign (arrows). Forearm of a patient with eosinophilic fasciitis shows a linear depression in the skin parallel to the course of the superficial veins, more obvious on raising the arm.</div><div class=\"graphic_reference\">Reproduced from: Pinal-Fernandez I, Callejas-Moraga EL, Roade-Tato ML, Simeon-Aznar CP. Groove sign in eosinophilic fasciitis. Lancet 2014; 384:1774. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98466 Version 1.0</div></div></div>"},"98467":{"type":"graphic_picture","displayName":"FADDIR Test for hip pathology","title":"FADDIR Test for hip pathology","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">FADDIR Test for hip pathology</div><div class=\"cntnt\"><img style=\"width:545px; height:710px;\" src=\"images/EM/98467_FADDIR_Test_hip_pathology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The FADDIR (Femoral ADDuction and Internal Rotation) test is used to help identify pathology within the hip acetabulum.</div><div class=\"graphic_reference\">Courtesy of Margot Putukian, MD.</div><div id=\"graphicVersion\">Graphic 98467 Version 1.0</div></div></div>"},"98468":{"type":"graphic_picture","displayName":"Patrick or FABER Test for hip pathology","title":"Patrick or FABER Test for hip pathology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patrick or FABER Test for hip pathology</div><div class=\"cntnt\"><img style=\"width:449px; height:711px;\" src=\"images/EM/98468_Ptrck_FABER_Test_hip_pthlgy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The FABER Test (Femoral ABduction External Rotation) is used to help identify pathology at the hip joint. A number of conditions can produce a positive test, which is marked primarily by reproducible pain with passive external hip rotation.</div><div class=\"graphic_reference\">Courtesy of Margot Putukian, MD.</div><div id=\"graphicVersion\">Graphic 98468 Version 1.0</div></div></div>"},"98469":{"type":"graphic_picture","displayName":"Trichoblastoma","title":"Trichoblastoma","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Trichoblastoma</div><div class=\"cntnt\"><img style=\"width:712px; height:505px;\" src=\"images/DERM/98469_Trichoblastoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Trichoblastoma presenting as a slightly erythematous papule with superficial telangiectasias in a 75-year-old woman.</div><div class=\"graphic_reference\">Reproduced with permission from: Diepgen TL, Yihune G, et al. Dermatology Online Atlas. Published online at: <a href=\"http://www.dermis.net/\" spellcheck=\"true\" target=\"_blank\">www.dermis.net</a>. Copyright &copy; 1996-2015 DermIS. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98469 Version 1.0</div></div></div>"},"98470":{"type":"graphic_picture","displayName":"Trichofolliculoma nose","title":"Trichofolliculoma","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Trichofolliculoma</div><div class=\"cntnt\"><img style=\"width:712px; height:462px;\" src=\"images/DERM/98470_Trichofolliculoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Trichofolliculoma presenting as a skin-colored confluent group of small follicular papules on the nose of an 83-year-old male patient.</div><div class=\"graphic_reference\">Reproduced with permission from: Diepgen TL, Yihune G, et al. Dermatology Online Atlas. Published online at: <a href=\"http://www.dermis.net/\" spellcheck=\"true\" target=\"_blank\">www.dermis.net</a>. Copyright &copy; 1996-2015 DermIS. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98470 Version 1.0</div></div></div>"},"98471":{"type":"graphic_picture","displayName":"Trichilemmoma","title":"Trichilemmoma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Trichilemmoma</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/98471_Trichilemmoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Trichilemmoma presenting as a small warty lesion in the mustache area of this patient.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98471 Version 1.0</div></div></div>"},"98472":{"type":"graphic_picture","displayName":"Trichodiscoma","title":"Trichodiscoma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Trichodiscoma</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/98472_Trichodiscoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple small skin-colored papules on the chest of a patient with Birt-Hogg-Dub&eacute; syndrome. Histology revealed trichodiscomas.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98472 Version 1.0</div></div></div>"},"98473":{"type":"graphic_picture","displayName":"Gillet test for sacroiliac pathology","title":"Gillet test for sacroiliac pathology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gillet test for sacroiliac pathology</div><div class=\"cntnt\"><img style=\"width:277px; height:710px;\" src=\"images/EM/98473_Gillet_test_sacroilc_pthlgy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gillet, or Gillet's, test is performed to asses sacroiliac joint mobility.</div><div class=\"graphic_reference\">Courtesy of Margot Putukian, MD.</div><div id=\"graphicVersion\">Graphic 98473 Version 1.0</div></div></div>"},"98474":{"type":"graphic_picture","displayName":"Gaenslen test for sacroiliac joint pathology","title":"Gaenslen test for sacroiliac joint pathology","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Gaenslen test for sacroiliac joint pathology</div><div class=\"cntnt\"><img style=\"width:514px; height:711px;\" src=\"images/EM/98474_Gnsln_tst_scrlc_jnt_pthlgy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Gaenslen test places stress on both sacroiliac joints simultaneously and is used to assess sacroiliac function.</div><div class=\"graphic_reference\">Courtesy of Margot Putukian, MD.</div><div id=\"graphicVersion\">Graphic 98474 Version 1.0</div></div></div>"},"98475":{"type":"graphic_picture","displayName":"Fulcrum test for femoral stress fracture","title":"Fulcrum test for femoral stress fracture","html":"<div class=\"graphic\"><div style=\"width: 599px\" class=\"figure\"><div class=\"ttl\">Fulcrum test for femoral stress fracture</div><div class=\"cntnt\"><img style=\"width:579px; height:856px;\" src=\"images/SM/98475_Flcrm_tst_fem_strss_frc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Fulcrum test is used to help detect a femoral stress fracture by creating stress at the suspected site of injury. To perform the test, the examiner places their forearm underneath the femur radial side up (photo A above). The bony ridge along the radius acts as the fulcrum as pressure is applied to the knee. The examiner gradually moves their forearm proximally and repeats the maneuver (photo B above). Pain marks a positive test.</div><div class=\"graphic_reference\">Courtesy of Jonathan Jackson, MD.</div><div id=\"graphicVersion\">Graphic 98475 Version 2.0</div></div></div>"},"98477":{"type":"graphic_picture","displayName":"Resisted hip abduction","title":"Resisted hip abduction","html":"<div class=\"graphic\"><div style=\"width: 731px\" class=\"figure\"><div class=\"ttl\">Resisted hip abduction</div><div class=\"cntnt\"><img style=\"width:711px; height:533px;\" src=\"images/EM/98477_Resisted_hip_abduction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Resisted hip abduction allows the examiner to assess the strength of the patient's hip abductors, particularly the gluteus medius.</div><div class=\"graphic_reference\">Courtesy of Margot Putukian, MD.</div><div id=\"graphicVersion\">Graphic 98477 Version 4.0</div></div></div>"},"98479":{"type":"graphic_picture","displayName":"Straight leg raise supine","title":"Straight leg raise supine","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Straight leg raise supine</div><div class=\"cntnt\"><img style=\"width:531px; height:712px;\" src=\"images/EM/98479_Straight_leg_raise_supine.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The straight leg raise performed with the patient supine is useful for assessing the strength of the hip flexor muscles.</div><div class=\"graphic_reference\">Courtesy of Margot Putukian, MD.</div><div id=\"graphicVersion\">Graphic 98479 Version 2.0</div></div></div>"},"98480":{"type":"graphic_table","displayName":"Diphtheria ddx","title":"Differential diagnosis of diphtheria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of diphtheria</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Onset</td> <td class=\"subtitle1\">Sore throat</td> <td class=\"subtitle1\">Fever</td> <td class=\"subtitle1\">Tonsillar enlargement</td> <td class=\"subtitle1\">Tonsillar exudate</td> <td class=\"subtitle1\">Cervical lymphadenopathy</td> <td class=\"subtitle1\">Extraoral manifestations</td> <td class=\"subtitle1\">Diagnosis</td> </tr> <tr> <td><strong>Diphtheria</strong></td> <td>Gradual</td> <td>+</td> <td>+</td> <td>+/&ndash;</td> <td>Gray, adherent and bleeds when scraped</td> <td>+</td> <td>Cardiac, neurologic involvement</td> <td>Culture, PCR</td> </tr> <tr> <td><strong>Group A <em>Streptococcus</em></strong></td> <td>Rapid</td> <td>+++</td> <td>+++</td> <td>+ (edema of uvula)</td> <td>Patchy, grayish to yellow</td> <td>++</td> <td>Headache,&nbsp;gastrointestinal symptoms</td> <td>Culture, rapid test</td> </tr> <tr> <td><strong>Infectious mononucleosis</strong></td> <td>Gradual</td> <td>++</td> <td>++</td> <td>++</td> <td>Primarily pharyngeal with palatal petechiae</td> <td>++</td> <td>Generalized lymphadenopathy, splenomegaly</td> <td>Heterophile Ab, serum Ab panel</td> </tr> <tr> <td><strong>Vincent's angina (acute necrotizing ulcerative gingivitis)</strong></td> <td>Rapid</td> <td>+</td> <td>+</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>Exam, imaging</td> </tr> <tr> <td><strong>Oropharyngeal candidiasis</strong></td> <td>Gradual</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>White with buccal and palatal involvement</td> <td>&ndash;</td> <td>+/&ndash; (depends on predisposing condition)</td> <td>Wet mount, exam findings</td> </tr> <tr> <td><strong>Deep tissue infection of neck</strong></td> <td>Rapid</td> <td>&ndash;</td> <td>++</td> <td>+/&ndash; (tonsil may bulge if abscess is present)</td> <td>May be absent</td> <td>&ndash;</td> <td>Toxic appearance, often very painful, asymmetrical swelling common</td> <td>Neck imaging</td> </tr> <tr> <td><strong>Lemierre's syndrome (septic thrombophlebitis of the internal jugular vein)</strong></td> <td>Gradual (pharyngitis prodrome followed by sepsis)</td> <td>+</td> <td>+++</td> <td>+</td> <td>Possibly exudative, ulcerative, or normal</td> <td>&ndash;</td> <td>Thrombosis of internal jugular vein, bacteremia, often toxic</td> <td>Blood culture, CT imaging of jugular vein</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PCR: polymerase chain reaction;&nbsp;Ab: antibody; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 98480 Version 2.0</div></div></div>"},"98481":{"type":"graphic_figure","displayName":"Ligaments of pelvic girdle","title":"Ligaments of pelvic girdle","html":"<div class=\"graphic\"><div style=\"width: 860px\" class=\"figure\"><div class=\"ttl\">Ligaments of pelvic girdle</div><div class=\"cntnt\"><img style=\"width:840px; height:556px;\" src=\"images/EM/98481_Ligamentspelvicgirdle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The sacrotuberous and sacrospinous ligaments convert the greater and lesser sciatic notches into foramina.</div><div class=\"graphic_reference\">Reproduced with permission from: Clinically Oriented Anatomy, 7th ed, Moore KL, Dalley AF, Agur AM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 98481 Version 3.0</div></div></div>"},"98482":{"type":"graphic_figure","displayName":"Muscles of gluteal region - Abductors and rotators of thigh","title":"Muscles of gluteal region: Abductors and rotators of thigh","html":"<div class=\"graphic\"><div style=\"width: 738px\" class=\"figure\"><div class=\"ttl\">Muscles of gluteal region: Abductors and rotators of thigh</div><div class=\"cntnt\"><img style=\"width:718px; height:1040px;\" src=\"images/EM/98482_Mscgltlrgnabdcrttrthgh.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* The spinal cord segmental innervation is indicated (e.g., \"S1, S2\" means that the nerves supplying the piriformis are derived from the first two sacral segments of the spinal cord). Numbers in boldface (S1) indicate the main segmental innervation. Damage to one or more of the listed spinal cord segments, or to the motor nerve roots arising from them, results in paralysis of the muscles concerned.<br />&para; The gemelli muscles blend with and share the tendon of the obturator internus as it attaches to the greater trochanter of the femur, collectively forming the triceps coxae.<br />&Delta; There are six lateral rotators of the thigh: piriformis, obturator internus, superior and inferior gemelli, quadratus femoris, and obturator externus. These muscles also stabilize the hip joint.</div><div class=\"graphic_reference\">Reproduced with permission from: Clinically Oriented Anatomy, 7th ed, Moore KL, Dalley AF, Agur AM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 98482 Version 3.0</div></div></div>"},"98483":{"type":"graphic_figure","displayName":"Muscles of gluteal region - Superficial and deep dissections","title":"Muscles of gluteal region: Superficial and deep dissections","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Muscles of gluteal region: Superficial and deep dissections</div><div class=\"cntnt\"><img style=\"width:488px; height:354px;\" src=\"images/EM/98483_Mscgltlrgnsprfdpdsctn.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Clinically Oriented Anatomy, 7th ed, Moore KL, Dalley AF, Agur AM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 98483 Version 3.0</div></div></div>"},"98484":{"type":"graphic_figure","displayName":"Gluteal muscles and bursae","title":"Gluteal muscles and bursae","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Gluteal muscles and bursae</div><div class=\"cntnt\"><img style=\"width:506px; height:532px;\" src=\"images/EM/98484_Glutealmusclesbursae.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Clinically Oriented Anatomy, 7th ed, Moore KL, Dalley AF, Agur AM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 98484 Version 3.0</div></div></div>"},"98485":{"type":"graphic_figure","displayName":"Dissection of gluteal region and posterior thigh","title":"Dissection of gluteal region and posterior thigh","html":"<div class=\"graphic\"><div style=\"width: 591px\" class=\"figure\"><div class=\"ttl\">Dissection of gluteal region and posterior thigh</div><div class=\"cntnt\"><img style=\"width:571px; height:705px;\" src=\"images/EM/98485_Dssctngltlrgnpstrrthgh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Most of the gluteus maximus and medius are removed, and segments of the hamstrings are excised, to reveal the neurovascular structures of the gluteal region and proximal posterior thigh. The sciatic nerve runs deep (anterior) to and is protected by the overlying gluteus maximus initially and then the biceps femoris.<br />(B) This dissection shows some of the lateral rotators of the thigh. The components of the triceps coxae share a common attachment into the trochanteric fossa adjacent to that of the obturator externus.</div><div class=\"graphic_reference\">Reproduced with permission from: Clinically Oriented Anatomy, 7th ed, Moore KL, Dalley AF, Agur AM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 98485 Version 3.0</div></div></div>"},"98492":{"type":"graphic_picture","displayName":"Mild inflammatory acne vulgaris","title":"Acne vulgaris","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Acne vulgaris</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/98492_Mild_inflammatory_acn_vlgrs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inflamed papules and pustules on the face. Postinflammatory hyperpigmentation also is present.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98492 Version 1.0</div></div></div>"},"98493":{"type":"graphic_picture","displayName":"Inflammatory acne vulgaris with small nodules","title":"Inflammatory acne vulgaris","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Inflammatory acne vulgaris</div><div class=\"cntnt\"><img style=\"width:700px; height:524px;\" src=\"images/DERM/98493_Inflmmtry_acn_vlgr_smll_ndl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inflamed papules, pustules, and small nodules on the face. Postinflammatory macular erythema is also present.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98493 Version 1.0</div></div></div>"},"98494":{"type":"graphic_picture","displayName":"Inflammatory facial acne","title":"Inflammatory acne","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Inflammatory acne</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/98494_Inflammatory_facial_acne.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inflammatory papules and pustules on the face. Postinflammatory erythema and scarring are also present.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98494 Version 1.0</div></div></div>"},"98495":{"type":"graphic_diagnosticimage","displayName":"Imaging pulmonary edema","title":"Radiograph and CT of acute pulmonary edema","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Radiograph and CT of acute pulmonary edema</div><div class=\"cntnt\"><img style=\"width:700px; height:304px;\" src=\"images/RADIOL/98495_Imaging_pulmonary_edema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) An anteroposterior radiograph shows perihilar consolidations and air bronchograms (arrows) of acute alveolar edema.<br />(B) A coronal reconstruction of a CT scan of the same patient shows acute alveolar edema with diffuse perihilar infiltrates and air bronchograms (arrows).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 98495 Version 3.0</div></div></div>"},"98496":{"type":"graphic_diagnosticimage","displayName":"Imaging solitary plasmacytoma of clavicle","title":"Solitary plasmacytoma of clavicle on radiograph and MRI","html":"<div class=\"graphic\"><div style=\"width: 700px\" class=\"figure\"><div class=\"ttl\">Solitary plasmacytoma of clavicle on radiograph and MRI</div><div class=\"cntnt\"><img style=\"width:680px; height:260px;\" src=\"images/RADIOL/98496_Img_sltry_plasmacytom_clvcl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A radiograph of the left clavicle in A-P projection shows a bubbly lesion within an expanded distal clavicle (A, arrow). Image B is a T2-weighted MRI showing a hyperintense lesion (arrow).</div><div class=\"graphic_footnotes\">A-P: anteroposterior; MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Richard Waite, MD.</div><div id=\"graphicVersion\">Graphic 98496 Version 1.0</div></div></div>"},"98497":{"type":"graphic_diagnosticimage","displayName":"Imaging plasmacytoma of acetabulum","title":"Solitary plasmacytoma of the acetabulum on radiography and CT","html":"<div class=\"graphic\"><div style=\"width: 672px\" class=\"figure\"><div class=\"ttl\">Solitary plasmacytoma of the acetabulum on radiography and CT</div><div class=\"cntnt\"><img style=\"width:652px; height:252px;\" src=\"images/RADIOL/98497_Img_plasmacytoma_acetabulum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An A-P view of the pelvis (A) shows an expansile lytic lesion in the right acetabulum (arrows). Image B is an axial CT scan through the lower pelvis and shows an expansile, homogenous soft tissue mass in the right acetabulum (arrows).</div><div class=\"graphic_footnotes\">A-P: anteroposterior; CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Richard Waite, MD.</div><div id=\"graphicVersion\">Graphic 98497 Version 1.0</div></div></div>"},"98498":{"type":"graphic_diagnosticimage","displayName":"MRI of a solitary plasmacytoma in pelvis","title":"Solitary plasmacytoma of acetabulum on MRI","html":"<div class=\"graphic\"><div style=\"width: 690px\" class=\"figure\"><div class=\"ttl\">Solitary plasmacytoma of acetabulum on MRI</div><div class=\"cntnt\"><img style=\"width:670px; height:246px;\" src=\"images/RADIOL/98498_MRI_sltry_plasmacytoma_plvs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A T1-weighted coronal image of the pelvis shows a low intensity expansile lesion in the right acetabulum (asterisk). Image B is a coronal view of the pelvis using a STIR sequence and it shows a high-intensity mass in the right acetabulum (asterisk).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; STIR: short tau inversion recovery.</div><div class=\"graphic_reference\">Courtesy of Richard Waite, MD.</div><div id=\"graphicVersion\">Graphic 98498 Version 1.0</div></div></div>"},"98499":{"type":"graphic_diagnosticimage","displayName":"Progressive ILD in scleroderma","title":"CT of progressive interstitial lung disease in a patient with scleroderma","html":"<div class=\"graphic\"><div style=\"width: 708px\" class=\"figure\"><div class=\"ttl\">CT of progressive interstitial lung disease in a patient with scleroderma</div><div class=\"cntnt\"><img style=\"width:688px; height:286px;\" src=\"images/RADIOL/98499_Progressive_ILD_scleroderma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT scan through the base of the lungs (A) shows a reticular pattern (dashed arrow), early bronchiectasis (arrowhead), and a patulous esophagus (arrow). Image (B) is a CT scan performed 10 years later and shows progressive septal thickening (dashed arrow), bronchiectasis (arrowhead), and bilateral pleural effusions (arrows). The thickening of the bronchial walls suggests inflammation from recurrent aspiration.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 98499 Version 1.0</div></div></div>"},"98500":{"type":"graphic_table","displayName":"Risk factors for hyperuricemia and gout","title":"Risk factors for hyperuricemia and gout (may not be causal)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for hyperuricemia and&nbsp;gout (may not be causal)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Nonmodifiable risk factors</td> <td class=\"subtitle1\">Modifiable risk factors</td> </tr> <tr> <td> <p>Age</p> <p>Gender</p> <p>Ethnicity</p> <p>Genetic variants</p> </td> <td> <p>Obesity</p> <p>Hypertension</p> <p>Hyperlipidemia</p> <p>Cardiovascular disease</p> <p>Diabetes mellitus</p> <p>Chronic kidney disease</p> <p>Dietary factors</p> <p>Alcohol</p> Medications altering urate balance</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 98500 Version 3.0</div></div></div>"},"98504":{"type":"graphic_table","displayName":"Types of sling procedures","title":"Terminology of sling procedures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Terminology of sling procedures</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Midurethral sling</td> </tr> <tr> <td class=\"indent1\">A suburethral sling that is placed at the level of the midurethra in a tension-free manner</td> </tr> <tr> <td class=\"indent1\">Made of synthetic mesh</td> </tr> <tr> <td class=\"subtitle1_single\">Retropubic midurethral sling</td> </tr> <tr> <td class=\"indent1\">A suburethral sling that is inserted from the vagina, through the retropubic space, and exits through the abdominal wall</td> </tr> <tr> <td class=\"indent1\">The sling may be inserted from bottom-to-top, vagina to abdominal wall (eg, TVT), or from top-to-bottom, abdominal wall to vagina (eg, Sparc)</td> </tr> <tr> <td class=\"subtitle1_single\">Transobturator midurethral sling</td> </tr> <tr> <td class=\"indent1\">Inserted through the vaginal incision to the bilateral obturator foramen</td> </tr> <tr> <td class=\"indent1\">May be inserted in-to-out through the vaginal incision, through the obturator foramen, and out through the groin skin (eg, TVT-O)</td> </tr> <tr> <td class=\"indent1\">May be inserted out-to-in through the groin incision, through the obturator foramen, and exit through the vaginal suburethral incision (eg, Monarc)</td> </tr> <tr> <td class=\"subtitle1_single\">Single incision midurethral sling</td> </tr> <tr> <td class=\"indent1\">Shorter in length, typically 8 cm instead of 40 cm</td> </tr> <tr> <td class=\"indent1\">Require only a vaginal incision</td> </tr> <tr> <td class=\"indent1\">May be retropubic: the arms anchor to the urogenital diaphragm (eg, TVT SECUR)</td> </tr> <tr> <td class=\"indent1\">May be transobturator: the arms anchor to the obturator internus muscle (eg, MiniArc)</td> </tr> <tr> <td class=\"subtitle1_single\">Bladder neck sling (proximal urethral sling)</td> </tr> <tr> <td class=\"indent1\">A suburethral sling that is placed at the level of the proximal urethra and bladder neck</td> </tr> <tr> <td class=\"indent1\">The procedure is typically performed using vaginal and abdominal incisions</td> </tr> <tr> <td class=\"indent1\">The sling material can be biologic (autograft) or synthetic mesh</td> </tr> <tr> <td class=\"subtitle1_single\">Pubovaginal sling</td> </tr> <tr> <td class=\"indent1\">A bladder neck sling that sutures the arms of the sling to the anterior rectus fascia (rather than the pubic bone or Cooper's ligament)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 98504 Version 1.0</div></div></div>"},"98505":{"type":"graphic_table","displayName":"Disease states associated with difficult airway management","title":"Disease states associated with difficult airway management","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disease states associated with difficult airway management</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Congenital</td> <td class=\"subtitle1\">Acquired</td> </tr> <tr> <td> <p>Pierre Robin syndrome</p> <p>Treacher-Collins syndrome</p> <p>Goldenhar syndrome</p> <p>Mucopolysaccharidoses</p> <p>Achondroplasia</p> <p>Micrognathia</p> <p>Down syndrome</p> <p>Cretinism</p> Beckwith syndrome</td> <td> <p>Morbid obesity</p> <p>Acromegaly</p> <p>Infections involving the airway (Ludwig's angina, epiglottitis, croup, retropharyngeal or intraoral abscess, papillomatosis)</p> <p>Rheumatoid arthritis</p> <p>Ankylosing spondylitis</p> <p>Obstructive sleep apnea</p> <p>Tumors involving the airway</p> <p>Trauma or burns of face, head, or neck</p> Radiation of face or neck</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 98505 Version 3.0</div></div></div>"},"98506":{"type":"graphic_table","displayName":"Conditions with increased aspiration risk anesthesia induction","title":"Conditions that increase risk of aspiration during induction of anesthesia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions that increase risk of aspiration during induction of anesthesia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Full stomach&nbsp;<span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">&ndash;</span> nonfasted, emergency surgery or trauma</td> </tr> <tr> <td>Pregnancy after 12 to 20&nbsp;weeks gestation (gestational age for increased risk is controversial)</td> </tr> <tr> <td>Symptomatic gastroesophageal reflux</td> </tr> <tr> <td>Diabetic or other gastroparesis</td> </tr> <tr> <td>Hiatal hernia</td> </tr> <tr> <td>Gastric outlet obstruction</td> </tr> <tr> <td>Esophageal pathology</td> </tr> <tr> <td>Bowel obstruction</td> </tr> <tr> <td>Increased intra-abdominal pressure&nbsp;<span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">&ndash;</span> ascites, abdominal mass</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 98506 Version 8.0</div></div></div>"},"98510":{"type":"graphic_table","displayName":"Psychosocial interventions for challenging behaviors","title":"Psychosocial interventions for management of behavioral and psychotic symptoms in patients with dementia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Psychosocial interventions for management of behavioral and psychotic symptoms&nbsp;in patients with&nbsp;dementia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>Routine activity. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Separate the person from what seems to be upsetting him or her. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Assess for the presence of pain, constipation or other physical problem. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Review medications, especially new medications. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Travel with them to where they are in time. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Don't disagree; respect the person's thoughts even if incorrect. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Physical interaction: Maintain eye contact, get to their height level, and allow space. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Speak slowly and calmly in a normal tone of voice. The person may not understand the words spoken, but he or she may pick up the tone of the voice behind the words and respond to that. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Avoid point finger-pointing, scolding or threatening. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Redirect the person to participate in an enjoyable activity or offer comfort food he or she may recognize and like. </li> </ul> </td> </tr> <tr> <td> <ul> <li>If you appear to be the cause of the problem, leave the room for a while. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Validate that the person seems to be upset over something. Reassure the person that you want to help and that you love him or her. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Avoid asking the person to do what appears to trigger an agitated or aggressive response. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Alzheimer's Association Position Statement on Treatment of BPSD. Copyright &copy; 2014 Alzheimer's Association. All rights reserved. Available at: <a href=\"http://www.alz.org/documents_custom/statements/challenging_behaviors.pdf\" target=\"_blank\">http://www.alz.org/documents_custom/statements/challenging_behaviors.pdf</a> (Accessed on December 5, 2014).</div><div id=\"graphicVersion\">Graphic 98510 Version 2.0</div></div></div>"},"98514":{"type":"graphic_movie","displayName":"2D echo pericardial effusion with stranding","title":"2D echocardiography of pericardial effusion with stranding","html":"<div class=\"graphic normal\"><div style=\"width: 656px\" class=\"figure\"><div class=\"ttl\">2D echocardiography of pericardial effusion with stranding</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/98514_2Dechopericardstrandvid.mp4\" style=\"width:636px;height:448px\"></div><img style=\"width:623px; height:438px;\" src=\"images/CARD/98514_2Dechopericardstrandimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two-dimensional (2D) echocardiogram showing a pericardial effusion with stranding, suggesting partial organization of the effusion.</div><div id=\"graphicVersion\">Graphic 98514 Version 1.0</div></div></div>"},"98515":{"type":"graphic_movie","displayName":"2D TTE parasternal long axis pericardial and pleural effusions","title":"2D transthoracic echocardiogram (TTE) from the parasternal long axis window showing both pericardial and pleural effusions","html":"<div class=\"graphic normal\"><div style=\"width: 656px\" class=\"figure\"><div class=\"ttl\">2D transthoracic echocardiogram (TTE) from the&nbsp;parasternal long axis window showing both pericardial and pleural effusions</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/98515_2DTTEpericardpleuralvid.mp4\" style=\"width:636px;height:448px\"></div><img style=\"width:623px; height:437px;\" src=\"images/CARD/98515_2DTTEpericardpleuralimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">2D transthoracic echocardiogram (TTE) from the&nbsp;parasternal long axis window showing both pericardial and pleural effusions. The pericardial stripe runs anterior to the descending thoracic aorta, allowing differentiation between pericardial fluid and the pleural effusion, which is seen posterior to the aorta.</div><div id=\"graphicVersion\">Graphic 98515 Version 1.0</div></div></div>"},"98517":{"type":"graphic_waveform","displayName":"ECG in Andersen-Tawil syndrome","title":"12-lead electrocardiogram (ECG) in Andersen-Tawil syndrome","html":"<div class=\"graphic\"><div style=\"width: 920px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) in Andersen-Tawil syndrome</div><div class=\"cntnt\"><img style=\"width:900px; height:510px;\" src=\"images/CARD/98517_ECGandersentawilsyndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">12-lead electrocardiogram (ECG) in a patient with Andersen-Tawil syndrome showing QTU prolongation with prominent U waves and biphasic U waves</div><div class=\"graphic_footnotes\">* Biphasic&nbsp;U wave.<br />Arrows indicate&nbsp;U wave.</div><div id=\"graphicVersion\">Graphic 98517 Version 3.0</div></div></div>"},"98518":{"type":"graphic_picture","displayName":"Drug-induced minocycline pigmentation","title":"Minocycline pigmentation","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Minocycline pigmentation</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/98518_Drg_indc_mncycln_pgmnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Discrete blue-gray areas of skin discoloration caused by minocycline among facial acne scars.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98518 Version 2.0</div></div></div>"},"98522":{"type":"graphic_picture","displayName":"Types of e-cigarettes","title":"E-cigarettes","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">E-cigarettes</div><div class=\"cntnt\"><img style=\"width:477px; height:265px;\" src=\"images/PC/98522_E_cigarettes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">From left to right: A conventional cigarette, a first-generation electronic cigarette that closely resembles a conventional cigarette,&nbsp;two pen-style second-generation electronic cigarettes, and&nbsp;two tank-style third-generation electronic cigarettes.</div><div class=\"graphic_reference\">Reproduced from: DrugFacts: Electronic Cigarettes (e-Cigarettes) (Revised September 2014). National Institute of Drug Abuse. Available at: <a href=\"http://www.drugabuse.gov/publications/drugfacts/electronic-cigarettes-e-cigarettes\" target=\"_blank\">http://www.drugabuse.gov/publications/drugfacts/electronic-cigarettes-e-cigarettes</a> (Accessed December 8, 2014).</div><div id=\"graphicVersion\">Graphic 98522 Version 1.0</div></div></div>"},"98524":{"type":"graphic_figure","displayName":"Percent of new cases by age group: Cervix uteri cancer","title":"Percent of new cases by age group: Cervix uteri cancer*","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Percent of new cases by age group: Cervix uteri cancer*</div><div class=\"cntnt\"><img style=\"width:515px; height:444px;\" src=\"images/PC/98524_New_cases_cervix_uteri_canc.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Infection of the cervix with human papillomavirus (HPV) is the most common cause of cervical cancer, although not all women with HPV infection will develop cervical cancer. The number of new cases of cervix uteri cancer was 7.8 per 100,000 women per year based on 2007 to 2011 cases. Cervix uteri cancer is most frequently diagnosed among women aged 35 to 44. Median age at diagnosis is 49.</div><div class=\"graphic_footnotes\">* SEER 18 2007-2011, all races, females.</div><div class=\"graphic_reference\">Reproduced from: SEER Cancer Statistics Factsheets: Cervix Uteri Cancer. National Cancer Institute. Bethesda, MD. Available at: <A spellcheck=true href=\"http://seer.cancer.gov/statfacts/html/cervix.html\" target=_blank>http://seer.cancer.gov/statfacts/html/cervix.html</A> (Accessed on December 8, 2014).</div><div id=\"graphicVersion\">Graphic 98524 Version 2.0</div></div></div>"},"98549":{"type":"graphic_picture","displayName":"External ear anomalies CHARGE syndrome","title":"External ear anomalies in a patient with CHARGE syndrome","html":"<div class=\"graphic\"><div style=\"width: 731px\" class=\"figure\"><div class=\"ttl\">External ear anomalies in a patient with CHARGE syndrome</div><div class=\"cntnt\"><img style=\"width:711px; height:531px;\" src=\"images/ALLRG/98549_Extrnl_ear_anml_CHARGE_synd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The outer ear of a child with CHARGE syndrome showing typical findings including a wide helix superiorly, thin/absent helical fold inferiorly, and absent earlobe.</div><div class=\"graphic_footnotes\">CHARGE: Coloboma, Heart anomaly, choanal Atresia, Retardation, Genital and Ear anomalies.</div><div id=\"graphicVersion\">Graphic 98549 Version 2.0</div></div></div>"},"98550":{"type":"graphic_picture","displayName":"IgAV (HSP) dorsal edema","title":"Dorsal hand edema and purpuric rash in a child with immunoglobulin A vasculitis (Henoch-Schönlein purpura)","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Dorsal hand edema and purpuric rash in a child with immunoglobulin A vasculitis (Henoch-Schönlein purpura)</div><div class=\"cntnt\"><img style=\"width:498px; height:667px;\" src=\"images/ALLRG/98550_IgAV_HSP_dorsal_edema.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 98550 Version 2.0</div></div></div>"},"98552":{"type":"graphic_algorithm","displayName":"Evaluation of elevated peak prosthetic aortic jet velocity","title":"Evaluation of elevated peak prosthetic aortic jet velocity","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Evaluation of elevated peak prosthetic aortic jet velocity</div><div class=\"cntnt\"><img style=\"width:526px; height:318px;\" src=\"images/CARD/98552_Eval_prosth_aortic_jet_velo.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Algorithm for evaluation of elevated peak prosthetic aortic jet velocity incorporating DVI, jet contour, and AT.</div><div class=\"graphic_footnotes\">AVR: aortic valve replacement; DVI: Doppler velocity index (Velocity<SUB>LVO</SUB>/Velocity<SUB>PrAV</SUB>) is the dimensionless ratio of the proximal velocity in the LVO tract to that of flow velocity through the prosthetic valve.<br />* PW Doppler sample too close to the valve (particularly when jet velocity by CW Doppler is ≥4 m/s).<br />¶ Stenosis further substantiated by EOA derivation compared with reference values if valve type and size are known. Fluoroscopy and TEE are helpful for further assessment, particularly in bileaflet valves.<br />Δ PW Doppler sample too far (apical) from the valve (particularly when jet velocity is 3 to 3.9 m/s).</div><div class=\"graphic_reference\">Reproduced from: Zoghbi WA, Chambers JB, Dumesnil JG, et al. Recommendations for evaluation of prosthetic valves with echocardiography and doppler ultrasound: a report From the American Society of Echocardiography's Guidelines and Standards Committee and the Task Force on Prosthetic Valves, developed in conjunction with the American College of Cardiology Cardiovascular Imaging Committee, Cardiac Imaging Committee of the American Heart Association, the European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography and the Canadian Society of Echocardiography, endorsed by the American College of Cardiology Foundation, American Heart Association, European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography, and Canadian Society of Echocardiography. J Am Soc Echocardiogr 2009; 22:975. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98552 Version 1.0</div></div></div>"},"98557":{"type":"graphic_figure","displayName":"Reding prognostic subgroups","title":"Reding prognostic subgroups for outcome after stroke","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Reding prognostic subgroups for outcome after stroke</div><div class=\"cntnt\"><img style=\"width:712px; height:374px;\" src=\"images/NEURO/98557_Redingprognosticsubgroups.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Life table curves for probability of reaching the goal of walking with assistance and assisted self-care function, defined as a Barthel Index score of &ge;60.</div><div class=\"graphic_reference\">From: Reding MJ, Potes E. Rehabilitation outcome following initial unilateral hemispheric stroke. Life table analysis approach. Stroke 1988; 19:1354. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 1998 American Heart Association. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 98557 Version 2.0</div></div></div>"},"98559":{"type":"graphic_figure","displayName":"Cardiovascular demands of different sports","title":"Cardiovascular demands of different sports","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Cardiovascular demands of different sports</div><div class=\"cntnt\"><img style=\"width:487px; height:487px;\" src=\"images/EM/98559_Cardiovasclr_dmnd_diff_sprt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MVC: maximal voluntary contraction; Max O<SUB>2</SUB>: maximum oxygen consumption.<br />* Danger of bodily collision.<br />¶ Increased risk if syncope occurs.</div><div class=\"graphic_reference\">Reproduced from: Mitchell JH, Haskell W, Snell P, Van Camp SP. Task Force 8: classification of sports. J Am Coll Cardiol 2005; 45:1364. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98559 Version 1.0</div></div></div>"},"98560":{"type":"graphic_figure","displayName":"TEE characteristics of mechanical valves","title":"Transesophageal echocardiographic characteristics of mechanical valves","html":"<div class=\"graphic\"><div style=\"width: 676px\" class=\"figure\"><div class=\"ttl\">Transesophageal echocardiographic characteristics of mechanical valves</div><div class=\"cntnt\"><img style=\"width:656px; height:526px;\" src=\"images/CARD/98560_TEE_char_mechanical_valves.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Examples of bileaflet, single-leaflet, and caged-ball mechanical valves and their transesophageal echocardiographic characteristics taken in the mitral position in diastole (middle) and in systole (right). The arrows in diastole point to the occluder mechanism of the valve and in systole to the characteristic physiologic regurgitation observed with each valve.</div><div class=\"graphic_reference\">Reproduced from: Zoghbi WA, Chambers JB, Dumesnil JG, et al. Recommendations for evaluation of prosthetic valves with echocardiography and doppler ultrasound: a report From the American Society of Echocardiography's Guidelines and Standards Committee and the Task Force on Prosthetic Valves, developed in conjunction with the American College of Cardiology Cardiovascular Imaging Committee, Cardiac Imaging Committee of the American Heart Association, the European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography and the Canadian Society of Echocardiography, endorsed by the American College of Cardiology Foundation, American Heart Association, European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography, and Canadian Society of Echocardiography. J Am Soc Echocardiogr 2009; 22:975. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98560 Version 1.0</div></div></div>"},"98561":{"type":"graphic_picture","displayName":"Triangular lunulae: Nail-patella syndrome","title":"Triangular lunulae in a patient with nail-patella syndrome","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Triangular lunulae in a patient with nail-patella syndrome</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/PEDS/98561_Triang_lunulae_nail_patella.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A photograph of the pathognomic finding of triangular lunulae in a patient with nail-patella syndrome. The lunula is the visible root of the nail that normally is a crescent-shaped, whitish area at the nail bed, rather than the triangular shape (apex away from the base) shown here and observed in 80 to 90 percent of patients with this syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98561 Version 1.0</div></div></div>"},"98562":{"type":"graphic_diagnosticimage","displayName":"Patellar aplasia: Nail-patella syndrome","title":"Patellar aplasia in a patient with nail-patella syndrome","html":"<div class=\"graphic\"><div style=\"width: 676px\" class=\"figure\"><div class=\"ttl\">Patellar aplasia in a patient with nail-patella syndrome</div><div class=\"cntnt\"><img style=\"width:656px; height:317px;\" src=\"images/PEDS/98562_Patellar_aplasia_nail_patel.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98562 Version 1.0</div></div></div>"},"98563":{"type":"graphic_picture","displayName":"Skin crease loss: Nail-patella syndrome","title":"Nail-patella syndrome: Skin crease loss","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Nail-patella syndrome: Skin crease loss</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/PEDS/98563_Skin_crease_loss_nail_patel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with nail-patella syndrome with loss of the skin creases overlying the distal interphalangeal joint.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98563 Version 2.0</div></div></div>"},"98565":{"type":"graphic_table","displayName":"Differential diagnosis of fibromyalgia","title":"Differential diagnosis of fibromyalgia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of fibromyalgia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Features not present in fibromyalgia</td> <td class=\"subtitle1\">Pitfalls in diagnosis</td> </tr> <tr> <td>Rheumatoid arthritis</td> <td>Joint swelling, elevated ESR and&nbsp;CRP</td> <td>\"False positive\" rheumatoid factor in FM occasionally</td> </tr> <tr> <td>Systemic lupus erythematosus</td> <td>Rash and renal, cardiac, pulmonary, and neurologic features</td> <td>\"False positive\" antinuclear antibody in some with FM and many symptoms</td> </tr> <tr> <td>Polymyalgia rheumatica</td> <td>Severe&nbsp;stiffness in the morning and when sedentary, elevated ESR and CRP, usual onset&nbsp;&#62;60 years, rapid response to glucocorticoids</td> <td>Like FM, often no abnormal physical findings in polymyalgia rheumatica</td> </tr> <tr> <td>Polymyositis</td> <td>Muscle weakness, elevated muscle enzymes, abnormal EMG/NCV</td> <td>FM patients often feel weak (but have normal strength)</td> </tr> <tr> <td>Spondyloarthritis</td> <td>Restricted spinal motion, elevated ESR or CRP</td> <td>May be no peripheral joint abnormality in spondyloarthritis</td> </tr> <tr> <td>Lyme disease</td> <td>Characteristic rash, joint swelling, serologic tests confirmatory</td> <td>\"Post-Lyme\" FM symptoms, false positive serologic tests, early flu-like symptoms</td> </tr> <tr> <td>Hypothyroidism</td> <td>Abnormal thyroid function tests, pain not prominent</td> <td>Hypothyroidism may present with a myopathy/mild myalgia</td> </tr> <tr> <td>Neuropathy</td> <td>Sensory or motor deficits, abnormal EMG/NCV</td> <td>Subtle neurologic disorders, small fiber neuropathy in some with FM</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; FM: fibromyalgia; EMG: electromyogram; NCV: nerve conduction velocity.</div><div id=\"graphicVersion\">Graphic 98565 Version 1.0</div></div></div>"},"98566":{"type":"graphic_figure","displayName":"Transcellular calcium reabsorption in the distal nephron","title":"Transcellular calcium reabsorption in the distal nephron","html":"<div class=\"graphic\"><div style=\"width: 509px\" class=\"figure\"><div class=\"ttl\">Transcellular calcium reabsorption in the distal nephron</div><div class=\"cntnt\"><img style=\"width:489px; height:351px;\" src=\"images/NEPH/98566_Calcium_reabsorption.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Calcium enters the cell via the transient receptor potential vanilloid 5 (TRPV5) channel on the apical membrane, is transported to the basolateral membrane by calbindin-D28k, and is extruded from the cell by the basolateral NCX1 (a 3Na/Ca exchanger) and PMCA1b (a Ca-ATPase) channels.</div><div class=\"graphic_reference\">Lambers TT, Bindels RJ, Hoenderop JG. Coordinated control of renal Ca2+ handling. Kidney Int 2006; 69:650.</div><div id=\"graphicVersion\">Graphic 98566 Version 1.0</div></div></div>"},"98568":{"type":"graphic_table","displayName":"Orpington Prognostic Scale","title":"Orpington Prognostic Scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Orpington Prognostic Scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">A. Motor deficit in arm</td> </tr> <tr> <td class=\"indent1\">Lying supine, patient flexes shoulder to 90&#176; and is given resistance.</td> </tr> <tr> <td class=\"indent2\">0.0 = MRC grade 5 (normal power)</td> </tr> <tr> <td class=\"indent2\">0.4 = MRC grade 4 (diminished power)</td> </tr> <tr> <td class=\"indent2\">0.8 = MRC grade 3 (movement against gravity)</td> </tr> <tr> <td class=\"indent2\">1.2 = MRC grade 1 to 2 (movement with gravity eliminated or trace)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">1.6 = MRC grade 0 (no movement)</td> </tr> <tr> <td class=\"subtitle2_left\">B. Proprioception (eyes closed)</td> </tr> <tr> <td class=\"indent1\">Locates affected thumb:</td> </tr> <tr> <td class=\"indent2\">0.0 = Accurately</td> </tr> <tr> <td class=\"indent2\">0.4 = Slight difficulty</td> </tr> <tr> <td class=\"indent2\">0.8 = Finds thumb via arm</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">1.2 = Unable to find thumb</td> </tr> <tr> <td class=\"subtitle2_left\">C. Balance</td> </tr> <tr> <td class=\"indent1\">0.0 = Walks 10 feet without help</td> </tr> <tr> <td class=\"indent1\">0.4 = Maintains standing position (unsupported for one minute)</td> </tr> <tr> <td class=\"indent1\">0.8 = Maintains sitting position</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">1.2 = No sitting balance</td> </tr> <tr> <td class=\"subtitle2_left\">D. Cognition</td> </tr> <tr> <td class=\"indent1\">Hodkinson's Mental Test: Score one point for each correct answer.</td> </tr> <tr> <td class=\"indent2\">_____ 1. Age of patient</td> </tr> <tr> <td class=\"indent2\">_____ 2. Time (to the nearest hour)</td> </tr> <tr> <td class=\"indent2\">I am going to give you an address, please remember it and I will ask you later: 42 West Street.</td> </tr> <tr> <td class=\"indent2\">_____ 3. Name of hospital</td> </tr> <tr> <td class=\"indent2\">_____ 4. Year</td> </tr> <tr> <td class=\"indent2\">_____ 5. Date of birth of patient</td> </tr> <tr> <td class=\"indent2\">_____ 6. Month</td> </tr> <tr> <td class=\"indent2\">_____ 7. Years of the Second World War</td> </tr> <tr> <td class=\"indent2\">_____ 8. Name of the President</td> </tr> <tr> <td class=\"indent2\">_____ 9. Count backwards (20 to 1)</td> </tr> <tr> <td class=\"indent2\">_____ 10. What is the address I asked you to remember: 42 West Street.</td> </tr> <tr> <td class=\"indent2\">0.0 = Mental test score of 10</td> </tr> <tr> <td class=\"indent2\">0.4 = Mental test score of 8 to 9</td> </tr> <tr> <td class=\"indent2\">0.8 = Mental test score of 5 to 7</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">1.2 = Mental test score of 0 to 4</td> </tr> <tr> <td><strong>TOTAL SCORE:</strong> 1.6 + Motor + Proprioception + Balance + Cognition.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MRC: Medical Research Council.</div><div class=\"graphic_reference\">From: Lai SM, Duncan PW, Keighley J. Prediction of functional outcome after stroke: comparison of the Orpington Prognostic Scale and the NIH Stroke Scale. Stroke 1998; 29:1838. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 1998 American Heart Association. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 98568 Version 2.0</div></div></div>"},"98571":{"type":"graphic_diagnosticimage","displayName":"Chest x-ray neonatal diaphragmatic paralysis","title":"Chest radiograph of diaphragmatic paralysis in a neonate","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of diaphragmatic paralysis in a neonate</div><div class=\"cntnt\"><img style=\"width:710px; height:600px;\" src=\"images/PEDS/98571_Chst_xry_nntl_dphrgm_prlys.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph in a neonate demonstrating a right elevated hemidiaphragm, which is suggestive of diaphragmatic paralysis.</div><div class=\"graphic_reference\">Courtesy of Ian J Griffin, MB ChB.</div><div id=\"graphicVersion\">Graphic 98571 Version 1.0</div></div></div>"},"98572":{"type":"graphic_diagnosticimage","displayName":"HSG intrauterine adhesions pre- and post-release","title":"Pre- and post-operative release of intrauterine adhesions by HSG","html":"<div class=\"graphic\"><div style=\"width: 738px\" class=\"figure\"><div class=\"ttl\">Pre- and post-operative release of intrauterine adhesions by HSG</div><div class=\"cntnt\"><img style=\"width:718px; height:356px;\" src=\"images/RADIOL/98572_HSG_intrt_adhsn_pre_pst_rls.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An HSG shows a large filling defect in the body and right horn of the uterus (arrows) with failed opacification of the right Fallopian tube. The left tube is patent (arrowhead). An HSG (B) following surgical release of the adhesions shows a patent right tube (arrowhead). There is residual deformity of the right fundal region (arrow).</div><div class=\"graphic_footnotes\">HSG: hysterosalpingogram.</div><div id=\"graphicVersion\">Graphic 98572 Version 1.0</div></div></div>"},"98573":{"type":"graphic_algorithm","displayName":"Evaluation of neonatal thrombocytopenia","title":"Diagnostic evaluation of neonatal thrombocytopenia","html":"<div class=\"graphic\"><div style=\"width: 737px\" class=\"figure\"><div class=\"ttl\">Diagnostic evaluation of neonatal thrombocytopenia</div><div class=\"cntnt\"><img style=\"width:717px; height:628px;\" src=\"images/PEDS/98573_Evaluation_nentl_thrmbcytpn.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">NEC: necrotizing enterocolitis; DIC: disseminated intravascular coagulation; NAIT: neonatal alloimmune thrombocytopenia; TAR: thrombocytopenia-absent radius syndrome.</div><div class=\"graphic_reference\">Adapted from: Sola-Visner M, Saxonhouse MA, Brown RE. Neonatal thrombocytopenia: what we do and don't know. Early Hum Dev 2008; 84:499.</div><div id=\"graphicVersion\">Graphic 98573 Version 2.0</div></div></div>"},"98574":{"type":"graphic_figure","displayName":"Sarcocystosis life cycle","title":"Sarcocystosis life cycle","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Sarcocystosis life cycle</div><div class=\"cntnt\"><img style=\"width:528px; height:624px;\" src=\"images/ID/98574_Sarcocystosis_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Both sporulated oocysts (containing two sporocysts) and individual sporocysts can be passed in stool <strong>(1)</strong>. Sporocysts contain four sporozoites and a refractile residual body. Sporocysts ingested by the intermediate host (cattle for <em>Sarcocystis hominis</em> and pigs for <em>S. suihominis</em>) rupture, releasing sporozoites. Sporozoites enter endothelial cells of blood vessels and undergo schizogony, resulting in first-generation schizonts. Merozoites derived from the first generation invade small capillaries and blood vessels, becoming second-generation schizonts. The second-generation merozoites invade muscle cells and develop into sarcocysts containing bradyzoites, which are the infective stage for the definitive host <strong>(2)</strong>. Humans become infected when they eat undercooked meat containing these sarcocysts. Bradyzoites are released from ruptured cysts in the small intestine <strong>(3)</strong> and invade the lamina propria of the intestinal epithelium <strong>(4)</strong>. There, they differentiate into macro- and microgametocytes. Fusion of male and female gametes <strong>(5)</strong> results in the formation of oocysts <strong>(6)</strong>. Oocysts sporulate in the intestinal epithelium and are shed from the host in stool. Due to the fragile nature of the oocyst wall, individual sporocysts may also be detected in stool <strong>(7)</strong>. Humans act as accidental hosts when sporocysts or oocysts passed in the feces of a definitive host <strong>(8)</strong> are inadvertently ingested <strong>(9)</strong>. Asexual development occurs in the intestine and then the vasculature (small arteries, arterioles, capillaries, venules, and veins) prior to forming sarcocysts in skeletal muscle <strong>(10)</strong>.</div><div class=\"graphic_reference\">Adapted from: Centers for Disease Control and Prevention. DPDx &ndash; Laboratory Identification of Parasitic Diseases of Public Health Concern. Available at: <a href=\"http://www.cdc.gov/dpdx/sarcocystosis/index.html\" target=\"_blank\">www.cdc.gov/dpdx/sarcocystosis/index.html</a>.</div><div id=\"graphicVersion\">Graphic 98574 Version 2.0</div></div></div>"},"98575":{"type":"graphic_table","displayName":"Acute effect of altitude on arterial blood gas values","title":"Acute effect of altitude on oxygen saturation and arterial blood gas values","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Acute effect of altitude on oxygen saturation and arterial blood gas values</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Population</td> <td class=\"subtitle1\">Altitude (meters)</td> <td class=\"subtitle1\">Altitude (feet)</td> <td class=\"subtitle1\">P<sub>B</sub> (mm Hg)</td> <td class=\"subtitle1\">PaO<sub>2</sub> (mm Hg)</td> <td class=\"subtitle1\">SaO<sub>2</sub> (%)</td> <td class=\"subtitle1\">PaCO<sub>2</sub> (mm Hg)</td> </tr> <tr class=\"divider_bottom\"> <td>Altitude residents</td> <td class=\"centered\">1646</td> <td class=\"centered\">5400</td> <td class=\"centered\">630</td> <td class=\"centered\">73 (65-83)</td> <td class=\"centered\">95.1 (93-97)</td> <td class=\"centered\">35.6 (30.7-41.8)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Acute exposure</td> <td class=\"centered\">2810</td> <td class=\"centered\">9219</td> <td class=\"centered\">543</td> <td class=\"centered\">60 (47.4-73.6)</td> <td class=\"centered\">91 (86.6-95.2)</td> <td class=\"centered\">33.9 (31.3-36.5)</td> </tr> <tr> <td class=\"centered\">3660</td> <td class=\"centered\">12,008</td> <td class=\"centered\">489</td> <td class=\"centered\">47.6 (42.2-53)</td> <td class=\"centered\">84.5 (80.5-89)</td> <td class=\"centered\">29.5 (23.5-34.3)</td> </tr> <tr> <td class=\"centered\">4700</td> <td class=\"centered\">15,420</td> <td class=\"centered\">429</td> <td class=\"centered\">44.6 (36.5-47.5)</td> <td class=\"centered\">78 (70.8-85)</td> <td class=\"centered\">27.1 (22.9-34)</td> </tr> <tr> <td class=\"centered\">5340</td> <td class=\"centered\">17,520</td> <td class=\"centered\">401</td> <td class=\"centered\">43.1 (37.6-50.4)</td> <td class=\"centered\">76.2 (65.4-81.6)</td> <td class=\"centered\">25.7 (21.7-29.7)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">6140</td> <td class=\"centered\">20,144</td> <td class=\"centered\">356</td> <td class=\"centered\">35 (26.9-40.1)</td> <td class=\"centered\">65.6 (55.5-73)</td> <td class=\"centered\">22 (19.2-24.8)</td> </tr> <tr> <td rowspan=\"6\">Subacute exposure</td> <td class=\"centered\">6500</td> <td class=\"centered\">21,325</td> <td class=\"centered\">346</td> <td class=\"centered\">41.1 &#177; 3.3</td> <td class=\"centered\">75.2 &#177; 6</td> <td class=\"centered\">20 &#177; 2.8</td> </tr> <tr> <td class=\"centered\">7000</td> <td class=\"centered\">22,966</td> <td class=\"centered\">324</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"centered\">8000</td> <td class=\"centered\">26,247</td> <td class=\"centered\">284</td> <td class=\"centered\">36.6 &#177; 2.2</td> <td class=\"centered\">67.8 &#177; 5</td> <td class=\"centered\">12.5 &#177; 1.1</td> </tr> <tr> <td class=\"centered\">8400</td> <td class=\"centered\">27,559</td> <td class=\"centered\">272</td> <td class=\"centered\">24.6 &#177; 5.3</td> <td class=\"centered\">54</td> <td class=\"centered\">13.3</td> </tr> <tr> <td class=\"centered\">8848</td> <td class=\"centered\">29,029</td> <td class=\"centered\">253</td> <td class=\"centered\">30.3 &#177; 2.1</td> <td class=\"centered\">58 &#177; 4.5</td> <td class=\"centered\">11.2 &#177; 1.7</td> </tr> <tr> <td class=\"centered\">8848</td> <td class=\"centered\">29,029</td> <td class=\"centered\">253</td> <td class=\"centered\">30.6 &#177; 1.4</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">11.9 &#177; 1.4</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">P<SUB>B</SUB>: barometric pressure; PaCO<SUB>2</SUB>: arterial partial pressure of carbon dioxide; PaO<SUB>2</SUB>: arterial partial pressure of oxygen; SaO<SUB>2</SUB>: arterial oxygen saturation.<br />* Data are mean values and (range) and were obtained in subjects 20 to 40 years of age during the first one to two days of arriving at altitude (acute exposure)&nbsp;and associated with good acclimatization (subacute exposure).</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Loeppky JA, Caprihan A, Luft UC. VA/Q inequality during clinical hypoxemia and its alterations. In: Shiraki K, Yousef, MK (Eds). Man in Stressful Environments, CC Thomas, Springfield, Il, 1987, p. 199.</li>&#xD;&#xA;    <li>McFarland RA, Dill DB. A comparative study of the effects of reduced oxygen pressure on man during acclimatization. J Aviat Med 1938; 9:18.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced from: Hackett PH, Roach RC. High-altitude medicine and physiology. In: Auerbach PS (Ed). Wilderness Medicine, 6th edition, Elsevier Mosby, Philadelphia, 2012. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98575 Version 3.0</div></div></div>"},"98576":{"type":"graphic_picture","displayName":"Muscular sarcocystosis","title":"Muscular sarcocystosis","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Muscular sarcocystosis</div><div class=\"cntnt\"><img style=\"width:550px; height:706px;\" src=\"images/ID/98576_Muscular_sarcocystosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is visible swelling of the muscles of mastication approximately five weeks after exposure in up to 10 percent&nbsp;of cases.</div><div class=\"graphic_reference\">Reproduced from: Italiano CM, Wong KT, AbuBakar S, et al. Sarcocystis nesbitti causes acute, relapsing febrile myositis with a high attack rate: description of a large outbreak of muscular sarcocystosis in Pangkor Island, Malaysia, 2012. PLoS Negl Trop Dis 2013; 8:e2876. Copyright &copy; 2014 Italiano et al, published by PLOS (Public Library of Science).</div><div id=\"graphicVersion\">Graphic 98576 Version 1.0</div></div></div>"},"98577":{"type":"graphic_algorithm","displayName":"Intraoperative management of the airway of burn patients","title":"Intraoperative management of the airway of burn patients","html":"<div class=\"graphic\"><div style=\"width: 652px\" class=\"figure\"><div class=\"ttl\">Intraoperative management of the airway of burn patients</div><div class=\"cntnt\"><img style=\"width:632px; height:244px;\" src=\"images/ANEST/98577_Intraop_airway_burn_patient.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Kaiser HE, Kim CM, Sharer SR, Olivar HP. Advances in Perioperative and Critical Care of the Burn Patient : Anesthesia Management of Major Thermal Burn Injuries in Adults. Adv Anesth 2013; 31:137. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98577 Version 1.0</div></div></div>"},"98578":{"type":"graphic_diagnosticimage","displayName":"Sarcocystosis MRI","title":"Sarcocystosis MRI","html":"<div class=\"graphic\"><div style=\"width: 591px\" class=\"figure\"><div class=\"ttl\">Sarcocystosis MRI</div><div class=\"cntnt\"><img style=\"width:571px; height:707px;\" src=\"images/ID/98578_Sarcocystosis_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Myositis may be observed with magnetic resonance imaging (MRI), particularly T2-weighted short tau inversion recovery (STIR) sequences.</div><div class=\"graphic_reference\">Reproduced from: Italiano CM, Wong KT, AbuBakar S, et al. Sarcocystis nesbitti causes acute, relapsing febrile myositis with a high attack rate: description of a large outbreak of muscular sarcocystosis in Pangkor Island, Malaysia, 2012. PLoS Negl Trop Dis 2013; 8:e2876. Copyright &copy; 2014 Italiano et al, published by PLOS (Public Library of Science).</div><div id=\"graphicVersion\">Graphic 98578 Version 1.0</div></div></div>"},"98579":{"type":"graphic_picture","displayName":"Sarcocystosis biopsy","title":"Sarcocystosis biopsy","html":"<div class=\"graphic\"><div style=\"width: 723px\" class=\"figure\"><div class=\"ttl\">Sarcocystosis biopsy</div><div class=\"cntnt\"><img style=\"width:703px; height:523px;\" src=\"images/ID/98579_Sarcocystosis_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A single sarcocyst (arrow) within a muscle fiber. Bar = 40 microns. H&amp;E stains, 620 objective lens. Typically, perivascular inflammation occurs within the endomysium and perimysium. The severity ranges from occasional foci of predominantly lymphohistiocytic infiltrate to more widespread foci of mixed inflammation. As visible sarcocysts are widely scattered within inflamed tissue, biopsies may demonstrate myositis only despite serial sections.</div><div class=\"graphic_reference\">Reproduced from: Italiano CM, Wong KT, AbuBakar S, et al. Sarcocystis nesbitti causes acute, relapsing febrile myositis with a high attack rate: description of a large outbreak of muscular sarcocystosis in Pangkor Island, Malaysia, 2012. PLoS Negl Trop Dis 2013; 8:e2876. Copyright &copy; 2014 Italiano et al, published by PLOS (Public Library of Science).</div><div id=\"graphicVersion\">Graphic 98579 Version 1.0</div></div></div>"},"98585":{"type":"graphic_figure","displayName":"E-cigarette ","title":"E-cigarette","html":"<div class=\"graphic\"><div style=\"width: 607px\" class=\"figure\"><div class=\"ttl\">E-cigarette</div><div class=\"cntnt\"><img style=\"width:587px; height:429px;\" src=\"images/PC/98585_E-cigarette.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 98585 Version 1.0</div></div></div>"},"98589":{"type":"graphic_movie","displayName":"Anterior glide test for SLAP tear","title":"Anterior glide test for SLAP tear","html":"<div class=\"graphic normal\"><div style=\"width: 644px\" class=\"figure\"><div class=\"ttl\">Anterior glide test for SLAP tear</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/98589_Anteriorglidetestvid.mp4\" style=\"width:624px;height:368px\"></div><img style=\"width:576px; height:334px;\" src=\"images/EM/98589_Anteriorglidetestimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The anterior glide test is used in combination with other maneuvers to help determine the presence of a superior labrum anterior-posterior (SLAP) ear.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 98589 Version 2.0</div></div></div>"},"98593":{"type":"graphic_diagnosticimage","displayName":"CT femoral artery embolus","title":"Femoral artery emboli on CT scan","html":"<div class=\"graphic\"><div style=\"width: 722px\" class=\"figure\"><div class=\"ttl\">Femoral artery emboli on CT scan</div><div class=\"cntnt\"><img style=\"width:702px; height:244px;\" src=\"images/RADIOL/98593_CTfemoralarteryembolus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A transverse CT scan through the pelvis (A) shows nonocclusive thrombus in the left superficial femoral and deep femoral arteries (circle). (B) is a magnified view of (A) and shows nonocclusive thrombus in the SFA (arrowhead) and in the DFA (arrow). (C) is a magnified sagittal reformat of the CT scan and shows the thrombus straddling the bifurcation (dashed arrow) and extending into the SFA (arrowhead) and DFA (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography; SFA: superficial femoral artery; DFA: deep femoral artery.</div><div id=\"graphicVersion\">Graphic 98593 Version 2.0</div></div></div>"},"98594":{"type":"graphic_diagnosticimage","displayName":"Metastatic bone disease pre- and post-surgery","title":"Symptomatic metastatic bone disease treated with dynamic screw and intramedullary nail","html":"<div class=\"graphic\"><div style=\"width: 692px\" class=\"figure\"><div class=\"ttl\">Symptomatic metastatic bone disease treated with dynamic screw and intramedullary nail</div><div class=\"cntnt\"><img style=\"width:672px; height:344px;\" src=\"images/RADIOL/98594_Mtsttc_bne_dss_pre_pst_srgy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A frog leg lateral radiograph (A) in a 57-year-old woman with hip pain and lung carcinoma shows a large lytic lesion (asterisk) in the lesser trochanter of the right femur without an obvious pathological fracture. Image B is a magnified view of the lytic lesion (asterisk) involving the lesser trochanter and proximal shaft. Image C is a postoperative A-P radiograph following placement of a compression screw and intramedullary nail.</div><div class=\"graphic_footnotes\">A-P: anteroposterior.</div><div id=\"graphicVersion\">Graphic 98594 Version 1.0</div></div></div>"},"98595":{"type":"graphic_diagnosticimage","displayName":"CT scan multicentric bladder carcinoma","title":"Multicentric urothelial carcinoma of the urinary bladder on CT scan","html":"<div class=\"graphic\"><div style=\"width: 686px\" class=\"figure\"><div class=\"ttl\">Multicentric&nbsp;urothelial carcinoma&nbsp;of the urinary bladder on CT scan</div><div class=\"cntnt\"><img style=\"width:666px; height:322px;\" src=\"images/RADIOL/98595_CT_scn_mltcntrc_blddr_crcnm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image A is a transverse CT scan through the bladder and shows a 1.2 cm&nbsp;urothelial carcinoma&nbsp;(arrow) and a second 2 cm&nbsp;urothelial carcinoma&nbsp;in the anterior bladder wall that extends into the surrounding fat (arrowhead). Image B is a magnified view of A and shows the two lesions, one situated posteriorly (arrow) and the second situated anteriorly, extending into the perivesical fat (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 98595 Version 3.0</div></div></div>"},"98596":{"type":"graphic_diagnosticimage","displayName":"MRI of urothelial carcinoma on bladder","title":"Urothelial carcinoma of the bladder on MRI","html":"<div class=\"graphic\"><div style=\"width: 672px\" class=\"figure\"><div class=\"ttl\">Urothelial carcinoma of the bladder on MRI</div><div class=\"cntnt\"><img style=\"width:652px; height:256px;\" src=\"images/RADIOL/98596_MRI_TCC_bladder.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial image through the bladder using a T2-weighted sequence (A), shows a 1.4 cm endophytic&nbsp;urothelial carcinoma&nbsp;(arrow). Image B is a fat-saturated T1-weighted image following contrast administration and shows homogeneous enhancement (arrow) without overt mural transgression.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 98596 Version 3.0</div></div></div>"},"98597":{"type":"graphic_diagnosticimage","displayName":"Radiography of MCP subluxation thumb","title":"MCP subluxation of the thumb on radiography","html":"<div class=\"graphic\"><div style=\"width: 630px\" class=\"figure\"><div class=\"ttl\">MCP subluxation of the thumb on radiography</div><div class=\"cntnt\"><img style=\"width:610px; height:376px;\" src=\"images/RADIOL/98597_Radiography_MCP_sblxtn_thmb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A frontal view of the left hand (A) shows dorsal subluxation at the first MCP (arrow). Image B is a magnified view showing subluxation with degenerative change that includes joint space narrowing, sclerosis (arrow), and osteophyte formation (arrowhead). Image C is a magnified oblique view that confirms subluxation and degenerative change (arrow).</div><div class=\"graphic_footnotes\">MCP: metacarpophalangeal.</div><div class=\"graphic_reference\">Courtesy of Greg Waryasz, MD.</div><div id=\"graphicVersion\">Graphic 98597 Version 2.0</div></div></div>"},"98600":{"type":"graphic_table","displayName":"DDx travel associated skin lesions","title":"Travel-associated skin lesions: Descriptions and differential diagnosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Travel-associated skin lesions: Descriptions and differential diagnosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td><strong>Maculopapular</strong></td> <td>Drug reaction, dengue, chikungunya, Zika, acute HIV, rickettsia, syphilis, leptospirosis, brucellosis, typhus, bartonellosis, typhoid, rubeola, rubella, scarlet fever, insect bites, cercarial dermatitis, seabather's eruption, eczema, tungiasis, myiasis, scabies, arthropod bites, miliaria rubra</td> </tr> <tr> <td><strong>Papulosquamous</strong></td> <td>Superficial mycoses or exacerbations of eczema or psoriasis</td> </tr> <tr> <td><strong>Petechial/ecchymoses</strong></td> <td><em>Rickettsia</em>, meningococcaemia, yellow fever, viral haemorrhagic fevers, dengue, leptospirosis</td> </tr> <tr> <td><strong>Vesicular</strong></td> <td>Varicella, herpes simplex, drug reactions, sunburn, photodermatitis</td> </tr> <tr> <td><strong>Erythaema migrans</strong></td> <td>Lyme</td> </tr> <tr> <td><strong>Eschar</strong></td> <td>Typhus, anthrax, African trypanosomiasis, Congo-Crimean hemorrhagic fever, tularaemia, spider bites</td> </tr> <tr> <td><strong>Nodules</strong></td> <td>Onchocerciasis, bartonellosis, myiasis, paracoccidioidomycosis</td> </tr> <tr> <td><strong>Ulcers</strong></td> <td>Leishmaniasis, tropical ulcers, anthrax, tularemia, cutaneous diphtheria, ecthyma, syphilis, yaws, tuberculosis, granulomas inguinale, lymphogranuloma venereum, plague, arthropod bite (eg, brown recluse spider)</td> </tr> <tr> <td><strong>Urticaria</strong></td> <td>Drug reactions, filariasis, onchocerciasis, cutaneous larva migrans, larva currens (strongyloidiasis), acute schistosomiasis, fascioliasis, hymenoptera stings, insect bites, enterobiasis, gnathostomiasis, scabies, cercarial dermatitis, seabather's eruption, nematocyst stings</td> </tr> <tr> <td><strong>Swelling/edema</strong></td> <td><em>Loa loa </em>calabar swellings, trichinosis (especially facial/periorbital)</td> </tr> <tr> <td><strong>Migrating</strong></td> <td>Cutaneous larva migrans, larva currens, gnathostomiasis, loiasis, myiasis, paragonimiasis sparganosis</td> </tr> <tr> <td><strong>Hypopigmentation</strong></td> <td>Tinea (pityriasis) versicolour, tinea corporis, leprosy, vitiligo</td> </tr> <tr> <td><strong>Vegetation/verrucae</strong></td> <td>Bartonellosis, histoplasmosis, leishmaniasis, maduromycosis, paracoccidioidomycosis, pinta, syphilis, tuberculosis, yaws</td> </tr> <tr> <td><strong>Linear</strong></td> <td>Photodermatitis, cutaneous larva migrans, gnathostomiasis, larva currens, flea bites, <em>Mycobacterium marinum</em>, sporotrichosis, nematocyst stings, lymphangitis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Spira AM. Assessment of travellers who return home ill. Lancet 2003; 361:1459. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98600 Version 3.0</div></div></div>"},"98603":{"type":"graphic_picture","displayName":"Gore-Tex mesh erosion into vagina after abdominal sacrocolpopexy","title":"Gore-Tex mesh erosion into vagina following abdominal sacrocolpopexy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gore-Tex mesh erosion into vagina following abdominal sacrocolpopexy</div><div class=\"cntnt\"><img style=\"width:432px; height:648px;\" src=\"images/OBGYN/98603_Goretex_mesh_eros_abd_sacro.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gore-Tex mesh exposure in the vaginal canal as a complication of abdominal sacrocolpopexy.</div><div class=\"graphic_reference\">Courtesy of Dr. John Gebhart, Mayo Clinic.</div><div id=\"graphicVersion\">Graphic 98603 Version 2.0</div></div></div>"},"98604":{"type":"graphic_picture","displayName":"Excised Gore-Tex mesh from abdominal sacrocolpopexy","title":"Excised Gore-Tex mesh (previously inserted during abdominal sacrocolpopexy)","html":"<div class=\"graphic\"><div style=\"width: 668px\" class=\"figure\"><div class=\"ttl\">Excised Gore-Tex mesh&nbsp;(previously&nbsp;inserted during&nbsp;abdominal sacrocolpopexy)</div><div class=\"cntnt\"><img style=\"width:648px; height:432px;\" src=\"images/OBGYN/98604_Goretex_plcd_time_abd_sacro.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dr. John Gebhart, Mayo Clinic.</div><div id=\"graphicVersion\">Graphic 98604 Version 1.0</div></div></div>"},"98646":{"type":"graphic_table","displayName":"Studies showing increased CVD risk in patients with diabetes","title":"Studies showing increased cardiovascular disease (CVD) risk in patients with diabetes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Studies showing increased cardiovascular disease (CVD) risk in patients with diabetes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"8%\"></colgroup><colgroup width=\"15%\"></colgroup><colgroup span=\"3\" width=\"8%\"></colgroup><colgroup width=\"27%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Author/study</td> <td class=\"subtitle1\">Recruitment period</td> <td class=\"subtitle1\">Type DM</td> <td class=\"subtitle1\">Type of study</td> <td class=\"subtitle1\">Number of patients</td> <td class=\"subtitle1\">Age (years)</td> <td class=\"subtitle1\">Gender</td> <td class=\"subtitle1\">Follow-up (years)</td> <td class=\"subtitle1\">Main findings</td> </tr> <tr> <td>Haffner et al.<sup>[1]</sup> (Finnish cohort)</td> <td>1982 to 1984</td> <td>Type 2</td> <td>Observational</td> <td> <p>N = 2432</p> <p>Non-DM = 1373</p> <p>(69 with prior MI)</p> <p>DM = 1059</p> (169 with prior MI)</td> <td>45 to 64</td> <td>50% men</td> <td>7</td> <td> <ul> <li>DM patients without prior MI and non-DM patients with prior MI had comparable CHD mortality risk (HR 1.2; 95% CI 0.6-2.4). </li> </ul> </td> </tr> <tr> <td>Whiteley et al.<sup>[2]</sup></td> <td>1972 to 1976</td> <td>NA</td> <td>Observational</td> <td> <p>N = 14,039</p> <p>Non-DM = 13,811</p> <p>(3015 with prior CHD)</p> <p>DM = 228</p> (77 with prior CHD)</td> <td>45 to 64</td> <td>46% men</td> <td>25</td> <td> <ul> <li>Men with DM only had similar risk of CHD mortality than non-DM patients with known CHD (HR 1.17; 95% CI 0.78-1.74). </li> <li>Women with DM only had increased risk of CHD mortality than women with known CHD (HR 1.97; 95% CI 1.27-3.08). </li> </ul> </td> </tr> <tr> <td>Juutilainen et al.<sup>[3]</sup> (Finnish cohort)</td> <td>1982 to 1984</td> <td>Type 2</td> <td>Observational</td> <td> <p>N = 2432</p> <p>Non-DM = 1373</p> <p>(69 with prior MI)</p> <p>DM = 1059</p> (169 with prior MI)</td> <td>45 to 64</td> <td>50% men</td> <td>18</td> <td> <ul> <li>DM patients without known CHD had twofold risk of CHD mortality compared with non-DM patients with known CHD (HR 1.89; 95% CI 1.36-2.64). </li> <li>HR for CHD mortality was larger in women than in men. </li> </ul> </td> </tr> <tr> <td>Franco et al.<sup>[4]</sup> (FHS)</td> <td>1948 to 1951</td> <td>Type 2</td> <td>Observational</td> <td> <p>N = 9033 (observations)</p> <p>Non-DM = 8540</p> DM = 493</td> <td>28 to 62</td> <td>64% men</td> <td>46</td> <td> <ul> <li>DM patients had twofold increased risk of incident CVD compared with non-DM (HR 2.27 and 2.34 for men and women, respectively). </li> <li>DM patients with known CVD had 1.5- to twofold risk of all-cause mortality compared with their non-DM counterparts (HR 1.66 and 2.16 for men and women, respectively). </li> </ul> </td> </tr> <tr> <td>Fox et al.<sup>[5]</sup> (FHS)</td> <td> <p>Early (1952 to 1974)</p> Late (1975 to 1998)</td> <td>Type 2</td> <td>Observational</td> <td> <p>Early N = 4599</p> <p>(181 DM)</p> <p>Late N = 4941</p> (351 DM)</td> <td>45 to 64</td> <td>45% men</td> <td>48</td> <td> <ul> <li>The multivariate adjusted attributable risk of DM for CVD increased from 5.2% in the early period to 7.8% in the late period. </li> <li>Most of the increase in attributable risk ratio was observed in men only (HR 1.88; 95% CI 0.99-3.77). </li> </ul> </td> </tr> <tr> <td>Pencina et al.<sup>[6]</sup> (FHS)</td> <td>1971 to 1974</td> <td>Type 2</td> <td>Observational</td> <td>N = 4506 <p>(71 DM)</p> </td> <td>20 to 59</td> <td>48% men</td> <td>30</td> <td> <ul> <li>DM was strongly associated with hard CVD outcomes (CHD death, MI, stroke) (HR 2.3; 95% CI 1.89-2.81). </li> </ul> </td> </tr> <tr> <td>Preis et al.<sup>[7]</sup> (FHS)</td> <td> <p>Early (1950 to 1975)</p> Late (1976 to 2001)</td> <td>Type 2</td> <td>Observational</td> <td> <p>Early N = 78 156 p-y</p> <p>(399 DM)</p> <p>Late N = 79,000 p-y</p> (679 DM)</td> <td>45 to 74</td> <td>44% men</td> <td>4</td> <td> <ul> <li>There was a 69% decrease in cardiovascular mortality among DM patients over time (early versus late). </li> <li>Compared with non-DM patients, DM patients had still fourfold and threefold increased risk of cardiovascular mortality in the early and late time periods. </li> </ul> </td> </tr> <tr> <td>Dagenais et al.<sup>[8]</sup></td> <td>1973 to 1974</td> <td>Type 2</td> <td>Observational</td> <td> <p>N = 4376</p> <p>(incident DM 137)</p> (incident CVD 527)</td> <td>35 to 64</td> <td>100% men</td> <td>24</td> <td> <ul> <li>Patients with incident DM had similar risk of CVD mortality compared with patients with incident CVD (RR 1.15; 95% CI 0.70-1.88). </li> </ul> </td> </tr> <tr> <td>Carnethon et al.<sup>[9]</sup> (CHS)</td> <td> <p>1989 to 1990</p> 1992 to 1993</td> <td>Type 2</td> <td>Observational</td> <td> <p>N = 5784</p> <p>Non-DM = 4865</p> <p>(868 with prior CHD)</p> <p>DM = 919</p> (260 with prior CHD)</td> <td>&#8805;65</td> <td>42% men</td> <td>11</td> <td> <ul> <li>Among older adults, patients with only DM had similar risk of cardiovascular mortality compared with non-DM patients with known CHD (HR 1.04; 95% CI 0.83-1.30). </li> </ul> </td> </tr> <tr> <td>Carson et al.<sup>[10]</sup> (ARIC and REGARDS studies)</td> <td> <p>ARIC 1987 to 1996</p> REGARDS 2003 to 2009</td> <td>NA</td> <td>Observational</td> <td> <p>Early N = 15,732</p> <p>(1673 DM)</p> <p>Late N = 14,992</p> (2297 DM)</td> <td>45 to 64</td> <td>42% men</td> <td>7</td> <td> <ul> <li>DM patients had sustained two- to threefold higher risk for CHD incidence and CHD mortality than non-DM patients in the early and late periods, despite declines in CHD incidence and mortality over time. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ARIC: Atherosclerosis Risk In Communities; CI: confidence interval; CHD: coronary heart disease; CVD: cardiovascular disease; DM: diabetes mellitus; FHS: Framingham Heart Study; HR: hazard ratio; MI: myocardial infarction; NA: not available; REGARDS: REasons for Geographic And Racial Differences in Stroke; RR: relative risk.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229.</li>&#xD;&#xA;    <li>Whiteley L, Padmanabhan S, Hole D, Isles C. Should diabetes be considered a coronary heart disease risk equivalent?: results from 25 years of follow-up in the Renfrew and Paisley survey. Diabetes Care 2005; 28:1588.</li>&#xD;&#xA;    <li>Juutilainen A, Lehto S, Ronnemaa T, et al. Type 2 diabetes as a \"coronary heart disease equivalent\": an 18-year prospective population-based study in Finnish subjects. Diabetes Care 2005; 28:2901.</li>&#xD;&#xA;    <li>Franco OH, Steyerberg EW, Hu FB, et al. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med 2007; 167:1145.</li>&#xD;&#xA;    <li>Fox CS, Coady S, Sorlie PD, et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 2007; 115:1544.</li>&#xD;&#xA;    <li>Pencina MJ, D'Agostino RB, Sr., Larson MG, et al. Predicting the 30-year risk of cardiovascular disease: the Framingham heart study. Circulation 2009; 119:3078.</li>&#xD;&#xA;    <li>Preis SR, Hwang SJ, Coady S, et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 2009; 119:1728.</li>&#xD;&#xA;    <li>Dagenais GR, St-Pierre A, Gilbert P, et al. Comparison of prognosis for men with type 2 diabetes mellitus and men with cardiovascular disease. CMAJ 2009; 180:40.</li>&#xD;&#xA;    <li>Carnethon MR, Biggs ML, Barzilay J, et al. Diabetes and coronary heart disease as risk factors for mortality in older adults. Am J Med 2010; 123:556.</li>&#xD;&#xA;    <li>Carson AP, Tanner RM, Yun H, et al. Declines in coronary heart disease incidence and mortality among middle-aged adults with and without diabetes. Ann Epidemiol 2014; 24:581.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 98646 Version 3.0</div></div></div>"},"98656":{"type":"graphic_table","displayName":"Studies showing no increased CVD risk in patients with diabetes","title":"Studies showing no increased cardiovascular disease (CVD) risk in patients with diabetes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Studies showing no increased cardiovascular disease (CVD) risk in patients with diabetes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"8%\"></colgroup><colgroup width=\"15%\"></colgroup><colgroup span=\"3\" width=\"8%\"></colgroup><colgroup width=\"27%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Author/study</td> <td class=\"subtitle1\">Recruitment period</td> <td class=\"subtitle1\">Type DM</td> <td class=\"subtitle1\">Type of study</td> <td class=\"subtitle1\">Number of patients</td> <td class=\"subtitle1\">Age (years)</td> <td class=\"subtitle1\">Gender</td> <td class=\"subtitle1\">Follow-up (years)</td> <td class=\"subtitle1\">Main findings</td> </tr> <tr> <td>Evans et al.<sup>[1]</sup></td> <td>1988 to 1995</td> <td>Type 2</td> <td>Observational</td> <td> <p>Non-DM with MI = 5350</p> DM = 3477</td> <td> <p>71</p> 66</td> <td>54% men</td> <td>7</td> <td> <ul> <li>DM patients had threefold lower risk of cardiovascular death compared with non-DM patients with prior MI (RR 0.34, 95% CI 0.29-0.39). </li> </ul> </td> </tr> <tr> <td>Cho et al.<sup>[2]</sup> (HPFS)</td> <td>1986</td> <td>Type 2</td> <td>Observational</td> <td> <p>N = 51,316</p> <p>Non-DM = 49,801</p> <p>(2038 with prior MI)</p> <p>DM = 1515</p> (230 with prior MI)</td> <td>54 to 54</td> <td>100% men</td> <td>10</td> <td> <ul> <li>DM patients without prior MI had lower relative risk for fatal CHD compared with non-DM patients with prior MI (RR 3.84 [95% CI 3.12-4.71] versus RR 7.88 [95% CI 6.86-9.05]). </li> <li>DM duration was independently associated with increased risk of CHD mortality. </li> </ul> </td> </tr> <tr> <td>Lee et al.<sup>[3]</sup> (ARIC)</td> <td>1987 to 1989</td> <td>NA</td> <td>Observational</td> <td> <p>N = 13,790</p> <p>Non-DM = 12,232</p> <p>(283 with prior MI)</p> <p>DM = 1558</p> (98 with prior MI)</td> <td>45 to 64</td> <td>42% men</td> <td>9</td> <td> <ul> <li>DM patients without prior MI had twofold lower risk of CHD mortality compared with non-DM patients with prior MI (RR 0.5, 95% CI 0.41-0.61; p&#60;0.001). </li> </ul> </td> </tr> <tr> <td>Wannamethee et al.<sup>[4]</sup></td> <td>1992</td> <td>NA</td> <td>Observational</td> <td> <p>N = 5934</p> <p>Non-DM = 5649</p> <p>(926 with prior CHD)</p> <p>DM = 285</p> (83 with prior CHD)</td> <td>52 to 74</td> <td>100% men</td> <td>10</td> <td> <ul> <li>DM patients without prior CHD had lower relative risk of CHD mortality compared with non-DM patients with prior MI (2.82 versus 3.91). </li> </ul> </td> </tr> <tr> <td>Hu et al.<sup>[5]</sup> (Finnish cohort)</td> <td>1972 to 1997</td> <td>Type 2</td> <td>Observational</td> <td> <p>N = 51,735</p> <p>Non-DM = 50,627</p> <p>(1038 with prior MI)</p> <p>DM = 1108</p> (146 with prior MI)</td> <td>25 to 74</td> <td>48% men</td> <td>17</td> <td> <ul> <li>DM men patients without prior MI had lower CHD mortality compared with non-DM men with prior MI (HR 0.56, 95% CI 0.44-0.72). </li> <li>In contrast, DM women patients without prior MI had higher CHD mortality than non-DM women with prior MI (HR 1.7, 95% CI 1.17-2.47). </li> </ul> </td> </tr> <tr> <td>Natarajan et al.<sup>[6]</sup> (NHANES I)</td> <td>1971 to 1975</td> <td>NA</td> <td>Observational</td> <td> <p>N = 10,871</p> <p>Non-DM = 10,332</p> <p>(594 with prior MI)</p> <p>DM = 539</p> (77 with prior MI)</td> <td>35 to 74</td> <td>43% men</td> <td>20</td> <td> <ul> <li>Independently of DM duration, DM men patients had comparable relative risk of CHD mortality than non-DM patients with prior MI. </li> <li>In contrast, women with long-term DM duration had higher relative risk of CHD mortality than women with recent DM diagnosis or non-DM women with prior MI. </li> <li>Each additional year of DM was associated with an HR for fatal CHD of 1.07 in men and 1.08 in women after adjusting for prevalent MI and other factors. </li> </ul> </td> </tr> <tr> <td>Pajunen et al.<sup>[7]</sup> (FINAMI)</td> <td>1993 to 2002</td> <td>NA</td> <td>Observational</td> <td> <p>N = 6988</p> <p>Non-DM = 5314</p> <p>(1375 recurrent MI)</p> <p>DM = 1674</p> (609 recurrent MI)</td> <td>45 to 74</td> <td>70% men</td> <td>9</td> <td> <ul> <li>The rate of recurrent MI among non-DM men was higher than the incidence of first MI among DM men &#60;55 years. The risk of first MI among DM men ages 55 to 64 years was comparable to the risk of recurrent MI in non-DM patients. Among men &#62;70 years old, the risk of first MI among DM patients was higher than the risk of recurrent MI among non-DM. </li> <li>In women, the risk of recurrent MI in non-DM patients was comparable to that of first MI among DM in all age groups. </li> </ul> </td> </tr> <tr> <td>Cano et al.<sup>[8]</sup></td> <td>1990 to 2003</td> <td>Type 2</td> <td>Observational</td> <td> <p>N = 4410</p> <p>Non-DM = 2150</p> <p>(with acute MI)</p> <p>DM = 2260</p> (without CHD)</td> <td>30 to 74</td> <td>65% men</td> <td>10</td> <td> <ul> <li>DM patients had lower risk of CHD and cardiovascular mortality compared with non-DM patients with acute MI (HR 0.12 [95% CI 0.08-0.18] and 0.22 [95% CI 0.17-0.28], respectively). </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ARIC: Atherosclerosis Risk In Communities; CI: confidence interval; CHD: coronary heart disease; CVD: cardiovascular disease; DM: diabetes mellitus; FINAMI: Finnish MI-registry; HPFS: Health Professionals Follow-up Study; HR: hazard ratio; MI: myocardial infarction; NA: not available; NHANES I: First National Health and Nutrition Examination Survey; REGARDS: REasons for Geographic And Racial Differences in Stroke; RR: relative risk.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Evans JM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ 2002; 324:939.</LI>&#xD;&#xA;<LI>Cho E, Rimm EB, Stampfer MJ, et al. The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men. J Am Coll Cardiol 2002; 40:954.</LI>&#xD;&#xA;<LI>Lee CD, Folsom AR, Pankow JS, Brancati FL. Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation 2004; 109:855.</LI>&#xD;&#xA;<LI>Wannamethee SG, Shaper AG, Lennon L. Cardiovascular disease incidence and mortality in older men with diabetes and in men with coronary heart disease. Heart 2004; 90:1398.</LI>&#xD;&#xA;<LI>Hu G, Jousilahti P, Qiao Q, et al. Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction. Diabetologia 2005; 48:856.</LI>&#xD;&#xA;<LI>Natarajan S, Liao Y, Sinha D, et al. Sex differences in the effect of diabetes duration on coronary heart disease mortality. Arch Intern Med 2005; 165:430.</LI>&#xD;&#xA;<LI>Pajunen P, Koukkunen H, Ketonen M, et al. Myocardial infarction in diabetic and non-diabetic persons with and without prior myocardial infarction: the FINAMI Study. Diabetologia 2005; 48:2519.</LI>&#xD;&#xA;<LI>Cano JF, Baena-Diez JM, Franch J, et al. Long-term cardiovascular risk in type 2 diabetic compared with nondiabetic first acute myocardial infarction patients: a population-based cohort study in southern Europe. Diabetes Care 2010; 33:2004.</LI></OL></div><div id=\"graphicVersion\">Graphic 98656 Version 1.0</div></div></div>"},"98657":{"type":"graphic_table","displayName":"Noninvasive testing to diagnose coronary heart disease","title":"Sensitivity and specificity of various noninvasive tests to diagnose the presence of coronary heart disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sensitivity and specificity of various noninvasive tests to diagnose the presence of coronary heart disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"2\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Diagnosis of coronary artery disease</td> </tr> <tr> <td class=\"subtitle2\">Sensitivity (%)</td> <td class=\"subtitle2\">Specificity (%)</td> </tr> <tr> <td><strong>Exercise ECG</strong></td> <td class=\"centered\">45 to 61</td> <td class=\"centered\">70 to 90</td> </tr> <tr> <td><strong>Exercise stress echocardiography</strong></td> <td class=\"centered\">70 to 85</td> <td class=\"centered\">77 to 89</td> </tr> <tr> <td><strong>Exercise stress SPECT</strong></td> <td class=\"centered\">73 to 92</td> <td class=\"centered\">63 to 88</td> </tr> <tr> <td><strong>Pharmacologic stress echocardiography</strong></td> <td class=\"centered\">72 to 90</td> <td class=\"centered\">79 to 95</td> </tr> <tr> <td><strong>Pharmacologic stress SPECT</strong></td> <td class=\"centered\">88 to 91</td> <td class=\"centered\">75 to 90</td> </tr> <tr> <td><strong>Coronary CTA</strong></td> <td class=\"centered\">93 to 99</td> <td class=\"centered\">64 to 90</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CTA: computed tomography angiography; ECG: electrocardiogram; SPECT: single photon emission computed tomography.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease. European Heart Journal 2013; 34:2949.</li>&#xD;&#xA;    <li>Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126(25):e354.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 98657 Version 1.0</div></div></div>"},"98658":{"type":"graphic_table","displayName":"Variations in percent body fat","title":"Variations in percent body fat for Caucasians, African Americans, and Asians","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Variations in percent body fat for Caucasians, African Americans, and Asians</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\"> <p>BMI (kg/m<sup>2</sup>)</p> </td> <td class=\"subtitle1\" colspan=\"3\">Body fat: Females (%)</td> <td class=\"subtitle1\" colspan=\"3\">Body fat: Males (%)</td> </tr> <tr> <td class=\"subtitle2\">African American</td> <td class=\"subtitle2\">Asian</td> <td class=\"subtitle2\">White</td> <td class=\"subtitle2\">African American</td> <td class=\"subtitle2\">Asian</td> <td class=\"subtitle2\">White</td> </tr> <tr> <td class=\"subtitle3\" colspan=\"7\">Age 20 to 39 years</td> </tr> <tr> <td class=\"centered\">&#60;18.5</td> <td class=\"centered\">20</td> <td class=\"centered\">25</td> <td class=\"centered\">21</td> <td class=\"centered\">8</td> <td class=\"centered\">13</td> <td class=\"centered\">8</td> </tr> <tr> <td class=\"centered\">&#8805;25</td> <td class=\"centered\">32</td> <td class=\"centered\">35</td> <td class=\"centered\">33</td> <td class=\"centered\">20</td> <td class=\"centered\">23</td> <td class=\"centered\">21</td> </tr> <tr> <td class=\"centered\">&#8805;30</td> <td class=\"centered\">38</td> <td class=\"centered\">40</td> <td class=\"centered\">39</td> <td class=\"centered\">26</td> <td class=\"centered\">28</td> <td class=\"centered\">26</td> </tr> <tr> <td class=\"subtitle3\" colspan=\"7\">Age 40 to 59 years</td> </tr> <tr> <td class=\"centered\">&#60;18.5</td> <td class=\"centered\">21</td> <td class=\"centered\">25</td> <td class=\"centered\">23</td> <td class=\"centered\">9</td> <td class=\"centered\">13</td> <td class=\"centered\">11</td> </tr> <tr> <td class=\"centered\">&#8805;25</td> <td class=\"centered\">34</td> <td class=\"centered\">36</td> <td class=\"centered\">35</td> <td class=\"centered\">22</td> <td class=\"centered\">24</td> <td class=\"centered\">23</td> </tr> <tr> <td class=\"centered\">&#8805;30</td> <td class=\"centered\">39</td> <td class=\"centered\">41</td> <td class=\"centered\">41</td> <td class=\"centered\">27</td> <td class=\"centered\">29</td> <td class=\"centered\">29</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BMI: body mass index.</div><div class=\"graphic_reference\">Adapted with permission from: Gallagher D, Heymsfield SB, Heo M, et al. Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. Am J Clin Nutr 2000; 72:694-701. Copyright &copy; 2000 American Society for Nutrition.</div><div id=\"graphicVersion\">Graphic 98658 Version 2.0</div></div></div>"},"98660":{"type":"graphic_picture","displayName":"Fire ant stings, hand","title":"Fire ant stings, hand","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fire ant stings, hand</div><div class=\"cntnt\"><img style=\"width:370px; height:243px;\" src=\"images/ALLRG/98660_Fire_ant_stings_hand.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 98660 Version 1.0</div></div></div>"},"98661":{"type":"graphic_picture","displayName":"Fire ant stings, ankle","title":"Fire ant stings, ankle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fire ant stings, ankle</div><div class=\"cntnt\"><img style=\"width:242px; height:368px;\" src=\"images/ALLRG/98661_Fire_ant_stings_ankle.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 98661 Version 1.0</div></div></div>"},"98662":{"type":"graphic_picture","displayName":"Fire ant stings, dorsum of hand","title":"Fire ant stings, dorsum of hand","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Fire ant stings, dorsum of hand</div><div class=\"cntnt\"><img style=\"width:544px; height:417px;\" src=\"images/ALLRG/98662_Fire_ant_stings_dorsum_hand.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 98662 Version 1.0</div></div></div>"},"98669":{"type":"graphic_picture","displayName":"Sebaceous carcinoma lower eyelid","title":"Sebaceous carcinoma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Sebaceous carcinoma</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/98669_Sbcts_crcnm_lwr_eyld.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sebaceous carcinoma presenting as an erythematous nodule on the lower eyelid.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98669 Version 2.0</div></div></div>"},"98686":{"type":"graphic_table","displayName":"Etiology of postoperative voiding dysfunction in women","title":"Etiology of postoperative voiding dysfunction in women","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of postoperative voiding dysfunction in women</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Detrusor</td> <td class=\"subtitle1\">Urethra/pelvic floor</td> </tr> <tr> <td> <ul> <li>Failure to sense bladder filling <ul> <li>Anesthesia/narcotics </li> <li>Nerve injury <ul> <li>Surgical </li> <li>Acute overdistention injury </li> </ul> </li> <li>Missed cystotomy </li> </ul> </li> </ul> </td> <td> <ul> <li>Mechanical obstruction of the urethra <ul> <li>Incontinence procedures </li> <li>Pelvic organ prolapse </li> <li>Urethral perforation/foreign body </li> <li>Constipation/pelvic mass </li> </ul> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Failure to contract bladder <ul> <li>Anesthesia/narcotic </li> <li>Nerve injury </li> <li>Preexisting voiding dysfunction </li> </ul> </li> </ul> </td> <td> <ul> <li>Functional obstruction of the urethra <ul> <li>Failure to relax the pelvic floor </li> </ul> </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 98686 Version 1.0</div></div></div>"},"98697":{"type":"graphic_diagnosticimage","displayName":"Transverse US of tarsal tunnel showing marked swelling","title":"Transverse US of the tarsal tunnel with marked swelling noted","html":"<div class=\"graphic\"><div style=\"width: 670px\" class=\"figure\"><div class=\"ttl\">Transverse US of the tarsal tunnel with marked swelling noted</div><div class=\"cntnt\"><img style=\"width:650px; height:395px;\" src=\"images/EM/98697_Trns_US_trsl_tnnl_mrk_swll.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Arrow) is at cortical surface of medial malleolus.<br />(Small arrowhead) is posterior tibialis tendon.<br />(Large arrowhead) points to tibial nerve.<br />(Dashed arrow) is on flexor hallucis.<br />Darker (hypoechoic) spaces represent fluid diffusely throughout the tarsal tunnel. (Short arrow) points to cortex of talus.<br />(Thick arrow) sits on the flexor digitorum tendon.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 98697 Version 2.0</div></div></div>"},"98701":{"type":"graphic_figure","displayName":"Hypothalamic-pituitary-ovarian axis and puberty","title":"Hypothalamic-pituitary-ovarian axis and puberty","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Hypothalamic-pituitary-ovarian axis and puberty</div><div class=\"cntnt\"><img style=\"width:540px; height:701px;\" src=\"images/PEDS/98701_HPO_axis_puberty.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Puberty is marked by an increase in the pulsatile secretion of GnRH from the hypothalamus. GnRH stimulates the secretion of FSH and LH from the gonadotroph cells in the anterior pituitary gland. In girls, FSH stimulates the growth of ovarian follicles and, in conjunction with LH, stimulates production of estradiol by the ovaries. Early in puberty, estradiol stimulates breast development and growth of the skeleton, leading to pubertal growth acceleration. Later in puberty, the interplay between pituitary secretion of FSH and LH and secretion of estradiol by ovarian follicles leads to ovulation and menstrual cycles. The skeletal maturation induced by estradiol eventually results in fusion of the growth plates and cessation of growth.</div><div class=\"graphic_footnotes\">GnRH: gonadotropin releasing hormone; FSH: follicle stimulating hormone; LH: luteinizing hormone.</div><div id=\"graphicVersion\">Graphic 98701 Version 2.0</div></div></div>"},"98702":{"type":"graphic_figure","displayName":"Hypothalamic-pituitary-testicular axis and puberty","title":"Hypothalamic-pituitary-testicular axis and puberty","html":"<div class=\"graphic\"><div style=\"width: 591px\" class=\"figure\"><div class=\"ttl\">Hypothalamic-pituitary-testicular axis and puberty</div><div class=\"cntnt\"><img style=\"width:571px; height:695px;\" src=\"images/PEDS/98702_HPT_axis_puberty.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Puberty is marked by an increase in the pulsatile secretion of GnRH from the hypothalamus. GnRH stimulates the secretion of FSH and LH from the gonadotroph cells of the anterior pituitary gland. In boys, FSH stimulates growth of seminiferous tubules, leading to an increase in testicular volume. FSH also stimulates the Sertoli cells of the testes to produce inhibin B, which inhibits secretion of FSH. LH stimulates the Leydig cells of the testes to produce testosterone, which induces growth of the penis, deepening of the voice, growth of facial and body hair, and increases in muscularity. The high local concentration of testosterone in the testes further stimulates growth of the seminiferous tubules. Some testosterone is converted to estradiol, which stimulates growth and skeletal maturation and frequently leads to some breast development (gynecomastia).</div><div class=\"graphic_footnotes\">GnRH: gonadotropin releasing hormone; FSH: follicle-stimulating hormone; LH: luteinizing hormone.</div><div id=\"graphicVersion\">Graphic 98702 Version 1.0</div></div></div>"},"98707":{"type":"graphic_table","displayName":"Contraceptive use in SLE patients on chronic medications","title":"Recommendations for contraceptive use in SLE patients on chronic medications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for contraceptive use in SLE patients on chronic medications</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication class</td> <td class=\"subtitle1\">Specific medications</td> <td class=\"subtitle1\">Combined hormonal contraceptive</td> <td class=\"subtitle1\">Progesterone-only pill</td> <td class=\"subtitle1\">DMPA</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Immunosuppressive</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">&nbsp;</td> <td>Mycophenolate</td> <td> <ul> <li>Not recommended </li> <li>May decrease efficacy of combined hormonal contraceptive </li> </ul> </td> <td>Unknown</td> <td>Unknown</td> </tr> <tr> <td>Cyclosporine</td> <td> <ul> <li>Use with careful follow-up&nbsp; </li> <li>May increase cyclosporine level </li> </ul> </td> <td>Unknown</td> <td>Unknown</td> </tr> <tr class=\"divider_bottom\"> <td>Glucocorticoid</td> <td> <ul> <li>Use with careful follow-up&nbsp; </li> <li>May increase&nbsp;glucocorticoid level </li> </ul> </td> <td>Unknown</td> <td>Unknown</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Anticoagulant</td> </tr> <tr> <td>&nbsp;</td> <td>Warfarin</td> <td> <ul> <li>Avoid or use with careful follow-up&nbsp; </li> <li>Reduces effect of warfarin </li> </ul> </td> <td> <ul> <li>Use with careful follow-up </li> <li>Unknown </li> </ul> </td> <td> <ul> <li>Use with careful follow-up </li> <li>Unknown </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Anticonvulsants</td> </tr> <tr> <td>&nbsp;</td> <td>Barbiturates</td> <td> <ul> <li>Not recommended&nbsp; </li> <li>Decreases efficacy of combined hormonal contraceptive </li> </ul> </td> <td>Not recommended</td> <td>No or minimal risk</td> </tr> <tr> <td>&nbsp;</td> <td>Carbamazepine</td> <td> <ul> <li>Not recommended </li> <li>Decreases efficacy of combined hormonal contraceptive </li> </ul> </td> <td>Not recommended</td> <td>No or minimal risk</td> </tr> <tr> <td>&nbsp;</td> <td>Oxcarbazepine</td> <td> <ul> <li>Not recommended </li> <li>Decreases efficacy of combined hormonal contraceptive </li> </ul> </td> <td>Not recommended</td> <td>No or minimal risk</td> </tr> <tr> <td>&nbsp;</td> <td>Topiramate</td> <td> <ul> <li>Not recommended </li> <li>Decreases efficacy of combined hormonal contraception </li> </ul> </td> <td>Not recommended</td> <td>No or minimal risk</td> </tr> <tr> <td>&nbsp;</td> <td>Phenytoin</td> <td> <ul> <li>Not recommended&nbsp; </li> <li>Increases phenytoin concentration and decreases efficacy of combined hormonal contraceptive </li> </ul> </td> <td>Not recommended</td> <td>No or minimal risk</td> </tr> <tr> <td>&nbsp;</td> <td>Lamotrigine</td> <td> <ul> <li>Not recommended&nbsp; </li> <li>Decreases lamotrigine concentration </li> </ul> </td> <td>No or minimal risk</td> <td>No or minimal risk</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Other medications</td> </tr> <tr> <td>&nbsp;</td> <td>Modafinil</td> <td> <ul> <li>Not recommended&nbsp; </li> <li>Decreases efficacy of combined hormonal contraceptive </li> </ul> </td> <td>Unknown</td> <td>Unknown</td> </tr> <tr> <td>&nbsp;</td> <td>Potassium-sparing diuretics&nbsp;</td> <td> <ul> <li>Use with careful follow-up&nbsp; </li> <li>Hyperkalemia risk with drospirenone-containing combined hormonal contraceptive </li> </ul> </td> <td>No or minimal risk</td> <td>No or minimal risk</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SLE: systemic lupus erythematosus; DMPA: depomedroxyprogesterone acetate.</div><div class=\"graphic_reference\">Adapted from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion. U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: World Health Organization Medical Eligibility Criteria for Contraceptive Use, 5th edition. MMWR Morb Mortal Wkly Rep 2016; 65:3.</LI>&#xD;&#xA;<LI>Sammaritano LR. Contraception in patients with rheumatic disease. Rheum Dis Clin North Am 2017; 43:173.</LI></OL></div><div id=\"graphicVersion\">Graphic 98707 Version 2.0</div></div></div>"},"98708":{"type":"graphic_table","displayName":"Recommendations for contraceptives in SLE/APS patients","title":"Summary of recommendations for contraceptives in SLE/APS patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of recommendations for contraceptives in SLE/APS patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical presentation</td> <td class=\"subtitle1\">Copper IUD</td> <td class=\"subtitle1\"> <p>LNG</p> IUD</td> <td class=\"subtitle1\">Progesterone-only pill</td> <td class=\"subtitle1\">DMPA</td> <td class=\"subtitle1\">COC</td> <td class=\"subtitle1\">Vaginal ring</td> <td class=\"subtitle1\">Patch</td> </tr> <tr> <td>SLE, low disease activity and (&ndash;) aPL</td> <td colspan=\"2\">Effective,<br /> Long-acting</td> <td>No increase flare</td> <td>Risk of osteoporosis with prolonged use</td> <td>No increase flare</td> <td>Similar estrogen level to COC, no data</td> <td>Higher estrogen levels than COC - <strong>avoid</strong></td> </tr> <tr> <td>SLE, active disease (&ndash;) aPL</td> <td colspan=\"2\">Effective,<br /> Long-acting</td> <td>No increase flare</td> <td>Risk of osteoporosis with prolonged use</td> <td colspan=\"3\">No studies - <strong>avoid</strong></td> </tr> <tr> <td>SLE stable on immunosuppressive medication (&ndash;) aPL</td> <td colspan=\"2\">Effective,<br /> Long-acting,<br /> No infection data but likely low-risk</td> <td>No increase flare</td> <td>Risk of osteoporosis with prolonged use</td> <td colspan=\"3\">Check for medication interactions</td> </tr> <tr> <td>SLE with renal impairment, (&ndash;) aPL</td> <td colspan=\"2\">Effective,<br /> Long-acting</td> <td>No increase flare</td> <td>Risk of osteoporosis with prolonged use</td> <td colspan=\"3\">Avoid drospirenone-containing COC due to risk of hyperkalemia</td> </tr> <tr> <td>SLE with (+) aPL</td> <td>Effective,<br /> Long-acting</td> <td>Low/no increase thrombosis</td> <td>Low/no increase thrombosis</td> <td>Low/uncertain risk thrombosis</td> <td colspan=\"3\">Increased risk of thrombosis - <strong>avoid</strong></td> </tr> <tr> <td>SLE with thrombosis/on anticoagulation</td> <td>Increase menstrual bleeding</td> <td>Low/no increase thrombosis; decreases menstrual bleeding/amenorrhea</td> <td>Low/no increase thrombosis</td> <td>Low/uncertain risk thrombosis</td> <td>Increased risk of thrombosis - <strong>avoid</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Note: Etonogestrel implant not included due to lack of data.</div><div class=\"graphic_footnotes\">SLE: systemic lupus erythematosus; APS: antiphospholipid syndrome; IUD: intrauterine device; LNG: levonorgestrel; DMPA: depot medroxyprogesterone acetate; COC: combined oral contraceptive; Vaginal ring: combined hormonal vaginal ring; Patch: combined hormonal patch; aPL: antiphospholipid antibody.</div><div id=\"graphicVersion\">Graphic 98708 Version 1.0</div></div></div>"},"98718":{"type":"graphic_table","displayName":"Basic score for brain metastases","title":"Basic score for brain metastases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Basic score for brain metastases</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Variable</td> <td class=\"subtitle1\" colspan=\"2\">Score</td> </tr> <tr> <td class=\"subtitle2\">0</td> <td class=\"subtitle2\">1</td> </tr> <tr> <td>KPS</td> <td class=\"centered\">50 to 70%</td> <td class=\"centered\">80 to 100%</td> </tr> <tr> <td>Control of SRS treated lesion(s)</td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> </tr> <tr class=\"divider_bottom\"> <td>Extracranial metastases</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td colspan=\"3\"><strong>Total points = 0 to 4</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Poor risk 0 to 1 versus good risk 2 to 3.</div><div class=\"graphic_footnotes\">KPS: Karnofsky performance status; SRS: stereotactic radiosurgery.</div><div class=\"graphic_reference\">Reproduced from: Lorenzoni JG, Devriendt D, Massager N, et al. Brain stem metastases treated with radiosurgery: prognostic factors of survival and life expectancy estimation. Surg Neurol. 2009; 71(2):188. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98718 Version 2.0</div></div></div>"},"98721":{"type":"graphic_table","displayName":"Score index for radiosurgery (SIR) in brain metastases","title":"Score index for radiosurgery (SIR) in brain metastases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Score index for radiosurgery (SIR) in brain metastases</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Variable</td> <td class=\"subtitle1\" colspan=\"3\">Points</td> </tr> <tr> <td class=\"subtitle2\">0</td> <td class=\"subtitle2\">1</td> <td class=\"subtitle2\">2</td> </tr> <tr> <td>Age (yrs)</td> <td class=\"centered\">&#8805;60</td> <td class=\"centered\">51 to 59</td> <td class=\"centered\">&#60;50</td> </tr> <tr> <td>KPS</td> <td class=\"centered\">&#8804;50%</td> <td class=\"centered\">60 to 70%</td> <td class=\"centered\">80 to 100%</td> </tr> <tr> <td>Systemic disease status</td> <td class=\"centered\">Progressive</td> <td class=\"centered\">Stable</td> <td class=\"centered\">NED</td> </tr> <tr> <td>Number of CNS lesions</td> <td class=\"centered\">&#8805;3</td> <td class=\"centered\">2</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td>Volume of treated lesions</td> <td class=\"centered\">&#8805;13 cm</td> <td class=\"centered\">5 to 13 cm</td> <td class=\"centered\">&#60;5 cm</td> </tr> <tr> </tr> <tr> <td><strong>Total score (0 to 10 points):</strong></td> <td><strong>&nbsp;</strong></td> <td><strong>&nbsp;</strong></td> <td><strong>&nbsp;</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The modified SIR score is calculated as the addition of partial scores obtained from five prognostic factors: Age, KPS, extracranial disease status, number of brain metastases, and volume of the largest brain metastasis.<br />Poor risk = 0 to 4 versus good risk = 5 to 10.</div><div class=\"graphic_footnotes\">KPS: Karnofsky performance status; NED: no evidence of disease; CNS: central nervous system.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Serizawa T, Higuchi Y, Nagano O, et al. A new grading system focusing on neurological outcomes for brain metastases treated with stereotactic radiosurgery: the modified Basic Score for Brain Metastases. J Neurosurg 2014; 121 Suppl 2:35.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced from: Weltman E, Salvajoli JV, Brandt RA, et al. Radiosurgery for brain metastases: a score index for predicting prognosis. Int J Radiat Oncol Biol Phys 2000; 46:1155. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98721 Version 1.0</div></div></div>"},"98722":{"type":"graphic_picture","displayName":"Trigger finger injection technique","title":"Trigger finger injection","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Trigger finger injection</div><div class=\"cntnt\"><img style=\"width:469px; height:351px;\" src=\"images/RHEUM/98722_Triggerfingerinjcttchnq.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The hand is placed flat with the palm up and the fingers outstretched. The injection is directed towards the point of maximal tenderness of the A1 pulley, which arises from the palmar aspect of the metacarpal head and metacarpophalangeal (MCP) joint. The injection site is prepped with iodine or chlorhexidine. Ethyl chloride is sprayed on the skin for anesthesia. A 5/8-inch, 25-gauge needle is inserted to a depth of 1/4 to 3/8 inch for trigger finger and 1/8 to 1/4 inch for trigger thumb. The needle is positioned at a 45-degree angle to the skin with the needle tip directed proximally, and is advanced down to the firm resistance of the flexor tendon, a rubbery sensation. The needle is backed up about 1 to 2 mm, and 1/4 mL of methylprednisolone (80 mg/mL) or 1&nbsp;mL of triamcinolone (10 mg/mL)&nbsp;mixed with a local anesthetic (such as 1/2 mL&nbsp;of lidocaine) is injected around the tendon sheath. If resistance is encountered during the injection, the needle should be advanced or withdrawn slightly before attempting further injection. </div><div class=\"graphic_reference\">Reproduced with permission from: Trigger finger injection. In: A Practical Guide to Joint and Soft Tissue Injection and Aspiration, McNabb JW, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 98722 Version 8.0</div></div></div>"},"98723":{"type":"graphic_picture","displayName":"SLE back","title":"Systemic lupus erythematosus (SLE)","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Systemic lupus erythematosus (SLE)</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/98723_SLE_back.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse erythematous eruption on the back of a patient with acute SLE.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98723 Version 2.0</div></div></div>"},"98725":{"type":"graphic_diagnosticimage","displayName":"Imaging metatarsal stress fracture","title":"Metatarsal stress fracture on radiography and MRI","html":"<div class=\"graphic\"><div style=\"width: 747px\" class=\"figure\"><div class=\"ttl\">Metatarsal stress fracture on radiography and MRI</div><div class=\"cntnt\"><img style=\"width:727px; height:251px;\" src=\"images/RADIOL/98725_Img_metatarsal_stress_frctr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A magnified A-P view of the right foot obtained at presentation is normal. An MRI performed one week later (B) using a PD FS FSE sequence shows significant soft tissue edema (arrow) bone marrow edema (arrowhead). An A-P view of the foot (C) three weeks later shows periosteal reaction (arrowhead) and a vague lucency (arrow).</div><div class=\"graphic_footnotes\">A-P: antero-posterior; MRI: magnetic resonance imaging; PD FS FSE: proton density fat saturated fast spin echo.</div><div id=\"graphicVersion\">Graphic 98725 Version 1.0</div></div></div>"},"98727":{"type":"graphic_diagnosticimage","displayName":"Radiograph of scapholunate ligament laxity: Clenched fist view","title":"Scapholunate ligament laxity on radiography without and with clenched fist (ie, power grip​)","html":"<div class=\"graphic\"><div style=\"width: 773px\" class=\"figure\"><div class=\"ttl\">Scapholunate ligament laxity on radiography without and with clenched fist (ie, power grip​)</div><div class=\"cntnt\"><img style=\"width:753px; height:482px;\" src=\"images/RADIOL/98727_Rdgrph_scphlnt_lgmnt_lxty.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An AP radiograph of the wrist following trauma (A) shows a scapholunate interval (arrow) of 1.1 mm. Image B is a radiograph performed during a power grip and shows an increase in the distance of the scapholunate interval (arrow) to 2.1 mm corresponding to stretching of the scapholunate ligament.</div><div class=\"graphic_footnotes\">AP: anteroposterior.</div><div class=\"graphic_reference\">Courtesy of Gregory Waryasz, MD.</div><div id=\"graphicVersion\">Graphic 98727 Version 3.0</div></div></div>"},"98728":{"type":"graphic_diagnosticimage","displayName":"Radiograph of \"Terry Thomas Sign\" for scapholunate dissociation","title":"SLAC with \"Terry Thomas Sign\" on radiograph without and with power grip","html":"<div class=\"graphic\"><div style=\"width: 669px\" class=\"figure\"><div class=\"ttl\">SLAC with \"Terry Thomas Sign\" on radiograph without and with power grip</div><div class=\"cntnt\"><img style=\"width:649px; height:469px;\" src=\"images/RADIOL/98728_Radiograph_terry_thomas_sgn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An A-P radiograph shows a scapholunate interval (arrow) greater than 4 mm (\"Terry Thomas Sign\"). Image B is an A-P view that shows widening of the SL interval (arrow) with the power grip.</div><div class=\"graphic_footnotes\">A-P: anteroposterior; SLAC: scapholunate advanced collapse; SL: scapholunate.</div><div class=\"graphic_reference\">Courtesy of Gregory Waryasz, MD.</div><div id=\"graphicVersion\">Graphic 98728 Version 1.0</div></div></div>"},"98729":{"type":"graphic_picture","displayName":"Erythropoietic protoporphyria face","title":"Erythropoietic protoporphyria","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Erythropoietic protoporphyria</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/98729_Erythropotc_prtprphyr_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse erythema and confluent petechiae on the face and lips following sun exposure in a child with erythropoietic protoporphyria.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98729 Version 2.0</div></div></div>"},"98730":{"type":"graphic_picture","displayName":"Erythropoietic protoporphyria scars","title":"Erythropoietic protoporphyria (EPP)","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Erythropoietic protoporphyria (EPP)</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/98730_Erythrptc_prtprphyr_scars.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chronic skin changes in EPP include shallow vacciniform scarring, perioral furrows, and waxy skin thickening.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98730 Version 2.0</div></div></div>"},"98732":{"type":"graphic_figure","displayName":"Global TB and HIV prevalence","title":"Estimated global HIV prevalence in new and relapsed tuberculosis cases, 2013","html":"<div class=\"graphic\"><div style=\"width: 787px\" class=\"figure\"><div class=\"ttl\">Estimated global HIV prevalence in new and relapsed tuberculosis cases, 2013</div><div class=\"cntnt\"><img style=\"width:767px; height:433px;\" src=\"images/ID/98732_Global_TB_HIV_prevalence.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: World Health Organization. Global Tuberculosis Report 2014. WHO, Geneva 2014. <a href=\"http://www.who.int/tb/publications/global_report/en/\" spellcheck=\"true\" target=\"_blank\">http://www.who.int/tb/publications/global_report/en/</a> Copyright &copy; 2014 World Health Organization.</div><div id=\"graphicVersion\">Graphic 98732 Version 1.0</div></div></div>"},"98746":{"type":"graphic_picture","displayName":"Trichofolliculoma eyelid","title":"Trichofolliculoma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Trichofolliculoma</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/98746_Trichofolliculoma_eyelid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Trichofolliculoma typically presents as a small follicular papule from which multiple vellus hairs emanate.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98746 Version 2.0</div></div></div>"},"98747":{"type":"graphic_picture","displayName":"Trichofolliculoma face","title":"Trichofolliculoma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Trichofolliculoma</div><div class=\"cntnt\"><img style=\"width:700px; height:524px;\" src=\"images/DERM/98747_Trichofolliculoma_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Trichofolliculoma typically presents as a small follicular papule with multiple protruding vellus hairs.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98747 Version 2.0</div></div></div>"},"98748":{"type":"graphic_table","displayName":"Management hypersensitivity reactions IV iron","title":"Management of hypersensitivity reactions to intravenous iron","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management of hypersensitivity reactions to intravenous iron</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Severity of HSR reaction</td> <td class=\"subtitle1\">Initial management approach</td> <td class=\"subtitle1\" colspan=\"2\">If patient improves after initial management</td> <td class=\"subtitle1\">If patient is deteriorating after initial management</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Mild:</strong> Itching, flushing, sensation of heat, slight chest tightness, hypertension, back/joint pains</td> <td class=\"divider_bottom\" rowspan=\"2\"> <ul> <li>Stop iron infusion for &#8805;15 minutes </li> <li>Inform doctor </li> <li>Monitor pulse, blood pressure, respiratory rate, O2 saturation </li> <li>Wait and watch </li> <li>Avoid use of antihistamines, which can cause hypotension,&nbsp;somnolence, diaphoresis, and tachycardia, mimicking anaphylaxis </li> </ul> </td> <td colspan=\"2\"> <ul> <li>Administer IV glucocorticoid (eg, hydrocortisone 200 mg or methylprednisolone 40 mg IV) </li> <li>Restart iron infusion at reduced rate (eg, 50%) </li> </ul> </td> <td class=\"divider_bottom\" rowspan=\"2\"> <ul> <li>Treat as for moderate/severe reaction </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>If symptoms recur after improvement</strong> <ul class=\"decimal_heading\"> <li>Stop iron infusion </li> <li>Use initial management approach </li> <li>Document event </li> </ul> </td> <td><strong>If patient remains well after improvement</strong> <ul class=\"decimal_heading\"> <li>Observe for one hour after infusion complete </li> <li>Document event </li> <li>Consider future treatment strategy (eg, use different agent) </li> </ul> </td> </tr> <tr> <td> <p><strong>Moderate:</strong> As in mild reaction plus urticaria, edema, cough, chest tightness, shortness of breath, nausea, emesis, tachycardia, or hypotension</p> <p><strong>or</strong></p> <strong>Severe:</strong> Wheezing/stridor, cyanosis, loss of consciousness, cardiac/respiratory arrest</td> <td> <ul> <li>Stop iron infusion </li> <li>Monitor pulse, blood pressure, respiratory rate, O2 saturation </li> <li>Call doctor or summon resuscitation team if severe </li> <li>Place in recumbent position if tolerated, elevate lower extremities; place pregnant patients on left side </li> <li><strong>Promptly give epinephrine</strong> (adrenaline) IM in the anterolateral thigh 0.3 to 0.5 mg of 1 mg/mL (1:1000) </li> <li>Initiate continuous electronic monitoring (BP, HR, RR, pulse oximetry) </li> <li>Oxygen 8 to 10 L per minute via facemask </li> <li>If hypotensive, give volume (eg, isotonic volume load, 1 to 2 liters IV) </li> <li>If severe, give IV glucocorticoid (eg, hydrocortisone 200 mg or methylprednisolone 40 mg IV) </li> </ul> </td> <td colspan=\"2\"> <ul> <li>Observe for one hour after infusion complete </li> <li>Document event </li> <li>Consider future treatment strategy </li> </ul> </td> <td> <ul> <li>Summon resuscitation team </li> <li>Initiate ACLS protocol if needed </li> <li>Repeat epinephrine (adrenaline) IM 0.3 to 0.5 mg of 1 mg/mL (1:1000) after five minutes if first dose and volume loading are not successful; most patients with anaphylaxis respond to one, two, or at most three doses of IM epinephrine </li> <li>If hypotensive, insert two large bore IV catheters and continue fluid resuscitation </li> <li><strong>Transfer quickly to critical care unit</strong> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HSR: hypersensitivity reaction; O2: oxygen; IV: intravenous; IM: intramuscular; BP: blood pressure; HR: heart rate; RR: respiratory rate; ACLS: advanced cardiac life support.</div><div class=\"graphic_reference\">Adapted from: Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica 2014; 99:1671.</div><div id=\"graphicVersion\">Graphic 98748 Version 1.0</div></div></div>"},"98749":{"type":"graphic_figure","displayName":"Rate of normal RBC loss","title":"Estimated RBC survival from the rate of fall of the RBC count in a patient with pure red cell aplasia","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Estimated RBC survival from the rate of fall of the RBC count in a patient with pure red cell aplasia</div><div class=\"cntnt\"><img style=\"width:554px; height:622px;\" src=\"images/HEME/98749_Rate_of_normal_RBC_loss.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This graph indicates the fall in RBC count over 40 days in a patient with relapsed pure red cell aplasia and an absolute reticulocyte count of zero during this entire period. The rate of fall (ie, slope of this curve) is 0.8% per day, with a projected \"extinction time\" of 125 days, indicating a normal survival of his circulating red cells.</div><div class=\"graphic_footnotes\">RBC: red blood cell.</div><div class=\"graphic_reference\">Data provided by Stephen A Landaw, MD, PhD.</div><div id=\"graphicVersion\">Graphic 98749 Version 1.0</div></div></div>"},"98751":{"type":"graphic_table","displayName":"Factors that exacerbate chronic spontaneous urticaria (CSU)","title":"Factors that exacerbate chronic spontaneous urticaria (CSU)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors that exacerbate chronic spontaneous urticaria (CSU)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Exacerbating factor</td> <td class=\"subtitle1\">Examples</td> <td class=\"subtitle1\">Alternate explanations to consider</td> </tr> <tr class=\"divider_bottom\"> <td>Nonsteroidal anti-inflammatory drugs (NSAIDs)</td> <td> <ul> <li>Urticaria may worsen in patients within 24 hours after ingestion; some within 2 hours and others (particularly children) up to 4 to 24 hours later. </li> </ul> </td> <td> <ul> <li>Consider alternate diagnosis of NSAID allergy or pseudoallergy if NSAIDs are the only or predominant trigger for hives or angioedema. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Environmental conditions</td> <td> <ul> <li>Heat. </li> <li>Cold. </li> <li>Sunlight. </li> </ul> </td> <td> <ul> <li>Consider alternate diagnosis of cholinergic urticaria if hives are small (1 to 3 mm), surrounded by large areas of erythema, and predominantly triggered by changes in core body temperature (eg, exercise, hot showers, sweating, emotional factors). </li> <li>Consider exercise-induced anaphylaxis if hives only occur during exercise and not with passive changes in core body temperature. </li> <li>Consider cold urticaria or cold-associated inflammatory disorder if hives are exclusively triggered by exposure to cold. </li> <li>Consider solar urticaria if hives appear to be exclusively triggered by exposure to sunlight. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Friction or pressure from clothing</td> <td> <ul> <li>Hives may form under clothing straps, in areas where tight clothing compresses the skin, or in areas of natural friction (axillae, between thighs). </li> </ul> </td> <td> <ul> <li>Consider diagnosis of delayed-pressure urticaria/angioedema if pressure on skin is followed in 4 to 24 hours by erythematous angioedema of affected area. Patients with delayed-pressure urticaria often have concomitant CSU. </li> <li>Consider vibratory urticaria if hives appear after exposure to vibration (eg, after clapping, mowing lawn, holding certain appliances). </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Alcohol</td> <td> <ul> <li>Hives may be more numerous or severe after drinking alcoholic beverages. </li> </ul> </td> <td> <ul> <li>If alcohol is the sole or predominant trigger, consider nonspecific reaction to histamine-releasing properties of some alcoholic beverages, or rarely, allergy to some component of the beverage. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Narcotic medications</td> <td> <ul> <li>Hives may be more numerous or severe and pruritus more pronounced after taking narcotics. </li> </ul> </td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Stress (emotional or physical) or sleep deprivation</td> <td> <ul> <li>Hives can appear during stressful events, and/or control of chronic hives can be more difficult during stressful periods or periods of reduced sleep. </li> </ul> </td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Concomitant infections</td> <td> <ul> <li>Hives can be more numerous or severe during viral illnesses (eg, common colds) or bacterial infections (eg, sinusitis). </li> </ul> </td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Menstruation or perimenstrual period</td> <td> <ul> <li>Some women with CSU observe fluctuations with their menstrual cycle. </li> </ul> </td> <td> <ul> <li>Consider alternate diagnoses of autoimmune progesterone dermatitis or other catamenial dermatoses if hives only occur in perimenstrual periods or lesions are not clearly urticarial. </li> </ul> </td> </tr> <tr> <td>Irregular use of antihistamines</td> <td> <ul> <li>Regular and consistent dosing of antihistamines is most effective in controlling CSU. Erratic or as-needed use may contribute to poor symptom control. </li> </ul> </td> <td>&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 98751 Version 3.0</div></div></div>"},"98768":{"type":"graphic_picture","displayName":"Vitiligo on vulva","title":"Vitiligo","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Vitiligo</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/98768_Vitiligo_vulva.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patchy depigmentation on the vulva secondary to vitiligo.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98768 Version 2.0</div></div></div>"},"98769":{"type":"graphic_picture","displayName":"Vulvovaginal candidiasis","title":"Vulvovaginal candidiasis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Vulvovaginal candidiasis</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/98769_Vulvovaginal_candidiasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous labia in a patient with vulvovaginal candidiasis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98769 Version 1.0</div></div></div>"},"98770":{"type":"graphic_picture","displayName":"Lichen sclerosus on vulva","title":"Vulvar lichen sclerosus","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Vulvar lichen sclerosus</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/98770_Lichen_sclerosus_vulva.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Depigmentation and atrophy on the vulva secondary to vulvar lichen sclerosus.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98770 Version 2.0</div></div></div>"},"98771":{"type":"graphic_table","displayName":"Causes chronic GI symptoms in CF","title":"Important causes of chronic gastrointestinal symptoms in individuals with cystic fibrosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important causes of chronic gastrointestinal symptoms in individuals with cystic fibrosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Cause of symptoms</td> <td class=\"subtitle1\">Mechanism</td> <td class=\"subtitle1\">Typical presentation</td> <td class=\"subtitle1\">Evaluation</td> </tr> <tr class=\"divider_bottom\"> <td>Gastroesophageal reflux disease (GERD)</td> <td>Lung hyperinflation, medications that reduce LES pressure, delayed gastric emptying. May be associated with constipation and/or generalized dysmotility.</td> <td>Heartburn, acid brash, increased cough not due to other causes.</td> <td>Empiric trial of acid suppressing medication, exclude other causes of symptoms.*<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Obstipation/constipation</td> <td>Abnormal intestinal secretions, dehydrated GI tract, dysmotility, pancreatic insufficiency. Constipation may contribute to GERD by delaying gastric emptying.</td> <td>Flatulence, poor appetite, stool mass in LLQ. Constipation often occurs in CF despite daily stooling. Difficulty evacuating stool is rare.</td> <td>History and physical exam; empiric treatment. Abdominal radiograph (if performed)&nbsp;shows stool mass throughout the colon.</td> </tr> <tr class=\"divider_bottom\"> <td>Distal ileal obstruction syndrome (DIOS)</td> <td>Inspissated intestinal contents in the ileocecal area, causing complete or incomplete intestinal obstruction.</td> <td>Acute or subacute onset of abdominal pain and distension &#177; vomiting; stool mass in RLQ.</td> <td>Abdominal radiograph shows stool mass especially in the RLQ. Often co-occurs with constipation.</td> </tr> <tr class=\"divider_bottom\"> <td>Small intestine bacterial overgrowth (SIBO)</td> <td>Bacteria in the small intestine cause enterocyte damage and deconjugation of bile salts, causing malabsorption.</td> <td>Bloating, flatulence, abdominal pain, watery diarrhea, dyspepsia, and weight loss.</td> <td>Breath hydrogen and methane test, or empiric trial of metronidazole or other anti-SIBO antibiotics.</td> </tr> <tr> <td>Cystic fibrosis-related diabetes (CFRD)</td> <td>Diabetes is primarily due to impaired insulin secretion; may worsen with pulmonary exacerbations. CFRD may be complicated by neuropathy, which contributes to gastrointestinal dysmotility.</td> <td>Weight loss, declining pulmonary function, especially in adolescent or young adult.</td> <td>Oral glucose tolerance test.<sup>&#916;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GERD: gastroesophageal reflux disease; LES: lower esophageal sphincter; GI: gastrointestinal; CF: cystic fibrosis; LLQ: left lower quadrant of the abdomen; DIOS: distal ileal obstruction syndrome; RLQ: right lower quadrant of the abdomen; SIBO: small intestine bacterial overgrowth; CFRD: cystic fibrosis-related diabetes.<br />* For suspected GERD, esophageal monitoring (pH probe or multichannel intraluminal impedance testing [MII]) may be useful in selected cases, but has limited value in predicting treatment outcomes. Contrast radiography (eg, barium swallow) is not useful for the diagnosis of GERD due to low specificity and sensitivity (refer to topic review on diagnosis of GERD). <br />¶ Most patients with CF are on acid-suppressing medications to optimize the effectiveness of pancreatic enzyme replacement therapy (PERT). Therefore, GERD and esophagitis can be difficult to diagnose, and an empiric trial of acid suppression may not be possible.<br />Δ Hemoglobin A1c has low sensitivity for CFRD and should not be used to screen for this disorder.</div><div class=\"graphic_reference\">Courtesy of Drucy Borowitz, MD.</div><div id=\"graphicVersion\">Graphic 98771 Version 3.0</div></div></div>"},"98779":{"type":"graphic_table","displayName":"Signs and symptoms of overtraining","title":"Signs and symptoms of overtraining","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Signs and symptoms of overtraining</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Parasympathetic alterations*</td> <td class=\"subtitle1\">Sympathetic alterations<sup>&#182;</sup></td> <td class=\"subtitle1\">Other manifestations</td> </tr> <tr> <td> <p>Fatigue</p> <p>Mental depression</p> <p>Bradycardia</p> Lethargy</td> <td> <p>Insomnia</p> <p>Irritability</p> <p>Tachycardia</p> <p>Agitation, restlessness</p> Hypertension</td> <td> <p>Anorexia</p> <p>Weight loss</p> <p>Poor mental concentration</p> <p>Loss of motivation</p> <p>Muscles feel \"heavy,\" sore, or stiff</p> <p>Anxiety</p> <p>Awaken feeling not well rested</p> <p>Mood swings</p> Upper respiratory infection</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* More common in aerobic sports.<br />&para; More common in anaerobic sports.</div><div class=\"graphic_reference\">Courtesy of Thomas Howard, MD.</div><div id=\"graphicVersion\">Graphic 98779 Version 1.0</div></div></div>"},"98780":{"type":"graphic_table","displayName":"Causes of early-onset dementia","title":"Causes of early-onset dementia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of early-onset dementia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Neurodegenerative dementias</td> </tr> <tr> <td class=\"indent1\">Alzheimer disease</td> </tr> <tr> <td class=\"indent2\">Presenilin 1 mutation</td> </tr> <tr> <td class=\"indent2\">Presenilin 2 mutation</td> </tr> <tr> <td class=\"indent2\">Amyloid precursor protein mutation</td> </tr> <tr> <td class=\"indent2\">APOE-&#949;4-associated disease</td> </tr> <tr> <td class=\"indent2\">Down syndrome related dementia</td> </tr> <tr> <td class=\"indent1\">Frontotemporal dementia</td> </tr> <tr> <td class=\"indent1\">Dementia with Lewy bodies</td> </tr> <tr> <td class=\"indent1\">Parkinson disease dementia</td> </tr> <tr> <td class=\"indent1\">Progressive supranuclear palsy</td> </tr> <tr> <td class=\"indent1\">Corticobasal degeneration</td> </tr> <tr> <td class=\"indent1\">Multiple systems atrophy</td> </tr> <tr> <td class=\"subtitle1_single\">Vascular diseases</td> </tr> <tr> <td class=\"indent1\">Vascular dementia</td> </tr> <tr> <td class=\"indent1\">Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy</td> </tr> <tr> <td class=\"indent1\">Cerebral amyloid angiopathy</td> </tr> <tr> <td class=\"indent1\">Primary angiitis of the central nervous system</td> </tr> <tr> <td class=\"indent1\">Secondary central nervous system vasculitis</td> </tr> <tr> <td class=\"subtitle1_single\">Infectious diseases</td> </tr> <tr> <td class=\"indent1\">Prion disease</td> </tr> <tr> <td class=\"indent1\">HIV associated neurocognitive disorder</td> </tr> <tr> <td class=\"indent1\">Herpes encephalitis</td> </tr> <tr> <td class=\"indent1\">Neurosyphilis</td> </tr> <tr> <td class=\"indent1\">Whipple disease</td> </tr> <tr> <td class=\"indent1\">Progressive multifocal leukoencephalopathy</td> </tr> <tr> <td class=\"indent1\">Subacute sclerosing panencephalitis</td> </tr> <tr> <td class=\"subtitle1_single\">Inflammatory and autoimmune diseases</td> </tr> <tr> <td class=\"indent1\">Multiple sclerosis</td> </tr> <tr> <td class=\"indent1\">Neurosarcoidosis</td> </tr> <tr> <td class=\"indent1\">Paraneoplastic encephalopathy</td> </tr> <tr> <td class=\"indent1\">Non-paraneoplastic autoimmune encephalopathy</td> </tr> <tr> <td class=\"indent1\">Encephalopathy due to systemic autoimmune disease</td> </tr> <tr> <td class=\"subtitle1_single\">Neurometabolic disorders</td> </tr> <tr> <td class=\"indent1\">Mitochondrial disease</td> </tr> <tr> <td class=\"indent1\">Late-onset lysosomal storage diseases</td> </tr> <tr> <td class=\"indent1\">Adult-onset leukodystrophies</td> </tr> <tr> <td class=\"indent1\">Adult polyglucosan body disease</td> </tr> <tr> <td class=\"indent1\">Diffuse hereditary leukoencephalopathy with axonal spheroids</td> </tr> <tr> <td class=\"indent1\">Adult neuronal ceroid lipofuscinosis</td> </tr> <tr> <td class=\"subtitle1_single\">Others</td> </tr> <tr> <td class=\"indent1\">Chronic traumatic encephalopathy</td> </tr> <tr> <td class=\"indent1\">Alcohol-related dementia</td> </tr> <tr> <td class=\"indent1\">Normal pressure hydrocephalus</td> </tr> <tr> <td class=\"indent1\">Huntington disease</td> </tr> <tr> <td class=\"indent1\">Wilson disease</td> </tr> <tr> <td class=\"indent1\">Spinocerebellar atrophy</td> </tr> <tr> <td class=\"indent1\">Dentatorubral pallidoluysian atrophy</td> </tr> <tr> <td class=\"indent1\">Familial encephalopathy with neuroserpin inclusion bodies</td> </tr> <tr> <td class=\"indent1\">Pantothenate kinase associated neurodegeneration</td> </tr> <tr> <td class=\"indent1\">Familial idiopathic basal ganglia calcification (Fahr disease)</td> </tr> <tr> <td class=\"indent1\">Superficial siderosis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 98780 Version 3.0</div></div></div>"},"98784":{"type":"graphic_diagnosticimage","displayName":"MRI ulnar nerve compression wrist","title":"Ulnar nerve compression at the wrist due to a ganglion cyst","html":"<div class=\"graphic\"><div style=\"width: 752px\" class=\"figure\"><div class=\"ttl\">Ulnar nerve compression at the wrist due to a ganglion cyst</div><div class=\"cntnt\"><img style=\"width:732px; height:575px;\" src=\"images/NEURO/98784_MRIulnarnervcmprssnwrst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Picture and MRI of the left wrist show the ganglion cyst and ulnar nerve.<br />(A) Ganglion cyst at the wrist.<br />(B, C) (Coronal and axial views) STIR MRI of the wrist with contrast shows a ganglion cyst (arrow) compressing an enhancing ulnar nerve (arrowhead).<br />(D) T1 MRI of the wrist (axial view) shows the cyst in relation to the anatomic structures.</div><div class=\"graphic_footnotes\">STIR: short tau inversion recovery; MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">From: Karam C, Quinn CC, Paganoni S, et al. Teaching NeuroImages: Ganglion cyst causing pure sensory ulnar neuropathy at the wrist. Neurology 2012; 79:e76. DOI: <A spellcheck=true href=\"http://www.neurology.org/content/79/8/e76.long\" target=_blank>10.1212/WNL.0b013e318266200c</A>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright © 2012 American Academy of Neurology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 98784 Version 3.0</div></div></div>"},"98797":{"type":"graphic_diagnosticimage","displayName":"Pinealoblastoma MRI","title":"Pinealoblastoma magnetic resonance image","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Pinealoblastoma magnetic resonance image</div><div class=\"cntnt\"><img style=\"width:726px; height:361px;\" src=\"images/PEDS/98797_Pinealoblastoma_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal and sagittal magnetic resonance images of a large ill-defined posterior fossa mass in a 34-month-old child with bilateral retinoblastoma consistent with a pinealoblastoma.</div><div id=\"graphicVersion\">Graphic 98797 Version 1.0</div></div></div>"},"98799":{"type":"graphic_diagnosticimage","displayName":"Retinoblastoma ultrasonography","title":"Ultrasonography of retinoblastoma (right eye)","html":"<div class=\"graphic\"><div style=\"width: 733px\" class=\"figure\"><div class=\"ttl\">Ultrasonography of retinoblastoma (right eye)</div><div class=\"cntnt\"><img style=\"width:713px; height:448px;\" src=\"images/PEDS/98799_Retinoblastoma_ultrsngrphy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound image of a dome-shaped retinal mass with diffuse intralesional calcification (hyper-reflective areas) consistent with retinoblastoma.</div><div id=\"graphicVersion\">Graphic 98799 Version 2.0</div></div></div>"},"98806":{"type":"graphic_figure","displayName":"Bacterial meningitis epidemiology","title":"Meningitis trends for different bacteria in the United States, 1997 to 2010","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Meningitis trends for different bacteria in the United States, 1997 to 2010</div><div class=\"cntnt\"><img style=\"width:598px; height:372px;\" src=\"images/ID/98806_Bacterial_meningitis_epidem.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Case estimation based on total number of cases per 100,000 people by International Classification of Diseases code (320.0, 320.1, 320.3, 320.82, and 036) from hospital discharges across the United States with the nationwide inpatient sample Healthcare Cost and Utilization Project net database.</div><div class=\"graphic_footnotes\">PCV7: 7-valent pneumococcal conjugate vaccine; MCV4: quadrivalent meningococcal conjugate vaccine.</div><div class=\"graphic_reference\">Original figure modified for this publication. Castelblanco RL, Lee M, Hasbun R. Epidemiology of bacterial meningitis in the USA from 1997 to 2010: a population-based observational study. Lancet Infect Dis 2014; 14:813. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 98806 Version 1.0</div></div></div>"},"98811":{"type":"graphic_figure","displayName":"Right colectomy for benign disease","title":"Right colectomy for benign disease","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Right colectomy for benign disease</div><div class=\"cntnt\"><img style=\"width:540px; height:720px;\" src=\"images/SURG/98811_Right_colectomy_benign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In benign pathologies (diverticular disease, volvulus), a segmental or an anatomic resection can be performed, but the vessels need not to be divided at their origin. </div><div id=\"graphicVersion\">Graphic 98811 Version 1.0</div></div></div>"},"98812":{"type":"graphic_figure","displayName":"Handling the mesentery during resection of benign colon disease","title":"Handling the mesentery during resection of benign colon disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Handling the mesentery during resection of benign colon disease</div><div class=\"cntnt\"><img style=\"width:367px; height:466px;\" src=\"images/SURG/98812_Lig_mes_vessels_benign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Main branches or named vessels should be individually divided and ligated. The mesenteric tissue can otherwise be divided between clamps and ligated or by using an energy device.</div><div id=\"graphicVersion\">Graphic 98812 Version 2.0</div></div></div>"},"98813":{"type":"graphic_table","displayName":"Suggested uses of TST and IGRA in children","title":"Suggested uses of TST and IGRA in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested uses of TST and IGRA in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">TST preferred</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Children younger than 5 years* </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">IGRA preferred, TST acceptable</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Children 5 years or older who have received BCG vaccine </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Children 5 years or older who are unlikely to return for the TST reading </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Both the TST and an IGRA should be considered when:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>The initial and repeat IGRA results are indeterminate/invalid </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>The initial test (TST or IGRA) result is <strong>negative</strong> and: <ul> <li>There is clinical suspicion of TB disease<sup>&#182;</sup> </li> <li>The child has a TB risk factor and is at high risk of progression and poor outcome (especially therapy with an immunomodulating biologic agent, such as a TNF-alpha antagonist)<sup>&#182;</sup> </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>The initial TST is <strong>positive</strong> and: <ul> <li>The patient is 5 years or older and has a history of BCG vaccination </li> <li>Additional evidence is needed to increase adherence with therapy </li> </ul> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TST: tuberculin skin test; IGRA: interferon-gamma release assay; BCG: Bacille Calmette-Guerin; TB: tuberculosis; TNF: tumor necrosis factor.<br />* Some experts will use an IGRA in children two to four years of age, especially if they have received a BCG vaccine but have no other significant risk factors. Most experts do not use an IGRA for children younger than two years because of lack of data for this age group and the high risk of progression to disease.<br />&para; A positive result of either test is considered significant in these groups.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 134, Pages e1763-73, Copyright © 2014 by the AAP.</div><div id=\"graphicVersion\">Graphic 98813 Version 4.0</div></div></div>"},"98814":{"type":"graphic_figure","displayName":"Small cell and large cell neuroendocrine carcinoma","title":"Small cell and large cell neuroendocrine carcinoma","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Small cell and large cell neuroendocrine carcinoma</div><div class=\"cntnt\"><img style=\"width:513px; height:190px;\" src=\"images/ONC/98814_Smll_lrg_cll_nrndc_crcnm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrographs (400x) of a hematoxylin and eosin (H&amp;E)-stained section of small cell (A) and large cell (B) neuroendocrine carcinoma.</div><div class=\"graphic_reference\">Courtesy of Dr. L Helgeland, Haukeland University Hospital, Bergen, Norway.</div><div id=\"graphicVersion\">Graphic 98814 Version 1.0</div></div></div>"},"98815":{"type":"graphic_figure","displayName":"Ki-67 immunostaining in neuroendocrine carcinoma","title":"Ki-67 immunostaining in neuroendocrine carcinoma","html":"<div class=\"graphic\"><div style=\"width: 817px\" class=\"figure\"><div class=\"ttl\">Ki-67 immunostaining&nbsp;in neuroendocrine carcinoma</div><div class=\"cntnt\"><img style=\"width:797px; height:300px;\" src=\"images/ONC/98815_Ki_67_nrndcrn_crcnm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrographs (400x) of sections of neuroendocrine carcinoma immunostained for the Ki-67 antigen with the MIB-1 monoclonal antibody and counterstained with hematoxylin. Ki-67 immunopositivity is &gt;20% by definition in neuroendocrine carcinomas, but may vary considerably: The panels depict two patients where Ki-67 positivity was 40% (A) versus 90% (B).</div><div class=\"graphic_reference\">Courtesy of Dr. L Helgeland, Haukeland University Hospital, Bergen, Norway.</div><div id=\"graphicVersion\">Graphic 98815 Version 1.0</div></div></div>"},"98816":{"type":"graphic_figure","displayName":"Platinum-based chemotherapy in gastroenteropancreatic NEC","title":"Response rates and survival after platinum-based chemotherapy in advanced gastroenteropancreatic neuroendocrine carcinoma","html":"<div class=\"graphic\"><div style=\"width: 764px\" class=\"figure\"><div class=\"ttl\">Response rates and survival after platinum-based chemotherapy in advanced gastroenteropancreatic neuroendocrine carcinoma</div><div class=\"cntnt\"><img style=\"width:744px; height:247px;\" src=\"images/ONC/98816_Pltnm_bsd_chm_gstrntrpn_NEC.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Response rates (A) and survival (B) after platinum-based chemotherapy in advanced gastroenteropancreatic neuroendocrine carcinoma patients according to Ki-67 level in 10% percentiles.</div><div class=\"graphic_reference\">Data from: Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Ann Oncol 2013; 24:152.</div><div id=\"graphicVersion\">Graphic 98816 Version 1.0</div></div></div>"},"98817":{"type":"graphic_picture","displayName":"Cavus foot with TMT bossing and splayed toes","title":"Cavus foot with TMT bossing and splaying between great and second toe","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cavus foot with TMT bossing and splaying between great and second toe</div><div class=\"cntnt\"><img style=\"width:401px; height:491px;\" src=\"images/EM/98817_CavufootTMTbosssplytoe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows a foot with a high longitudinal arch (cavus foot), bossing at the TMT region involving the first and second rays (arrow), and splaying between the great and second toe (arrowhead).</div><div class=\"graphic_footnotes\">TMT: tarsometatarsal.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 98817 Version 3.0</div></div></div>"},"98818":{"type":"graphic_picture","displayName":"Pes planus (flat foot) rear view","title":"Pes planus (flat foot) seen from rear","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">Pes planus (flat foot) seen from rear</div><div class=\"cntnt\"><img style=\"width:715px; height:396px;\" src=\"images/EM/98818_Pesplanuflatfootrearvw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows a patient with pronounced pes planus (flat foot). There is no longitudinal arch (arrows)&nbsp;and&nbsp;the midfoot is significantly pronated, the navicular is dropped, and the calcaneous (or heel) is in valgus (curved lines).</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 98818 Version 2.0</div></div></div>"},"98820":{"type":"graphic_table","displayName":"Accessory ossicles of the foot","title":"Accessory ossicles of the foot","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Accessory ossicles of the foot</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td><strong>Os trigonum</strong></td> <td>Rear foot</td> <td>Posterior of talus and superior to calcaneous</td> </tr> <tr> <td><strong>Os peroneum</strong></td> <td>Mid foot</td> <td>Within peroneus longus tendon at cuboid</td> </tr> <tr> <td><strong>Accessory navicular</strong></td> <td>Mid foot</td> <td>At the navicular prominence in posterior tibial tendon</td> </tr> <tr> <td><strong>Os supranaviculare</strong></td> <td>Mid foot</td> <td>Above talonavicular joint</td> </tr> <tr> <td><strong>Os vesalianum</strong></td> <td>Mid foot</td> <td>At base of fifth metatarsal within peroneus brevis tendon</td> </tr> <tr> <td><strong>Os supratalare</strong></td> <td>Rear foot</td> <td>Above neck of talus</td> </tr> <tr> <td><strong>Os talotibiale</strong></td> <td>Rear foot</td> <td>Anterior to talotibial joint</td> </tr> <tr> <td><strong>Os calcaneus secundarium</strong></td> <td>Rear foot</td> <td>Proximal to the anterior calcaneal process</td> </tr> <tr> <td><strong>Os intermetatarseum</strong></td> <td>Forefoot</td> <td>Between first and second metatarsals</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 98820 Version 1.0</div></div></div>"},"98822":{"type":"graphic_picture","displayName":"Symptomatic congenital CMV","title":"Symptomatic congenital cytomegalovirus infection","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Symptomatic congenital cytomegalovirus infection</div><div class=\"cntnt\"><img style=\"width:462px; height:616px;\" src=\"images/PEDS/98822_Symptomatic_congenital_CMV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Term&nbsp;neonate born with symptomatic congenital cytomegalovirus infection involving many organ systems. At birth the infant was jaundiced and had diffuse&nbsp;petechiae and purpura.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98822 Version 1.0</div></div></div>"},"98823":{"type":"graphic_diagnosticimage","displayName":"Fetal ascites CMV","title":"Fetal ascites","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Fetal ascites</div><div class=\"cntnt\"><img style=\"width:590px; height:405px;\" src=\"images/PEDS/98823_Fetal_ascites_CMV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fetal ultrasound at 24 weeks gestation, showing ascites (arrow) in a fetus with in utero congenital cytomegalovirus infection.</div><div id=\"graphicVersion\">Graphic 98823 Version 1.0</div></div></div>"},"98824":{"type":"graphic_diagnosticimage","displayName":"Fetal brain ultrasonography congenital CMV","title":"Fetal brain ultrasonography, congenital cytomegalovirus infection","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Fetal brain ultrasonography, congenital cytomegalovirus infection</div><div class=\"cntnt\"><img style=\"width:527px; height:486px;\" src=\"images/PEDS/98824_Fetal_brain_US_congenit_CMV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fetal ultrasonography of the brain in a 24-weeks gestation fetus with in utero congenital cytomegalovirus infection, showing enlarged cerebral ventricle and periventricular echogenicities (arrows) suggestive of calcification.</div><div id=\"graphicVersion\">Graphic 98824 Version 1.0</div></div></div>"},"98825":{"type":"graphic_diagnosticimage","displayName":"Congenital CMV, thickening of placenta","title":"Thickening of placenta in congenital cytomegalovirus","html":"<div class=\"graphic\"><div style=\"width: 686px\" class=\"figure\"><div class=\"ttl\">Thickening of placenta in congenital cytomegalovirus</div><div class=\"cntnt\"><img style=\"width:666px; height:479px;\" src=\"images/PEDS/98825_Congenit_CMV_thick_placenta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fetal ultrasonography performed at 24 weeks gestation in fetus with in utero congenital cytomegalovirus infection, showing thickening of placenta (arrows).</div><div id=\"graphicVersion\">Graphic 98825 Version 1.0</div></div></div>"},"98838":{"type":"graphic_diagnosticimage","displayName":"Asymptomatic congenital CMV cranial CT","title":"Unenhanced cranial computed tomography in infant with asymptomatic congenital cytomegalovirus infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Unenhanced cranial computed tomography in infant with asymptomatic congenital cytomegalovirus infection</div><div class=\"cntnt\"><img style=\"width:449px; height:516px;\" src=\"images/PEDS/98838_Congenital_CMV_cranial_CT2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Unenhanced cranial computed tomography scan in an infant born with asymptomatic congenital cytomegalovirus infection. There is a unilateral enlarged lateral ventricle, periventricular leukomalacia, and one punctate periventricular calcification (arrow).</div><div id=\"graphicVersion\">Graphic 98838 Version 1.0</div></div></div>"},"98839":{"type":"graphic_diagnosticimage","displayName":"Symptomatic congenital CMV cranial CT","title":"Unenhanced cranial computed tomography in infant with symptomatic congenital cytomegalovirus infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Unenhanced cranial computed tomography in infant with symptomatic congenital cytomegalovirus infection</div><div class=\"cntnt\"><img style=\"width:203px; height:310px;\" src=\"images/PEDS/98839_Congenital_CMV_cranial_CT3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Unenhanced cranial computed tomography scan of a newborn with congenital cytomegalovirus disease, and severe central nervous system involvement.&nbsp;The infant was born with severe microcephaly with overriding sutures. He also had neonatal seizures and progressive chorioretinitis.</div><div id=\"graphicVersion\">Graphic 98839 Version 1.0</div></div></div>"},"98840":{"type":"graphic_diagnosticimage","displayName":"Premature congenital CMV cranial CT","title":"Cranial computed tomography scan in a premature infant with congenital cytomegalovirus infection","html":"<div class=\"graphic\"><div style=\"width: 670px\" class=\"figure\"><div class=\"ttl\">Cranial computed tomography scan in a premature infant with congenital cytomegalovirus infection</div><div class=\"cntnt\"><img style=\"width:650px; height:424px;\" src=\"images/PEDS/98840_Congenital_CMV_cranial_CT4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cranial computed tomography (CT) scan of a premature female newborn with symptomatic congenital cytomegalovirus infection, diagnosed prenatally. Cranial CT scan shows bilateral ventriculomegaly and punctate periventricular calcifications. At birth she demonstrated hepatosplenomegaly, ascites, and thrombocytopenia. She experienced progressive, bilateral profound sensorineural hearing loss, which was eventually treated with cochlear implantation.</div><div id=\"graphicVersion\">Graphic 98840 Version 1.0</div></div></div>"},"98843":{"type":"graphic_diagnosticimage","displayName":"Congenital CMV MRI","title":"Brain magnetic resonance imaging of an infant with symptomatic congenital cytomegalovirus infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Brain magnetic resonance imaging of an infant with symptomatic congenital cytomegalovirus infection</div><div class=\"cntnt\"><img style=\"width:240px; height:240px;\" src=\"images/PEDS/98843_Congenital_CMV_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance imaging of an infant with symptomatic congenital cytomegalovirus infection that demonstrates unilateral cortical maldevelopment and polymicrogyria. Clinical features included neurologic involvement with microcephaly, seizures, and unilateral hearing loss.</div><div id=\"graphicVersion\">Graphic 98843 Version 2.0</div></div></div>"},"98846":{"type":"graphic_picture","displayName":"Sarcocyst in muscle","title":"Sarcocyst in muscle","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Sarcocyst in muscle</div><div class=\"cntnt\"><img style=\"width:712px; height:526px;\" src=\"images/ID/98846_Sarcocyst_muscle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hematoxylin and eosin stain x40 objective.</div><div class=\"graphic_reference\">Courtesy of Professor Kum Thong Wong, University of Malaya.</div><div id=\"graphicVersion\">Graphic 98846 Version 1.0</div></div></div>"},"98847":{"type":"graphic_diagnosticimage","displayName":"Os trigone close-up radiograph","title":"Os trigone close-up radiograph","html":"<div class=\"graphic\"><div style=\"width: 623px\" class=\"figure\"><div class=\"ttl\">Os trigone close-up radiograph</div><div class=\"cntnt\"><img style=\"width:603px; height:493px;\" src=\"images/EM/98847_Os_trigone_close_up_rdgaph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Os trigone (arrow) is a common extra ossicle off the posterior talus that occurs in approximately 20% of individuals.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 98847 Version 2.0</div></div></div>"},"98848":{"type":"graphic_picture","displayName":"Os peroneum external appearance","title":"Os peroneum external appearance","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Os peroneum external appearance</div><div class=\"cntnt\"><img style=\"width:726px; height:240px;\" src=\"images/EM/98848_Os_perineum_external_apprnc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The os peroneum is an ossicle present in the lateral foot of up to 20 percent&nbsp;of individuals.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 98848 Version 1.0</div></div></div>"},"98849":{"type":"graphic_picture","displayName":"Fourth brachymetatarsia anterior and lateral views","title":"Fourth brachymetatarsia anterior and lateral views","html":"<div class=\"graphic\"><div style=\"width: 670px\" class=\"figure\"><div class=\"ttl\">Fourth brachymetatarsia anterior and lateral views</div><div class=\"cntnt\"><img style=\"width:650px; height:720px;\" src=\"images/SM/98849_Frth_brchymttrs_antrr_ltrl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fourth brachymetatarsia is an unusual congenital condition that causes hypogenesis of the lateral foot column.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 98849 Version 2.0</div></div></div>"},"98850":{"type":"graphic_picture","displayName":"First brachymetatarsia","title":"First brachymetatarsia","html":"<div class=\"graphic\"><div style=\"width: 658px\" class=\"figure\"><div class=\"ttl\">First brachymetatarsia</div><div class=\"cntnt\"><img style=\"width:638px; height:476px;\" src=\"images/SM/98850_First_brachymetatarsia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">First brachymetatarsia is the most common brachydystrophy. In this patient, the extremely short first metatarsal has led to medial migration of the second foot ray to assist with the toe-off phase of gait.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 98850 Version 2.0</div></div></div>"},"98851":{"type":"graphic_picture","displayName":"First brachymetatarsia with hallux varus","title":"First brachymetatarsia with hallux varus","html":"<div class=\"graphic\"><div style=\"width: 801px\" class=\"figure\"><div class=\"ttl\">First brachymetatarsia with hallux varus</div><div class=\"cntnt\"><img style=\"width:781px; height:338px;\" src=\"images/SM/98851_Frst_brachymetatar_hllx_vrs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These photographs show advanced breakdown of the forefoot in an elite runner. Both feet demonstrate first brachymetatarsia (congenital short first ray) and a cavus foot (high arch). In addition, the left foot demonstrates hallux varus with a gap between the great and second toes and extreme widening of the forefoot.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 98851 Version 2.0</div></div></div>"},"98852":{"type":"graphic_picture","displayName":"Cavus feet showing effects of impact","title":"Cavus feet showing effects of impact","html":"<div class=\"graphic\"><div style=\"width: 727px\" class=\"figure\"><div class=\"ttl\">Cavus feet showing effects of impact</div><div class=\"cntnt\"><img style=\"width:707px; height:692px;\" src=\"images/SM/98852_Cavus_feet_show_effct_impct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cavus feet appear to absorb greater forces during the impact of gait, which over time can cause damage.<br />(A) This photograph shows hypertrophy of the first metatarsophalangeal joints - more prominent in right foot (arrowhead) - as well as widening of the forefoot and hammering of several toes (arrows).<br />(B) This photograph shows the soles of this patient's&nbsp;running shoes. The soles of her shoes&nbsp;reveal marked wear over the area of the first metatarsophalangeal joint.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 98852 Version 2.0</div></div></div>"},"98853":{"type":"graphic_movie","displayName":"Askling hamstring exercises: The Extender","title":"Askling hamstring exercises: The Extender","html":"<div class=\"graphic normal\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">Askling hamstring&nbsp;exercises: The&nbsp;Extender</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/98853_Asklingexercextendervid.mp4\" style=\"width:592px;height:352px\"></div><img style=\"width:590px; height:368px;\" src=\"images/EM/98853_Asklingexercextenderimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To perform the Extender, the patient holds and stabilizes the thigh of the injured leg with the hip flexed approximately 90 degrees, and then performs slow knee extensions to a point just before pain is felt. This exercise is used during the&nbsp;initial stages of rehabilitation from a hamstring muscle strain.&nbsp; </div><div class=\"graphic_footnotes\">Adapted from: Askling CM, Tengvar M, Thorstensson A. Acute hamstring injuries in Swedish elite football: a prospective randomised controlled clinical trial comparing two rehabilitation protocols. Br J Sports Med 2013; 47:953. Reproduced with permission from BMJ Publishing Group Ltd. Copyright © 2013</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 98853 Version 3.0</div></div></div>"},"98854":{"type":"graphic_picture","displayName":"Lateral foot ganglion","title":"Lateral foot ganglion","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Lateral foot ganglion</div><div class=\"cntnt\"><img style=\"width:712px; height:390px;\" src=\"images/EM/98854_Lateral_foot_ganglion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows a large ganglion arising from the articulation between the cuboid and the base of the fifth metatarsal.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 98854 Version 1.0</div></div></div>"},"98856":{"type":"graphic_picture","displayName":"Hallux rigidus","title":"Hallux rigidus","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Hallux rigidus</div><div class=\"cntnt\"><img style=\"width:712px; height:687px;\" src=\"images/SM/98856_Hallux_rigidus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These two photographs of the same patient show hallux rigidus with outward signs of first metatarsal degenerative joint disease and bone spurring (arrows). Only 10 degrees of passive extension can be achieved at the first metatarsal joint. A Haglund deformity can be seen at the patient's heel in the first photograph (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 98856 Version 2.0</div></div></div>"},"98857":{"type":"graphic_picture","displayName":"Metatarsal plantar callus with transverse arch breakdown","title":"Metatarsal plantar callus with transverse arch breakdown","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">Metatarsal plantar callus with transverse arch breakdown</div><div class=\"cntnt\"><img style=\"width:551px; height:366px;\" src=\"images/SM/98857_Mttrsl_plntr_cll_trnsvr_arc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These photographs show plantar calluses over the second and third metatarsals in both feet. The findings were associated with breakdown of the transverse arches. The patient is a runner who strikes down with her forefoot.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 98857 Version 2.0</div></div></div>"},"98858":{"type":"graphic_picture","displayName":"Haglund deformity","title":"Haglund deformity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Haglund deformity</div><div class=\"cntnt\"><img style=\"width:391px; height:338px;\" src=\"images/EM/98858_Haglund_deformity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A Haglund deformity is a bony exostosis that extends from the supero-posterior aspect of the lateral calcaneus. The lesion is likely due to excessive traction on the Achilles tendon insertion.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 98858 Version 1.0</div></div></div>"},"98859":{"type":"graphic_figure","displayName":"Resection of right colon for benign disease","title":"Resection of right colon for benign disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Resection of right colon for benign disease</div><div class=\"cntnt\"><img style=\"width:344px; height:459px;\" src=\"images/SURG/98859_Resect_mesentery_benign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For benign disease (eg, diverticulitis, volvulus), it is not necessary to divide the mesenteric vessels at their origin.</div><div id=\"graphicVersion\">Graphic 98859 Version 1.0</div></div></div>"},"98862":{"type":"graphic_table","displayName":"Lab tests for congenital CMV","title":"Comparison of laboratory tests for the detection of cytomegalovirus (CMV) in neonates with suspected congenital infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of laboratory tests for the detection of cytomegalovirus (CMV) in neonates with suspected congenital infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"12%\"></colgroup><colgroup width=\"52%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Laboratory method</td> <td class=\"subtitle1\">Sample used for testing</td> <td class=\"subtitle1\">Reported sensitivity<br /> (percent)*</td> <td class=\"subtitle1\">Reported specificity<br /> (percent)*</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Viral culture</td> <td class=\"divider_bottom\" rowspan=\"4\">Urine or saliva obtained within first three weeks of life</td> <td class=\"divider_bottom\" rowspan=\"4\">100</td> <td class=\"divider_bottom\" rowspan=\"4\">100</td> <td>Traditional reference standard.</td> </tr> <tr> <td>Detects CMV based on cytopathic changes in cell culture with fibroblast cell lines.</td> </tr> <tr> <td>Usually positive within 1 to 3 days of incubation, but may take up to 28 days before a negative result&nbsp;is declared.</td> </tr> <tr class=\"divider_bottom\"> <td>Disadvantages: 1) relatively long time required to detect the virus, 2) labor- and resource-intensive, and 3) requires tissue culture facilities.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Rapid culture<br /> (also called shell vial assay or shell vial culture)<sup>&#182;</sup></td> <td class=\"divider_bottom\" rowspan=\"5\">Urine or saliva obtained within first three weeks of life</td> <td class=\"divider_bottom\" rowspan=\"5\">92.3 to 100</td> <td class=\"divider_bottom\" rowspan=\"5\">100</td> <td>Enhanced culture method using centrifugation and staining for early antigen production.</td> </tr> <tr> <td>Allows for identification of the virus within 24 hours.</td> </tr> <tr> <td>Advantage over standard viral culture is that it is rapid, simple to perform, and less expensive.</td> </tr> <tr> <td>False positive results may occur due to retained CMV antigen on the shell vial monolayer, producing a low positive result.</td> </tr> <tr class=\"divider_bottom\"> <td>A confirmatory test (either viral culture or PCR) should be performed to establish the diagnosis of congenital CMV.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">PCR<sup>&#182;</sup></td> <td class=\"divider_bottom\" rowspan=\"5\">Urine or saliva obtained within first three weeks of life</td> <td class=\"divider_bottom\" rowspan=\"5\">97.4 to 100</td> <td class=\"divider_bottom\" rowspan=\"5\">99.9</td> <td>Detects CMV DNA in the urine or saliva.</td> </tr> <tr> <td>Advantages over standard and shell vial culture techniques include: 1) rapid turnaround, 2) does not require live virus for detection of CMV, thus is not affected by storage and transport conditions, and 3) lower cost.</td> </tr> <tr> <td>Available in many hospital-based and reference laboratories.</td> </tr> <tr> <td>Occasional false positive results occur; we suggest confirming positive tests with repeat PCR on urine or saliva or both.</td> </tr> <tr class=\"divider_bottom\"> <td>Newborns with congenital CMV infection shed large quantities of CMV from both urine and saliva for prolonged periods; therefore, these tests should be positive repeatedly.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">PCR</td> <td class=\"divider_bottom\" rowspan=\"4\">DBS</td> <td class=\"divider_bottom\" rowspan=\"4\">28 to 73</td> <td class=\"divider_bottom\" rowspan=\"4\">99.9</td> <td>Detects CMV DNA in the DBS obtained for newborn screening.</td> </tr> <tr> <td>Allows retrospective diagnosis of congenital CMV infection.</td> </tr> <tr> <td>Not all infected infants are viremic at birth, accounting for low sensitivity of this test compared with PCR in urine or saliva samples.</td> </tr> <tr class=\"divider_bottom\"> <td>Available in research or public health laboratories (CDC).</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Quantitative PCR<br /> (CMV DNAemia)</td> <td class=\"divider_bottom\" rowspan=\"3\">Whole blood or plasma</td> <td class=\"divider_bottom\" rowspan=\"3\">NA</td> <td class=\"divider_bottom\" rowspan=\"3\">&nbsp;NA</td> <td>Measures amount of CMV DNA in the blood.</td> </tr> <tr> <td>Used for monitoring infants during therapy; not used for establishing the diagnosis of congenital CMV.</td> </tr> <tr class=\"divider_bottom\"> <td>Preferred over CMV antigenemia for quantitative measurement of viremia.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">CMV antigenemia</td> <td class=\"divider_bottom\" rowspan=\"2\">Blood</td> <td class=\"divider_bottom\" rowspan=\"2\">&nbsp;NA</td> <td class=\"divider_bottom\" rowspan=\"2\">&nbsp;NA</td> <td>Detects CMV proteins (pp65) in peripheral blood leukocytes.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Not</strong> recommended in the diagnostic evaluation of infants with congenital CMV.</td> </tr> <tr> <td rowspan=\"3\">Serology</td> <td rowspan=\"3\">Blood</td> <td rowspan=\"3\">&nbsp;NA</td> <td rowspan=\"3\">&nbsp;NA</td> <td><strong>Not</strong> recommended for routine diagnosis of congenital CMV.</td> </tr> <tr> <td>Presence of CMV IgG antibody in the newborn may only reflect passive transfer of maternal antibody; however, its absence makes CMV infection very unlikely.</td> </tr> <tr> <td>CMV IgM antibody in the newborn is insensitive and may be falsely negative in over half of infected newborns.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NA: not available; PCR: polymerase chain reaction; DBS: dried blood spot; CDC: Centers for Disease Control and Prevention; IgG: immunoglobulin G; IgM: immunoglobulin M.<br />* Compared with viral culture in most studies.<br />¶ Shell vial assay or PCR tests have largely replaced viral culture as the methods of choice for diagnosis of congenital CMV infection because of more rapidly available results and lower cost. The choice of test used may depend on the availability.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Harrison GJ. Cytomegalovirus. In: Feigin and Cherry's Textbook of Pediatric Infectious Diseases, 7th ed, Cherry JD, Harrison GJ, Kaplan SL, et al (Eds), Elsevier Saunders, Philadelphia 2014. p.1969.</LI>&#xD;&#xA;<LI>Britt W. Cytomegalovirus. In: Infectious Diseases of the Fetus and Newborn Infant, 7th ed, Remington JS, Klein JO, Wilson CB, et al (Eds), Elsevier Saunders, Philadelphia 2011. p.706.</LI>&#xD;&#xA;<LI>Boppana SB, Smith RJ, Stagno S, Britt WJ. Evaluation of a microtiter plate fluorescent-antibody assay for rapid detection of human cytomegalovirus infection. J Clin Microbiol 1992; 30:721.</LI>&#xD;&#xA;<LI>Balcarek KB, Warren W, Smith RJ, et al. Neonatal screening for congenital cytomegalovirus infection by detection of virus in saliva. J Infect Dis 1993; 167:1433.</LI>&#xD;&#xA;<LI>Demmler GJ, Buffone GJ, Schimbor CM, May RA. Detection of cytomegalovirus in urine from newborns by using polymerase chain reaction DNA amplification. J Infect Dis 1988; 158:1177.</LI>&#xD;&#xA;<LI>Ross SA, Ahmed A, Palmer AL, et al. Detection of congenital cytomegalovirus infection by real-time polymerase chain reaction analysis of saliva or urine specimens. J Infect Dis 2014; 210:1415.</LI>&#xD;&#xA;<LI>Boppana SB, Ross SA, Shimamura M, et al. Saliva polymerase-chain-reaction assay for cytomegalovirus screening in newborns. N Engl J Med 2011; 364:2111.</LI>&#xD;&#xA;<LI>Pinninti SG, Ross SA, Shimamura M, et al. Comparison of saliva PCR assay versus rapid culture for detection of congenital cytomegalovirus infection. Pediatr Infect Dis J 2015; 34:536.</LI>&#xD;&#xA;<LI>Boppana SB, Ross SA, Novak Z, et al. Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection. JAMA 2010; 303:1375.</LI>&#xD;&#xA;<LI>Soetens O, Vauloup-Fellous C, Foulon I, et al. Evaluation of different cytomegalovirus (CMV) DNA PCR protocols for analysis of dried blood spots from consecutive cases of neonates with congenital CMV infections. J Clin Microbiol 2008; 46:943.</LI></OL></div><div id=\"graphicVersion\">Graphic 98862 Version 2.0</div></div></div>"},"98865":{"type":"graphic_picture","displayName":"Extensive plantar callus with severe transverse arch collapse","title":"Extensive plantar callus with severe transverse arch collapse","html":"<div class=\"graphic\"><div style=\"width: 723px\" class=\"figure\"><div class=\"ttl\">Extensive plantar callus with severe transverse arch collapse</div><div class=\"cntnt\"><img style=\"width:703px; height:385px;\" src=\"images/SM/98865_Extnplntclltrnsvrarccl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The extensive plantar callus seen here over the area of the heads of the second, third, and fourth metatarsals was associated with severe collapse of the transverse arch. On palpation, the metatarsal heads were immobile.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 98865 Version 2.0</div></div></div>"},"98878":{"type":"graphic_picture","displayName":"Rigid pes planus with Morton foot","title":"Rigid pes planus with Morton foot","html":"<div class=\"graphic\"><div style=\"width: 700px\" class=\"figure\"><div class=\"ttl\">Rigid pes planus with Morton foot</div><div class=\"cntnt\"><img style=\"width:680px; height:437px;\" src=\"images/SM/98878_Rigid_pes_planus_Mrtn_ft.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows a patient with rigid pes planus (no medial arch) and a Morton foot with a long second metatarsal (note second toes indicated by arrows that&nbsp;extend distally). This foot pattern is seen with tarsal coalition involving the medial calcaneus.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 98878 Version 2.0</div></div></div>"},"98879":{"type":"graphic_table","displayName":"Statin treatment diabetes","title":"Recommendations for statin treatment in people with diabetes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for statin treatment in people with diabetes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Risk factors</td> <td class=\"subtitle1\">Recommended statin dose*</td> <td class=\"subtitle1\">Monitoring with lipid panel</td> </tr> <tr> <td>&#60;40 years</td> <td> <p>None</p> <p>CVD risk factor(s)<sup>&#182;</sup></p> Overt CVD<sup>&#916;</sup></td> <td> <p>None</p> <p>Moderate or high</p> High</td> <td>Annually or as needed to monitor for adherence</td> </tr> <tr> <td>40 to 75 years</td> <td> <p>None</p> <p>CVD risk factors</p> Overt CVD</td> <td> <p>Moderate</p> <p>High</p> High</td> <td>As needed to monitor adherence</td> </tr> <tr> <td>&#62;75 years</td> <td> <p>None</p> <p>CVD risk factors</p> Overt CVD </td> <td> <p>Moderate</p> <p>Moderate or high</p> High</td> <td>As needed to monitor adherence</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CVD: cardiovascular disease; LDL: low-density lipoprotein.<br />* In addition to lifestyle therapy.<br />&para; CVD risk factors include LDL cholesterol &ge;100 mg/dL (2.6 mmol/L), high blood pressure, smoking, and overweight and obesity.<br />&Delta; Overt CVD includes those with previous cardiovascular events or acute coronary syndromes.</div><div class=\"graphic_reference\">From: American Diabetes Association. 8. Cardiovascular Disease and Risk Management. Diabetes Care 2015; 38:S49. American Diabetes Association, Diabetes Care, 2015. Copyright and all rights reserved. Material from this publication has been used with the permission of American Diabetes Association.</div><div id=\"graphicVersion\">Graphic 98879 Version 1.0</div></div></div>"},"98881":{"type":"graphic_figure","displayName":"Tendons and bursae in the trochanteric region","title":"Tendons and bursae in the trochanteric region","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Tendons and bursae in the trochanteric region</div><div class=\"cntnt\"><img style=\"width:522px; height:545px;\" src=\"images/RHEUM/98881_Tendons_bursae_trochanteric.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anterolateral view of the greater trochanter. </div><div class=\"graphic_reference\">Modified from: Lequesne M. From \"periarthritis\" to hip \"rotator cuff\" tears. Trochanteric tendinobursitis. Joint Bone Spine 2006; 73:344.</div><div id=\"graphicVersion\">Graphic 98881 Version 2.0</div></div></div>"},"98916":{"type":"graphic_picture","displayName":"Lateral plantar foot callus","title":"Lateral plantar foot callus","html":"<div class=\"graphic\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">Lateral plantar foot callus</div><div class=\"cntnt\"><img style=\"width:640px; height:347px;\" src=\"images/SM/98916_Lateral_plantar_foot_callus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph above shows callus below the area of the fifth metatarsal, as well as significant displacement of the second and third toes. The patient&nbsp;demonstrated extreme foot supination during gait, which&nbsp;led to the development of&nbsp;the abnormal lateral callus and toe displacement.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 98916 Version 3.0</div></div></div>"},"98917":{"type":"graphic_diagnosticimage","displayName":"Avulsion fracture fifth metatarsal close-up view","title":"Avulsion fracture of the fifth metatarsal close-up view","html":"<div class=\"graphic\"><div style=\"width: 598px\" class=\"figure\"><div class=\"ttl\">Avulsion fracture of the fifth metatarsal close-up view</div><div class=\"cntnt\"><img style=\"width:578px; height:326px;\" src=\"images/EM/98917_Avlsnfrctrffthmttrslcls.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An avulsion fracture of the proximal fifth metatarsal (arrow) is a relatively common cause of acute lateral foot pain following injury. Other fractures of the proximal fifth metatarsal are prone to complications so clinicians must be certain of the diagnosis.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 98917 Version 3.0</div></div></div>"},"98918":{"type":"graphic_figure","displayName":"Lipoproteins in cholesterol efflux from cholesterol-loaded cells","title":"Summary of the major lipoprotein particles that participate in cholesterol efflux from cholesterol-loaded cells","html":"<div class=\"graphic\"><div style=\"width: 625px\" class=\"figure\"><div class=\"ttl\">Summary of the major lipoprotein particles that participate in cholesterol efflux from cholesterol-loaded cells</div><div class=\"cntnt\"><img style=\"width:605px; height:447px;\" src=\"images/CARD/98918_Lipoproteinschlstrlefflux.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cholesterol-deficient and phospholipid-depleted apoA-I complexes (preβ migrating HDL/HDL-VS) and lipid-poor E-HDL secreted from the macrophage interact with the ABCA1 transporter; HDL-M (αHDL) and spherical E-HDL interact with the ATP-binding cassette transporter G1 (ABCG1) transporter. Cholesterol is also removed by passive diffusion and by SR-B1 utilizing either HDL-M or spherical E-HDL.</div><div class=\"graphic_footnotes\">E-HDL: apolipoprotein E; HDL-VL: very-large HDL.</div><div class=\"graphic_reference\">From: Rosenson RS, Brewer HB Jr, Davidson WS, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 2012; 125:1905. DOI: <a href=\"http://circ.ahajournals.org/content/125/15/1905.long\" target=\"_blank\">10.1161/CIRCULATIONAHA.111.066589</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2012 American Heart Association. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 98918 Version 2.0</div></div></div>"},"98920":{"type":"graphic_diagnosticimage","displayName":"CT cholesterol emboli to the kidney","title":"Cholesterol emboli to the kidney on CT scan","html":"<div class=\"graphic\"><div style=\"width: 726px\" class=\"figure\"><div class=\"ttl\">Cholesterol emboli to the kidney on CT scan</div><div class=\"cntnt\"><img style=\"width:706px; height:232px;\" src=\"images/RADIOL/98920_CT_cholesterol_emboli_kidny.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A axial CT scan through the kidneys (A) shows punctate perfusion defects in the renal parenchyma (arrows) and regions of diffuse thinning of the cortex (arrowheads). Image B is a magnified view showing tiny perfusion defects (arrows), as well as larger regions of parenchymal thinning (arrowheads).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 98920 Version 1.0</div></div></div>"},"98921":{"type":"graphic_picture","displayName":"Sinus tarsi syndrome","title":"Sinus tarsi syndrome","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Sinus tarsi syndrome</div><div class=\"cntnt\"><img style=\"width:469px; height:350px;\" src=\"images/EM/98921_Sinus_tarsi_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows a patient with bilateral sinus tarsi syndrome. Puffiness can be see below and anterior to the lateral malleolus in both feet.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 98921 Version 1.0</div></div></div>"},"98922":{"type":"graphic_picture","displayName":"Piezogenic papules","title":"Piezogenic papules","html":"<div class=\"graphic\"><div style=\"width: 892px\" class=\"figure\"><div class=\"ttl\">Piezogenic papules</div><div class=\"cntnt\"><img style=\"width:872px; height:242px;\" src=\"images/SM/98922_Pzgnc_ppls.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Piezogenic papules are yellowish to flesh colored papules that represent small fat herniations through the heel capsule (arrows).<br />(B) The photograph of the medial foot shows multiple piezogenic papules at the heel in a patient with Ehlers Danlos.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 98922 Version 2.0</div></div></div>"},"98923":{"type":"graphic_diagnosticimage","displayName":"Radiograph of brachytherapy for prostate carcinoma","title":"Brachytherapy for prostate carcinoma on radiography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Brachytherapy for prostate carcinoma on radiography</div><div class=\"cntnt\"><img style=\"width:404px; height:521px;\" src=\"images/RADIOL/98923_Rdgr_brchythrpy_prstt_crcnm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiograph in A-P projection shows the delivery device (arrowhead) situated in the perineum and multiple radioactive seeds (arrow) positioned in the prostate gland.</div><div class=\"graphic_footnotes\">A-P: anteroposterior.</div><div id=\"graphicVersion\">Graphic 98923 Version 1.0</div></div></div>"},"98925":{"type":"graphic_diagnosticimage","displayName":"Radiograph and CT of total  hip arthroplasty displacement","title":"Radiograph and CT of total hip arthroplasty displacement","html":"<div class=\"graphic\"><div style=\"width: 744px\" class=\"figure\"><div class=\"ttl\">Radiograph and CT of total hip arthroplasty displacement</div><div class=\"cntnt\"><img style=\"width:724px; height:335px;\" src=\"images/RADIOL/98925_Img_frctr_dslct_ttl_hprplcm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Total hip arthroplasty displacement and acetabular&nbsp;fracture. Right hip radiograph AP view (A) shows that the femoral head (asterisk) and the acetabular cup (delta) of the prosthesis have migrated&nbsp;cranially relative to the acetabulum (arrowhead). A superior acetabular fracture&nbsp;is&nbsp;also seen (arrow). CT axial (B), coronal reconstruction (C) and sagittal reconstruction (D) images of the right hip shows the relationship of the dislocated femoral head (asterisk) and acetabular cup (delta) and relative to the empty acetabulum (arrowhead). Fractures of the superior and inferior acetabulum (arrows) are also noted.</div><div class=\"graphic_footnotes\">AP: aneteroposterior; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 98925 Version 4.0</div></div></div>"},"98926":{"type":"graphic_diagnosticimage","displayName":"Radiograph of a dislocated hemiarthroplasty of the hip","title":"Radiograph of a dislocated hemiarthroplasty of the hip","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiograph of a dislocated hemiarthroplasty of the hip</div><div class=\"cntnt\"><img style=\"width:426px; height:348px;\" src=\"images/RADIOL/98926_Rdgrph_dslct_hmrthrplsty_hp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dislocated hemiarthroplasty of the hip. Radiograph of the pelvis AP view shows&nbsp;the head of the right&nbsp;femoral prosthesis (asterisk) dislocated from the acetabulum (delta).</div><div class=\"graphic_footnotes\">AP: anteroposterior.</div><div id=\"graphicVersion\">Graphic 98926 Version 2.0</div></div></div>"},"98951":{"type":"graphic_table","displayName":"Diagnostic criteria for CBD","title":"Diagnostic criteria for corticobasal degeneration*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for corticobasal degeneration*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Clinical research criteria for probable sporadic CBD</td> <td class=\"subtitle1\">Clinical criteria for possible CBD<sup>&#182;</sup></td> </tr> <tr> <td><strong>Presentation</strong></td> <td>Insidious onset and gradual progression</td> <td>Insidious onset and gradual progression</td> </tr> <tr> <td><strong>Minimum duration of symptoms, years</strong></td> <td>1</td> <td>1</td> </tr> <tr> <td><strong>Age at onset, years</strong></td> <td>&#8805;50</td> <td>No minimum</td> </tr> <tr> <td><strong>Family history (two or more relatives)</strong></td> <td>Exclusion</td> <td>Permitted</td> </tr> <tr> <td><strong>Permitted phenotypes</strong></td> <td> <ol class=\"numbers_to_nine\"> <li>Probable CBS<br /> or </li> <li>FBS or NAV plus at least one CBS feature: <ul> <li>Limb rigidity or akinesia</li> <li>Limb dystonia</li> <li>Limb myoclonus</li> <li>Orobuccal or limb apraxia</li> <li>Cortical sensory deficit</li> <li>Alien limb phenomena</li> </ul> </li> </ol> </td> <td> <ol class=\"numbers_to_nine\"> <li>Possible CBS<br /> or </li> <li>FBS or NAV<br /> or </li> <li>PSPS plus at least one CBS feature: <ul> <li>Limb dystonia</li> <li>Limb myoclonus</li> <li>Orobuccal or limb apraxia</li> <li>Cortical sensory deficit</li> <li>Alien limb phenomena</li> </ul> </li> </ol> </td> </tr> <tr> <td><strong>Genetic mutation affecting tau (eg, MAPT)</strong></td> <td>Exclusion</td> <td>Permitted</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CBD: corticobasal degeneration; CBS: corticobasal syndrome; FBS: frontal behavioral-spatial syndrome; MAPT: microtubule-associated protein tau;&nbsp;NAV: nonfluent/agrammatic variant of primary progressive aphasia; PSPS: progressive supranuclear palsy syndrome.<br />* Exclusion criteria for both clinical research criteria for probable sporadic CBD and possible CBD: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Evidence of Lewy body disease: classic 4 Hz Parkinson disease resting tremor, excellent and sustained levodopa response, or hallucinations. </LI>&#xD;&#xA;<LI>Evidence of multiple system atrophy: dysautonomia or prominent cerebellar signs. </LI>&#xD;&#xA;<LI>Evidence of amyotrophic lateral sclerosis: presence of both upper and lower motor neuron signs. </LI>&#xD;&#xA;<LI>Semantic- or logopenic-variant primary progressive aphasia. </LI>&#xD;&#xA;<LI>Structural lesion suggestive of focal cause. </LI>&#xD;&#xA;<LI>Granulin mutation or reduced plasma progranulin levels; TDP-43 mutations; FUS mutations. </LI>&#xD;&#xA;<LI>Evidence of Alzheimer disease (this will exclude some cases of CBD with coexisting amyloid; data from one brain bank suggest that excluding cases with evidence of amyloid may result in missing approximately 14 percent&nbsp;of CBD cases [Dickson D, 2012, personal communication]): laboratory findings strongly suggestive of Alzheimer disease such as low cerebrospinal fluid beta-amyloid 42-to-tau ratio or positive <SUP>11</SUP>C-Pittsburgh compound B PET; or genetic mutation suggesting Alzheimer disease (eg, presenilin, amyloid precursor protein).</LI></OL>¶ Possible CBD emphasizes clinical presentations consistent with CBD but ones that may also overlap with other tau-based pathologies.</div><div class=\"graphic_reference\">From: Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013; 80:496. DOI: <A spellcheck=true href=\"http://www.neurology.org/content/80/5/496.abstract\" target=_blank>10.1212/WNL.0b013e31827f0fd1</A>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright © 2013 American Academy of Neurology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 98951 Version 3.0</div></div></div>"},"98961":{"type":"graphic_table","displayName":"Medical treatment for refractory ulcerative colitis in children","title":"Medical rescue therapies in pediatric glucocorticoid-refractory ulcerative colitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medical rescue therapies in pediatric glucocorticoid-refractory ulcerative colitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"16%\"></colgroup><colgroup span=\"3\" width=\"28%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Cyclosporine</td> <td class=\"subtitle1\">Tacrolimus</td> <td class=\"subtitle1\">Infliximab</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Initial dosing</strong></td> <td> <p>2 mg/kg/day continuous intravenous infusion.</p> Once remission is achieved, convert to oral (microemulsion) cyclosporine 5 to 8 mg/kg/day in 2 divided doses. Stop medication after&nbsp;three to&nbsp;four months.</td> <td>0.2 mg/kg/day orally in two divided doses. Stop medication after&nbsp;three to&nbsp;four months.</td> <td> <p>5 mg/kg intravenous infusion over 2 to 4 hours; subsequent doses given&nbsp;two weeks and&nbsp;six weeks after the initial infusion.</p> Some centers utilize higher doses (10 mg/kg/dose), or infuse the second dose after 7 to 10 days.*</td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>Trough drug levels</strong></p> (whole blood)</td> <td> <p>Initially, aim for trough levels of 150 to 300 ng/mL.</p> Once remission is achieved, aim for trough levels of 100 to 200 ng/mL (for timing see below).</td> <td> <p>Initially, aim for trough levels of 10 to 15 ng/mL.</p> Once remission is achieved, aim for trough levels of 5 to 10 ng/mL (for timing see below).</td> <td>Not indicated.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Tests before treatment</strong></td> <td colspan=\"2\"> <p>Measure blood pressure and blood tests: Creatinine, glucose, electrolytes, liver profile, magnesium, cholesterol.</p> Hypomagnesemia and hypocholesterolemia are associated with increased risk of neurotoxicity (particularly with cyclosporine).<sup>&#182;</sup></td> <td>Documentation of negative tuberculosis testing and chest x-ray; consider varicella, hepatitis B and C serology in endemic areas.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Main toxicity</strong></td> <td colspan=\"2\"> <p>Hypertension<sup>&#916;</sup>, hyperglycemia, hypomagnesemia, immune suppression, azotemia<sup>&#9674;</sup> (dose dependent), seizures<sup>&#182;</sup> (dose and hypocholesterolemia dependent), hirsutism (more with cyclosporine), tremor (more with tacrolimus). Tacrolimus increases QT interval.</p> Interactions: Grapefruit juice, erythromycin, ketoconazole, and a number of other drugs can increase cyclosporine and tacrolimus levels.<sup>&#167;</sup></td> <td>Infusion reactions, increased infection rate, rare opportunistic infections, possible association with hepatosplenic T-cell lymphoma.</td> </tr> <tr> <td><strong>Monitor toxicity</strong></td> <td colspan=\"2\"> <p>Monitor every other day during induction, weekly for the first month, and then monthly:<sup>&#165;</sup> Drug levels (starting after third dose), creatinine, glucose, electrolytes (including magnesium), lipid levels, liver function tests, blood pressure, and neurological symptoms.</p> Consider: Measure creatinine clearance at baseline and initiate pneumocystis pneumonia prophylaxis.</td> <td>Frequent assessment of vital signs during infusion.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table outlines the main options for medical therapy of acute severe ulcerative colitis in children that is refractory to treatment with glucocorticoids (ie, no clinically meaningful response to a 7- to 10-day course of intravenous glucocorticoids). Use of sequential therapy (infliximab followed by cyclosporine or tacrolimus, or vice-versa) remains controversial and is not recommended.<br />If the patient with severe or refractory colitis responds to rescue therapy with cyclosporine, tacrolimus or infliximab, then the glucocorticoids can be gradually tapered and withdrawn. If cyclosporine or tacrolimus was used for induction, the patient should be transitioned to a thiopurine or other long-term maintenance agent within three to four months.</div><div class=\"graphic_footnotes\">* Maintenance therapy can be given every&nbsp;eight weeks after induction, if clinically indicated.<br />¶ Neurotoxicity (manifested as paresthesias, tremors, and seizures) is promoted by hypocholesterolemia (&lt;120 mg/dL) and hypomagnesemia (&lt;1.5 mg/dL): If the latter occurs, dose of cyclosporine should be lowered.<br />Δ Hypertension can be seen in up to 40 percent&nbsp;of subjects and usually responds to calcium channel blockers (the latter, however, can increase cyclosporine levels).<br /><FONT class=lozenge>◊</FONT> Serum creatinine &gt;1.4 mg/dL or at least 33 percent&nbsp;over baseline (usually respond to cyclosporine dose adjustment).<br />§ Drug interactions should be checked with Lexi-Interact when initiated and for any change in drug therapy.<br />¥ If oral drug dose has been changed, monitor levels&nbsp;one week later.</div><div class=\"graphic_reference\">Adapted by permission from Macmillan Publishers Ltd: American Journal of Gastroenterology. Turner D, Travos SP, Groffotjs AM, et al. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastroenterol 2011; 106:574. Copyright &copy; 2011. <a href=\"http://www.nature.com/ajg\" target=\"_blank\">www.nature.com/ajg</a>.</div><div id=\"graphicVersion\">Graphic 98961 Version 3.0</div></div></div>"},"98973":{"type":"graphic_diagnosticimage","displayName":"Type 1 angiographic SCAD","title":"Type 1 angiographic spontaneous coronary artery dissection","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Type 1 angiographic spontaneous coronary artery dissection</div><div class=\"cntnt\"><img style=\"width:513px; height:590px;\" src=\"images/CARD/98973_Type_1_angiographic_SCAD.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Jacqueline Saw, MD.</div><div id=\"graphicVersion\">Graphic 98973 Version 1.0</div></div></div>"},"98974":{"type":"graphic_diagnosticimage","displayName":"Type 2 angiographic SCAD","title":"Type 2 angiographic spontaneous coronary artery dissection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Type 2 angiographic spontaneous coronary artery dissection</div><div class=\"cntnt\"><img style=\"width:450px; height:590px;\" src=\"images/CARD/98974_Type_2_angiographic_SCAD.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Jacqueline Saw, MD.</div><div id=\"graphicVersion\">Graphic 98974 Version 1.0</div></div></div>"},"98975":{"type":"graphic_diagnosticimage","displayName":"Type 3 angiographic SCAD","title":"Type 3 angiographic spontaneous coronary artery dissection","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Type 3 angiographic spontaneous coronary artery dissection</div><div class=\"cntnt\"><img style=\"width:543px; height:590px;\" src=\"images/CARD/98975_Type_3_angiographic_SCAD.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Jacqueline Saw, MD.</div><div id=\"graphicVersion\">Graphic 98975 Version 1.0</div></div></div>"},"98977":{"type":"graphic_picture","displayName":"Circinate balanitis in reactive arthritis 2","title":"Circinate balanitis in reactive arthritis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Circinate balanitis in reactive arthritis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/98977_Crcnt_blnt__rctv_arthrts_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous plaques with scale on the genitals in a circumcised patient with circinate balanitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98977 Version 2.0</div></div></div>"},"98978":{"type":"graphic_picture","displayName":"Palmoplantar pustulosis on foot","title":"Palmoplantar pustulosis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Palmoplantar pustulosis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/98978_Plmplntr_pstls_foot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pustules within an erythematous, scaly plaque on the foot.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98978 Version 2.0</div></div></div>"},"98996":{"type":"graphic_picture","displayName":"Bowel-associated dermatosis-arthritis syndrome","title":"Bowel-associated dermatosis-arthritis syndrome","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Bowel-associated dermatosis-arthritis syndrome</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/98996_Bwl_assct_drmt_arth_synd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous macules and a papulopustule on the upper extremity.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98996 Version 1.0</div></div></div>"},"98997":{"type":"graphic_picture","displayName":"Bowel-associated dermatosis-arthritis syndrome multiple lesions","title":"Bowel-associated dermatosis-arthritis syndrome","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Bowel-associated dermatosis-arthritis syndrome</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/98997_Bwl_ass_drmt_art_syn_mlt_ls.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous macules, papules, and papulopustules on the upper extremity.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 98997 Version 1.0</div></div></div>"}};